

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07H 21/00, C12N 15/18, C07K 14/495		A1	(11) International Publication Number: WO 95/19987
			(43) International Publication Date: 27 July 1995 (27.07.95)
(21) International Application Number: PCT/US95/01153		(81) Designated States: JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 25 January 1995 (25.01.95)		Published With international search report.	
(30) Priority Data: 08/188,227 25 January 1994 (25.01.94) US			
(71) Applicant: THE SCRIPPS RESEARCH INSTITUTE (US/US); 10666 North Torrey Pines Road, La Jolla, CA 92037 (US).			
(72) Inventors: LOCKUTOFF, David, J.; 426 Glencrest Drive, Solana Beach, CA 92075 (US). CURRIDEN, Scott, A.; 2432 Caminito Ocean Cove, Cardiff, CA 92007 (US).			
(74) Agents: FITTING, Thomas et al.; The Scripps Research Institute, 10666 North Torrey Pines Road, TPC-8, La Jolla, CA 92037 (US).			
(54) Title: A NEW SENSITIVE METHOD FOR QUANTIFYING ACTIVE TRANSFORMING GROWTH FACTOR-BETA AND COMPOSITIONS THEREFOR			
(57) Abstract <p>The present invention describes a highly sensitive and specific non-radioactive quantitative assay method for quantifying transforming growth factor-beta (TGF-β) in a liquid sample. Also disclosed are TGF-β responsive expression vectors that express the indicator molecule, luciferase, in a dose-dependent response to TGF-β activation. Eucaryotic cells transformed with the disclosed expression vectors are also described. Diagnostic systems in the form of kits for quantifying the amount of TGF-β in a liquid sample using the disclosed methods and expression vectors are described.</p>			

BEST AVAILABLE COPY

ATTORNEY DOCKET NUMBER: 10177-211-999
SERIAL NUMBER: 09/910,388
REFERENCE: B130

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07H 21/00, C12N 15/18, C07K 14/495		A1	(11) International Publication Number: WO 95/19987 (43) International Publication Date: 27 July 1995 (27.07.95)
(21) International Application Number: PCT/US95/01153 (22) International Filing Date: 25 January 1995 (25.01.95) (30) Priority Data: 08/188,227 25 January 1994 (25.01.94) US (71) Applicant: THE SCRIPPS RESEARCH INSTITUTE (US/US); 10666 North Torrey Pines Road, La Jolla, CA 92037 (US). (72) Inventors: LOCKUTOFF, David, J.; 426 Glencrest Drive, Solana Beach, CA 92075 (US). CURRIDEN, Scott, A.; 2432 Caminito Ocean Cove, Cardiff, CA 92007 (US). (74) Agents: FITTING, Thomas et al.; The Scripps Research Institute, 10666 North Torrey Pines Road, TPC-8, La Jolla, CA 92037 (US).			(81) Designated States: JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report.
(54) Title: A NEW SENSITIVE METHOD FOR QUANTIFYING ACTIVE TRANSFORMING GROWTH FACTOR-BETA AND COMPOSITIONS THEREFOR			
(57) Abstract The present invention describes a highly sensitive and specific non-radioactive quantitative assay method for quantifying transforming growth factor-beta (TGF- β) in a liquid sample. Also disclosed are TGF- β responsive expression vectors that express the indicator molecule, luciferase, in a dose-dependent response to TGF- β activation. Eucaryotic cells transformed with the disclosed expression vectors are also described. Diagnostic systems in the form of kits for quantifying the amount of TGF- β in a liquid sample using the disclosed methods and expression vectors are described.			

BEST AVAILABLE COPY

5

10

15

20

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

25

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

30

35

-1-

A NEW SENSITIVE METHOD FOR QUANTIFYING
ACTIVE TRANSFORMING GROWTH FACTOR-BETA
AND COMPOSITIONS THEREFOR

5 Technical Field

 The present invention relates to a sensitive assay method
for quantifying the amount of active transforming growth factor
beta (TGF- β) and vector compositions for use therein for
expressing an indicator molecule in response to TGF- β
0 activation of a TGF- β response element in the vector.

Background

 Transforming growth factor beta, hereinafter referred to
as TGF- β , is a 25 kilodalton (kD) homodimeric protein that
5 belongs to a family of regulators of cell growth and
differentiation that includes activins, inhibins, Mullerian
inhibiting substance, the Drosophila decapentaplegic complex
and bone morphogenic proteins. For review, see, Massague, Ann.
Rev. Cell Biol., 6:597-641 (1990); Roberts et al., In Peptide
0 Growth Factors and Their Receptors, Sporn et al., Eds.,
Springer-Verlag, Berlin, 1:419-472 (1990); and Hoffman, Curr.
Opin. Cell Biol., 3:947-952 (1991). TGF- β was initially
defined by its ability to induce morphological transformation
of fibroblastic cells in monolayer culture and stimulation of
5 colony formation in soft agar. Delarco et al., Proc. Natl.
Acad. Sci. USA, 75:4001-4005 (1978) and Todaro et al., Proc.
Natl. Acad. Sci. USA, 77:5258-5262 (1980).

 Three distinct molecular isoforms of TGF- β , the genes of
which are located on different chromosomes, have been
0 identified in mammals and are designated TGF- β 1, TGF- β 2 and
TGF- β 3. Derynck et al., Nature, 316:701-705 (1985); Hanks et
al., Proc. Natl. Acad. Sci. USA, 85:71-72 (1988); and Madisen
et al., DNA, 7:1-8 (1988). Each of the isoforms are first
synthesized as high molecular weight latent or inactive
5 precursor polypeptides that are then processed to 12.5 kD

monomers. Activation of the latent complex can occur through a variety of physiochemical or enzymatic treatments as well as in various tissue culture systems. For review, see Barnard et al., Biochim. Biophys. Acta., 1032:79-87 (1990). Two processed monomers then dimerize to form biologically active TGF- β .

The activation process must occur to allow binding of the dimerized TGF- β to the high affinity TGF- β receptors expressed on the surfaces of all normal cells and most all neoplastic cells. Tucker et al., Proc. Natl. Acad. Sci., USA, 81:6757-6761 (1984); Frolik et al., J. Biol. Chem., 259:10995-11000 (1984); Pircher et al., Biochem. Biophys. Res. Commun., 136:30-37 (1986).

Although some TGF- β activation systems generate the mature TGF- β in nanogram quantities, the majority liberate picogram amounts. These low concentrations, however, are sufficient to induce a variety of biological responses such as macrophage chemotaxis (Wahl et al., Proc. Natl. Acad. Sci., USA, 84:5788-5792 (1987)), inhibition of endothelial cell migration and proliferation (Heimark et al., Science, 233:1078-1080 (1986)), stimulation of extracellular matrix deposition (Ignatz et al., J. Biol. Chem., 261:4337-4345 (1986)) and decreased plasminogen activator (PA) activity as a result of decreased PA production (Laiho et al., J. Cell. Biol., 103:2403-2410 (1986) and Flaumenhaft et al., J. Cell. Physiol., 152:48-55 (1992)) along with increased secretion of its inhibitor, plasminogen activator inhibitor-1 (PAI-1) (Laiho et al., J. Biol. Chem., 262:17467-17474 (1987)).

PAI-1 is the primary inhibitor of both tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA), and as such is a potent anti-fibrinolytic molecule. PAI-1 synthesis by cultured cells in vitro is induced by a variety of molecules including cytokines, growth factors, hormones, and other agents such as endotoxin and phorbol myristate acetate. Nuclear transcription run-on assays demonstrate that the regulation of PAI-1 by many of these

-3-

agents, including TGF- β , occurs primarily at the level of transcription.

5 TGF- β released from platelets may be an important negative regulator of the fibrinolytic system of the vessel wall since the TGF- β in releasates of thrombin-activated platelets causes large increases in PAI-1 synthesis by endothelial cells. This increased PAI-1 synthesis may account for the resistance of platelet-rich thrombi to thrombolytic therapy. The accumulation of PAI-1 in the extracellular matrix in response to TGF- β protects matrix proteins from proteolytic degradation. Thus, the induction of PAI-1 by TGF- β may also play a role in both wound healing and fibrotic responses.

10 These and other biological effects of TGF- β activity have been used to develop a variety of semiquantitative and quantitative bioassays including those based on chondrogenesis, inhibition of DNA synthesis and cell growth, differentiation, migration or PA activity. Differentiation-based assays include the induction of cartilage specific proteoglycan expression (ED₅₀ = 5 ng/ml; 200 pM) (Ogawa et al., In Peptide Growth Factors, Barnes et al., Eds, Academic Press Inc., 198:317-327 (1991); Seyedin et al., Proc. Natl. Acad. Sci. USA, 82:2267-2271 (1985)) and inhibition of rat L6 myoblast differentiation (ED₅₀ = 0.2 ng/ml; 8 pM) (Florini et al., J. Biol. Chem., 261:16509-16513 (1986)). An ED₅₀ represents the half-maximal amount of factor required to produce an effect, activation or inhibition, on differentiation of target cells. The abbreviations ng/ml, pg/ml, nM and pM respectively stand for nanograms/milliliter, picograms/milliliter, nanomolar and picomolar. These assays are utilized primarily for studying differentiation rather than for quantification of TGF- β .

15 Assays based on TGF- β 's ability to inhibit DNA synthesis and cell growth in mink lung epithelial cells (MLE cells) (ED₅₀ = 10-20 pg/ml; 0.4-0.8 pM) (Lucas et al., In Peptide Growth Factors, Barnes et al., Eds, Academic Press Inc. 198:303-316 (1991) and Danielpour et al., J. Cell. Physiol., 138:79-86

(1989)), African green monkey kidney epithelial cells (ED_{50} = 1 ng/ml; 40 pM) (Holley et al., Proc. Natl. Acad. Sci. USA, 77:5989-5992 (1980)), rat hepatocytes (ED_{50} = 0.4 ng/ml; 16 pM) (Nakamura et al., Biochem. Biophys. Res. Comm., 133:1042-1050 (1985)), and fetal bovine heart endothelial cells (ED_{50} = 75-125 pg/ml; 3-5 pM) (Qian et al., Proc. Natl. Acad. Sci. USA, 89:6290-6294 (1992)) are sensitive but can be affected by a variety of molecules such as insulin, EGF, PDGF, and bFGF.

Migration and plasminogen activator (PA) activity assays have also been described. The migration of bovine aortic endothelial cells (BAEs) into a denuded area of a monolayer is inhibited by TGF- β (ED_{50} = 2 μ g/ml; 80 pM; sensitivity 10-20 pg/ml; 0.4-0.8 pM) (Sato et al., J. Cell Biol., 107:1199-1205 (1988); Sato et al., J. Cell Biol., 109:309-315 (1989); and Sato et al., J. Cell Biol., 111:757-763 (1990)). Migration of BAEs, however, can be simultaneously stimulated by endogenously or exogenously supplied bFGF that can abrogate TGF- β 's inhibitory effect (Sato et al., J. Cell Biol., 107:1199-1205 (1988)). The PA assay for measurement of TGF- β concentration is very sensitive and rapid (Flaumenhaft et al., J. Cell. Physiol., 152:48-55 (1992)). The assay is based on the ability of TGF- β to decrease PA activity of BAEs by inhibiting PA synthesis and secretion and by inducing expression of its inhibitor, PAI-1. This assay, however, is also sensitive to other molecules, such as bFGF, that can alter PA activity (Flaumenhaft et al., J. Cell. Physiol., 152:48-55 (1992) and Sato et al., J. Cell Biol., 107:1199-1205 (1988)). The ED_{50} of the assay varies from 1 to 35 pg/ml (0.04-1.4 pM) of TGF- β depending on differences in basal PA levels and sensitivity to TGF- β among primary BAE cultures.

The ability of TGF- β to stimulate PAI-1 expression has recently been used to study TGF- β receptors. Wrana et al., Cell, 71:1003-1014 (1992) transiently transfected a PAI-1 luciferase construct together with a human type II TGF- β receptor expression vector into TGF- β resistant MLE cells.

-5-

This luciferase construct contained a short, synthetic TGF- β response element based on the human PAI-1 promoter and was used to report functional expression of the receptor. Although only used to screen transfected mutant cell lines, this construct
5 appeared to be less sensitive to TGF- β than the constructs of this invention when transiently transfected into MLE cells, and no information was reported regarding its dose-responsiveness or specificity.

In another study of the TGF- β -stimulation of PAI-1
10 expression, Riccio et al., Mol. Cell. Biol., 12:1846-1855 (1992), transiently transfected TGF- β responsive cells with constructs containing varying regions of the 5'-flanking domain of the human PAI-1 gene to determine the transcription
15 regulatory mechanism used by TGF- β . All the constructs contained the gene encoding the enzyme chloramphenicol acetyltransferase to provide for an indirect determination of the transcriptional effect of the various constructs. With
this approach, a 67 base pair region that contained binding
20 sites for the two proteins, CCAAT-binding transcription factor-nuclear family I family and USF factor. Both sites were necessary to obtain TGF- β induction. The constructs, however, were not utilized in assays to determine dose-responsiveness nor measure the amount of TGF- β in a sample.

The most specific assays for TGF- β are the radioreceptor,
25 radioimmunoassay (RIA), and enzyme-linked immunosorbent assay (ELISA). Radioreceptor assays using a variety of cell types, such as A549 human lung carcinomas and murine AKR-213, have been described and have ranges of 125 pM/ml to 25 ng/ml (5 pM-1
nM) with ED₅₀ of approximately 0.5 ng/ml (20 pM). See,
30 Wakefield et al., J. Cell. Biol., 105:965-975 (1987); Sato et al., J. Cell Biol., 111:757-763 (1990); Lucas et al., In Peptide Growth Factors, Barnes et al., Eds, Academic Press Inc. 198:303-316 (1991) and O'Connor-McCourt et al., J. Biol. Chem.,
262:14090-14099 (1987). RIAs specific for TGF- β 1 and β 2 have
35 ED50s of 12 and 37 pM, respectively (Danielpour et al., J. Cell

5 Physiol., 138:79-86 (1989)). Others, using different
antibodies, describe the range of TGF- β 1 specific RIAs to be
6.25-200 ng/ml (0.25-8 nM), with a sensitivity of 2.4 ng/ml
(0.1 nM) (Lucas et al., In Peptide Growth Factors, Barnes et
al., Eds, Academic Press Inc. 198:303-316 (1991)). As
demonstrated by the differences in these results, the
affinities of the antibodies can greatly alter the sensitivity
of the assay.

10 Isoform-specific double antibody or sandwich ELISAs
(SELISA) are also very sensitive to the affinities of the
antibodies. One such assay, using two different monoclonal
antibodies specific for TGF- β 1, had a useful range of 0.63 to
40 ng/ml (0.025-16 nM) (Lucas et al., In Peptide Growth
Factors, Barnes et al., Eds, Academic Press Inc. 198:303-316
15 (1991)). Using a combination of isoform-specific turkey and
rabbit antibodies, Danielpour et al., J. Cell Physiol., 138:79-
86 (1989) created a SELISA with detection limits of 2-5 pg/well
(20-50 pg/ml; 0.8-2 pM). Although highly sensitive and
specific, SELISAs such as these are not readily available and
are expensive.

20 Although all of these other TGF- β assays can detect mature
TGF- β , the low concentrations (<2 pM) generated in various
biological systems make many of them impractical without prior
concentration of the sample. This can result in large losses
25 of the mature growth factor or more importantly activation of
latent TGF- β . Moreover, many of the assays are complicated to
establish and can be influenced by other factors present in the
samples thus reducing their utility for accurately measuring
the amount of TGF- β in the sample. For this reason, a need
30 exists for a relatively simple, sensitive and nonconfounding
assay for TGF- β .

Brief Description of the Invention

35 A highly sensitive and specific, non-radioactive assay,
for mature (active) TGF- β has now been developed. When

compared to the sensitive and widely used proliferation-based MLEC method for measuring TGF- β concentration, the TGF- β assay method of this invention is more rapid, has comparable sensitivity, and has a greater detection range. Specificity of this novel assay was also higher as evidenced by its relative insensitivity to factors such as EGF and bFGF which can greatly affect other assays. The use of a truncated PAI-1 promoter that does not respond to other growth modulators such as PDGF found in biological samples, the method of this invention can be used in conditions where other bioassays are difficult to interpret. Because of its large range and specificity, the rapid, sensitive, non-radioactive, easily performed assay method of this invention is useful in determining active TGF- β concentrations in complex solutions.

Thus, the present invention overcomes the limitations of existing methods used to quantify the amount of TGF- β in a liquid sample. This invention contemplates a method for quantifying the amount of TGF- β in a sample using a system comprising a TGF- β responsive cell containing an expression vector having a regulatory region comprising a TGF- β response element operatively linked to a promoter and having a structural region encoding an indicator molecule. Following TGF- β induced activation of the TGF- β response element, transcription results in the expression of an indicator molecule, the amount of which allows for the measurement of the amount of TGF- β responsible for the induced activation.

In particular, in one embodiment of the invention contemplates a method for quantifying the amount of TGF- β in a liquid sample, which method comprises:

- (a) incubating the liquid sample together with eucaryotic cells that contain a TGF- β responsive expression vector having a gene encoding luciferase for a predetermined time period sufficient for the eucaryotic cells to express a detectable amount of the luciferase;
- (b) measuring the amount of the luciferase expressed

during the time period; and

(c) determining the amount of TGF- β present in the sample by comparing the measured amount of the luciferase against a reference curve.

5 The invention further contemplates that the reference
curve represents a quantitative relationship derived from a
series of measured amounts of luciferase produced from a series
of known concentrations of TGF- β . 5

10 Another embodiment of the invention contemplates a method
for quantifying the amount of transforming growth factor- β
(TGF- β) in a liquid sample comprising: 10

15 (a) providing, in eucaryotic cells capable of expressing
an indicator molecule, a plasmid comprising, in the direction
of transcription, a regulatory region that includes at least
one TGF- β inducible response element that is operatively linked 15
to a promoter, and a structural region downstream of the
promoter, where the response element is capable of inducing
dose-dependent indicator molecule activity and where the
structural region codes for the indicator molecule;

20 (b) incubating the liquid sample with the eucaryotic
cells for a predetermined time period sufficient for the
eucaryotic cells to express a detectable amount of the
indicator molecule; 20

25 (c) measuring the amount of the indicator molecule
expressed during the time period; and 25

30 (d) comparing the measured amount of the indicator
molecule produced in step (c) with the amount of indicator
molecule produced in a control assay performed according to
steps (a) through (c) by treating the liquid sample with an
anti-TGF- β antibody to obtain a net measured amount of the 30
indicator molecule induced by TGF- β .

35 Contemplated for use with the methods of this invention
are plasmids having identifying characteristics of plasmids on
deposit with ATCC having the ATCC Accession Numbers 75627,
75628 and 75629. Also contemplated are stably transformed 35

eucaryotic cells that contain the TGF- β response element having the nucleotide sequence in SEQ ID NO 11 where the cells correspond to cells on deposit with ATCC having the ATCC Accession Number CRL 11508.

5 The invention describes plasmids for use in the methods that comprise a nucleotide sequence corresponding to nucleotide sequences listed in SEQ ID NOS 1-10. TGF- β inducible response elements that comprise a nucleotide sequence corresponding to nucleotide sequences listed in SEQ ID NOS 11-17 are also
10 described. Contemplated promoter nucleotide sequences are listed in SEQ ID NOS 18 and 19.

 A further embodiment of the methods of the invention are eucaryotic cells that are stably transformed cells containing a plasmid having a gene encoding a selectable marker for the
15 selection of said stably transformed cells. The invention describes such plasmids having nucleotide sequences listed in SEQ ID NOS 1-6. The invention further describes a stably
transformed eucaryotic cell on deposit with ATCC having ATCC
Accession Number CRL 11508 containing the TGF- β response
20 element having the nucleotide sequence in SEQ ID NO 11.

 An additional embodiment are eucaryotic cells that are transiently transformed cells with plasmids corresponding to the nucleotide sequences listed in SEQ ID NOS 7-10.

 The invention describes quantifying the amount of TGF- β in
25 a body fluid, in culture medium, and in a tissue extract. A further preferred embodiment is the determination of the amount of a specific isoform of TGF- β , specifically TGF- β 1, TGF- β 2 or TGF- β 3, in a liquid sample.

 In a preferred embodiment, this invention describes the
30 use of mammalian cells. Preferred mammalian cells include mink lung epithelial cells, HeLa cells, Chinese hamster ovary cells, Hep3B cells, GM7373 cells, and NIH 3T3 cells.

 A preferred indicator molecule also described for use with the methods of this invention is a chemiluminescent molecule,
35 preferably luciferase.

The invention describes a composition of a plasmid vector in capable of causing expression of an indicator molecule in a eucaryotic cell, where the plasmid contains nucleotide sequences comprising a regulatory region that includes at least one TGF- β inducible response element operatively linked to a promoter, a structural region downstream of said promoter and coding for said indicator molecule, and a gene encoding a selectable marker for the selection of a stably transformed cell, where the response element is capable of inducing dose-dependent luciferase activity.

In preferred embodiments, plasmids with selectable marker genes have the nucleotide sequences corresponding to SEQ ID NOS 1-6. Preferred TGF- β inducible response elements for use in the expression vectors of this invention have the nucleotide sequences corresponding to SEQ ID NOS 11-17.

A further preferred embodiment of the expression vectors of this invention is the use of the neomycin gene for selecting stable transformants, the nucleotide sequence of which is listed in SEQ ID NO 20.

The invention further describes plasmids lacking a selectable marker gene having the identifying characteristics of plasmid ATCC Accession Numbers 75627, 75628, 75629, corresponding to SEQ ID NOS 8-10, respectively.

The invention describes a eucaryotic cell containing a plasmid having a nucleotide sequence listed in SEQ ID NOS 1-10.

Kits useful in assaying the amount of TGF- β in a liquid sample comprising (a) packaging material; (b) eucaryotic cells capable of expressing an indicator molecule and containing a plasmid of this invention and an aliquot of TGF- β , where the latter is used for generating a reference curve.

Other embodiments will be apparent to one skilled in the art.

Brief Description of the Drawings

Figure 1 shows the structure and construction of the

-11-

p800neoLuc expression vector. p800Luc was digested with AccI and blunt-ended. pMAMneo was then digested with Sal I and Eco RI, blunt-ended, and the fragment containing the neomycin-resistance gene (neo^r) was ligated to the linearized p800Luc to form p800neoLuc. Clones were analyzed via restriction enzyme mapping and one clone with the proper insert was selected. (MCS, multiple cloning site; PA1, 2, 3, polyadenylation regions 1, 2, and 3). The details of the construction are described in Example 1A.

Figure 2A, having an inset (Figure 2B), shows the dose-dependent induction of the plasminogen activator inhibitor-1/luciferase (PAI/L) construct in p800neoLuc expression vector in stably transformed MLE cells by TGF- β 1, TGF- β 2, and TGF- β 3. The TGF- β assay was performed as described in Example 3 with DMEM-BSA containing the indicated concentrations in picomoles (pM) of recombinant (r) TGF- β 1 (closed squares), TGF- β 2 (closed circles), or TGF- β 3 (closed triangles) on the X-axis. The amount of expressed luciferase detected by a luminometer is plotted on the Y-axis and is expressed in relative light units (RLU). The results shown in Figures 2A, 2B and 2C are described in Example 3B. Figure 2B shows the treatment of p800neoLuc-transformed MLE cells with all three TGF- β isoforms in a TGF- β assay that resulted in a linear dose-response over the range of 0 to 4 pM of TGF- β . In Figure 2C, the TGF- β assay was performed with 8 pM rTGF- β 1, TGF- β 2 or TGF- β 3 in DMEM-BSA in the presence (cross-hatched bars) or absence (open bars) of 100 μ g/ml of anti-TGF- β , TGF- β 2 and TGF- β 3 monoclonal antibody. Baseline induction is indicated by medium alone (filled bars).

Figures 3A, 3B, 3C and 3D show the effects of medium, cell density and incubation time on sensitivity of the TGF- β assay as described in Example 3B with the amount of TGF- β 1 plotted on the X-axis in pM against the measured RLU on the Y-axis. In Figure 3A, the assay was performed with increasing rTGF- β 1 concentrations in DMEM (closed squares), alpha-MEM (closed circles), CMEM (closed triangles: Eagles MEM supplemented with

-12-

non-essential amino acids) or RPMI-1640 (closed diamonds: Bio-Whittaker). All media contained 0.1% BSA. In Figure 3B, increasing concentrations of rTGF- β 1 in DMEM, 0.1% BSA were measured using 3.2×10^4 (closed squares), 1.6×10^4 (closed circles), or 0.8×10^4 (closed triangles) clone 32 (C32) of
5 mink lung epithelial cells/well (MLE cells) after a three hour attachment period. Samples were incubated with the cells for 14 hours prior to assaying for luciferase activity. In Figures 3C and 3D (an inset in Figure 3C), 1.6×10^4 C32 cells were
10 allowed to attach for 3 hours prior to addition of the indicated concentrations of rTGF- β 1. The samples were incubated for 6 (closed squares), 14 (closed circles), or 22 (closed triangles) hours prior to assaying for luciferase activity. The results are described in Example 3B.

15 Figures 4A and 4B show the effects of growth factors on the TGF- β assay and MLEC assay while Figure 4C shows the effects caused by serum. For all figures, either the growth factors or TGF- β are plotted on the X-axis against the RLU on the Y-axis. In Figure 4A, the TGF- β assays were performed with
20 DMEM-BSA containing the indicated concentrations of rTGF- β 1 (closed squares), recombinant human bFGF (closed circles), recombinant IL-1 α (closed triangles), recombinant PDGF-BB (closed diamonds), or EGF (open squares). In Figure 4B, TGF- β assays were performed with DMEM-BSA containing 1 pM rTGF- β 1
25 (closed squares) and the indicated concentrations of recombinant human bFGF (closed circles), recombinant IL-1 α (closed triangles), recombinant PDGF (closed triangles), or EGF (open squares). The assays and results are described in Example 3C. In Figure 4C, TGF- β assays were performed with
30 DMEM-BSA containing the indicated concentrations of rTGF- β 1 alone (closed squares) or with 0.5% (closed circles), 1% (closed triangles), or 2% (closed diamonds) calf serum. The assays and results are described in Example 3D.

35 Figure 5 shows the comparison of CMs assayed by the TGF- β (shown as the PAI/L assay) and MLEC assays. DMEM BSA (closed

-13-

5 squares), COS (X-marked lines), BSM (closed triangles) or BAE (closed circles) cell conditioned medium (CM) with the indicated concentrations of rTGF- β 1 were assayed by PAI/L (TGF- β) assay (broken line) as measured by RLU on the right-hand Y-axis and MLEC (unbroken line) assay as measured by tritiated thymidine (3 H-thymidine) incorporation percent of controls described in Example 3E. The data points were normalized to DMEM-BSA.

10 Figure 6 shows the effects of growth factors on DNA synthesis as measured by 3 H-thymidine incorporation percent of control. In the graph, DMEM-BSA containing rTGF- β 1 (closed squares), TGF- β 2 (closed circles), TGF- β 3 (closed triangles), recombinant human bFGF (closed diamonds), recombinant IL-1 α (open squares), EGF (open circles), or recombinant PDGF-BB (open triangles) were separately assayed using the MLEC assay as described Example 3C.

Detailed Description of the Invention

A. Definitions

20 Recombinant DNA (rDNA) Molecule: A DNA molecule produced by operatively linking two DNA segments. Thus, a recombinant DNA molecule is a hybrid DNA molecule comprising at least two nucleotide sequences not normally found together in nature. rDNA's not having a common biological origin, i.e., evolutionarily different, are said to be "heterologous".

25 Vector: A rDNA molecule capable of autonomous replication in a cell and to which a DNA segment, e.g., gene or polynucleotide, can be operatively linked so as to bring about replication of the attached segment. Vectors capable of directing the expression of genes encoding for one or more polypeptides are referred to herein as "expression vectors".

30 Upstream: In the direction opposite to the direction of DNA transcription, and therefore going from 5' to 3' on the non-coding strand, or 3' to 5' on the mRNA.

35 Downstream: Further along a DNA sequence in the direction

of sequence transcription or read out, that is traveling in a 3'- to 5'-direction along the non-coding strand of the DNA or 5'- to 3'-direction along the RNA transcript.

Reading Frame: Particular sequence of contiguous
5 nucleotide triplets (codons) employed in translation that
define the structural protein encoding-portion of a gene, or
structural gene. The reading frame depends on the location of
the translation initiation codon.

Response Element: Also referred to as an enhancer
10 element, is a short DNA sequence that occurs further upstream
than the upstream promoter element. Response elements contain
specific nucleotide sequences recognized by transcription
factors that are DNA-binding proteins.

Promoter: A region on a DNA molecule, generally from 100
15 to 200 base pairs long, upstream from the coding sequence; an
area to which the RNA polymerase initially binds prior to the
initiation of transcription. The nucleotide sequence of the
promoter, or at least part of it, determines the nature of the
polymerase that associates with it. Certain consensus
20 sequences, CAT and TATA boxes, with the promoter region are
important for binding of RNA polymerase.

Regulatory Region: A DNA control module upstream from the
coding sequence containing an upstream promoter element and
response elements, the latter of which is also referred to as
25 enhancer elements.

Growth Factor: A small protein that binds to a receptor
for controlling cell proliferation.

Receptor: A molecule, such as a protein, glycoprotein and
the like, that can specifically (non-randomly) bind to another
30 molecule. Receptors of one type are plasma membrane proteins
that bind specific molecules including growth factors,
hormones, or neurotransmitters, resulting in the transmission
of a signal to the cell's interior causing the cell to respond
in a specific manner.

35 Sense Strand: A nucleotide sequence referred to as a

5

10

15

20

25

30

35

sense strand of a double-stranded deoxyribonucleic acid sequence is the nucleotide sequence that when read in the 5' to 3' direction by the genetic code defines an amino acid sequence of interest. Alternatively, sense strand is referred to as a coding strand.

B. Transforming Growth Factor- β (TGF- β)

Transforming growth factor- β , hereinafter referred to as TGF- β , is a growth inhibitor that exhibits a diversity of biological activities in addition to its effects on cellular proliferation. TGF- β belongs to a large family of related molecules with a wide range of regulatory activities as described in the Background. For review, see Barnard et al., Biochim. Biophys. Acta., 1032:79-87 (1990), the disclosure of which is hereby incorporated by reference.

As previously discussed, TGF- β is produced and secreted from cells in three distinct molecular isoforms of TGF- β , the genes of which are located on different chromosomes, have been identified in mammals and are designated TGF- β 1, TGF- β 2 and TGF- β 3. Derynck et al., Nature, 316:701-705 (1985); Hanks et al., Proc. Natl. Acad. Sci., USA, 85:71-72 (1988); and Madisen et al., DNA, 7:1-8 (1988). Each of the isoforms are synthesized as high molecular weight latent or inactive precursor polypeptides that are then processed to 12.5 kD monomers that then dimerize to form biologically active, also referred to as mature, TGF- β .

The activation process must occur to allow binding of the dimerized TGF- β to the high affinity TGF- β receptors expressed on the surfaces of all normal cells and most all neoplastic cells. Tucker et al., Proc. Natl. Acad. Sci., USA, 81:6757-6761 (1984); Frolik et al., J. Biol. Chem., 259:10995-11000 (1984); Pircher et al., Biochem. Biophys. Res. Commun., 136:30-37 (1986).

TGF- β has been shown to induce the increase secretion of the inhibitor, plasminogen activator inhibitor-1 (PAI-1) (Laiho

-16-

et al., J. Biol. Chem., 262:17467-17474 (1987)). PAI-1 is the primary inhibitor of both tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA), and as such is a potent anti-fibrinolytic molecule. As a consequence of PAI-1 induction by TGF- β , the activity of plasminogen activator (PA) is decreased. The resulting cascade of activation of plasminogen to plasmin is thereby inhibited resulting in the subsequent degradation of fibrin.

While PAI-1 synthesis by TGF- β has been shown to occur primarily at the level of transcription following the TGF- β receptor-ligand interaction, the mechanism of activation of the PAI-1 promoter resulting in the transcription of the PAI-1 gene is less well understood. Studies of PAI-1 gene transcription have shown that the signal transduction mechanisms are independent of de novo protein synthesis as determined by the lack of inhibition by cycloheximide and rapid onset of induction as described by Sawdey et al., J. Biol. Chem., 264:10396-10401 (1989), the disclosure of which is hereby incorporated by reference. The TGF- β -induced enhancement of promoter activity for the α_2 collagen gene has been shown to be mediated by a binding site for nuclear factor I as described by Sporn et al., J. Cell Biol., 105:1039-1045 (1987).

As shown in Example 4, the PAI-1 promoter contains AP-1-like nucleotide sequences which is bound by the AP-1 heterodimeric transcription factor complex of Fos and Jun protein subunits. Although AP-1-like DNA enhancer sites are present in PAI-1, as shown in Example 4, activation of these sites by the AP-1 heterodimeric complex was independent of the TGF- β -mediated induction of PAI-1 synthesis.

Although the exact transcriptional mechanism of PAI-1 promoter activation following TGF- β receptor-ligand interaction is not known as well as the identification of the responsible TGF- β -related transcription factor, the activation of a TGF- β response element of this invention following TGF- β occupancy of the TGF- β receptor will be referred to as TGF- β -induced

-17-

activation. Since the TGF- β response element is activated by TGF- β resulting in the induction of indicator protein expression, the TGF- β response element is also referred to as a TGF- β inducible response element

5

C. TGF- β Response Elements

The present invention is based on the discovery that when eucaryotic cells, transformed with a TGF- β -responsive expression vector of this invention, were exposed to liquid samples of TGF- β , the resulting expression of an indicator molecule was dose-dependent in relationship to the amount of TGF- β present in the sample. Thus, the present invention provides for a method to quantify the amount of TGF- β in an liquid sample by measuring the amount of indicator molecules expressed.

15

The induced expression of the indicator molecules was the result of activation of TGF- β response elements present in the regulatory region of the TGF- β responsive expression vectors, the latter of which are described in Section D.

20

In practicing this invention, the regulation of transcription in the TGF- β responsive expression vector-transformed eucaryotic cells is dependent TGF- β . As described above, the TGF- β occupation of the TGF- β receptor expressed on the surface of cells results in the activation of a TGF- β -related transcription factor. In general, transcription factors are site-specific DNA-binding proteins. Typically, usually positioned 5' to a structural gene is a region of nucleotide sequences that are responsible for controlling transcription. This region has been coined the "control module".

25
30

The control module comprises two categories of regulatory sequences, the promoter element and the enhancer elements. The promoter is referred to as an upstream promoter as it lies upstream of the structural genes. Promoter elements are usually 100 to 200 base pairs long and the segment of DNA is

35

-18-

relatively close to the site of initiation of transcription. A particular sequence recognized by one of several transcription factors that are known to bind to the promoter region is the TATA box, a region that is rich in A-T base pairs.

5 The enhancer regions are also referred to as response regions or response elements. Thus the term "TGF- β response element" can also be designated "TGF- β enhancer", "TGF- β enhancer region", or "TGF- β response region", and the like. The enhancer region is hereinafter referred to as a response
10 element. They are short DNA segments that occur further upstream from the initiator site than the upstream promoter element. Response elements contain specific sequences that are recognized by transcription factors. The response elements are often a few 1000 base pairs 5' to the promoter but may even be
15 20,000 base pairs or more distant.

The binding of a transcription factor to either a nucleotide sequence comprising a response element or promoter resembles an "on switch". In the context of the present invention, the binding of the TGF- β -related transcription
20 factor results in the dose-dependent activation of the promoter resulting in the transcription of a structural region gene from DNA into RNA. In most cases, the resulting RNA molecule serves as a template for synthesis of a specific molecule, such as the indicator molecule of this invention.

25 Thus, "activation" of a TGF- β response element refers to a process whereby the functional state of the TGF- β response element is altered. The result of the TGF- β activation of the TGF- β response element is an increase in the transcriptional efficiency of the structural gene driven from the promoter.

30 A further embodiment of a TGF- β response element is that it is inducible. The term "inducible" refers to a an enhancement of a particular function. In this invention, the functional activity of a TGF- β response element is increased or induced following activation by the TGF- β -related transcription
5 factor. Thus, the TGF- β response element is also referred to

5

10

15

20

25

30

35

i:
m

-19-

as a TGF- β inducible response element.

The result of TGF- β response element activation is the coordinate transcription and translation of the structural region containing a gene encoding an indicator protein of this invention as described in Section D. The resulting expression
5 of an indicator molecule is dose-dependent in relationship to the amount of TGF- β present in the sample.

The term "dose-dependent" refers to the functional relationship between the amount of TGF- β activating the TGF- β
10 response element and the resulting expression of the indicator molecule. Thus, the functional relationship between TGF- β activation and expression of an indicator molecule can be referred to as a linear relationship. Because of the dose-dependent expression of an indicator molecule, such as
15 luciferase, in response to TGF- β exposure, the amount of TGF- β responsible for the activation of the expression can be readily determined using the methods of this invention.

Thus, based on the teachings herein, a TGF- β response element nucleotide sequence is characterized by its ability to
20 be responsive to TGF- β -induced activation. Such a TGF- β response element is useful herein as a component in the expression vectors of this invention to provide for the ability to quantify the amount of TGF- β responsible for the transcriptional activation. Thus, a TGF- β response element of
25 this invention comprises any nucleotide sequence that is activated by TGF- β , the process of which is as described in Section B.

In the context of this invention, the term nucleotide sequence refers to a plurality of joined nucleotide units
30 formed from naturally- or non-naturally occurring bases and cyclofuranosyl groups joined by phosphodiester bonds. Thus, the nucleotide sequence includes the use of nucleotide analogs.

One embodiment of a TGF- β response element of this invention is an isolated double-stranded deoxyribonucleic acid
35 molecule comprising a sequence of nucleotide bases that defines

-20-

5 a TGF- β response element. However, neither is it necessary
that the obtained TGF- β be a naturally occurring sequence
present in the other genes nor that the TGF- β response element
be limited to deoxyribonucleotides. The TGF- β response element
may be found in DNA or RNA, in regulatory sequences, exons, or
introns.

Preferred TGF- β response elements are derived from
selected regions of the promoter regions of the plasminogen
activator inhibitor type 1 gene, hereinafter referred to as
10 PAI-1, as described by Loskutoff et al., Biochem., 26:3763-3768
(1987), the disclosure of which is hereby incorporated by
reference. Loskutoff et al. describes a cosmid containing the
entire PAI-1 gene. In a related study, the glucocorticoid
regulation of the PAI-1 promoter was described by van Zonneveld
15 et al., Proc. Natl. Acad. Sci., 85:5525-5529 (1988), the
disclosure of which is hereby incorporated by reference. The
sequence of the PAI-1 promoter corresponding to nucleotide
positions -800 and extending through the TATA box and
initiation site and ending at nucleotide position +200, the
20 latter of which corresponds to the PAI-1 encoded protein at the
ninth amino acid residue, is available in the GenBank™/EMBL
Data Bank with Accession Number J03836.

Moreover, Bosma et al., J. Biol. Chem., 263:9129-9141
(1986), have described the entire 15,867 bp PAI-1 gene sequence
25 including significant stretches of DNA that extend into its 5'-
and 3'-flanking DNA regions, the nucleotide sequence of which
is available in the GenBank™/EMBL Data Bank with Accession
Number J03764.

The PAI-1 promoter-derived TGF- β response elements for use
30 in this invention are identified by the nucleotide positions
corresponding to the region in the PAI-1 promoter as listed in
the GenBank™/EMBL Data Bank Accession Number J03836.

Exemplary TGF- β response elements derived from the PAI-1
promoter have the nucleotide sequences listed in the Sequence
35 Listing in SEQ ID NOS 11-17. The nucleotide sequences are

-21-

listed showing only the sense strand in the 5' to 3' direction of a double-stranded isolated TGF- β response element nucleotide sequence. The PAI-1-derived TGF- β response elements corresponding to SEQ ID NOs 11-17 have the respective

5 designations with the nucleotide regions corresponding to the PAI-1 promoter indicated in parentheses: 1) SEQ ID NO 11 = 1500 (-1481 to -40); 2) SEQ ID NO 12 = 800 (-800 up to -40); 3) SEQ ID NO 13 = 800/636 (-800 up to -636); 4) SEQ ID NO 14 = 56 (-56 to -41); 5) SEQ ID NO 15 = 674 (-674 to -650); 6) SEQ ID

10 NO 16 = 743 (-743 to -708); and 7) SEQ ID NO 17 = 732 (-732 to -708).

In one embodiment, a TGF- β response element useful for practicing the present invention may be derived from any promoter nucleotide sequence. In a further embodiment, a TGF- β

15 response element may be designed to contain preselected nucleotide bases. In other words, a subject TGF- β response element need not be identical to the nucleotide sequence of the PAI-1-derived TGF- β response elements described herein, so long as the nucleotide sequence is activatable by TGF- β .

20 A TGF- β response element of this invention thus may contain a variety of nucleotide units of any length, typically from about 5 to about 2000 nucleotides in length. More preferably, a TGF- β response element comprises nucleotide units from about 15 to about 1500 nucleotides in length.

25 A preferred embodiment is a TGF- β response element having nucleotide sequences that is greater than 50 base pairs in length. Exemplary long TGF- β response elements derived from PAI-1 are listing in the Sequence Listing in SEQ ID NOs 11-13.

30 A preferred embodiment is a TGF- β response element having nucleotide sequences that is less than 50 base pairs in length. Exemplary short TGF- β response elements derived from PAI-1 are listing in the Sequence Listing in SEQ ID NOs 14-17.

In one embodiment, the invention contemplates the presence of at least one TGF- β response element present in the

35 regulatory region of the expression vectors as described in

-22-

Section D. Thus, one or more stretches of a nucleotide sequence comprising a TGF- β response element may be present within a regulatory region. If more than one TGF- β response element is present, they are not required to be identical. In other words, TGF- β response elements having different nucleotide sequences as well as different lengths can be combined in a regulatory region of an expression vector of this invention.

TGF- β response elements can be derived or produced from the PAI-1 promoter by truncation or expansion of the native or wild-type PAI-1 promoter nucleotide sequence or as a variant of the native PAI-1 promoter by site-directed substitution of a preselected nucleotide base or bases.

Also contemplated in this context are regulatory regions containing multiple TGF- β response elements that can be either longer, shorter, tandemly arranged, reversed in orientation, and permutations thereof. The design and construction of such arrangements are well known to one of ordinary skill in the art of oligonucleotide design and synthesis and are described by Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Laboratory, pp 390-401 (1982).

It is also contemplated that nucleotide base modifications can be made resulting in nucleotide analogs to provide certain advantages to the TGF- β response elements of this invention.

A nucleotide analog refers to moieties that function similarly to nucleotide sequences in a TGF- β response element of this invention but which have non-naturally occurring portions. Thus, nucleotide analogs can have altered sugar moieties or inter-sugar linkages. Exemplary are the phosphorothioate and other sulfur-containing species, analogs having altered base units, or other modifications consistent with the spirit of this invention.

Preferred modifications include, but are not limited to, the ethyl or methyl phosphonate modifications disclosed in the U.S. Patent No., 4,469,863 and the phosphorothioate modified

-23-

deoxyribonucleotides described by LaPlanche et al., Nucl. Acids Res., 14:9081 (1986) and Stec et al., J. Am. Chem. Soc., 106:6077 (1984), the disclosures of which are hereby incorporated by reference. These modifications provide resistance to nucleolytic degradation. Preferred modifications are the modifications of the 3'-terminus using phosphothionate (PS) sulfurization modification described by Stein et al., Nucl. Acids Res., 16:3209 (1988).

TGF- β response elements comprising nucleotide sequences can be obtained by a variety of procedures well known in the art, including de novo chemical synthesis of complementary oligonucleotides and derivation of nucleic acid fragments from native nucleic acid sequences existing as genes, or parts of genes, in a genome, plasmid, or other vector, such as by restriction endonuclease digestion of larger nucleic acid fragments and strand separation or by enzymatic synthesis using a nucleic acid template.

De novo chemical synthesis of oligonucleotides can be carried out, for example, by the phosphotriester method described by Matteucci et al., J. Am. Chem. Soc., 103:3185 (1981), or as described in U.S. Patent No. 4,356,270, the disclosures of which are hereby incorporated by reference. A particularly preferred method is the phosphoramidite method using commercial automated synthesizers, such as the ABI automated synthesizer by Applied Biosystems, Inc., (Foster City, CA). Oligonucleotides can be purified after synthesis using published procedures as described by Miller et al., J. Biol. Chem., 255:9659 (1980). Thereafter, complementary oligonucleotides are hybridized to form double-stranded DNA segments that are TGF- β response elements. Particularly preferred chemically-synthesized oligonucleotides are described in Example 1C and the sense strands of which are listed in SEQ ID NOs 14-17, as described above.

Derivation of a TGF- β response element from nucleic acids involves the cloning of a nucleic acid into an appropriate host

by means of a cloning vector, replication of the vector and therefore multiplication of the amount of the cloned nucleic acid followed by isolation of subfragments of the cloned nucleic acids. For a description of subcloning nucleic acid fragments, see Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Laboratory, pp 390-401 (1982); and see U.S. Patent Nos 4,416,988 and 4,403,036.

In one embodiment, TGF- β response elements are obtained by restriction digestion of cloned vectors containing the PAI-1 promoter as described in Example 1A and 1C. Particularly preferred nucleotide sequences containing TGF- β response elements as well as the minimal promoter sequence obtained in this manner include nucleotide sequences corresponding to the nucleotide positions in the PAI-1 promoter sequence from -1481 to +76, specifically a Kpn I/Eco RI digest and -800 to +76, specifically a Hind III/Eco RI digest.

In an additional embodiment, in the practice of this invention, it is not necessary that the TGF- β response element nucleotide sequence be known in order to obtain a TGF- β response element capable of being activated by TGF- β . To that end, contemplated for use in this invention are TGF- β response elements obtained from promoter regions of other genes that can be determined to contain TGF- β response elements using the methods of this invention.

D. TGF- β Responsive Plasmid Expression Vectors

The present invention contemplates TGF- β responsive plasmid expression vectors in substantially pure form capable of causing expression of an indicator molecule in a eucaryotic cell. The term "TGF- β responsive" identifies an expression vector of this invention that by its composition contains TGF- β response elements that are activated by TGF- β mediated through a TGF- β response element specific transcription factor as described in Section C. Vectors capable of directing the expression of genes to which they are operatively linked are

referred to herein as "expression vectors".

As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting between different genetic environments another nucleic acid to which it has been
5 operatively linked. One type of preferred vector is an episome, i.e., a nucleic acid capable of extra-chromosomal replication. Preferred vectors are those capable of autonomous replication and/or expression of nucleic acids to which they are linked.

10 A TGF- β expression vector of this invention is a circular double-stranded plasmid that contains at least the following elements: 1) a regulatory region having at least one TGF- β response element as defined in Section C, where the regulatory region is operatively linked to a promoter; and 2) a structural
15 region downstream of the promoter that contains a gene coding for an indicator molecule of this invention.

In a separate embodiment, a TGF- β expression vector also contains a gene, the expression of which confers a selective advantage, such as a drug resistance, to the eucaryotic host
20 cell when introduced or transformed into those cells. A typical eucaryotic drug resistance genes confers resistance to neomycin, also referred to as G418 or Geneticin.

The choice of vector to which the regulatory region, promoter, and structural region of the present invention is
25 operatively linked depends directly, as is well known in the art, on the functional properties desired, e.g., replication or protein expression, and the host cell to be transformed, these being limitations inherent in the art of constructing recombinant DNA molecules.

30 In preferred embodiments, the vector utilized includes procaryotic sequences that facilitate the propagation of the vector in bacteria, i.e., a DNA sequence having the ability to direct autonomous replication and maintenance of the recombinant DNA molecule extra-chromosomally when introduced
35 into a bacterial host cell. Such replicons are well known in

the art. In addition, the TGF- β expression vector of this invention includes one or more transcription units that are expressed only in eucaryotic cells.

5 The eucaryotic transcription unit consists of noncoding sequences and sequences encoding selectable markers. The expression vectors of this invention also contain distinct sequence elements that are required for accurate and efficient polyadenylation, referred to as PA1, 2 and 3 and as shown in Figure 1. In addition, splicing signals for generating mature
10 mRNA are included in the vector. The eucaryotic TGF- β responsive expression vectors contain viral replicons, the presence of which provides for the increase in the level of expression of cloned genes. A preferred replication sequence is provided by the simian virus 40 or SV40 papovavirus.

15 Operatively linking refers to the covalent joining of nucleotide sequences, preferably by conventional phosphodiester bonds, into one strand of DNA, whether in single- or double-stranded form. Moreover, the joining of nucleotide sequences results in the joining of functional elements such as response
20 elements in regulatory regions with promoters and downstream structural regions as described herein.

A preferred eucaryotic expression vector of this invention as prepared in Example 1 contains a regulatory region having TGF- β response elements derived from the 5' promoter end of the
25 human plasminogen activator inhibitor type 1 (PAI-1) gene operatively linked to PAI-1 minimal promoter and a downstream structural region containing a gene coding for an indicator polypeptide, preferably luciferase.

30 Exemplary TGF- β responsive expression vectors include the following expression vectors, the designations of which are indicated along with the corresponding SEQ ID NO in which the sense strand of the expression vector is listed where the first nucleotide of the double-stranded circular vector is the middle "T" nucleotide present in the Eco RI restriction site as
35 described in Example 1: 1) p800neoLuc (SEQ ID NO 1); 2)

p8
p6
p7
(S
5 ID
ar
de
se
10 ve
of
ar
in
15 de
de
cc
re
Th
20 or
pr
pr
TG
qu
25 me
de
pr
ve
30 Cl
Yc
La

-27-

p800/636neoLuc (SEQ ID NO 2); 3) p56neoLuc (SEQ ID NO 3); 4) p674neoLuc (SEQ ID NO 4); 5) p743neoLuc (SEQ ID NO 5); 6) p732neoLuc (SEQ ID NO 6); 7) p56Luc (SEQ ID NO 7); 8) p674Luc (SEQ ID NO 8); 9) p743Luc (SEQ ID NO 9); and 10) p732Luc (SEQ ID NO 10).

The exemplary TGF- β expression vectors of this invention are derived from the starting cloning expression vector, designated p19Luc, as described in Example 1. The nucleotide sequence of the sense strand of an Eco RI-linearized p19Luc vector is listed in the Sequence Listing as SEQ ID NO 21.

A further embodiment of this invention is the preparation of TGF- β responsive expression vectors having altered arrangements of and selected types of TGF- β response elements in the regulatory region. To that end, p19Luc and the p19Luc-derived p39Luc expression cloning vectors, both of which is described in Example 1, are vectors that allow for the construction of TGF- β responsive vectors having any selected regulatory region operatively ligated to a selected promoter. Therefore, any regulatory region of any length containing one or more TGF- β response elements can be paired with any promoter, a non-TGF- β responsive PAI-1 or heterologous HBV promoter as used herein but not limited to that, to prepare TGF- β responsive expression vectors that provide for the quantitation of inducing TGF- β .

In a related embodiment, in addition to the construction methods detailed herein, other methods of preparing p19Luc-derived expression vectors having TGF- β response elements and promoters are familiar to one of ordinary skill in the art of vector construction and are described by Auebel, et al., In Current Protocols in Molecular Biology, Wiley and Sons, New York (1993) and by Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, 1989.

1. Plasmid Vectors for Stable Transformations

In practicing one aspect of this invention, a

preferred embodiment is a TGF- β responsive expression vector having a gene for encoding a selectable marker providing for stably transformed cells. Stably transformed cells confer the ability to utilize a reproducible source for practicing the methods of this invention over a course of time. A preferred selectable marker gene is the gene conferring neomycin-resistance. Such a gene for encoding the selectable marker was derived from an expression vector, designated pMAMneo, as described in Example 1. The nucleotide sequence of the neomycin-resistance conferring gene is listed in SEQ ID NO 20.

In one embodiment, a TGF- β responsive expression vector contains a first nucleotide sequence comprising a regulatory region that includes at least one TGF- β inducible response element operatively linked to a promoter, a second nucleotide sequence comprising a structural region downstream of the promoter and coding for an indicator molecule, and a third nucleotide sequence comprising a gene encoding a selectable marker for the selection of a stably transformed cell, where the response element is capable of inducing dose-dependent luciferase activity and the structural region codes for luciferase.

Preferred expression vectors containing the neomycin-resistance conferring gene include the following designations followed in parenthesis by the corresponding SEQ ID NO in which the sense strand of each Eco RI-linearized vector is listed according to the convention adopted in this invention for listing vector sequences: 1) p800neoLuc (SEQ ID NO 1); 2) p800/636neoLuc (SEQ ID NO 2); 3) p56neoLuc (SEQ ID NO 3); 4) p674neoLuc (SEQ ID NO 4); 5) p743neoLuc (SEQ ID NO 5); 6) p732neoLuc (SEQ ID NO 6).

In a further embodiment, the plasmid expression vectors of this invention contain TGF- β inducible response elements that correspond to a nucleotide sequence listed in SEQ ID NOS 11-17 as described in Section C.

Preferred promoters for use in the TGF- β expression

ve
as
se
th
NO
pr
al
or

ve
ha
el

ve
el
As
re

to
co
an
ar
on
Th
to
an
Cl
40

re
th
th
TG
th

5 vectors of this invention for stably transforming cells as well as for transient transformation are the PAI-1 minimal promoter sequence and the hepatitis B virus minimal promoter sequence, the sense sequences of which are respectively listed in SEQ ID NOs 18 and 19. Contemplated for use in this invention are promoters that are not responsive to TGF- β . The selection of alternative promoters is within the scope of one having ordinary skill in the art.

10 This invention contemplates additional TGF- β expression vectors for stably transforming cells that can be designed to have regulatory regions that contain alternative TGF- β response elements and promoters.

15 a. Regulatory Region

The regulatory region of a TGF- β expression vector of this invention contains at least one TGF- β response element as described herein and in Section C of this invention. As contemplated for use in this invention, the regulatory region of a TGF- β expression vector can range in length from 5 to 2000 base pairs, preferably 15 to 1500 base pairs, and can contain more than one TGF- β response element in any orientation and arrangement. Thus, if two or more TGF- β response elements are present in a regulatory region, they may be contiguous with one another or separated by an intervening nucleotide sequence. 20 The design and construction of such arrangements are well known to one of ordinary skill in the art of oligonucleotide design and synthesis and are described by Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Laboratory, pp 390-401 (1982).

0 Preferred TGF- β response elements present in the regulatory region of a TGF- β expression vector are derived from the PAI-1 promoter and have the nucleotide sequences listed in the Sequence Listing in SEQ ID NOs 11-17. The PAI-1-derived TGF- β response elements corresponding to SEQ ID NOs 11-17 have the respective designations with the nucleotide regions

-30-

corresponding to the PAI-1 promoter indicated in parentheses:
1) SEQ ID NO 11 = 1500 (-1481 to -40); 2) SEQ ID NO 12 = 800 (-
800 up to -40); 3) SEQ ID NO 13 = 800/636 (-800 up to -636); 4)
SEQ ID NO 14 = 56 (-56 to -41); 5) SEQ ID NO 15 = 674 (-674 to
5 -650); 6) SEQ ID NO 16 = 743 (-743 to -708); and 7) SEQ ID NO
17 = 732 (-732 to -708).

b. Structural Region

A plasmid vector of the present invention
10 contain a structural region having a nucleotide sequence that
encodes an indicator molecule. The structural region is
operatively linked to the regulatory region such that the
inducible promoter of the regulatory region, under the
inducible control of the TGF- β response element, controls
15 transcription and expression of the indicator molecule. Thus,
upon induction of the TGF- β response element, the regulatory
region transcribes and thereby expresses the indicator molecule
resulting in a detectable event in the cell, which event can be
measured by detection of the amount of the expressed indicator
20 molecule. In other words, the response element is capable of
inducing the expression of the indicator molecule by virtue of
it's controlling expression of the indicator through the
promoter to which the response element is operatively linked.

Typically, the structural region is "downstream" of the
25 regulatory region in the plasmid, and positioned to be under
the direct control of the regulatory region. Other
configurations can be utilized so long as the induction of the
TGF- β response element results in the expression of the
indicator polypeptide. Exemplary and preferred configurations
30 are described in Examples.

The term "indicator molecule" as used in this invention
refers to a molecule encoded by a reporter gene, the expression
of which in the expression vectors of this invention, results
in a detectable measurable protein, polypeptide, enzyme and the
35 like. Alternative expressions for indicator molecule are

-31-

reporter molecule, reporter polypeptide, indicator protein, indicator polypeptide and the like. In preferred embodiments, the indicator molecule is a protein.

There are any of a variety of indicator polypeptides suitable for use in the present invention, and the invention need not be so limited to any particular indicator. A preferred indicator polypeptide is luciferase encoded by the firefly luciferase gene. Use of the luciferase gene for expression of luciferase has been described by Gould et al., Anal. Biochem., 7:5-13 (1988) and Brasier et al., Bio-Techniques, 7:1116-1122 (1989). A preferred structural region includes a nucleotide sequence having the sequence characteristics of the luciferase gene shown in SEQ ID NO 21.

Alternative embodiments include indicator proteins such as β -galactosidase and chloramphenicol acetyltransferase (CAT). Use of a β -galactosidase and CAT as reporter molecules have been respectively by Luskin et al., Neuron, 1:635-647 (1988) and Gorman et al., Mol. Cell Biol., 2:1044-1051 (1982).

Associated with the use of an indicator molecule in the quantifying TGF- β are means for measuring the indicator molecule. A preferred method for detecting the luciferase indicator molecule is the use of a luminometer commercially available from Dynatech Laboratories Inc., Chantilly, VA as described in Example 3A and analyzed according to manufacturer's instructions. For detecting CAT activity, a simple-phase extraction assay has been developed and described by Seed et al., Gene, 67:271-277 (1988), the disclosure of which is hereby incorporated by reference. Alternative preferred methods for detecting CAT activity are described in Current Protocols in Molecular Biology, Eds, Ausubel et al., Unit 9.0, John Wiley & Sons (1993). Expression of β -galactosidase activity is performed in activity assays performed essentially as described by Miller, Experiments in Molecular Genetics, Cold Spring Harbor Laboratory, New York, (1972), the disclosure of which is hereby incorporated by

-32-

reference. With β -galactosidase additional reagents are required to visualize its presence following induced expression. Such additional reagents for β -galactosidase include o-nitrophenyl- β -D-galactopyransoside and the like for the development of a color reaction by absorbance at wavelengths of 500 and 420.

c. Selectable Marker Gene

In preferred embodiments, the plasmid vector of the present invention includes a gene that encodes a selectable marker that is effective in a eucaryotic cell, preferably a drug resistance selection marker. A preferred drug resistance selection marker is a gene whose expression results in neomycin resistance, i.e., the neomycin phosphotransferase (neo) gene [Southern et al., J. Mol. Appl. Genet., 1:327-341 (1982)] or a gene whose expression results in kanamycin resistance, i.e., the chimeric gene containing nopaline synthetase promoter, Tn5 neomycin phosphotransferase II and nopaline synthetase 3' non-translated region described by Rogers et al., Methods for Plant Molecular Biology, A. Weissbach and H. Weissbach, eds., Academic Press, Inc., San Diego, CA (1988). Other selectable markers which are utilizable in eucaryotic cells can be utilized in the present vectors and methods and therefore the invention need not be limited to any particular selectable marker. Thus, the invention contemplates the use of a nucleotide sequence which confers a eucaryotic selection means, including but not limited to genes for resistance to neomycin and kanamycin.

A preferred nucleotide sequence defining a selectable marker gene is a nucleotide sequence having the sequence characteristics of the neomycin resistance gene shown in SEQ ID NO. 20.

The use of a selectable marker for eucaryotic cells provides the advantage of producing stably transformed cells, as discussed herein. Thus, one can produce a eucaryotic cell

-33-

line containing a plasmid vector of this invention for use in the present methods wherein all the cells of the culture are selected to be uniform and each contain intact plasmid vector, thereby assuring that all of the eucaryotic cell in the culture are substantially similar in responsiveness to TGF- β , thereby increasing the reliability and sensitivity of the assay.

In addition, preferred embodiments that include a procaryotic replicon also include a gene whose expression confers a selective advantage, such as a drug resistance, to the bacterial host cell when introduced into those transformed cells. Typical bacterial drug resistance genes are those that confer resistance to ampicillin or tetracycline.

Those vectors that include a procaryotic replicon also typically include convenient restriction sites for insertion of a recombinant DNA molecule of the present invention. Typical of such vector plasmids are pUC8, pUC9, pBR322, and pBR329 available from BioRad Laboratories, (Richmond, CA) and pPL, pK and K223 available from Pharmacia, (Piscataway, NJ), and pBLUESCRIPT and pBS available from Stratagene, (La Jolla, CA). A vector of the present invention may also be a Lambda phage vector including those Lambda vectors described in Molecular Cloning: A Laboratory Manual, Second Edition, Maniatis et al., eds., Cold Spring Harbor, NY (1989).

Plasmid vectors for use in the present invention are also compatible with eucaryotic cells. Eucaryotic cell expression vectors are well known in the art and are available from several commercial sources. Typically, such vectors provide convenient restriction sites for insertion of the desired recombinant DNA molecule, and further contain promoters for expression of the encoded genes which are capable of expression in the eucaryotic cell, as discussed earlier. Typical of such vectors are pSVO and pKSV-10 (Pharmacia), and pPVV-1/PML2d (International Biotechnology, Inc.), and pTDT1 (ATCC, No. 31255).

35

-34-

2. Plasmid Vectors for Co-transformation and Transient Transformation

This invention contemplates the use of TGF- β responsive expression vectors having regulatory, promoter and structural regions but lacking a gene for encoding a selectable marker. In other words, in practicing this invention, TGF- β expression vectors for transient transformation of eucaryotic cells are contemplated. This embodiment allows for an alternative to stable transformation of cells for use practicing the methods of this invention. Transiently transformed cells produced as described in Example 2D. are useful for performing TGF- β assays when having stably transformed cells is not required or necessitated. As described in Example 4, transiently transformed cells are useful for determining the nucleotide sequence of TGF- β response elements as well as quantifying the amount of TGF- β present in a heterogeneous or homogeneous liquid sample.

Preferred TGF- β expression vectors used for transiently transforming eucaryotic cells include the following vectors shown with their designations and SEQ ID NOs in which the sense strand of the double-stranded Eco RI-linearized vectors is listed: 1) p56Luc (SEQ ID NO 7); 2) p674Luc (SEQ ID NO 8); 3) p743Luc (SEQ ID NO 9); and 4) p732Luc (SEQ ID NO 10).

The invention further describes TGF- β responsive plasmids lacking a selectable marker gene having the identifying characteristics of plasmids that have been deposited with the American Type Culture Collection, Rockville, MD having the assigned ATCC Accession Numbers 75627, 75628, 75629, the plasmids of which respectively correspond to the Eco RI-linearized sense strand nucleotide sequences listed SEQ ID NOS 8-10.

In an additional embodiment, this invention describes the co-transformation of TGF- β expression vectors for transient transformation in conjunction with a second expression vector from which a selectable marker is expressed. A preferred

-35-

selectable marker expressing plasmid is RSVneo as described in Example 2C. The ability to prepare stably transformed cells through the use of a vector that only confers transient transformation is accomplished with this approach. The advantage this approach provides is that further vector constructions for inserting selectable marker genes can be avoided, thereby providing stably transformed cells for use in practicing this invention when necessitated. Thus, eucaryotic cells that have been co-transformed with a transient TGF- β expression vector and a second plasmid such as RSVneo provide for an alternative approach to create stably transformed eucaryotic cells.

Any transient TGF- β expression vector of this invention can be used in this context. A preferred co-transformed eucaryotic cell is the cell line Hep3B that has been co-transformed with RSVneo and the p1500Luc expression vector having the TGF- β response element in SEQ ID NO 11. This stably transformed cell line has been deposited with the American Type Culture Collection, Rockville, MD and has been assigned ATCC having ATCC Accession Number CRL 11508.

With the teachings of this invention, additional TGF- β expression vectors for transiently transforming cells can be designed to have regulatory regions that contain alternative TGF- β response elements and promoters. In a further embodiment, these additional vectors can be used to prepare stably transformed cells through the use of the co-transformation approach.

3. Recipient Cells for Transformations

Insofar as the invention describes plasmid vectors for use in the present invention, the invention also contemplates a eucaryotic cell containing a plasmid vector of the present invention.

A eucaryotic cell suitable for use can be any eucaryotic cell which expresses a TGF- β receptor on its cell surface and

-36-

is capable of induction of a TGF- β response element. There are a variety of means to identify a suitable eucaryotic cell, including, but not limited to transformation by a plasmid vector of this invention, followed by assay for expression of the indicator polypeptide upon challenge by TGF- β .

In a preferred embodiment, this invention contemplates the use of mammalian cells. Preferred mammalian cells include mink lung epithelial cells, HeLa cells, Chinese hamster ovary cells, Hep3B cells, GM7373 cells, NIH 3T3 cells, and the like cells. These and other suitable mammalian cells are widely available. Suitable mammalian cells for use in the invention can also be obtained from the American Type Culture Collection (ATCC; Rockville, MD).

Introduction of a plasmid vector of the present invention into a eucaryotic cell can be accomplished by a variety of methods well known in the art, including, but not limited to transfection, transformation, electroporation, microinjection, liposome fusion, and the like introduction methods. Such methods are well known and are not to be considered essential to the invention. Furthermore, the introduction of the plasmid vector can be transient or stable.

A transient introduction is one where there is no selection to maintain the plasmid vector within the host eucaryotic cell through multiple rounds of cell division. Therefore, the assay is to be conducted in a short time period after introduction, and before several rounds of cell division. Stable introduction of plasmid involves the culturing of the cell under conditions that select for the maintenance of the plasmid vector, typically by the use of a gene on the plasmid that encodes a selectable marker, as described further herein.

Following the introduction of the plasmid vector, the resulting eucaryotic cell containing a plasmid vector is used in the assay methods described herein. A preferred eucaryotic cell contains a plasmid vector of this invention, which plasmid vector comprises a nucleotide sequence having a TGF- β response

-37-

element and a gene encoding an indicator polypeptide, wherein the plasmid is capable of expression of the indicator polypeptide in response to TGF- β induction. Particularly preferred are eucaryotic cells that contain a plasmid vector having a nucleotide sequence with the nucleotide sequence characteristics of the TGF- β response element selected from the group consisting of the sequences shown in SEQ ID NOS 11-17. A particularly preferred eucaryotic cell contains a plasmid vector having a nucleotide sequence with the nucleotide sequence characteristics of the plasmid vector selected from the group consisting of the sequences shown in SEQ ID NOS 1-10.

A preferred eucaryotic cell described further herein is Hep3B stably transformed with the plasmid vector p1500Luc, referred to as LUCI, and having the ATCC accession No. CRL 11508.

E. Methods for Quantifying TGF- β

The present invention describes methods for detecting the presence, and preferably quantifying the amount, of TGF- β in a liquid sample, either containing purified TGF- β or TGF- β in a heterogeneous admixture, and is also referred to herein as a TGF- β assay. The assay system provides for the quantification of TGF- β through the expression of an indicator polypeptide which is expressed in levels proportional to the amount of TGF- β being detected.

The assay is a highly sensitive and specific, non-radioactive assay, for detecting mature (active) TGF- β . When compared to the sensitive and widely used proliferation-based mink lung epithelial cell (MLE cells) method for measuring TGF- β concentration, the TGF- β assay method of this invention is more rapid, has comparable sensitivity, and has a greater detection range. Specificity of this novel assay was also higher as evidenced by its relative insensitivity to factors such as epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) which can greatly affect other assays.

-38-

The use of a TGF- β response element, such as the truncated PAI-1 promoter, that does not respond to other growth modulators such as platelet-derived growth factor (PDGF) found in biological samples provides an added advantage-that the method of this invention can be used in conditions where other bioassays are difficult to interpret. Because of its large range and specificity, the rapid, sensitive, non-radioactive, easily performed assay method of this invention is useful in determining active TGF- β concentrations in complex solutions.

Thus, the present invention overcomes the limitations of existing methods used to quantify the amount of TGF- β in a liquid sample. This invention contemplates a method for quantifying the amount of TGF- β in a sample using a system comprising a TGF- β responsive cell containing an expression vector having a TGF- β response element and an indicator molecule. Following TGF- β induction, transcription results in the expression of an indicator molecule, the amount of which allows for the measurement of the amount of TGF- β responsible for the induction.

TGF- β receptor-bearing cells are transfected with a TGF- β responsive expression vector of this invention, and are subsequently exposed to TGF- β whereupon the TGF- β receptor-bearing cells activate the TGF- β response element in the vector which results in the concomitant expression of the indicator polypeptide. The resulting expressed indicator polypeptide is then measured in a manner depending upon the indicator polypeptide employed.

The measured indicator polypeptide resulting from activation by TGF- β in the test liquid sample is then compared to a standardized reference curve produced using known amounts of TGF- β .

In particular, one embodiment of the invention contemplates a method for quantifying the amount of TGF- β in a liquid sample, which method comprises:

(a) incubating the liquid sample together with eucaryotic

-39-

cells that contain a TGF- β responsive expression vector having a gene encoding an indicator polypeptide for a predetermined time period sufficient for the eucaryotic cells to express a detectable amount of the indicator polypeptide;

5 (b) measuring the amount of the indicator polypeptide expressed during the time period; and

(c) determining the amount of TGF- β present in the sample by comparing the measured amount of the indicator polypeptide against a reference curve.

10 Preferably, the reference curve represents a quantitative relationship derived from a series of measured amounts of indicator polypeptide produced from a series of known concentrations of TGF- β .

The standardized reference curve is obtained from parallel
15 assays performed by exposing similarly transfected cells to a range, usually in serial dilution, of known (measured) amounts of one or more of the known TGF- β isoforms. The resulting expressed indicator polypeptide is then determined by direct detection of the indicator polypeptide. A reference curve is
20 then generated by plotting the measured amount of expressed indicator polypeptide against the known range of inducing amounts of TGF- β . The amount of unknown TGF- β in the test liquid sample is then determined by extrapolating the measured amount of test indicator polypeptide to the reference curve.

25 The use of standard curves in quantifying the amount of protein in a liquid sample in general has been described by Lowry et al., J. Biol. Chem., 193:265-275 (1951), the disclosure of which is hereby incorporated by reference. As shown in the Examples herein, the TGF- β assay of this invention
30 allows for the measurement of TGF- β from the expression and subsequent detection of an indicator polypeptide from a concentration range from less than 5 picograms/ml (pg/ml) equivalent to 0.2 pM up to 10 ng/ml equivalent to 40 pM (or 0.4 nM). The dose-dependent response to TGF- β is linear
35 between 0.2 pM up to 100 pM depending on the assay conditions.

As described further herein, any of a variety of indicator polypeptides can be utilized in the present methods, and the invention is not to be construed as limited to any particular indicator polypeptide. However, a preferred embodiment
5 utilizes a chemiluminescent molecule, more preferably
luciferase, as the indicator polypeptide, and therefore the
examples herein using luciferase are to be considered exemplary
of all indicator polypeptides and of preferred embodiments.
The level of expressed luciferase is easily and conveniently
10 measured using a luminometer as described herein. 10

In another embodiment of the present invention, the assay method for quantifying TGF- β in complex solutions is practiced generally as described above, but with the additional use of a neutralizing anti-TGF- β monoclonal antibody admixed with the
15 test liquid sample in assays run in parallel to untreated test
liquid samples as described in Example 3B. These control
assays are used to determine if other molecules are present in
the test sample that can affect the assay through either
inhibition or activation of other regions of the TGF- β response
20 element. For example, conditioned medium obtained from cell
cultures and body fluids contain growth factors and DNA binding
proteins that function as transcriptional activators or
inhibitors. If a corresponding response element for an
additional non-TGF- β activator is present in the expression
25 vector, the binding of the activator to the response element
may cause enhanced or diminished expression of the indicator
polypeptide. By antibody neutralization of the TGF- β in the
test sample, any residual measured indicator polypeptide can
then be ascribed to non-TGF- β activation.

30 The shorter TGF- β response elements used in the expression
vector systems of this invention are less likely to have non-
TGF- β response elements as shown in Examples 3E and 3F. Thus,
the use of parallel antibody control assays to allow for a
determination of the amount of luciferase produced from only
35 TGF- β activation is preferred when using expression vectors 35

-41-

having longer response elements or elements likely to exhibit responsiveness to transcription factors other than those induced by TGF- β . Moreover, while the TGF- β assay is not generally isoform specific, the assay can be TGF- β isoform-specific by the use of the appropriate standard reference curves and parallel assays with neutralizing antibodies immunospecific to a particular TGF- β isoform species, thereby allowing for quantification of unique TGF- β isoforms.

Thus, in another embodiment of the invention, a method for quantifying the amount of transforming growth factor- β (TGF- β) in a liquid sample is contemplated, the method comprising:

(a) providing, in eucaryotic cells capable of expressing an indicator molecule, a plasmid comprising, in the direction of transcription, a regulatory region that includes at least one TGF- β inducible response element that is operably linked to a promoter, and a structural region downstream of the promoter, where the response element is capable of inducing dose-dependent indicator molecule activity and where the structural region codes for the indicator molecule;

(b) incubating the liquid sample with the eucaryotic cells for a predetermined time period sufficient for the eucaryotic cells to express a detectable amount of the indicator molecule;

(c) measuring the amount of the indicator molecule expressed during the time period; and

(d) comparing the measured amount of the indicator molecule produced in step (c) with the amount of indicator molecule produced in a control assay performed according to steps (a) through (c) by treating the liquid sample with an anti-TGF- β antibody to obtain a net measured amount of the indicator molecule induced by TGF- β .

The use of a monoclonal antibody specific for TGF- β provides particular advantages in practicing the invention. First, one can use a variety of TGF- β response elements,

including those which exhibit responsiveness to factors in addition to TGF- β , which activity is subtracted out by the use of the control data obtained using the antibody treatment. Second, one can correct for spurious induction or inhibition of a TGF- β response element by factors other than TGF- β . The analysis of comparative data (comparing) produced by conducting the present method both with and without anti-TGF- β antibody for the purpose of determining the level of TGF- β in a liquid sample, can be conducted by a variety of statistical methods that are not to be construed as limiting to the invention. Exemplary comparative analyses are described in the Examples.

Contemplated for use with any of the above TGF- β assay methods of this invention are plasmids having identifying characteristics of plasmids on deposit with ATCC having the ATCC Accession Numbers 75627, 75628 and 75629. Also contemplated are eucaryotic cells that contain the TGF- β response element having the nucleotide sequence in SEQ ID NO 11 where the cells correspond to cells on deposit with ATCC having the ATCC Accession Number CRL 11508. In one embodiment, the use of stably transformed eucaryotic cells are contemplated.

The invention describes plasmids for use in the methods that comprise a nucleotide sequence corresponding to nucleotide sequences listed in SEQ ID NOS 1-10. TGF- β inducible response elements that comprise a nucleotide sequence corresponding to nucleotide sequences listed in SEQ ID NOS 11-17 are also described. Contemplated promoter nucleotide sequences are listed in SEQ ID NOS 18 and 19.

A further embodiment of the methods of the invention are eucaryotic cells that are stably transformed cells containing a plasmid having a gene encoding a selectable marker for the selection of said stably transformed cells. The invention describes such plasmids having nucleotide sequences listed in SEQ ID NOS 1-6. The invention further describes a stably transformed eucaryotic cell on deposit with ATCC having ATCC Accession Number CRL 11508 containing the TGF- β response

element having the nucleotide sequence in SEQ ID NO 11.

An additional embodiment are eucaryotic cells that are transiently transformed cells with plasmids corresponding to the nucleotide sequences listed in SEQ ID NOS 7-10.

5 The use of stably transformed cells is particularly preferred because it provides uniformity and reproducibility to the cell based assay without the need for additional controls for the efficiency of transformation typically associated with methods using transient transformation. Stably transformed
10 cells do not require the use of an internal standard for transformation efficiency, and all of the cells utilized are typically uniformly transformed. Furthermore, the methods do not require the additional step of transforming the cells transiently because the stably transformed cell line is already
15 available.

 The invention describes quantifying the amount of TGF- β in a body fluid, in culture medium, in a tissue extract, and in the like liquid samples. A further preferred embodiment is the determination of the amount of a specific isoform of TGF- β ,
20 specifically TGF- β 1, TGF- β 2 or TGF- β 3, in a liquid sample.

 In a preferred embodiment, this invention describes the use of any eucaryotic host cell that contains a TGF- β receptor and is capable of inducing a TGF- β response element upon activation by TGF- β . Exemplary assays for measuring activation
25 by TGF- β and induction of a TGF- β response element are described herein and can be used to identify candidate host cells suitable for use in the present diagnostic methods. A preferred host cell is a mammalian cell. Preferred mammalian cells include mink lung epithelial (MLE) cells, particularly
30 clone C32 from MLE cells, HeLa cells, Chinese hamster ovary (CHO) cells, Hep3B cells, GM7373 cells, NIH 3T3 cells, and the like cells.

 Conditions for incubating a eucaryotic cell in the present methods are the same as general cell culture methods. Typical
35 cell culture media for culturing and incubating eucaryotic

-44-

cells include alpha-MEM, Eagle's MEM (having non-essential amino acids), RPMI 1640 and Dulbecco's modified MEM (DMEM), all which are well known in the art. The culture medium preferably contains 0.5 to 2 % (v/v) serum, preferably a fetal calf or fetal bovine serum (FCS or FBS). Cell culture conditions include the use of cells plated at a density of about 0.8 to about 3.2×10^4 cells per well of a 96-well tissue culture plate, preferably about 1.6×10^4 cells per well. Cells are typically plated at the indicated density, and allowed to grow until they reach a confluence density of from about 70% confluent to about 1 day post-confluent, but should preferably be allowed to grow after plating for a time period sufficient for the cells to express detectable levels of TGF- β receptor, which time period is typically about 0.5-24 hours, preferably about 1-5 hours, and preferably is about 3 hours.

After plating and culturing, the eucaryotic cells are incubated under culturing conditions with culture medium that includes a predetermined volume of a liquid sample believed to contain TGF- β . The incubation time period is a time sufficient for any TGF- β present in the liquid sample to interact with the eucaryotic cell TGF- β receptor and thereby induce the TGF- β response element and express the indicator polypeptide. The time required for the expressed indicator polypeptide to accumulate to detectable levels will vary with the choice of indicator and method of detection, and can be predetermined. However, typical incubation times for contacting the cell with the liquid sample can range from 2 to 24 hours, preferably about 6 to 22 hours, more preferably 10 to 20 hours, and particularly about 14 hours. Particularly preferred culturing and incubation conditions for use in the present methods are described in the Examples.

The detection of TGF- β in liquid samples such as body fluid or tissue extract samples is useful in following the levels of TGF- β in patients experiencing a variety of conditions where the TGF- β level is important to the clinician.

For example, TGF- β levels are significant in diseases characterized by excessive fibrosis such as hepatic fibrosis and the like, in proliferative and in conditions where there is an increase in collagen expression, and the like conditions where TGF- β is believed to participate. In addition, there are many therapeutic uses of TGF- β , and therefore, the present assay methods are useful for measuring the therapeutic fate of administered TGF- β in patients being treated therapeutically with TGF- β .

F. Diagnostic Methods and Kits

The present invention also contemplates a diagnostic system in kit form for assaying the amount of TGF- β in a liquid sample according to the present methods. The diagnostic kit contains, in an amount sufficient for at least one assay, a eucaryotic cell of this invention useful for practicing the diagnostic methods for detection of TGF- β .

The kit can further contain a packaging material. Packaging material can include container(s) for storage of the materials of the kit, and can include a label or instructions for use.

The kit can additionally contain an aliquot of reference TGF- β for use in generating a standard reference curve using the methods of the invention.

Thus in preferred embodiments, a diagnostic kit includes, in an amount sufficient for at least one assay, the following: (a) packaging material; (b) eucaryotic cells contained within the packaging material, where the cells are capable of expressing an indicator molecule and containing a plasmid comprising, in the direction of transcription, a regulatory region that includes at least one TGF- β inducible response element that is operatively linked to a promoter, and a structural region downstream of said promoter, where the TGF- β response element is capable of inducing dose-dependent indicator molecule activity and the structural region coding

for said indicator molecule; and (c) an aliquot of TGF- β contained within said packaging material, where the TGF- β is used for generating a reference curve as described herein representing a measured amount of the indicator molecule produced from a known concentration of TGF- β .

As used herein, the term "packaging material" refers to a solid matrix or material such as glass, plastic, paper, foil and the like capable of holding within fixed limits eucaryotic cells and an aliquot of TGF- β . Thus, for example, packaging material can be a plastic vial used to contain eucaryotic cells in growth medium to which liquid samples can be added for activating the TGF- β responsive plasmid within the cells. Packaging material can also be a glass vial in which an aliquot of TGF- β is contained for use in generating a reference curve, the latter of which is described in Section E.

As used herein, an "aliquot" of TGF- β refers to an amount of TGF- β sufficient to generate a reference curve of this invention. In preferred embodiments, the aliquot of TGF- β is provided in the form of a substantially dry powder, i.e., in lyophilized form, for subsequent reconstitution or in the form of a solution, i.e., a liquid dispersion. Preferably the amount of powdered TGF- β is in the range of 25 nanograms (ng), more preferably 125 ng to 625 ng, and most preferably 250 ng. Preferably the amount of TGF- β in liquid solution is in the range of 1 to 50 nanomolar (nM), more preferably 5 to 25 nM and most preferably 10 nM. Preferred serial dilutions of TGF- β used in generating the reference curve are described in Section E. The TGF- β provided in the kit preferably includes each of the three TGF- β isoforms as described in Section B.

The term "indicator molecule or indicator polypeptide" as used in this invention and described in Section D1 refers to a molecule encoded by a reporter gene, the expression of which in the expression vectors of this invention, results in a detectable measurable protein, polypeptide, enzyme and the like.

-47-

In preferred embodiments, the packaging material includes a label indicating that eucaryotic cells containing TGF- β responsive expression vectors can be used for determining the amount of TGF- β in a liquid sample that includes the steps of
5 (a) incubating the cells with the selected liquid sample; (b) measuring the amount of the induced indicator molecule; and (c) comparing the amount of measured indicator molecule with a reference curve. Thus, the packaging material contains a label that is a tangible expression describing the methods of this
10 invention as described in Section E. of using plasmid-transformed eucaryotic cells for quantifying the amount of TGF- β in a test liquid sample.

The packaging materials discussed herein in relation to the kit of this invention are those customarily utilized in
15 kits or diagnostic systems. Such materials include glass and plastic, the latter of which include polyethylene, polypropylene and polycarbonate, bottles, vials, plastic and plastic-foil laminated envelopes and the like.

The eucaryotic cells transformed with the TGF- β responsive expression vectors of this invention are cells that express TGF- β receptor on their cell surface as described in Section E. All normal cells and most all neoplastic cells have cell surface membrane receptors also referred to a binding proteins for TGF- β . For review, see Tucker et al., Proc. Natl. Acad. Sci. USA, 81:6757-6761 (1984) and Frolik et al., J. Biol. Chem., 259:10995-11000 (1984). The receptors have previously
20 been described in Section E. Preferred cells for use with the TGF- β assay kit include mink lung epithelial cells (MLE cells), HeLa cells, Chinese Hamster Ovary cells, Hep3B cells, GM7373 cells and NIH 3T3 cells, with the C32 clone from the mink lung
25 epithelial cells being the most preferred cell line.

In preferred embodiments, the eucaryotic cells are transformed with the expression vector plasmids described in Section D have a nucleotide sequence that corresponds to a
30 sequence in SEQ ID NOs 1-10. Contemplated for use in the kit

are stably and transiently transformed eucaryotic cells. As described in Section D1, for preparing stably transformed eucaryotic cells, the plasmids corresponding to SEQ ID NOs 1-6 are preferred for use. A further preferred eucaryotic cell for use in the kit is the Hep3B cell line co-transfected with p1500Luc and RSVneo for preparing stably transformed cells that have been deposited with ATCC having the ATCC Accession Number CRL 11508 and identified by the designation "LUCI". For preparing transiently transformed eucaryotic cells, the plasmids corresponding to SEQ ID NOs 7-10 are preferred for use.

In preferred embodiments, eucaryotic cells for use with the kit contain a plasmid having the identifying characteristics of a plasmid on deposit with ATCC having the Accession Numbers 75627, 74628 and 75629 as described in Section C.

The kit of this invention further includes an anti-TGF- β antibody for use in a parallel control assay for determining the amount of indicator molecule produced other than by TGF- β induction. Preferred anti-TGF- β antibodies are anti-TGF- β 1, anti-TGF- β 2 or anti-TGF- β 3 monoclonal antibodies commercially available from Genzyme Corp., Cambridge, MA.

Preferred diagnostic assays accomplished with the kit performed as described herein are for the quantitation of the amount of TGF- β in a liquid sample. A liquid sample can include an isoform of TGF- β , specifically TGF- β 1, TGF- β 2 or TGF- β 3. A liquid sample further includes any body fluid, culture medium and a tissue extract that may contain unknown quantities of TGF- β . Thus, the liquid sample includes the body fluids, serum, plasma, whole blood, lymph fluid, synovial fluid, follicular fluid, seminal fluid, amniotic fluid, urine, spinal fluid, saliva, sputum, tears, perspiration, mucus and the like. Culture medium includes culture supernatant, also referred to as conditioned medium, collected from cells maintained in tissue culture as described in Example 3B.

Tissue extracts also encompass extracts of cells, referred to as cellular extracts. In addition, organs such as placentas can be obtained and extracted with well known procedures to prepare placental extracts. Extracts can also be obtained of any body organ or portion thereof, tissue or cells, including normal, tumorigenic, and malignant cells. This is generally accomplished by surgical means, i.e., by biopsy samples including needle aspirates, tissue scrapings, or freshly dissected tissues and the like. Extracts are the collected samples are then prepared by means including homogenization in lysis buffers, including detergents such as NP-40, Triton X-100, and the like. Common methods include using potters, blenders, ultrasound generators, and dounce homogenizers.

15 EXAMPLES

The following examples relating to this invention are illustrative and should not, of course, be construed as specifically limiting the invention. Moreover, such variations of the invention, now known or later developed, which would be within the purview of one skilled in the art are to be considered to fall within the scope of the present invention hereinafter claimed.

1. Preparation of Expression Vectors Containing TGF- β Response Elements

A. Source Cloning Vector Constructs and Preparation of Expression Vectors for Stable Transformation

Eucaryotic expression vectors having a regulatory region having at least one TGF- β response element derived from the 5' promoter end of the human plasminogen activator inhibitor type 1 (PAI-1) gene operatively linked to a PAI-1 minimal promoter and a downstream structural region containing a gene coding for an indicator polypeptide, preferably luciferase, were prepared and designated generally as PAI/L

eukaryotic expression constructs. Operatively linking refers to the covalent joining of nucleotide sequences, preferably by conventional phosphodiester bonds, into one strand of DNA, whether in single- or double-stranded form. Moreover, the joining of nucleotide sequences results in the joining of functional elements such as response elements in regulatory regions with promoters and downstream structural regions as described herein.

The expression vector constructs of this invention were then used for preparing stably transformed cells for use in the quantitative TGF- β assays of this invention. The expression vectors were designed to contain varying lengths and arrangements of the TGF- β response elements from the PAI-1 promoter, a neomycin-resistance conferring gene for selection and a gene encoding an indicator polypeptide, preferably luciferase. Two starting vectors were required to prepare the expression vectors having a neomycin-resistance conferring gene. One of these starting cloning plasmid vectors, designated p19Luc, was previously described by van Zonneveld et al., Proc. Natl. Acad. Sci. USA, 85:5525-5529 (1988), the disclosure of which is hereby incorporated by reference.

1) Preparation of Cloning Vector p19Luc

The promoter-less reporter gene p19Luc plasmid was originally designed by van Zonneveld et al., Proc. Natl. Acad. Sci. USA, 85:5525-5529 (1988) to monitor promoter activity with a structural region, having the firefly luciferase gene to function as a reporter gene, fused to a SV40 splice and polyadenylation site. The p19Luc plasmid also contained a multiple cloning site preceded by two SV-40-derived polyadenylation sites. The p19Luc plasmid was constructed from pSVOAL-AA5', a vector described by De Wet et al., Mol. Cell. Biol., 7:725-737 (1987). The pSVOAL-AA5' was first linearized with Hind III and one portion of the plasmid was blunt-ended by filling in the Hind III sites with E. coli DNA polymerase I

lar

lin

res

the

5 ori

iso

was

res

and

10 was

circ

thre

mult

15 the

p19L

21.

sequ

vect

20 the

alwa

spec

foll

25 the

the

nucle

ID NO

site

30 conf

the

immed

with

with

35 Xma I

large fragment (Klenow), ligated to phosphorylated Eco RI linkers (New England Biolabs, Beverly, MA). Two of the resulting fragments, the 621 bp fragment originally containing the 5' end of the luciferase gene and the 2718 bp fragment originally located on the 5' end of this fragment, were isolated. A second portion of the Hind III-cleaved pSVOAL-AA5' was ligated to a 55 bp polylinker and cleaved with Eco RI. The resulting 2831 bp fragment containing the multiple cloning site and the pBR322-derived ampicillin resistance-conferring gene was isolated. These fragments were ligated to create the circular double-stranded p19Luc plasmid that contained the three fragments in their original orientation but with the multiple cloning site in the original Hind III site.

The continuous 6170 bp sense strand, also referred to as the coding strand, nucleotide sequence of an Eco RI-linearized p19LUC vector is listed in the Sequence Listing as SEQ ID NO 21. The convention adopted for listing the nucleotide sequences of the p19Luc vector as well as all the expression vectors of this invention derived from p19Luc is to list only the sense strand of each vector with the nucleotide position 1 always beginning with the middle of the Eco RI site, specifically the first T nucleotide.

The Eco RI-linearized p19Luc vector contained the following list of elements and restriction sites beginning with the 5' middle Eco RI "T" nucleotide position 1 and extending to the 3' end of the vector ending with the middle Eco RI "A" nucleotide position 6170 (nucleotide positions as listed in SEQ ID NO 21 are indicated in parentheses): a Pst I restriction site (750-755) within the pBR322-derived ampicillin resistance-conferring gene (amp); an Acc I restriction site downstream of the amp gene (2113-2118); two tandem polyadenylation sites immediately upstream of the multiple cloning site beginning with Bam HI (2771-2776) and Hind III (2778-2783), continuing with adjacent Sph I, Pst I, Hinc II/Acc I/Sal I, Xba I, Bam HI, Xma I/Sma I, Kpn I, Sst I, and ending with Eco RI (2829-2834);

the luciferase gene adjacent to the Eco RI site in which are
four restriction sites, Xba I (2910-2915), Eco RI (3450-3455);
Sph I (3522-3527), and Xba I (4564-4569); an SV40 splice site
adjacent to the 3' end of the luciferase gene followed by a
third polyadenylation site; a Bam HI restriction site (5417-
5422); and lastly a Pst I restriction site (5962-5967).

For use in preparing the expression vectors of this
invention, the multiple cloning site in the promoterless p19Luc
plasmid described above allowed for the directional ligation of
both non-TGF- β responsive promoters and TGF- β responsive
regulator regions containing TGF- β response elements, the
latter of which comprised the regulatory region of the
resultant vectors. The promoters and TGF- β response elements
and the ligation thereof to form TGF- β expression vectors are
described herein and below.

Thus, the p19Luc plasmid was used as a cloning vector for
construction of all the expression vectors of this invention.
The advantage of using the p19Luc and the p19Luc-derived p39Luc
expression cloning vectors, the latter of which is described
below, is that the vectors allow for the construction of TGF- β
responsive vectors having a selected regulatory region
operatively ligated to a selected promoter. Therefore, any
regulatory region of any length containing one or more TGF- β
response elements can be paired with any promoter, a non-TGF- β
responsive PAI-1 or heterologous HBV promoter as used herein
but not limited to that, to prepare TGF- β responsive expression
vectors that provide for the quantitation of inducing TGF- β .

While specific expression vector constructs having the
preselected regulatory regions as described herein were
prepared for use in this invention, also contemplated are
expression vectors having regulatory regions with TGF- β
response elements that are either longer, shorter, tandemly
arranged, reversed, permutations thereof and the like
operatively ligated to a selected promoter. Moreover, in
addition to the construction methods detailed herein, other

ITCD BAH

dcacaeE

ccBhaaT

NffNppccpnnffdc

(:sfCGr

re

methods of preparing p19Luc-derived expression vectors having TGF- β response elements and promoters are familiar to one of ordinary skill in the art of vector construction and are described by Ausebel, et al., In Current Protocols in Molecular Biology, Wiley and Sons, New York (1993) and by Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, 1989.

2) Preparation of Expression Vector p1500Luc

One expression vector of this invention, designated p1500Luc, was constructed from p19Luc and a cosmid containing the PAI-1 promoter in which TGF- β response elements are located. To prepare p1500Luc, a 1547 base pair (bp) Kpn I-Eco RI fragment of the PAI-1 promoter was obtained from a cosmid containing the entire PAI-1 gene (Loskutoff et al., Biochem., 26:3763-3768 (1987), the disclosure of which is hereby incorporated by reference, and was cloned into the Kpn I and Eco RI sites of pUC19, a plasmid available from American Type Culture Collection, Rockville, MD with the ATCC Accession Number 37254, to create a vector designated pUCEK19. The fragment contained the 1442 bp TGF- β response element (SEQ ID NO 11) from the PAI-1 promoter that corresponded to nucleotide position -1481 and extended to the nucleotide position -40 continuous with a 115 bp minimal (non-TGF- β responsive) PAI-1 promoter sense strand sequence (SEQ ID NO 18) corresponding to nucleotide position -39 ending with an E. coli DNA polymerase filled-in Eco RI site at nucleotide position at +76 as described by Bosma et al., J. Biol. Chem., 263:9129-9141 (1988). The entire 15,867 bp PAI-1 gene sequence including significant stretches of DNA that extend into its 5'- and 3'-flanking DNA regions was described by Bosma et al., J. Biol. Chem., 263:9129-9141 (1986), and is available in the GenBank™/EMBL Data Bank with accession number(s) J03764.

To create a sensitive reporter gene system with a regulatory region having the 1442 TGF- β response element of the

-54-

PAI-1 promoter contiguous with the minimal PAI-1 promoter, the pUCEK19 plasmid prepared above was then digested with Kpn I and Eco RI and the isolated fragment was then ligated into the multiple cloning site of a similarly digested p19Luc. The resulting vector was designated p1500Luc.

3) Preparation of Expression Vector p800Luc

Another vector, designated p800Luc, was prepared for subsequent construction of p800neoLuc as described below. The p800Luc plasmid, having a deletion in the 5' end of the PAI-1 construct so that the 5' end began with the -800 nucleotide in the native PAI-1 promoter, was prepared by digesting the PAI-1-gene-containing cosmid described above with Hind III and Eco RI. The actual Hind III-Eco RI digest of the PAI-1 promoter resulted in a fragment that corresponded to nucleotides -799 to +71 bp in the PAI-1 promoter that was subsequently ligated into a similarly digested p19Luc vector forming a PAI-1 region extending from nucleotide -800 to +76. The resulting p800Luc plasmid retained all the features of p19Luc with the exception of the insertion of the PAI-1-derived regulatory region having a TGF- β response element and a promoter.

The restriction fragments described to prepare p1500Luc and p800Luc had an identical 3' end (an Eco RI site at +71 nucleotide of the PAI-1 promoter) and a different 5' end. The vectors, p1500Luc and p800Luc, were used for transient transformations as they lacked a selectable marker gene. The p1500Luc plasmid was also used to prepare stable transformations with a second vector as described in Example 1C. In addition, the p800Luc served as the starting cloning construct for the preparation of p800neoLuc as described below. The TGF- β response element in the -800 to +76 PAI-1 promoter region began at -800 and ended at -40, the nucleotide sequence of which is listed in SEQ ID NO 12. The remaining nucleotides comprised the non-TGF- β responsive minimal promoter in this

PAI-1 fragment are listed in SEQ ID NO 18.

4) Preparation of Cloning Vector p39Luc

An expression vector, designated p39Luc, having a promoter for activating transcription of the luciferase gene while lacking TGF- β response elements, thereby lacking responsiveness to TGF- β , was prepared as described by Keeton et al., J. Biol. Chem., 266:23048-23052 (1991). A fragment of the PAI-1 promoter (i.e., between -39 and +76, which had been determined in the TGF- β assay as described in Example 3A to have low basal activity and only minimal response to TGF- β (average induction of 2.7-fold), was used as a minimal promoter in the constructs for use in quantifying the amount of TGF- β in a test liquid sample. Since the minimal promoter sequence conferred only a minimal background response to TGF- β as shown in Example 3A, the minimal PAI-1-derived promoter is also referred to as being "non-TGF- β responsive".

Briefly, the p800Luc vector was linearized by digestion with Hind III followed by 5' digestion of PAI-1 promoter with Bal-31 slow exonuclease (International Biotechnologies, New Haven, CT) as described by Keeton et al., J. Biol. Chem., 266:23048-23052 (1991). The digestion was allowed to proceed until the -39 nucleotide position of the PAI-1 promoter was reached. Thereafter, the linearized and Bal-31 digested plasmid was ligated with T4 ligase forming a double-stranded circular vector designated p39Luc.

The resultant expression vector, into which TGF- β response elements were subsequently ligated as described in Example 1C, contained the PAI-1 minimal promoter nucleotide sequence corresponding to -39 to +76 of the promoter as listed in SEQ ID NO 18. This minimal promoter was operatively linked to and continuous with the structural region that contained the firefly luciferase gene present in the vector. Since the p39Luc cloning vector was derived from p800Luc which itself was derived from p19Luc, the remaining elements and features of the

-56-

vector were retained unchanged from p19Luc. The 6229 bp sense strand nucleotide sequence of the Eco RI-linearized p39Luc vector is listed in the SEQ ID NO 23.

5 The p39Luc cloning expression vector is also obtained by preparing a double-stranded oligonucleotide sequence corresponding to the sequence in SEQ ID NO 18 and ligating it into the Hind III/Eco RI multiple cloning site of p19Luc. The overhang from the Hind III/Eco RI digests in the p19Luc vector is first digested with mung bean nuclease and followed by
10 ligation with the blunt-ended double-stranded oligonucleotide promoter. Other construction methods are well known to and easily accomplished by one of ordinary skill in the art.

The p39Luc vector was useful for operatively ligating regulatory regions that contained TGF- β response elements
15 resulting in an expression vector that was responsive to DNA-binding proteins, the result of which was induction of the transcription and translation of the indicator molecule, luciferase. TGF- β responsive expression vectors for use in practicing this invention having TGF- β response elements other
20 than those specified herein are readily constructed through the use of either p19Luc or p39Luc starting cloning expression vectors.

5) Preparation of Cloning Vector HBVLuc

25 To create expression vectors having heterologous non-TGF- β responsive promoters instead of having the PAI-1-derived minimal promoter described above, a minimal promoter construct derived from the Hepatitis B viral promoter (HBV) was selected. This promoter contained the nucleotide sequence from
30 -188 to +145 of the Hepatitis B promoter and showed only a 4-fold induction in response to TGF- β . The sense strand of the double-stranded nucleotide sequence of the HBV minimal promoter is listed in SEQ ID NO 19. This promoter corresponded to the nucleotide sequence from -188 to +145 of the Hepatitis B
35 promoter and showed only 4-fold induction in response to TGF- β .

The 6464 bp sense strand nucleotide sequence of the Eco RI-linearized pHBVLuc vector is listed in the SEQ ID NO 25.

6) Preparation of Expression Vector
p800neoLuc

For preparing an expression vector for use in stable transformations, the neomycin-resistance conferring gene from pMAMneo (Clontech, Palo Alto, CA) was inserted into the p800Luc vector containing -800 to +76 of the 5' end of the human PAI-1 gene followed by the firefly luciferase gene. As shown in Figure 1, p800Luc prepared above was first digested with Acc I, repaired to blunt ends with the Klenow fragment of DNA polymerase I, and then was isolated. The pMAMneo plasmid was digested with Sal I and Eco RI then blunt-ended with Klenow. The neomycin-resistance gene containing fragment was then isolated and had the 4302 bp sense strand nucleotide sequence listed in the Sequence Listing in SEQ ID NO 20. The linearized p800Luc and neomycin-resistance fragment were ligated, and one clone with the insert in the correct orientation was selected by restriction mapping and designated p800neoLuc. The entire Eco RI-linearized 11293 bp nucleotide sequence of the sense strand of the double-stranded p800neoLuc vector is listed in the Sequence Listing in SEQ ID NO 1. DNA sequencing was performed by a modification of the dideoxy chain-termination procedure with a Sequenase kit (United States Biochemical; Cleveland, OH). This clone, purified from large scale plasmid preparations via CsCl₂ gradients, was used for subsequent transfections.

Since the p800neoLuc cloning vector was derived from p800Luc which itself was derived from p19Luc, the remaining elements and features of the vector were retained unchanged from p19Luc. The p800neoLuc vector thus contained the neomycin-resistance conferring gene providing for stable transformants. The p800neoLuc vector also contained an operatively ligated regulatory region that contained TGF- β

-58-

response element in the sequence corresponding to -800 to -40 of the PAI-1 promoter resulting in an expression vector that was responsive to TGF- β . With this expression vector construct, the induced activation of the transcription and translation of the indicator molecule, luciferase, was obtained further allowing for the quantitation of the amount of TGF- β responsible for activating gene expression.

7) Preparation of Cloning Vector p39neoLuc

To create an expression vector useful for constructing TGF- β responsive vectors that resulted in stably transformed cells, the p39Luc cloning vector prepared above was linearized as described above for p800Luc and ligated with the neomycin-resistance conferring gene fragment from pMAMneo. The construction of the vector was performed as described in Example 1A6). The resultant p39neoLuc cloning expression vector had the Eco RI-linearized 10533 bp sense strand nucleotide sequence listed in the SEQ ID NO 22. Regulatory regions containing TGF- β response elements were operatively ligated 5' to the minimal promoter sequence of the p39neoLuc as described in Example 1C for the preparation of plasmids for transient transformation.

8) Preparation of Cloning Vector pHBVneoLuc

To create an expression vector useful for constructing TGF- β responsive vectors with a heterologous promoter for stably transforming cells, the pHBVLuc cloning vector prepared above was linearized as described above for p800Luc and ligated with the neomycin-resistance conferring gene fragment from pMAMneo. The construction of the vector was performed as described in Example 1A6). The resultant pHBVneoLuc cloning expression vector had the Eco RI-linearized 10768 bp sense strand nucleotide sequence listed in the SEQ ID NO 24. Regulatory regions containing TGF- β response elements were operatively ligated 5' to the minimal promoter sequence of

-59-

the pHBVneoLuc as described in Example 1C for preparing plasmids for transient transformation.

9) Preparation of p1500neoLuc,
p800/636neoLuc, p56neoLuc,
p674neoLuc, p743neoLuc and p732neoLuc
Expression Vectors

5 The p1500Luc vector prepared above is similarly
ligated with the neomycin-resistance gene from pMAMneo to form
10 p1500neoLuc. Other PAI-1-promoter containing expression
vectors lacking the neomycin resistance gene, p800/636Luc,
p56Luc, p674Luc, p743Luc and p732Luc, containing smaller TGF- β
response elements were prepared as described in Example 1C. To
15 create the corresponding neomycin-resistance expression vectors
for stably transforming recipient cells, the neomycin-
resistance gene from pMAMneo is separately ligated with each of
these five vectors to form expression vectors used for
generating stable cell transformations. The five resultant
20 vectors having the neomycin-resistance gene inserted are
designated p800/636neoLuc (10697 bp), p56neoLuc (10549 bp),
p674neoLuc (10558 bp), p743neoLuc (10569 bp) and p732neoLuc
(10558 bp) and have the respective complete nucleotide
sequences of the sense strand from the Eco RI-linearized
double-stranded vectors in SEQ ID NOs 2-6.

25 Depending on the vector into which the PAI-1 promoter
fragments were cloned, the designated names either had "Luc"
alone or "neoLuc" respectively for vectors lacking the neomycin
(neo) selectable marker gene or containing it. In addition,
the plasmids were further designated by the 5' end of the PAI-1
30 TGF- β response element. For example, five plasmids with
shorter TGF- β response elements were thus named p800/636neoLuc,
p56Luc, p674Luc, p743Luc and p732Luc.

35 As with all the expression vectors of this invention, the
operative elements from the original cloning vector p19Luc,
from which the vectors were all derived, were retained.

The above neomycin-resistance containing expression vectors were then used in the TGF- β assay method as described in Example 3 following transformation of host recipient cells.

5 B. Expression Vectors for Co-Transformation of
TGF- β Responsive Vectors and a Selectable
Marker Vector for Stable Transformation

Stably transformed Hep3B cells were also obtained as described in Example 2B below through the use of co-transfections of a TGF- β responsive vector lacking a selectable marker gene of this invention, specifically the p1500Luc prepared in Example 1A3), with a selectable marker vector, RSVneo, available from American Type Culture Collection (ATCC), Rockville, MD, ATCC Accession Number 37198. The stably transformed cell line containing plasmid p1500Luc, designated LUCI, was deposited with the ATCC on or before December 16, 1993 and was assigned the ATCC Accession Number CRL 11508.

C. Expression Vectors for Transient Transformation

20 Additional TGF- β responsive expression vectors were prepared for use in this invention. In the vectors prepared as described herein, the TGF- β response elements having a smaller length, thereby providing responsiveness to TGF- β with reduced or absent responsiveness to other growth modulators, were made
25 by either restriction digestion of the PAI-1 promoter or synthesizing double-stranded blunt-end oligonucleotides. The oligonucleotide sequences corresponded to preselected regions of the PAI-1 promoter sequence. The resultant TGF- β response elements present within a regulatory region were then
30 directionally ligated into p39Luc or p39HBV.

The regulatory region from the PAI-1 promoter corresponding to nucleotide position -800 up to and including -636 was obtained by restriction digestion and had the following sense strand sequence:

35 5' AAGCTTACCATGGTAACCCCTGGTCCCGTTTCAGCCACCACCACCCACCCAGCACACCTCC

-61-

AACCTCAGCCAGACAAGGTTGTTGACACAAGAGAGCCCTCAGGGGCACAGAGAGTCTGGAC
ACGTGGGGAGTCAGCCGTGTATCATCGGAGGCGGCCGGGCA3' (SEQ ID NO 13).

The additional selected regions for preparing oligonucleotides included the following sense strand nucleotide sequences with the indicated nucleotide positions as present in the intact PAI-1 promoter: 1) promoter nucleotide position -56 up to and including -41: 5'AGTTCATCTATTTCT3' (SEQ ID NO 14); 3) promoter nucleotide position -674 up to and including -650: 5'GTGGGGAGTCAGCCGTGTATCATCG3' (SEQ ID NO 15); 4) nucleotide position -743 up to and including -708: 5'CTCCAACCTCAGCCAGACAAGGTTGTTGACACAAGA3' (SEQ ID NO 16); and 5) nucleotide position -732 up to and including -708: 5'GCCAGACAAGGTTGTTGACACAAGA3' (SEQ ID NO 17). The complementary sequences to each of the sense oligonucleotide sequences were also synthesized to allow for the formation of double-stranded oligonucleotides for ligation 5' to the PAI-1 minimal promoter sequence containing the TATA box.

The resulting double-stranded oligonucleotides were then separately operatively linked to the -39 position of this minimal promoter sense strand sequence listed in SEQ ID NO 18 present in the expression vector, p39Luc, prepared as described in Example 1A4). The sequences were confirmed by double-stranded sequencing methods.

The resulting five plasmids with shorter TGF- β response elements were thus named p800/636Luc, p56Luc, p674Luc, p743Luc and p732Luc. The plasmids, p56Luc, p674Luc, p743Luc and p732Luc, have the respective complete sense strand nucleotide sequences beginning with the middle T of the Eco RI site as previously described listed in SEQ ID NOs 7-10. The plasmids, p674Luc, p743Luc and p732Luc, were deposited with ATCC as described in Example 5 and respectively assigned the ATCC Accession Numbers 75627, 75628 and 75629.

In similar procedures, five plasmids having a heterologous hepatitis B viral promoter, HBV, instead of the PAI-1 minimal promoter were prepared with the shorter TGF- β response

elements, p800/636Luc, p56Luc, p674Luc, p743Luc and p732Luc. The HBVLuc cloning expression vector was prepared as described in Example 1A4). The TGF- β response elements were ligated into linearized HBVLuc, prepared as described in Example 1A5), to form TGF- β response element-containing plasmids lacking the neomycin-resistance-conferring gene.

Furthermore, as previously mentioned, the cloning vector constructs, p19Luc and p39Luc, provide for the operative linking of preselected regulatory regions with preselected promoters, both of which are not limited to the specific constructs described herein and above. Additional TGF- β response elements in varied lengths and arrangements along with promoters that provide for the transcription of the reporter gene are contemplated for use in this invention.

2. Transformation of Eucaryotic Cells with Expression Vectors Containing TGF- β Response Elements

A. Recipient Eucaryotic Cells

To identify the cell types most responsive to TGF- β in which to transfect the TGF- β responsive expression vectors for use in assaying the amount of TGF- β , the vectors prepared in Example 1 were transfected as described in Example 2B and 2C into recipient cell lines including mink lung epithelial cells (MLE cells) (ATCC CCL 64), HeLa cells (ATCC CCL 2), Chinese hamster ovary (CHO cells) (ATCC CCL 61), GM7373 (chemically transformed metal bovine aortic endothelial cells or BAEs) (NIGMS Human Genetic Mutant Cell Repository, Camden, NJ), Hep3B (ATCC HB 8064) and NIH 3T3 cells (ATCC CRL 1658).

B. Stable Transformation

For preparing stably transfected cells for use with expression vectors containing the pMAMneo construct prepared in Example 1A, transfections of mink lung epithelial cells (hereinafter referred to as MLE cells to distinguish from the TGF- β proliferation assay called MLEC) were performed. The MLE

-63-

cells were seeded at 7×10^5 cells/100 mm dish for 24 hours at which point they were transfected with the PAI/L construct, p800neoLuc, by calcium phosphate precipitation as described by Wigler et al., Proc. Natl. Acad. Sci. USA, 76:1373-1376

(1979). Twenty-four hours after transfection, the medium was replaced and supplemented with 400 $\mu\text{g/ml}$ of Geneticin. The resistant cells were expanded in mass culture or cloned by limiting dilution for further experiments. Following selection, transfected MLE cells were maintained in DMEM containing 10% fetal calf serum and 250 $\mu\text{g/ml}$ Geneticin (G-418 sulfate) (Gibco BRL, Grand Island, NY).

Stable transformations are also performed as described above with the expression vectors, p800/636neoLuc, p56neoLuc, p674neoLuc, p743neoLuc and with p732neoLuc, all of which are prepared as described in Example 1A.

C. Stable Transformation Obtained by Co-transfection of Cells

For transfecting 6 wells, 15 micrograms (μg) of p1500Luc expression vector prepared in Example 1A2) that did not have a neomycin-resistance gene was admixed with 3 μg of a plasmid encoding the neomycin selectable marker gene driven from a respiratory syncytial virus promoter, RSVneo. The RSVneo plasmid is available from ATCC with ATCC Accession Number 37198. Hep3B cells at a concentration of 6×10^5 cells/well were seeded as described above in Example 1B for 24 hours at which point they were transfected with the PAI/L construct, p1500Luc, by calcium phosphate precipitation followed by selection with Geneticin. The resultant cell line stably transformed with p1500Luc, designated LUCI, was deposited with ATCC on December 16, 1993 and was assigned the ATCC Accession Number CRL 11508.

D. Transient Transformation

For preparing transiently transformed cells

containing TGF- β responsive expression vectors lacking the neomycin resistance gene prepared as described in Example 1C, Hep3B human hepatoma cells obtained from ATCC (ATCC Accession Number HB8064) were maintained in DMEM/HAMs F-12 (Whittaker Bioproducts, Walkersville, MD) supplemented with 10% fetal bovine serum (Hyclone Laboratories, Logan, UT), glutamine, sodium pyruvate, non-essential amino acids and penicillin/streptomycin (Whittaker). For transfection experiments, semiconfluent cells in 6-well (10 cm² per well) tissue culture plates (Corning Inc., Corning, NY) were washed twice with serum free media (DMEM/F-12) then incubated in serum free media. Separate mixtures (50 μ l/well) of lipofectin (GIBCO, Grand Island, NY) at a concentration of 12.5 μ g/well and DNA vector constructs prepared in Example 1A-1C at a concentration of 2.5 μ g/well each in water were added to the cell-containing wells and the plates were incubated for 18 hours. After lipofection, plates were incubated an additional 24 hours in the absence or presence of 1 ng/ml TGF- β provided by Berlix Biosciences, South San Francisco, CA. The monolayers were then washed followed by extraction into 0.25% Triton X-100. Each construct was tested with at least 2 independent DNA preparations in order to rule out any effects related to differences in DNA preparation. For each experiment, two independent transfections were performed with every construct.

3. Method for Quantifying the Amount of TGF- β in a Sample

A. The TGF- β Assay Method

The p800neoLuc construct stably transfected into Hep3B cells was used in the initial characterization of the assay method as described herein. TGF- β measurement assays performed with cells transiently transformed with the remaining expression vectors containing TGF- β response elements are presented in Example 4.

The TGF- β assay allows for the quantification of the

amount of TGF- β in a liquid sample, either containing purified TGF- β or TGF- β in a heterogeneous admixture. The assay system provides for the quantification of TGF- β through the expression of an indicator polypeptide, such as luciferase. When TGF- β receptor-bearing cells, transfected with a TGF- β responsive expression vector of this invention, are exposed to TGF- β , the activation of the TGF- β response element in the vector results in the concomitant expression of luciferase. The resulting expressed luciferase is isolated then measured as described herein. The measured luciferase resulting from activation by TGF- β in the test liquid sample is then compared to a standardized reference curve.

This reference curve is obtained from parallel assays performed by exposing similarly transfected cells to a range of known measured amounts of TGF- β , one or more of the known TGF- β isoforms. The resulting expressed luciferase is then determined in a luminometer. A reference curve is then generated by plotting the measured amount of expressed luciferase against the known range of inducing amounts of TGF- β . The amount of unknown TGF- β in the test liquid sample is then determined by extrapolating the measured amount of test luciferase to the reference curve. The use of standard curves in quantifying the amount of protein in a liquid sample in general has been described by Lowry et al., J. Biol. Chem., 193:265-275 (1951), the disclosure of which is hereby incorporated by reference. As shown in the Examples herein, the TGF- β assay of this invention allows for the measurement of TGF- β from the expression and subsequent detection of an indicator polypeptide from a concentration range from less than 5 picograms/ml (pg/ml) equivalent to 0.2 pM to 10 ng/ml equivalent to 0.4 nM. The dose-dependent response is linear between 0.2 pM up to 30 pM and even up to 100 pM depending on the assay conditions.

An additional aspect of the assay for quantifying TGF- β in complex solutions was the use of neutralizing anti-TGF- β

-66-

monoclonal antibodies admixed with the test liquid sample in assays run in parallel to untreated test liquid samples as described in Example 3B. These control assays are used to determine if other molecules are present in the test sample that can affect the assay through either inhibition or activation of other regions of the truncated PAI-1 promoter. For example, conditioned medium obtained from cell cultures and body fluids contain growth factors and DNA binding proteins that function as transcriptional activators or inhibitors. If a corresponding response element for an additional non-TGF- β activator or inhibitor is present in the expression vector, the binding of that molecule to the response element may cause enhanced or diminished expression of the indicator polypeptide. By antibody neutralization of the TGF- β in the test sample, any residual measured luciferase can then be ascribed to non-TGF- β activation.

The shorter TGF- β response elements used in the expression vector systems of this invention, even including the longer p800neoLuc, are less likely to have non-TGF- β response elements that are bound by other DNA-binding proteins as shown in Examples 3C-3F. Thus, the use of parallel antibody control assays to allow for a determination of the amount of luciferase produced from only TGF- β activation is preferred when expression vectors having longer response elements are used. Moreover, while the TGF- β assay is not isoform specific, using the appropriate standard reference curves and parallel assays with neutralizing antibodies to the various TGF- β species allows for quantification of unique TGF- β isoforms..

In the assays described herein, the various following reagents including their sources are listed: recombinant human TGF- β 1 (rTGF- β 1) (gift from Berlix Biosciences, South San Francisco, CA); rTGF- β 2 and neutralizing monoclonal antibodies against TGF- β 1, TGF- β 2 and TGF- β 3 (Genzyme, Cambridge, MA); rTGF- β 3, recombinant human interleukin-1alpha (rIL-1alpha) and recombinant human platelet-derived growth factor-BB (PDGF-BB)

-67-

(R&D Systems, Minneapolis, MN); recombinant human basic fibroblast growth factor (bFGF) (Synergen Inc., Boulder, CO); epidermal growth factor (EGF) from mouse submaxillary glands (Boehringer Mannheim Biochemicals, Indianapolis, IN); dexamethasone, retinoic acid, and plasmin (Sigma Chemical Co., St. Louis, MO); thrombin (Armour Pharmaceutical Co., Kankakee, IL); and hematopoietic factors granulocyte-colony stimulating factor (GCSF), granulocyte-macrophage-colony stimulating factor (GM-CSF), stem cell factor, and IL-3 (Amgen, Thousand Oaks, CA).

The TGF- β quantification assay of this invention was performed as follows: 1.6×10^4 stably transfected MLE cells per well plated in 96 well tissue culture dishes were allowed to attach for 3 hours at 37°C in a 5% CO₂ incubator. The medium was replaced with the test sample containing unknown quantities of TGF- β , DMEM, 0.1% BSA (DMEM-BSA) containing rTGF- β 1, rTGF- β 2, rTGF- β 3, IL-1 α , PDGF-BB, bFGF, or EGF for 14 hours at 37°C. Time courses of exposure to the samples were performed as shown for optimizing the assay as shown below. However, in general, approximately 24 hours after additions of the sample to the transfected cells, the cells were observed under phase contrast microscopy. At least in one vector-transfected cell line, Hep3B cells, the presence of TGF- β in quantities at least or greater than 0.1 ng/ml TGF- β in the sample was detected visually by the change of morphology and density of the cell population. The untreated cells remained organized with cell size decreasing upon confluence until the cell borders were no longer visible. In the presence of TGF- β , the untreated cell density was never attained and the cells were larger, flatter and less organized.

Following visual inspection, cell extracts were prepared and assayed for luciferase activity using the enhanced luciferase assay kit (Analytical Luminescence, San Diego, CA) as per the manufacturer's instructions. Treated cells were first washed twice with 2 ml phosphate-buffered saline (PBS) without Ca⁺⁺ and Mg⁺⁺ and then extracted with 100 μ l of 0.25%

Triton-X 100 (cell lysis buffer, Analytical Luminescence). The plates were gently shaken until the monolayer detached from the plastic. The plates were then placed on a rotator at room temperature for 20 minutes.

5 Eighty ul of the resultant lysates were transferred to a
Microlight 1 96-well plate (Dynatech Laboratories Inc.,
Chantilly, VA) and were analyzed using an ML1000 luminometer
(Dynatech) with 100 ul injections of both Substrates A and B
10 (Analytical Luminescence). Luciferase activity was reported as
relative light units (RLU) as measured by the light generated
over a ten second period. All assays were performed in
triplicate. Error bars in the collected data represent the
standard error of the mean of the samples.

15 To quantitate the amount of TGF- β inducing the measured
amount of luciferase from liquid samples, reference curves were
prepared from parallel assays performed by exposing similarly
transfected cells to a range of known measured amounts of TGF-
20 β , one or more of the known TGF- β isoforms. Serial dilutions
of the control TGF- β concentrations were prepared from a 1
nanomolar (nM) concentration down to 0.078 picomolar (pM). The
TGF- β assay was performed for each serial dilution and the
resulting expressed luciferase was then determined in a
luminometer. A reference (standard) curve was then generated
25 by plotting the measured amount of expressed luciferase against
each of the known concentrations of inducing amounts of TGF- β .
The amount of unknown TGF- β in the test liquid sample was then
determined by extrapolating the measured amount of test
luciferase to the reference curve.

30 B. Sensitivity of the TGF- β Assay Method

To identify the cell type most responsive to TGF- β
for use in the methods of this invention, the p800neoLuc
construct prepared in Example 1A was stably transfected as
described in Example 2B into a variety of cell lines including
35 MLE cells, HeLa, Chinese hamster ovary (CHO), GM7373 cells

(chemically transformed fetal bovine aortic endothelial cells obtained from the NIGMS Human Genetic Mutant Cell Repository, Camden, NJ) and NIH 3T3 cells. After treatment of the transfected cell lines with recombinantly-produced TGF- β 1, designated rTGF- β 1, the cell lysates were assayed for luciferase activity and protein content. There was a linear relationship between the luciferase activity and the protein content of the cell lysates between 0.7 and 14 μ g for all of the cell lines. Nontransfected parental cells demonstrated no detectable luciferase activity. Of the various cell lines, the transfected MLE cells demonstrated the greatest sensitivity to TGF- β . After cloning the transfected MLE cells by limiting dilution, cells from clone 32 (C32) were found to be the most sensitive and were used for all subsequent assays.

C32 cells were sensitive to rTGF- β 1, β 2 and β 3 in the picomolar (pM) to the nanomolar (nM) range as evidenced by increased luciferase activity in relative light units (RLU) as shown in Figure 2A. All three isoforms, rTGF- β 1, rTGF- β 2 and rTGF- β 3, respectively graphed as closed squares, closed circles and closed triangles, demonstrated good dose dependant responses particularly at low TGF- β concentrations (<4 pM: 100 pg/ml) where the responses were essentially linear (Figure 2B). rTGF- β 3 was the most potent inducer of luciferase activity consistent with the observation that MLE cells were most sensitive to this isoform of TGF- β 3 as described by van Zonneveld et al., Proc. Natl. Acad. Sci. USA, 85:5525-5529 (1988) (see also Figure 6 as described in Example 3E).

To further assess the dose-dependent responsiveness of luciferase activity by TGF- β induction, the TGF- β assay was performed with 8 pM of rTGF- β 1, rTGF- β 2 or rTGF- β 3 in DMEM-BSA in the presence (partially filled squares) or absence (open squares) of 100 μ g/ml of anti-TGF- β 1, anti-TGF- β 2 or anti-TGF- β 3 monoclonal antibodies (Genzyme Corp., Cambridge, MA). As shown in Figure 2C, the induction of luciferase activity by rTGF- β 1, rTGF- β 2 and rTGF- β 3 was inhibited by the addition of

-70-

rTGF- β 1, rTGF- β 2 and rTGF- β 3 neutralizing monoclonal antibodies as compared to the baseline induction obtained when using medium alone (filled squares).

5 The effects of cell culture medium, cell density and assay incubation time on the sensitivity of the TGF- β assay was also assessed. To test the effects of cell culture medium, the TGF- β assay was performed using increasing concentration of rTGF- β 1 in DMEM (closed squares), alpha-MEM (closed circles), CMEM (Eagles medium supplemented with nonessential amino acids; 10 closed triangles), or RPMI-1640 (closed diamonds). All media contained 0.1% BSA. The quantification of TGF- β in test samples was accomplished in the TGF- β assay in all tested media as shown in Figure 3A, although samples assayed in DMEM yielded the greatest luciferase activity.

15 The effect of different cell plating densities on the induction of luciferase activity by rTGF- β 1 were also examined when transfected cells were maintained in the presence of DMEM. For this assay, increasing concentrations of rTGF- β 1 in DMEM and 0.1% BSA were measured using 3.2×10^4 (closed squares), 20 1.6×10^4 (closed circles), or 0.2×10^4 (closed triangles) C32 cells/well after a three hour attachment period. The test samples were maintained with the transfected cells for 14 hours prior to assaying for luciferase activity. The results graphed in Figure 3B show that 1.6×10^4 cells/well were found to yield 25 the best overall results. Cell densities greater than 1.6×10^4 cells/well decreased the sensitivity of the assay at low TGF- β concentrations and did not significantly increase sensitivity at higher TGF- β levels. Decreasing the concentration of cells to 0.8×10^4 cells/well increased the 30 sensitivity at low TGF- β levels (Figure 3D (inset in Figure 3C) but decreased sensitivity at higher TGF- β concentrations.

35 Unlike the traditional MLEC assay where the density of the cells prior to plating affects the sensitivity, there was little or no difference whether the cells were 70% confluent, confluent or 1 day post confluent prior to plating for the TGF-

-71-

5 β assay. The cell attachment and incubation times, however, did affect the sensitivity. When C32 cells were plated for 2, 3 or 4 hours prior to the addition of samples, a 3 hour plating time appeared to be optimal. Shorter plating times decreased sensitivity, whereas longer times had little effect on the subsequent assay.

0 Incubation time with the sample also affected the assay. After a three hour attachment period, 1.6×10^4 C32 cells were incubated with various concentrations of rTGF- β 1 ranging from 0 to 50 pM for 6 (closed squares), 14 (closed circles) or 22 hours (closed triangles) prior to assaying for luciferase activity as shown in Figure 3C. Incubation times of 12-14 hours were found to give the best results over the widest concentration range. The sensitivity of cells incubated for 6 hours was not as great at higher TGF- β 1 concentrations, whereas the sensitivity of cells incubated for 22 hours was decreased at low TGF- β 1 concentrations. There also appeared to be a slight decrease in sensitivity to TGF- β as the cells were repeatedly passaged (>30). This phenomenon was observed for the MLEC assay as well.

C. Specificity of the TGF- β Assay Method

After examining the sensitivity of the assay, specificity of the TGF- β assay was then examined. Four known inducers of PAI-1 expression, were incubated with C32 cells and the luciferase activity determined. The inducers tested included fibroblast growth factor (bFGF) (Saksela et al., J. Cell Biol., 105:957-963 (1987)), platelet-derived growth factor (PDGF-BB) (Reilly et al., J. Biol. Chem., 266:9419-9427 (1991)), interleukin-1 alpha (rIL-1alpha) (Schleef et al., J. Biol. Chem., 263:5797-5803 (1988)) and epidermal growth factor (EGF) (Seebacher et al., Exp. Cell Res., 203:504-507 (1992) and Sato et al., Exp. Cell Res., 204:223-229 (1993)). The assay was performed as described in Example 3A with DMEM-BSA containing rTGF- β 1 (closed squares), recombinant human bFGF

(closed circles), recombinant IL-1 α (closed triangles), recombinant PDGF-BB (closed triangles) or EGF (open squares) ranging in concentration from 0.1 to 500 pM. As seen in Figure 4A, even at high concentrations of these factors (500 pM), there was little or no induction of luciferase expression except by PDGF which demonstrated a slight induction.

Additional inducers of PAI-1, dexamethasone (10^{-7} M), retinoic acid (1 μ M), plasmin (0.1 U/ml), thrombin (1 U/ml), and the hematopoietic factors granulocyte colony stimulating factor (10 ng/ml; 525 pM), granulocyte-macrophage-colony stimulating factor (10 ng/ml; 690 pM), stem cell factor (50 ng/ml; 2.7 nM) and IL-3 (10 ng/ml; 666 pM), were also tested for their ability to induce luciferase expression in the assay method of this invention. Only plasmin and thrombin elicited minor elevations of luciferase activity that were inhibited by the addition of aprotinin or hirudin, respectively. Of the molecules tested in the TGF- β cell assay, only the TGF- β s demonstrated dose-dependent increases in luciferase expression.

When these factors were tested in the presence of TGF- β 1, a slightly different pattern emerged. These assays were performed with C32 cells maintained in DMEM/BSA containing 1 pM rTGF- β 1 (closed squares) separately admixed with each of the growth factors, bFGF (closed circles), recombinant IL-1 α (closed triangles), recombinant PDGF (closed diamonds) or EGF (open squares), ranging in concentration from 0.2 to 500 pM. The results, graphed in Figure 4B, show that high concentrations (500 pM) of PDGF-BB and rIL-1 α increased the luciferase activity above that induced by TGF- β alone. bFGF had a similar effect that was observed at lower concentrations. This induction, maximal at 10 pM bFGF, was abrogated by the addition of bFGF neutralizing antibodies, and did not increase at higher concentrations (>10 nM) of bFGF.

Because this enhancement may have resulted from a bFGF-mediated increase in total cell number and/or protein, crystal violet staining of parallel cultures and protein assays of the

cell lysates was performed. The normalization of the amount of protein using these values, however, did not reduce the luciferase activity in the bFGF plus rTGF- β 1-treated cultures to that of cells treated with rTGF- β 1 alone. Interestingly, uncloned transfected MLE cells were less sensitive to bFGF and other factors including TGF- β .

Additional TGF- β assays were performed using the ATCC deposited LUCI cell line containing the p1500Luc expression vector co-transfected with RSVneo as described in Example 2C to determine the specificity of activation of the PAI-1 promoter by other cell activating molecules (agents). The TGF- β assays were performed as described in Example 3A with the exception that the p1500Luc vector was used instead of the p800neoLuc vector. Controls in these assays included the use of two additional luciferase-expressing vectors that had the vitronectin (VN) and respiratory syncytial virus (RSV) promoters in place of the PAI-1 truncated promoter. The molecules used in the assays included the following: (the source and concentrations are indicated in the parentheses) 1) human recombinant IL-6 (Boehringer Mannheim, Indianapolis, IN; 500 U/ml); 2) dexamethasone (Sigma Chemical Co.; 10^{-5} M); 3) TGF- β (Berlix Biosciences; 1 ng/ml); 4) lipopolysaccharide (LPS) (Sigma Chemical Co.; 1 ng/ml); 5) human recombinant alpha tumor necrosis factor (TNF) (Boehringer Mannheim; 100 ng/ml); 6) human recombinant IL-1 (Sigma Chemical Co.; 50 U/ml); and 7) thrombin (NY State Department of Health, Albany, NY; 10 U/ml).

The assays were performed as indicated in Table 1 in which the fold induction is indicated as measured by relative light units of luciferase that resulted from the activation of either the PAI-1, VN or RSV promoters when exposed to the various agents.

-74-

Table 1

Agents	PAI-1	VN	RSV
Control	1X	1X	1X
IL-6	2X	15X	1X
Dexamethasone	1X	1X	1X
IL-6 + Dex.	6X	26X	2X
TGF- β	147X	1X	2X
LPS	2X	1X	1X
TNF	0.7X	0.3X	0.8X
IL-1	0.9X	0.3X	1X
Thrombin	1X	0.9X	1X

The 1500 bp PAI-1 promoter present in the p1500Luc vector was slightly responsive to IL-6, LPS and a mixture of IL-6 plus dexamethasone. In contrast, the induction of luciferase expressing in response to activation by TGF- β was 147-fold over that seen in the control untreated cells. Furthermore, IL-6 and IL-6 plus dexamethasone were effective activating agents when used in the presence of a vitronectin promoter. None of the agents were significantly effective at inducing expression from the RSV promoter.

These results confirm that TGF- β is the predominant activator of the PAI-1 promoter and that the TGF- β assay of this invention exhibits remarkable specificity. Thus, the assay is valuable in that the measurement of TGF- β that has been purified or even TGF- β present in unknown quantities in a complex solution containing many promoter-specific molecules can be readily determined without confounding by contaminants. With the added control of pre-treating the liquid samples with neutralizing antibodies to TGF- β isomers, the absolute amounts of TGF- β as well as isomer type can be determined.

D. Effects of Serum for Quantifying TGF- β in the TGF- β Assay Method

To assess the effects of serum on the quantification

-75-

of TGF- β , TGF- β assays were performed in the presence of DMEM-BSA containing rTGF- β 1 alone (closed squares), or with 0.5% (closed circles), 1% (closed triangles), or 2% (closed diamonds) calf serum. The rTGF- β 1 concentrations in the assays ranged from 0 to 8 pM. As shown in Figure 4C, serum similarly enhanced the induction of the PAI/L construct by rTGF- β 1 similar to that by purified growth factors as shown in Example 3C. At low rTGF- β 1 concentrations (<1 pM), addition of 0.5, 1 or 2% serum had little effect on the luciferase activity. As the rTGF- β 1 concentration was increased, the serum-containing curves were shifted upwards possibly as a result of growth factors such as bFGF in the serum.

E. Comparison of the TGF- β Assay with the MLEC Assay and the Radioreceptor Assay for Quantifying TGF- β

Quantification of TGF- β in a defined media (DMEM-BSA) lacking growth factors or serum as demonstrated in Example 3D, however, is rarely found in the laboratory. For this reason, TGF- β assays were also performed in COS, BSM and BAE cell conditioned medium (CM), all of which normally contain latent but little, if any, active TGF- β . These samples were tested using the TGF- β assay method of this invention in comparison with the MLEC (mink lung epithelial cell tritiated thymidine uptake cell assay).

The TGF- β assay was performed as described in Example 3A with rTGF- β 1 ranging in concentration from 0 to 40 pM in the presence of either DMEM-BSA (closed squares), COS CM (crosses), BSM CM (closed triangles) or BAE CM (closed circles). To prepare conditioned medium, BAE cells were cultured in alphaMEM medium (Bio-Whittaker, Walkersville, MD) containing 5% fetal calf serum. BSM and COS cells were cultured in DMEM supplemented with 10% calf serum (Bio-Whittaker). Conditioned medium was prepared by a 24 hour incubation of the indicated cells with DMEM containing 0.1% pyrogen-poor BSA

(weight/volume) (Pierce, Rockford, IL). All media were supplemented with L-glutamine (2 mM), penicillin G (100 U/ml) and streptomycin sulfate (100 µg/ml) (Irvine Scientific, Santa Ana, CA).

- 5 The MLEC assay was performed essentially as described by Lucas et al., In Peptide Growth Factors, Barnes et al., Eds, Academic Press Inc. 198:303-316 (1991). Briefly, 100 µl
10 aliquots of the samples were placed in 96-well plates containing 10^4 MLE cells per well in 100 µl of assay buffer (DMEM containing 0.25% fetal calf serum and 10 mM HEPES).
15 After 20 hours at 37°C, one µCi of ^3H -thymidine (6.7Ci/mmol, Du Pont Co., Boston, MA) in 20 µl of the assay buffer was added to each well, and the plates incubated an additional 4 hours. The cells were harvested by incubation with 100 µl of 0.25%
20 trypsin/1ml EDTA at 37°C for 15 minutes, transferred onto glass fiber filters, and placed into vials containing liquid scintillation solution. The amount of radioactivity was quantified with a Beckman LS 3801 β -scintillation counter (Fullerton, CA).
25 As clearly shown by the data indicated by the unbroken lines in Figure 5, both BAE and BSM CM contained factors that stimulated thymidine incorporation in the MLEC assay 5-6 fold. Only at rTGF- β 1 levels greater than or equal to 1 pM was the ^3H -thymidine incorporation suppressed to a level equal to that
30 of non-conditioned medium (DMEM-BSA). In contrast, COS CM contained factors that strongly inhibited ^3H -thymidine incorporation. With all three of these CM, calculation of TGF- β concentration would be very difficult using ^3H -thymidine incorporation. In contrast, when different CM were used in the
35 TGF- β assay as indicated in Figure 5 with the data plotted with broken lines, there were also slight changes but these differences were much less significant than those seen with the MLEC assay. BAE CM, which contains bFGF, shifted the response curve to higher values. BSM and COS CM had only minor effects on the standard curves.

When bFGF (closed diamonds), EGF (open circles), PDGF-BB (open triangles), rIL-1 α (open squares), and the TGF- β s (rTGF- β 1 (closed squares), rTGF- β 2 (closed circles), and rTGF- β 3 (closed triangles) were tested for their ability to affect ^3H -thymidine incorporation into non-transfected MLE cells in the MLEC assay performed as described above, more striking effects were observed as shown in Figure 6. The three TGF- β isoforms, especially TGF- β 3, decreased ^3H -thymidine incorporation as expected. IL-1 α and PDGF-BB had little effect, but bFGF and EGF had strong dose-dependent stimulatory effects on ^3H -thymidine incorporation. Such effects can make the MLEC assays inaccurate and difficult to analyze.

F. Quantitation of Total TGF- β Levels in Activated

In order to analyze total levels of TGF- β , BAE CM collected after 12 or 24 hours was heat treated at 80°C for 10-12 minutes to activate endogenous latent TGF- β as described by Brown et al., Growth Fact., 3:35-43 (1990). After cooling, the samples were diluted to 5, 10 or 20% of their original concentration with DMEM-BSA and were quantified using the TGF- β assay. TGF- β concentrations of 23.4 \pm 3.4 pM (12 hour CM) and 122.1 \pm 16 pM (24 hours CM) were determined via comparison with a rTGF- β standard reference curve generated from plotting the detected amounts of luciferase activity that resulted from a range of predetermined amounts of TGF- β as described in Example 3A.

The heat-activated CM were also assayed using the highly specific radioreceptor assay as described by Kojima et al., J. Cell. Physiol., 155:323-332 (1993), the disclosure of which is hereby incorporated by reference. Briefly, murine AKR-2B fibroblasts at 1 X 10⁵ cells/well were plated in a 24-well plate in McCoy's 5A medium (Gibco BRL) supplemented with 5% fetal calf serum. The following day, the cells were washed 3 times with binding buffer (McCoy's 5A, 0.1% BSA, 25 mM HEPES at pH 7.4) and were pre-incubated in 250 μ l of binding buffer for

-78-

1 hour at room temperature. The medium was removed, and the cells were incubated for 2 hours at room temperature in a mixture of 125 μ l of binding buffer containing 50 pM 125 I-rTGF- β 1 and an equal volume of heat-activated (80°C for 10 minutes) BAE CM or serial dilutions of cold rTGF- β 1. The cells were washed 3 times with binding buffer, and the bound radioactivity was solubilized in cell lysis buffer (Analytical Luminescence) and was measured in a Packard Multi-PRIAS1 gamma counter (Meriden, CT). The radioreceptor assay was sensitive between 0.0004 and 2 nM rTGF- β 1.

In the radioreceptor assay, concentrations of 24 ± 1.1 pM (12 hour CM) and 128 ± 48.8 pM (24 hour CM) were calculated. The essentially identical results quantifying the amount of TGF- β in conditioned medium between the TGF- β assay described above and the radioreceptor assay verify the accuracy and specificity of the TGF- β assay of this invention.

Thus, a highly sensitive and specific, non-radioactive assay for mature TGF- β has now been developed. When compared to the sensitive and widely used MLEC method for measuring TGF- β concentration, the TGF- β assay was more rapid, had comparable sensitivity, and a greater detection range. Specificity of this assay was also higher as evidenced by its relative insensitivity to factors such as EGF and bFGF which can greatly affect other assays. The most remarkable example of the TGF- β assay specificity was observed with COS cell CM which completely inhibited the MLEC assay, while having no detrimental effects in the TGF- β assay.

In addition to the TGF- β assay of this invention and the MLEC and radioreceptor assays described herein, other assays have been used to detect mature TGF- β including anchorage-independent growth assays, differentiation-based assays, cell migration and plasminogen activity assays, radioimmunoassays and enzyme-linked immunosorbent assays. Although all of these assays can detect mature TGF- β , the low concentrations of TGF- β , generally less than 2 pM, generated in many biological

sy
cc
th
Tr
by
nc
ar
-8
re
as
(1
el
fo
ac
qua
abo
 β :
spe
met
20
wic
the
wit
als
25
gro
gre
spe
lir
ass
shc
the
nel
qua
35
thi

systems make many of them impractical without prior concentration of the sample that can result in large losses of the mature growth factor or even activation of latent TGF- β . The TGF- β assay of this invention overcomes these deficiencies by being highly sensitive and specific as well as nonradioactive. The specificity and sensitivity of the assay are the result of using a truncated PAI-1 promoter beginning at -800 and extending through 76 of the PAI-1 5' promoter that retains two regions responsible for maximal response to TGF- β as described by Keeton et al., J. Biol. Chem., 266:23048-23052 (1991). Use of the complete PAI-1 promoter and upstream elements result in decreased specificity as responsive elements for other molecules present in complex solutions may be activated or inhibited deleteriously effecting the ability to quantify TGF- β . Moreover, the truncated PAI-1 promoter used above has been further fragmented to smaller more specific TGF- β response elements as described in Example 4 to enhance specificity and increase the sensitivity of the TGF- β assay method.

When the TGF- β assay is compared to the sensitive and widely used MLEC assay for quantifying TGF- β concentrations, the TGF- β assay was more rapid, had comparable sensitivity but with a greater detection range. Specificity of the assay was also higher as evidenced by the TGF- β 's assay insensitivity to growth factors such as EGF and bFGF that have been shown to greatly effect other assays. The most striking example of the specificity of the TGF- β assay was observed with the COS cell line conditioned medium that completely inhibited the MLEC assay while having no detrimental effects in the TGF- β assay as shown in Figure 5.

Although the TGF- β assay is not isoform specific, use of the appropriate standard reference curves and addition of neutralizing antibodies to the various TGF- β species allows for quantification of unique isoforms. While the TGF- β assay of this invention is highly specific, the use of highly specific

-80-

neutralizing antibodies to TGF- β was used to verify that no other molecules were present in test liquid samples that may have affected the quantitation of TGF- β in the assay. Considering its large range and specificity, this rapid, sensitive, non-radioactive, easily performed assay is of invaluable use in determining active TGF- β concentrations in complex solutions, particularly so with the use of parallel assays with neutralizing antibodies to TGF- β in complex unknown samples to verify that no other molecules are present that can affect the assay through either inhibition or activation of other regions of the truncated PAI-1 promoter.

4. Quantifying TGF- β with Cells Transiently Transformed with Expression Vectors Having Shorter Fragments of the PAI-1 Promoter Containing TGF- β Response Elements

The regulation of PAI-1 by TGF- β appears to affect a number of biological systems and the mechanism of transcriptional regulation by TGF- β has been studied by a number of groups. For example, the autoinduction of the TGF- β 1 promoter suggests a feedback loop designed to amplify the response to TGF- β under certain conditions. This response was shown to involve specific AP-1 sites. AP-1 is a heterodimeric complex of Fos and Jun protein subunits that binds to specific DNA enhancer sites which have the consensus sequence TGASTCA (SEQ ID NO 26), where S can be either G or C. AP-1 is believed to mediate the transcriptional effects of the tumor promoting phorbol esters.

In contrast to these results, the TGF- β response sequence in the promoter for type 1 collagen, has been localized to a sequence with homology to a nuclear factor 1 (NF-1) binding site. A number of different consensus sequences for NF-1 have been described and these include the sequences TGGN₇GCCAA (SEQ ID NO 27), where N can be either A, C, G or T, and TGGCA (SEQ ID NO 28). The effect of TGF- β on the PAI-1 promoter has been

studied resulting in the demonstration that the responsive regions contain sequences with homology to the AP-1 consensus sequence.

5 To determine the role of AP-1 in the regulation of the PAI-1 promoter in more detail and to identify smaller TGF- β responsive regions with the PAI-1 promoter of p800neoLuc expression vector prepared in Example 1 for use in quantifying TGF- β in Example 3, the effect of both TGF- β and AP-1 on the activity of a 25 bp fragment corresponding to the PAI-1
10 promoter between -674 and -650 in the 5' flanking region was evaluated. This fragment contained one of the AP-1 like sequences that responded to TGF- β . The expression vectors for use in assessing the requirement for AP-1, including the one containing the 25 bp fragment, were prepared as described in
15 Example 1C.

A. TGF- β Activation of PAI-1 Promoter Fragments

AP-1 like sites are located within each of three regions of the 5' flanking region of the PAI-1 promoter from
20 -87 to -49, from -674 to -636 and from -740 to -703. Oligonucleotides having portions or all of these regions were synthesized and cloned into a pUC-luciferase expressing plasmid containing the minimal promoter as described in Example 1C. The resultant plasmids were transiently transfected into
25 recipient Hep3B cells as described in Example 2C and evaluated for their response to TGF- β as measured by luciferase expression as described in Example 3A. The plasmid designated p56Luc contained an oligonucleotide sequence that corresponded to -56 to -41 of the PAI-1 promoter gene (also referred to as
30 region A) and conferred a 10-fold induction of measurable TGF- β as compared to a 3-fold induction obtained with a plasmid expression vector only containing the minimal promoter sequence.

Another plasmid designated p674Luc, deposited with ATCC
35 and having ATCC Accession Number 75627, contained an

-82-

oligonucleotide sequence 25 bp in length that corresponded to -674 to -650 of the PAI-1 promoter (also referred to as region B). This nucleotide sequence conferred a 70-fold induction on the minimal promoter. The plasmid designated p743Luc contained an oligonucleotide sequence 35 bp in length that corresponded to -743 to -708 of the PAI-1 promoter (also referred to as region C). This nucleotide sequence conferred a 35-fold induction in the promoter. The plasmid designated p732Luc exhibited 62-fold induction while the plasmid, p732HBV, having the hepatitis B virus (HBV) minimal promoter sequence instead of the PAI-1 sequence exhibited 47-fold induction.

This result is in comparison to 6-fold basal induction from a control plasmid having only the HBV minimal promoter without having any TGF- β response elements. The nucleotide sequence of the sense strand of the HBV-minimal promoter-containing plasmid having or lacking the neomycin selectable marker gene are listed respectively in SEQ ID NOs 23 and 24. In parallel assays, the p800Luc plasmid that contained 3 AP-1-like sequences conferred greater than 150-fold induction of TGF- β responsiveness as compared to the minimal promoter sequence. The stably transformed p1500Luc similarly resulted in approximately 150-fold induction. These results as well as the others presented in the Examples represent the average of at least 4 independent experiments, each performed in duplicate.

Regions A and C contained only a single AP-1 like sequence whereas region B contained 2 AP-1 like binding sequences. Thus, oligonucleotides containing AP-1 like sequences from each region were able to confer TGF- β responsiveness to a non-responsive minimal promoter.

B. Responsiveness of the TGF- β responsive Regions

A. B and C to c-fos/c-jun

In order to directly test the response of the p56Luc, p674Luc and p743Luc plasmids to AP-1, they were cotransfected

-83-

together into Hep3B cells with plasmids containing the mouse genes for c-fos and c-jun under the control of the RSV promoter. All three of these regions showed a dose dependent response to increasing amounts of c-fos/c-jun, with maximum responses seen using 0.1 µg/well of c-fos and c-jun plasmids. This response was dependent on co-transfection of both plasmids since neither c-fos or c-jun alone was able to cause this induction.

C. Detailed Analysis of the TGF-β Responsive Nucleotide Sequence in the PAI-1 Promoter from Nucleotide -743 to -708 (Region C)

To find the minimal TGF-β responsive sequence in the PAI-1 promoter region from nucleotide position -743 to -708, the sequence of which is listed in SEQ ID NO. 16, two oligonucleotides were made, the first from the 3' side of region C which contained the AP-1 like sequence (C2: -723 to -708 corresponding to the sequence in SEQ ID NO 16 from 21 to 36) and the second from the remaining 5' sequence (C3: -743 to -727 corresponding to the sequence in SEQ ID NO 16 from 1 to 17). When the oligonucleotides were examined for response to TGF-β, neither the C2 or C3 sequence showed maximal induction with TGF-β (10-fold and 3-fold induction, respectively) as compared to region C itself (25-fold induction). This result suggested that a portion of a TGF-β responsive binding site located between -723 and -727 was deleted. The 5' side of C2 was then progressively extended to include bases between -723 to -728 (7-fold induction) but found that this did not improve the TGF-β response. However when this region was extended another 4 bp there was a dramatic increase in the TGF-β response (63-fold induction) indicating that this region was crucial to this response.

D. Site-Specific Mutations of the PAI-1 Promoter from Nucleotide -732 to -708, Region C5

- 84 -

To assess the role of the AP-1 site compared to the 5' TGF- β responsive site, the response of the minimal promoter having the 5' flanking region of the PAI-1 promoter from -39 to +76 to direct stimulation with c-fos/c-jun was determined. It showed 10-fold induction with AP-1 compared to only 3-fold induction with TGF- β . When C5 was tested in a similar manner there was only a 2-fold increase above the vector background induced by c-fos/c-jun compared to a greater than 20-fold increase above background seen with TGF- β (C5 itself showed 63-fold induction). Thus, although the wild type AP-1 site in C5 was only a relatively poor responsive sequence to c-fos/c-jun, this region still showed a strong response to TGF- β . The AP-1 site was therefore mutated to produce a consensus AP-1 sequence (TGACACA to TGAGTCA, SEQ ID NOS 29 and 30, respectively) and the response of mutant to both c-fos/c-jun and TGF- β was compared. This mutation increased the AP-1 response from 19-fold to 105-fold but did not improve the TGF- β response. In fact, a consistent decrease was seen in the TGF- β response following this mutation (63-fold induction with TGF- β for the wild type AP-1 like site to 30-fold for the consensus AP-1 site).

The AP-1 like site was then mutated by changing the critical TGA bases, a change shown by others to decrease the activity of the AP-1 binding site. Although this mutation had the expected effect of abolishing the AP-1 response, it did not completely abolish the response of this construct to TGF- β (10-fold induction with c-fos/c-jun [i.e., vector background] but a 13-fold induction with TGF- β [i.e., 5-fold above vector background]).

30 This result once again suggested that the 5' portion of C5
(-732 to -708) was more critical than the AP-1 like sequence in
mediating the TGF- β response. To further test this hypothesis,
4 bp between -728 and -732 was mutated (the resultant mutated
vector designated C8) since the previous deletion results
35 suggested that this sequence was critical to the TGF- β

-85-

response. A 3 bp sequence between -726 and -728 was also mutated (the resultant vector was designated C9). As expected, both of these 5' mutations caused dramatic reductions in the response of C5 to TGF- β (60-fold to 4-fold for both C8 and C9). These changes had little effect on the AP-1 response which decreased only slightly from 19-fold to 13-fold. A double mutation of both of these sites was also created and this abolished both the TGF- β and the AP-1 activity.

E. Heterologous Promoter Induction

To test whether the 25 bp oligonucleotide from the PAI-1 promoter region C5, -732 to -708 (SEQ ID NO 15), was able to activate a heterologous promoter, it was cloned into a hepatitis B viral promoter, the latter of which had the nucleotide sequence from -188 to +145 of the viral promoter (SEQ ID NO 19). Control experiments found that this construct alone showed 28-fold induction with fos/jun. However, the viral promoter showed only 4-fold induction with TGF- β . Thus, even though the hepatitis B viral promoter had active AP-1 like sites, these were not sufficient for a strong TGF- β response.

The region between -708 and -732 of the PAI-1 promoter (C5) was then cloned into the viral promoter and the resultant construct was tested as above. The 25 bp PAI-1 fragment was able to dramatically increase the TGF- β response of the viral promoter from 4-fold to 47-fold but did not alter the AP-1 response (25-fold compared to 28-fold). Finally, mutation of bases between -732 and -728 of the PAI-1 promoter oligonucleotide dramatically reduced the TGF- β induction of this fragment but did not lower the response to AP-1.

F. AP-1-Independent TGF- β Induction

To determine if the 5' -732 to -708 nucleotide sequence from the PAI-1 promoter could function independently of the AP-1 site in the TGF- β response, a 15 bp oligonucleotide containing bases between -732 and -718, corresponding to the

-86-

nucleotide sequence from position 1 to 15 in SEQ ID NO 17) (which excludes the AP-1 like site) was cloned into a pUC-luciferase expression vector having the minimal PAI-1 promoter. This 15 bp sequence was able to confer 20-fold induction with TGF- β with the minimal PAI-1 promoter and did not show any AP-1 activity.

With regard to the AP-1 like sites involved in this response, unlike the consensus sequence for AP-1 (TGASTCA, where S is G or C (SEQ ID NO 26), the most active sequences from the PAI-1 promoter all have the sequence TGA(N)ACA where N is either A, C, G or T (SEQ ID NO 31) (PAI-1 promoter: -717 to -711 = TGACACA (SEQ ID NO 29); -659 to -653 = TGATACA (SEQ ID NO 32). It is possible that the T to A substitution may affect the binding affinity enough to preferentially bind another protein other than c-fos/c-jun. This is consistent with the functional data on the AP-1 like site of the PAI-1 promoter (between -711 to -717) which indicates that the wild type sequence is a poor AP-1 binding site and yet is still important in the TGF- β response.

The mutation and deletion data of the 25 bp sequence from the wild type PAI-1 promoter (-732 to -708) suggested that the 5' side of the oligonucleotide may contain a second binding site of importance in the TGF- β response. In fact this region appeared to be more critical than the AP-1 sequence since mutation of this region almost completely abolished the TGF- β response even though the AP-1 region was intact. When this sequence alone was evaluated, it was able to act independently of the AP-1 site and promote strong TGF- β induction of the normally unresponsive minimal promoter. However, the full TGF- β response was dependent on the functional activity of both the AP-1 like site and the 5' site. When the sequence of the 5' 15 bp sequence was compared to the other region of the PAI-1 promoter which also showed strong TGF- β induction (region B = 60-fold), a sequence was found that was common to both of these regions (CCNTGTNT, where N is either A, C, G or T (SEQ ID NO

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

-87-

33)).

In summary, the TGF- β response of the PAI-1 promoter has been localized to specific AP-1 like sites. However, the full TGF- β response of this region of the PAI-1 promoter is dependent on the interaction of two binding sites. The first site has homology to an AP-1 site but does not appear to bind AP-1. While this site is not essential it is required for the full TGF- β induction from this region. The second site, located 5' to the AP-1 site, appears to be critical in the TGF- β response. This site is 15 bp in size and contains a motif that is present in both active regions of the PAI-1 promoter as well as in the most responsive region of the TGF- β promoter. This novel sequence does not appear to match any previously described transcription factor binding sites and may represent a new and specific binding site which is critical for a strong TGF- β response.

5. Deposit of Materials

The plasmids, p674Luc, p743Luc and p732Luc, were deposited on or before December 16, 1993, with the American Type Culture Collection, 1301 Parklawn Drive, Rockville, MD, USA (ATCC) and assigned the respective ATCC Accession Numbers ATCC 75627, ATCC 75628 and ATCC 75629. The cell line, Hep3B, stably transfected with plasmid p1500Luc for a transformed cell line designated LUCI, was also deposited on or before December 16, 1993 with ATCC and assigned the ATCC Accession Number CRL 11508. The deposit thus provides plasmids and a stably transfected cell line containing plasmid p1500Luc. These deposits were made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of viable plasmids and cell lines for 30 years from the date of deposit. The plasmids and cell line will be made available by ATCC under the terms of the Budapest Treaty which assures permanent and

-88-

unrestricted availability of the progeny of the culture to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35 U.S.C. §122 and the Commissioner's rules pursuant thereto (including 37 CFR §1.14 with particular reference to 886 OG 638). The assignee of the present application has agreed that if the plasmid or cell line deposits should die or be lost or destroyed when cultivated under suitable conditions, they will be promptly replaced on notification with a viable specimen of the same plasmid or cell culture. Availability of the deposited plasmids is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.

(1)

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the plasmids deposited, since the deposited embodiment is intended as a single illustration of one aspect of the invention and any plasmids that are functionally equivalent are within the scope of this invention. The deposit of material does not constitute an admission that the written description herein contained is inadequate to enable the practice of any aspect of the invention, including the best mode thereof, nor is it to be construed as limiting the scope of the claims to the specific illustration that it represents. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims.

(2)

35

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: The Scripps Research Institute
(B) STREET: 10666 North Torrey Pines Road
(C) CITY: La Jolla
(D) STATE: CA
(E) COUNTRY: USA
(F) POSTAL CODE (ZIP): 92037
(G) TELEPHONE: 619-554-2937
(H) TELEFAX: 619-554-6312

(ii) TITLE OF INVENTION: A NEW SENSITIVE METHOD FOR QUANTIFYING
ACTIVE TRANSFORMING GROWTH FACTOR-BETA AND COMPOSITIONS
THEREFOR

(iii) NUMBER OF SEQUENCES: 33

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

(v) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: PCT/US 95/
(B) FILING DATE: 25-JAN-1995

(vi) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBERS: US 08/188,227
(B) FILING DATE: 25-JAN-1994

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11293 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TTCTTGAAGA CGAAAGGGCC TCGTGATACG CCTATTTTAA TAGGTAAATG TCATGATAAT	60
AATGGTTTCT TAGACGTCAG GTGGCACTTT TCGGGGAAAT GTGCGCGGAA CCCCTATTTG	120
TTTATTTTTC TAAATACATT CAAATATGTA TCGGCTCATG AGACAATAAC CCTGATAAAT	180
GCTTCAATAA TATTGAAAAA GGAAGAGTAT GAGTATTCAA CATTTCCTG TCGCCCTTAT	240
TCCCTTTTTT GCGGCATTTT GCCTTCCTGT TTTTGCTCAG CCAGAAACGC TGGTGAAAGT	300
AAAAGATGCT GAAGATCAGT TGGGTGCACG ACTGGGTAC ATCGAACTGG ATCTCAACAG	360
CGGTAAGATC CTTGAGAGTT TTCGCCCGA AGAACGTTT CCAATGATGA GCACTTTTAA	420
AGTTCTGCTA TGTGGCGCGG TATTATCCCG TGTGACGCC GGGCAAGAGC AACTCGGTGC	480
CCGCATACAC TATTCTCAGA ATGACTTGGT TGAGTACTCA CCAGTCACAG AAAAGCATCT	540
TACGGATGGC ATGACAGTAA GAGAATTATG CAGTGCTGCC ATAACCATGA GTGATAACAC	600
TGCGGCCAAC TTACTTCTGA CAACGATCGG AGGACCGAAG GAGCTAACCG CTTTTTTGCA	660
CAACATGGGG GATCATGTAA CTCGCCCTGA TCGTTGGGAA CCGGAGCTGA ATGAAGCCAT	720
ACCAAACGAC GAGCGTGACA CCACGATGCC TGCAGCAATG GCAACAACGT TCGCGAAACT	780
ATTAAGTGGC GAACTACTTA CTCTAGCTTC CCGGCAACAA TTAATAGACT GGATGGAGGC	840
GGATAAAGTT GCAGGACCAC TTCTGCGCTC GGCCTTCCG GCTGGCTGGT TTATTGCTGA	900
TAAATCTGGA GCCGGTGAGC GTGGGTCTCG CCGTATCATT GCAGCACTGG GGCCAGATGG	960
TAAGCCCTCC CGTATCGTAG TTATCTACAC GACGGGGAGT CAGGCAACTA TGGATGAACG	1020
AAATAGACAG ATCGCTGAGA TAGGTGCCCTC ACTGATTAAG CATTGGTAAC TGTCAGACCA	1080
AGTTTACTCA TATATACTTT AGATTGATT AAAACTTCAT TTTTAATTAA AAAGGATCTA	1140
GGTGAAGATC CTTTTTGATA ATCTCATGAC CAAAATCCCT TAACGTGAGT TTTGTTCCA	1200
CTGAGCGTCA GACCCCGTAG AAAAGATCAA AGGATCTTCT TGAGATCCTT TTTTCTGCG	1260
CGTAATCTGC TGCTTGCAAA CAAAAAACC ACCGCTACCA GCGGTGTTT GTTTGCCGGA	1320
TCAAGAGCTA CCAACTCTTT TTCCGAAGGT AACTGGCTTC AGCAGAGCGC AGATACCAAA	1380
TACTGTCCTT CTAGGTIAGC CGTAGTTAGG CCACCACTTC AAGAACTCTG TAGCACC GCC	1440

TACATACCTC GCTCTGCTAA TCCTGTTACC AGTGGCTGCT GCCAGTGGCG ATAAGTCGTG 1500
TCTTACCGGG TTGGACTCAA GACGATAGTT ACCGGATAAG GCGCAGCGGT CGGGCTGAAC 1560
GGGGGGTTCC TGCACACAGC CCAGCTTGGG GCGAACGACC TACACCGAAC TGAGATACCT 1620
ACAGCGTGAG CATTGAGAAA GCGCCACGCT TCCCGAAGGG AGAAAGGCGG ACAGGTATCC 1680
GGTAAGCGGC AGGCTCGGAA CAGGAGAGCG CACGAGGGAG CTTCAGGGG GAAACGCCTG 1740
GTATCTTTAT AGTCCTGTCG GGTTCGCCA CCTCTGACTT GAGCGTCGAT TTTTGTGATG 1800
CTCGTCAGGG GGGCGGAGCC TATGAAAAA CGCCAGCAAC GCGGCCTTTT TACGGTTCCT 1860
GGCCTTTTGC TGGCCTTTTG CTCACATGTT CTTTCCTGCG TTATCCCTG ATTCTGTGGA 1920
TAACCGTATT ACCGCCTTTG AGTGAGCTGA TACCGCTCGC CGCAGCCGAA CGACCGAGCG 1980
CAGCGAGTCA GTGAGCGAGG AAGCGGAAGA GCGCCTGATG CGGTATTTTC TCCTTACGGA 2040
TCTGTGCGGT ATTTACACACC GCATATGGTG CACTCTCAGT ACAATCTGCT CTGATGCCGC 2100
ATAGTTAAGC CAGTATTGGA CCTCGAGGGA TCTTTGTGAA GGAACCTTAC TTCTGTGGTG 2160
TGACATAATT GGACAACTA CCTACAGAGA TTAAAGCTC TAAGGTAAAT ATAAAATTTT 2220
TAAGTGATA ATGTGTTAAA CTAAGTATTC TAATTGTTTG TGTATTTTAG ATTCCAACCT 2280
ATGGAAGTGA TGAATGGGAG CAGTGGTGGA ATGCCTTTAA TGAGGAAAAC CTGTTTTGCT 2340
CAGAAGAAAT GCCATCTAGT GATGATGAGG CTAAGTCTGA CTCTCAACAT TCTACTCTC 2400
CAAAAAAGAA GAGAAAGGTA GAAGACCCCA AGGACTTTCC TTCAGAATTG CTAAGTTTTT 2460
TGAGTCATGC TGTGTTTAGT AATAGAACTC TTGCTTGCTT TGCTATTTAC ACCACAAAGG 2520
AAAAAGCTGC ACTGCTATAC AAGAAAATTA TGGAAAAATA TTCTGTAACC TTTATAAGTA 2580
GGCATAACAG TTATAATCAT AACATACTGT TTTTCTTAC TCCACACAGG CATAGAGTGT 2640
CTGCTATTAA TAACTATGCT CAAAAATTGT GTACCTTTAG CTTTTTAATT TGTAAGGGG 2700
TTAATAAGGA ATATTTGATG TATAGTGCTT TGACTAGAGA TCATAATCAG CCATACCACA 2760
TTGTAGAGG TTTTACTTGC TTAAAAAAC CTCCACACC TCCCCCTGAA CCTGAAACAT 2820
AAAATGAATG CAATTGTTGT TGTTAACTTG TTTATTGCAG CTTATAATGG TTACAAATAA 2880
AGCAATAGCA TCACAAATTT CACAAATAAA GCATTTTTTT CACTGCATTC TAGTTGTGGT 2940
TTGTCCAAAC TCATCAATGT ATCTTATCAT GTCTGGATCC GGCTGTGGAA TGTGTGTCAG 3000

TTAGGGTGTG GAAAGTCCCC AGGCTCCCCA GCAGGCAGAA GTATGCAAAG CATGCATCTC	3060
AATTAGTCAG CAACCAGGTG TGGAAAGTCC CCAGGCTCCC CAGCAGGCAG AAGTATGCAA	3120
AGCATGCATC TCAATTAGTC AGCAACCATA GTCCCGCCCC TAACTCGGCC CATCCCGCCC	3180
CTAACTCCGC CCAGTTCGGC CCATTCTCCG CCCCATGGCT GACTAATTTT TTTTATTTAT	3240
GCAGAGGCGG AGGCCGCCCTC GGCCTCTGAG CTATTCCAGA AGTAGTGAGG AGGCTTTTTT	3300
GGAGGCCTAG GCTTTTGCAA AAAGCTTCAC GCTGCCGCAA GCACTCAGGG CGCAAGGGCT	3360
GCTAAAGGAA GCGGAACACG TAGAAAGCCA GTCCGCAGAA ACGGTGCTGA CCCC GGATGA	3420
ATGTCAGCTA CTGGGCTATC TGGACAAGGG AAAACGCAAG CGCAAAGAGA AAGCAGGTAG	3480
CTTGCACTGG GCTTACATGG CGATAGCTAG ACTGGGCGGT TTTATGGACA GCAAGCGAAC	3540
CGGAATTGCC AGCTGGGGCG CCTCTGGTA AGTTGGGAA GCCCTGCAA GTAACTGGA	3600
TGGCTTTCTT GCCGCCAAGG ATCTGATGGC GCAGGGGATC AAGATCTGAT CAAGAGACAG	3660
GATGAGGATC GTTTCGCATG ATTGAACAAG ATGGATTGCA CGCAGTTCT CCGGCCGCTT	3720
GGTGAGAG GCTATTCGGC TATGACTGGG CACAACAGAC AATCGGCTGC TCTGATGCCG	3780
CCGTGTTCCG GCTGTCAGCG CAGGGGCGCC CGGTTCTTTT TGTCAAGACC GACCTGTCCG	3840
GTGCCCTGAA TGAATGCAG GACGAGGCAG CGCGGCTATC GTGGCTGGCC ACGACGGGCG	3900
TTCCTTGCGC AGCTGTGCTC GACGTGTGCA CTGAAGCGGG AAGGGACTGG CTGCTATTGG	3960
GCGAAGTGCC GGGGCAGGAT CTCCTGTCAT CTCACCTTGC TCCTGCCGAG AAAGTATCCA	4020
TCATGGCTGA TGCAATGCGG CGGCTGCATA CGCTTGATCC GGCTACCTGC CCATTGACC	4080
ACCAAGCGAA ACATCGCATC GAGCGAGCAC GTACTCGGAT GGAAGCCGGT CTTGTGCATC	4140
AGGATGATCT GGACGAAGAG CATCAGGGGC TCGCGCCAGC CGAACTGTTT GCCAGGCTCA	4200
AGGCGCGCAT GCCCGACGGC GAGGATCTCG TCCTGACCCA TGGCGATGCC TGCTTGCCGA	4260
ATATCATGGT GAAAAATGGC CGCTTTTCTG GATTTCATCGA CTGTGGCCGG CTGGGTGTGG	4320
CGGACCGCTA TCAGGACATA GCGTTGGCTA CCCGTGATAT TGCTGAAGAG CTGCGCGCGC	4380
AATGGGCTGA CCGCTTCCTC GTGCTTTACG GTATCGCCGC TCCGATTTCG CAGCGCATCG	4440
CCTTCTATCG CCTTCTTGAC GAGTTCTTCT GAGCGGGACT CTGGGGTTTCG AAATGACCGA	4500
CCAAGCGACG CCCAACCTGC CATCAGGAGA TTTTGATTCC ACCGCCGCT TCTATGAAAG	4560

GTGGGGCTTC GGAATCGTTT TCCGGGACGC CGGCTGGATG ATCCTCCAGC GCGGGGATCT 4620
CATGCTGGAG TTCTTCGCCC ACCCCGGGCT CGATCCCCCTC GCGAGTTGGT TCAGCTGCTG 4680
CCTGAGGCTG GACGACCTCG CGGAGTTCTA CCGGCAGTGC AAATCCGTCG GCATCCAGGA 4740
AACCAGCAGC GGCTATCCGC GCATCCATGC CCCCGAAGTGC CAGGAGTGGG GAGGCACGAT 4800
GGCCGCTTTG GTCCCGGATC TTTGTGAAGG AACCTTACTT CTGTGGTGTG ACATAATTGG 4860
ACAAACTACC TACAGAGATT TAAAGCTCTA AGGTAAATAT AAAATTTTAA AGTGTATAAT 4920
GTGTTAAACT ACTGATTCTA ATTGTTTGTG TATTTTAGAT TCCAACCTAT GGAAGTATG 4980
AATGGGAGCA GTGGTGAAT GCCTTTAATG AGGAAAACCT GTTTTGCTCA GAAGAAATGC 5040
CATCTAGTGA TGATGAGGCT ACTGCTGACT CTCAACATTC TACTCCTCCA AAAAAGAAGA 5100
GAAAGGTAGA AGACCCCAAG GACTTTCCTT CAGAATTGCT AAGTTTTTTG ACTCATGCTG 5160
TGTTTAGTAA TAGAACTCTT GCTTGCTTTG CTATTTACAC CACAAAGGAA AAAGCTGCAC 5220
TGCTATACAA GAAAATTATG GAAAAATATT CTGTAACCTT TATAAGTAGG CATAACAGTT 5280
ATAATCATAA CATACTGTTT TTTCTTACTC CACACAGGCA TAGAGTGTCT GCTATTAATA 5340
ACTATGCTCA AAAATTGTGT ACCTTTAGCT TTTTAATTG TAAAGGGGTT AATAAGGAAT 5400
ATTTGATGTA TAGTGCCTTG ACTAGAGATC ATAATCAGCC ATACCACATT TGTAGAGGTT 5460
TTRACTTGCTT TAAAAAACCT CCCACACCTC CCCCTGAACC TGAAACATAA AATGAATGCA 5520
ATTGTTGTTG TTAAGTTGTT TATTGCAGCT TATAATGGTT ACAAATAAAG CAATAGCATC 5580
ACAAATTTCA CAAATAAAGC ATTTTTCCTA CTGCATCTA GTGTGGTTT GTCCAAACTC 5640
ATCAATGTAT CTTATCATGT CTGGATCCCC AGGAAGCTCC TCTGTGTCTT CATAAACCTT 5700
AACCTCCTCT ACTTGAGAGG ACATTCCAAT CATAGGCTGC CCATCCACCC TCTGTGTCTT 5760
CCTGTTAATT AGGTCACCTA AAAAAAGGA AATTGGGTAG GGGTTTTTCA CAGACCGCTT 5820
TCTAAGGGTA ATTTTAAAT ATCTGGGAAG TCCCTTCCAC TGCTGTGTTT CAGAAGTGT 5880
GGTAAACAGC CCACAAATGT CAACAGCAGA AACATACAAG CTGTCAGCTT TGCACAAGGG 5940
CCCAACACCC TGCTCATCAA GAAGCACTGT GGTGCTGTG TTAGTAATGT GCAAAACAGG 6000
AGGCACATT TCCCCACCTG TGTAGGTCC AAAATATCTA GTGTTTTTCA TTTTACTTGG 6060
ATCAGGAACC CAGCACTCCA CTGGATAAGC ATTATCCTTA TCCAAAACAG CTTGTGGTC 6120

AGTGTTCATC TGCTGACTGT CAACTGTAGC ATTTTTTGGG GTTACAGTTT GAGCAGGATA	6180	GC
TTTGGTCTG TAGTTTGCTA ACACACCCTG CAGCTCCAAA GGTTCCCCAC CAACAGCAAA	6240	GT
AAAATGAAAA TTTGACCCTT GAATGGGTTT TCCAGCACCA TTTTCATGAG TTTTTGTGT	6300	AG
CCCTGAATGC AAGTTTAAAC TAGCAGTTAC CCCAATAACC TCAGTTTAA EAGTAACAGC	6360	GC
TTCCACATC AAAATATTTC CACAGGTAA GTCTCATTT AAATTAGGCA AAGGAATTAT	6420	AA
ACACTCCGCT ATCGCTACCT GACTGGGTCA TGGCTGCGCC CCGACACCCG CCAACACCCG	6480	GT
CTGACGCGCC CTGACGGGCT TGTCTGCTCC CGGCATCCGC TTACAGACAA GCTGTGACCG	6540	AT
TCTCCGGGAG CTGCATGTGT CAGAGGTTTT CACCGTCATC ACCGAAACGC GCGAGGCAGC	6600	CA
GGATCATAAT CAGCCATACC ACATTTGTAG AGGTTTTACT TGCTTTAAAA AACCTCCAC	6660	TG
ACCTCCCCT GAACCTGAAA CATAAAATGA ATGCAATTGT TGTGTAAAC TTGTTTATTG	6720	TC
CAGCTTATAA TGGTTACAAA TAAAGCAATA GCATCACAAA TTTCACAAAT AAAGCATTTT	6780	GA
TTTCACTGCA TTCTAGTTGT GGTGTGTCCA AACTCATCAA TGTATCTTAT CATGTCTGGA	6840	AC
TCATAATCAG CCATACCACA TTTGTAGAGG TTTTACTTGC TTTAAAAAC CTCCCACACC	6900	TG
TCCCCCTGAA CCTGAAACAT AAAATGAATG CAATTGTTGT TGTTAACTTG TTTATTGCAG	6960	AG
CTTATAATGG TTACAAATAA AGCAATAGCA TCACAAATTT CACAAATAAA GCATTTTTTT	7020	AC
CACTGCATTC TAGTTGTGGT TTGTCCAAAC TCATCAATGT ATCTTATCAT GTCTGGATCC	7080	CT
CAAGCTTACC ATGGTAACCC CTGGTCCCGT TCAGCCACCA CCACCCCAACC CAGCACACCT	7140	TC
CCAACCTCAG CCAGACAAGG TTGTTGACAC AAGAGAGCCC TCAGGGGCAC AGAGAGAGTC	7200	GT
TGGACACCTG GGGAGTCAGC CGTGTATCAT CGGAGGCGGC CGGGCACATG GCAGGGATGA	7260	GA
GGGAAAGACC AAGAGTCCTC TGTTGGGCCC AAGTCCTAGA CAGACAAAAC CTAGACAATC	7320	AT
ACGTGGCTGG CTGCATGCCT GTGGCTGTTG GGCTGGGCAG GAGGAGGGAG GGGCGCTCTT	7380	CT
TCCTGGAGGT GGTCCAGAGC ACCGGGTGGA CAGCCCTGGG GGAAAACTTC CACGTTTGA	7440	TT
TGGAGTTAT CTTTGATAAC TCCACAGTGA CCTGGTTCGC CAAAGGAAAA GCAGGCAACG	7500	GA
TGAGCTGTTT TTTTTTCTC CAAGCTGAAC ACTAGGGGTC CTAGGCTTTT TGGGTCACCC	7560	CG
GGCATGGCAG ACAGTCAACC TGGCAGGACA TCCGGGAGAG ACAGACACAG GCAGAGGGCA	7620	GG
GAAAGGTCAA GGGAGGTTCT CAGGCCAAGG CTATTGGGGT TTGCTCAATT GTTCCTGAAT	7680	CC

GCTCTTACAC ACGTACACAC ACAGAGCAGC ACACACACAC ACACACACAT GCCTCAGCAA 7740
GTCCCAGAGA GGGAGGTGTC GAGGGGGACC CGCTGGCTGT TCAGACGGAC TCCCAGAGCC 7800
AGTGACTGGG TGGGGCTGGA ACATGAGTTC ATCTATTTCC TGCCCACATC TGGTATAAAA 7860
GGAGGCAGTG GCCCACAGAG GAGCACAGCT GTGTTTGCT GCAGGGCCAA GAGCGCTGTC 7920
AAGAAGACCC ACACGCCCC CTCCAGCAGC TGAATTCCAG CTGGCATTCC GGTACTGTTG 7980
GTAAAATGGA AGACGCCAAA AACATAAAGA AAGGCCCGGC GCCATTCTAT CCTCTAGAGG 8040
ATGGAACCGC TGGAGAGCAA CTGCATAAGG CTATGAAGAG ATACGCCCTG GTTCCTGGAA 8100
CAATTGCTTT TACAGATGCA CATATCGAGG TGAACATCAC GTACGGGAA TACTTCGAAA 8160
TGTCCGTTCC GTTGGCAGAA GCTATGAAAC GATATGGGCT GAATACAAAT CACAGAATCG 8220
TCGTATGCAG TGAAACTCT CTTCAATTCT TTATGCCGGT GTTGGGCGCG TTATTTATCG 8280
GAGTTGCACT TGCGCCCGCG AACGACATT ATAATGAACG TGAATTGCTC AACAGTATGA 8340
ACATTTCCGA GCCTACCGTA GTGTTTGTTC CAAAAAGGG GTTGCAAAAA ATTTTGAACG 8400
TGCAAAAAAA ATTACCAATA ATCCAGAAAA TTATTATCAT GGATTCTAAA ACGGATTACC 8460
AGGGATTICA GTCGATGTAC ACGTTCGTCA CATCTCATCT ACCTCCCGGT TTTAATGAAT 8520
ACGATTTTGT ACCAGAGTCC TTTGATCGTG ACAAACAAT TGCACTGATA ATGAATTCCT 8580
CTGGATCTAC TGGGTTACCT AAGGGTGTGG CCCTTCGCA TAGAACTGCC TCGTCAGAT 8640
TCTCGCATGC CAGAGATCCT ATTTTGGCA ATCAAATCAT TCCGGATACT GCGATTTTAA 8700
GTGTGTTC ATTCCATCAC GGTTTTGGAA TGTTTACTAC ACTCGGATAT TTGATATGTG 8760
GATTTGAGT CGTCTTAATG TATAGATTG AAGAAGAGCT GTTTTACGA TCCCTTCAGG 8820
ATTACAAAAT TCAAAGTGGG TTGCTAGTAC CAACCTTATT TTCATTCTTC GCCAAAAGCA 8880
CTCTGATTGA CAAATACGAT TTATCTAATT TACAGGAAAT TGCTTCTGGG GGCGCACCTC 8940
TTTCGAAAGA AGTCGGGGAA GCGGTGCAA AACGCTTCCA TCTCCAGGG ATACGACAAG 9000
GATATGGGCT CACTGAGACT ACATCAGCTA TTCTGATTAC ACCCGAGGGG GATGATAAAC 9060
CGGGCGCGGT CGGTAAAGTT GTTCCATTTT TTGAAGCGAA GTTGTGGAT CTGATACCG 9120
GGAAAACGCT GGGCGTTAAT CAGAGAGGCG AATTATGTGT CAGAGGACCT ATGATTATGT 9180
CCGGTTATGT AAACAATCCG GAAGCGACCA ACGCCTTGAT TGACAAGGAT GGATGGCTAC 9240

ATTCTGGAGA CATAGCTTAC TGGGACGAAG ACGAACACTT CTTCATAGTT GACCGCTTGA 9300
AGTCTTTAAT TAAATACAAA GGATATCAGG TGGCCCCCGC TGAATTGGAA TCGATATTGT 9360
TAGAACACCC CAACATCTTC GACGCGGGCG TGGCAGGTCT TCCCGACGAT GACGCGGGTG 9420
AACTCCCGC CGCCGTTGTT GTTTGGAGC ACGGAAAGAC GATGACGGAA AAAGAGATCG 9480
TGGATTACGT CGCCAGTCAA GTAACAACCG CGAAAAAGTT GCGCGGAGGA GTTGTGTTTG 9540
TGGACGAAGT ACCGAAAGGT CTTACCGGAA AACTCGACGC AAGAAAAATC AGAGAGATCC 9600
TCATAAAGGC CAAGAAGGGC GGAAAGTCCA AATTGTAAAA TGTAAGTGTG TTCAGCGATG 9660
ACGAAATTCT TAGCTATTGT AATGACTCTA GAGGATCTTT GTGAAGGAAC CTTACTTCTG 9720
TGGTGTGACA TAATTGGACA AACTACCTAC AGAGATTIAA AGCTCTAAGG TAAATATAAA 9780
ATTTTAAAGT GTATAATGTG TTAACTACT GATTCTAATT GTTTGTGTAT TTTAGATTCC 9840
AACCTATGGA ACTGATGAAT GGGAGCAGTG GTGGAATGCC TTTAATGAGG AAAACCTGTT 9900
TTGCTCAGAA GAAATGCCAT CTAGTGATGA TGAGGCTACT GCTGACTCTC AACATTCTAC 9960
TCCTCCAAAA AAGAAGAGAA AGGTAGAAGA CCCCAAGGAC TTTCTTCAG AATTGCTAAG 10020
TTTTTTGAGT CATGCTGTGT TTAGTAATAG AACTCTTGCT TGCTTTGCTA TTTACACCAC 10080
AAAGGAAAAA GCTGCACTGC TATACAAGAA AATTATGGAA AAATATTCTG TAACCTTTAT 10140
AAGTAGGCAT AACAGTTATA ATCATAACAT ACTGTTTTTT CTTACTCCAC ACAGGCATAG 10200
AGTGCTGCT ATTAATAACT ATGCTCAAAA ATTGTGTACC TTTAGCTTTT TAATTTGTAA 10260
AGGGGTAAAT AAGGAATATT TGATGTATAG TGCCTTGACT AGAGATCATA ATCAGCCATA 10320
CCACATTTGT AGAGGTTTTA CTGCTTTTAA AAAACCTCCC ACACCTCCCC CTGAACCTGA 10380
AACATAAAAT GAATGCAATT GTTGTTGTTA ACTTGTTTAT TGCAGCTTAT AATGGTTACA 10440
AATAAAGCAA TAGCATCACA AATTCACAA ATAAAGCATT TTTTCACTG CATTCTAGTT 10500
GTGGTTTGTC CAAACTCATC AATGTATCTT ATCATGTCTG GATCCCCAGG AAGCTCCTCT 10560
GTGTCCTCAT AAACCCTAAC CTCCTCTACT TGAGAGGACA TTCCAATCAT AGGCTGCCCC 10620
TCCACCCTCT GTGTCCTCCT GTTAATTAGG TCACTTAACA AAAAGGAAAT TGGGTAGGGG 10680
TTTTTCACAG ACCGCTTTCT AAGGTAATT TTAAATATC TGGGAAGTCC CTTCCACTGC 10740
TGTTTCCAG AAGTGTGGT AAACAGCCCA CAAATGTCAA CAGCAGAAAC ATACAAGCTG 10800

W

T

G

T

AA

AC

TC

TC

GT

TT

(2)

TTC

AATC

TTTA

GCTI

TCCC

AAAA

CGGT

AGTT

TCAGCTTTGC ACAAGGGCCC AACACCCTGC TCAGCAAGAA GCACTGTGGT TGCTGTGTTA 10860
GTAATGTGCA AAACAGGAGG CACATTTTCC CCACCTGTGT AGGTTCCAAA ATATCTAGTG 10920
TTTTCATTTT TACTTGGATC AGGAACCCAG CACTCCACTG GATAAGCATT ATCCTTATCC 10980
AAAACAGCCT TGTGGTQAGT GTTCATCTGC TGA CTGTAGGATT TTTTGGGGTT 11040
ACAGTTTGAG CAGGATATTT GGTCTGTAG TTTGCTAACA CACCCTGCAG CTCCAAAGGT 11100
TCCCACAGAA CAGCAAAAAA ATGAAAAATT GACCCTTGAA TGGGTTTTCC AGCACCATT 11160
TCATGAGTTT TTTGTGTCCC TGAATGCAAG TTTAACATAG CAGTTACCCC AATAACCTCA 11220
GTTTAAACAG TAACAGCTTC CCACATCAAA ATATTTCCAC AGGTTAAGTC CTCATTTAAA 11280
TTAGGCAAAG GAA 11293

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10697 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

TTCTTGAAGA CGAAAGGGCC TCGTGATAGC CCTATTTTIA TAGGTTAATG TCATGATAAT 60
AATGGTTTCT TAGACGTCAG GTGGCACTTT TCGGGGAAAT GTGCGGGAA CCCCTATTG 120
TTTATTTTTC TAAATACATT CAAATATGTA TCCGCTCATG AGACAATAAC CCTGATAAAT 180
GCTTCAATAA TATTGAAAAA GGAAGAGTAT GAGTATTCAA CATTTCCGTG TCGCCCTTAT 240
TCCCTTTTTT GCGGCATTTT GCCTTCCTGT TTTTGCTCAC CCAGAAACGC TGGTGAAAGT 300
AAAAGATGCT GAAGATCAGT TGGGTGCACG AGTGGGTAC ATCGAACTGG ATCTCAACAG 360
CGGTAAGATC CTTGAGAGTT TTCGCCCCGA AGAACGTTTT CCAATGATGA GCACTTTTAA 420
AGTTCTGCTA TGTGGCGCGG TATTATCCCG TGTGACGCC GGGCAAGAGC AACTCGGTCC 480

CCGCATACAC TATTCTCAGA ATGACTTGGT TGAGTACTCA CCAGTGACAG AAAAGCATCT 540
TACGGATGGC ATGACAGTAA GAGAATTATG CAGTGCTGCC ATAACCATGA GTGATAACAC 600
TGCGGCCAAC TTACTTCTGA CAACGATCGG AGGACCGAAG GAGCTAACCG CTTTTTTGCA 660
CAACATGGGG GATCATGTAA CTGCGCTTGA TCGTTGGGAA CCGGAGCTGA ATGAAGCCAT 720
ACCAAACGAC GAGCGTGACA CCACGATGCC TGCAGCAATG GCAACAACGT TGCGCAAAC 780
ATTAAGTGGC GAACTACTTA CTCTAGCTTC CCGGCAACAA TTAATAGACT GGATGGAGGC 840
GGATAAAGTT GCAGGACCAC TTCTGCGCTC GCGCCTTCCG GCTGGCTGGT TTATTGCTGA 900
TAAATCTGGA GCCGGTGAGC GTGGGTCTCG CGGTATCATT GCAGCACTGG GGCCAGATGG 960
TAAGCCCTCC CGTATCGTAG TTATCTACAC GACGGGGAGT CAGGCAACTA TGGATGAACG 1020
AAATAGACAG ATCGCTGAGA TAGGTGCCTC ACTGATTAAG CATTGGTAACT TGTGAGACCA 1080
AGTTTACTCA TATATACTTT AGATTGATTT AAAACTTCAT TTTAATTTA AAAGGATCTA 1140
GGTGAAGATC CTTTTTGATA ATCTCATGAC CAAAATCCCT TAACGTGAGT TTTCGTTCCA 1200
CTGAGCGTCA GACCCCGTAG AAAAGATCAA AGGATCTTCT TGAGATCCTT TTTTCTGCG 1260
CGTAATCTGC TGCTTGCAA CAAAAAACC ACCGCTACCA GCGGTGTTT GTTGCCGGA 1320
TCAAGAGCTA CCAACTCTTT TTCCGAAGGT AACTGGCTTC AGCAGAGCGC AGATACCAA 1380
TACTGTCTT CTAGTGAGC CGTAGTTAGG CCACCACTTC AAGAACTCTG TAGCACC GCC 1440
TACATACCTC GCTCTGTAA TCCTGTTACC AGTGGCTGCT GCCAGTGGC ATAAGTCTG 1500
TCTTACCGGG TTGACTCAA GACGATAGT ACCGGATAAG GCGCAGCGT CCGGCTGAAC 1560
GGGGGGTTCG TGCACACAGC CCAGCTTGA GCGAACGACC TACACCGAAC TGAGATACCT 1620
ACAGCGTGAG CATTGAGAAA GCGCCAGCT TCCCGAAGG AGAAAGGCG ACAGGTATCC 1680
GGTAAGCGGC AGGGTCGGAA CAGGAGAGC CACGAGGAG CTTCAGGGG GAAACGCCTG 1740
GTATCTTAT AGTCCTGTG GGTTCGCCA CCTCTGACTT GAGCGTCGAT TTTTGTGATG 1800
CTCGTCAGG GGGCGGAGC TATGAAAAA CGCCAGCAAC GCGGCCTTTT TACGGTTCCT 1860
GGCCTTTTGC TGGCCTTTTG CTCACATGTT CTTTCCTGCG TATCCCTG ATTCTGTGGA 1920
TAACCGTATT ACCGCCTTTG AGTGAGCTGA TACCGCTCGC CGCAGCCGAA CGACCGAGCG 1980
CAGCGAGTCA GTGAGCGAGG AAGCGGAAGA GCGCCTGATG CGGTATTTTC TCCTTACGCA 2040

TC

AT

TG

TAA

ATC

CAG

CAA

TGA

AAA

GGC

CTG

TTA

TTT

AAA

AGC

TTG

TTA

AAT

AGC

CTA

GCA

GGA

GCT

ATG

CTT

CGG

TCTGTGCGGT ATTCACACC GCATATGGTG CACTCTCAGT ACAATCTGCT CTGATGCCGC	2100
ATAGTTAAGC CAGTATTCGA CCTCGAGGGA TCTTTGTGAA GGAACCTTAC TTCTGTGGTG	2160
TGACATAATT GGACAACTA CCTACAGAGA TTAAAGCTC TAAGGTAAAT ATAAAATTTT	2220
TAAGTGATA ATGTGTIAAA CTACTGATTG TAATTGTTTG TGTATTTTAG ATTCCAACCT	2280
ATGGAAGTGA TGAATGGGAG CAGTGGTGA ATGCCTTAA TGAGGAAAAC CTGTTTGTCT	2340
CAGAAGAAAT GCCATCTAGT GATGATGAGG CTACTGCTGA CTCTCAACAT TCTACTCCTC	2400
CAAAAAGAA GAGAAAGGTA GAAGACCCCA AGGACTTTCC TTCAGAATTG CTAAGTTTTT	2460
TGAGTCATGC TGTGTTTACT AATAGAACTC TTGCTTGCTT TGCTATTAC ACCACAAAGG	2520
AAAAAGCTGC ACTGCTATAC AAGAAAATTA TGGAAAAATA TTCTGTAACC TTTATAAGTA	2580
GGCATAACAG TTATAATCAT AACATACTGT TTTTCTTAC TCCACACAGG CATAGAGTGT	2640
CTGCTATTAA TAACTATGCT CAAAAATTGT GTACCTTTAG CTTTTTAATT TGTAAGGGG	2700
TTAATAAGGA ATATTTGATG TATAGTCCT TGACTAGAGA TCATAATCAG CCATACCACA	2760
TTTGTAGAGG TTTTACTTGC TTTAAAAAAC CTCCACACC TCCCCTGAA CCTGAAACAT	2820
AAAATGAATG CAATTGTTGT TGTTAACTTG TTTATTGCAG CTTATAATGG TTACAAATAA	2880
AGCAATAGCA TCACAAATT CACAAATAAA GCATTTTTT CACTGCATTG TAGTTGTGGT	2940
TTGTCCAAAC TCATCAATGT ATCTTATCAT GTCTGGATCC GGCTGTGGAA TGTGTGTCAG	3000
TTAGGGTGTG GAAAGTCCCC AGGCTCCCCA GCAGGCAGAA GTATGCAAAG CATGCATCTC	3060
AATTAGTCAG CAACCAGGTG TGGAAAGTCC CCAGGCTCCC CAGCAGGCAG AAGTATGCAA	3120
AGCATGCATC TCAATTAGTC AGCAACCATA GTCCGCCCC TAACTCCGCC CATCCGCCCC	3180
CTAACTCCGC CCAGTCCGC CCATTCTCCG CCCCATGGCT GACTAATTTT TTTTATTAT	3240
GCAGAGGCCG AGGCCGCCTC GGCCTCTGAG CTATTCCAGA AGTACTGAGG AGGCTTTTTT	3300
GGAGGCCTAG GCTTTTGCAA AAAGCTTCAC GCTGCCGCAA GCACTCAGG CGCAAGGGCT	3360
GCTAAAGGAA GCGGAACACG TAGAAAGCCA GTCCGAGAA ACGGTGCTGA CCCCGATGA	3420
ATGTCAGCTA CTGGGCTATC TGGACAAGG AAAACGCAAC CGCAAAGAGA AAGCAGGTAG	3480
CTTGCACTGG GCTTACATGG CGATAGCTAG ACTGGGCGGT TTTATGGACA GCAAGCGAAC	3540
CGGAATTGCC AGCTGGGGCG CCCTCTGGTA AGTTGGGAA GCCCTGCAA GTAACTGGA	3600

TGGCTTTCTT GCCGCCAAGG ATCTGATGGC GCAGGGGATC AAGATCTGAT CAAGAGACAG 3660
GATGAGGATC GTTTCGCATG ATTGAACAAG ATGGATTGCA CGCAGGTTCT CCGGCCGCTT 3720
GGGTGGAGAG GCTATTCGGC TATGACTGGG CACAACAGAC AATCGGCTGC TCTGATGCCG 3780
CCGTGTTCGG GCTGTCAGCG CAGGGGGCCC CGGTTCTTTT TGTCAAGACC GACCTGTCCG 3840
GTGCCCTGAA TGAAGTGCAG GACGAGGCAG CGCGGCTATC GTGGCTGGCC ACCACGGGCG 3900
TTCCTTGCGC AGCTGTGCTC GACGTTGTCA CTGAAGCGGG AAGGGACTGG CTGCTATTGG 3960
GCGAAGTGCC GGGGCAGGAT CTCCTGTCACT CTCACCTTGC TCCTGCCGAG AAAGTATCCA 4020
TCATGGCTGA TGCAATGCGG CGGCTGCATA CGCTTGATCC GGCTACCTGC CCATTGACC 4080
ACCAAGCGAA ACATCGCATC GAGCGAGCAC GACTCGGAT GGAAGCCGGT CTTGTGATC 4140
AGGATGATCT GGACGAAGAG CATCAGGGGC TCGCGCCAGC CGAACTGTTT GCCAGGCTCA 4200
AGGCGCGCAT GCCCGACGGC GAGGATCTCG TCGTGACCCA TGGCGATGCC TGCTTGCCGA 4260
ATATCATGGT GAAAATGGC CGCTTTTCTG GATTCAATGA CTGTGGCCGG CTGGGTGTGG 4320
CGGACCGCTA TCAGGACATA GCGTTGGCTA CCCGTGATAT TGCTGAAGAG CTGGCGGGCG 4380
AATGGGCTGA CCGCTTCCTC GTGCTTTACG GTATCGCCGC TCCCGATTCC CAGCGCATCG 4440
CCTTCTATCG CCTTCTTGAC GAGTTCTTCT GAGCGGGACT CTGGGGTTCC AAATGACCGA 4500
CCAAGCGACG CCCAACCTGC CATCAGGAGA TTTGATTCC ACCGCGCGCT TCTATGAAAG 4560
GTGGGGCTTC GGAATCGTTT TCCGGGACGC CGGCTGGATG ATCCTCCAGC CGGGGGATCT 4620
CATGCTGGAG TTCTTCGCCC ACCCGGGGCT CGATCCCCTC GCGAGTTGGT TCAGCTGCTG 4680
CCTGAGGCTG GACGACCTCG CGGAGTTCTA CCGGCAGTGC AAATCCGTCC GCATCCAGGA 4740
AACCAGCAGC GGCTATCCGC GCATCCATGC CCCCAGACTG CAGGAGTGGG GAGGCACGAT 4800
GGCCGCTTTC GTCCCGGATC TTTGTGAAGG AACCTTACTT CTGTGGTGTG ACATAATTGG 4860
ACAACTIACC TACAGAGATT TAAAGCTCTA AGGTAAATAT AAAATTTTAA AGTGATAAT 4920
GTGTTAAACT ACTGATTCTA ATTGTTTGTG TATTTTAGAT TCCAACCTAT GGAAGTATG 4980
AATGGGAGCA GTGGTGAAT GCCTTTAATG AGGAAAACCT GTTTTGCTCA GAAGAAATGC 5040
CATCTAGTGA TGATAGGCT ACTGCTGACT CTCAACATTC TACTCCTCCA AAAAAGAAGA 5100
GAAAGGTAGA AGACCCCAAG GACTTTCCTT CAGAATTGCT AAGTTTTTTG ACTCATGCTG 5160

WO

TG

TG

AT

AC

AT

TT

AT

AC

ATC

AAC

CCI

TCT

GGT

CCC

AGG

ATC

AGT

TTT

AAA

CCC

TTC

ACAC

CTGA

TCTC

GGAT

ACCT

TGTTTAGTAA TAGAACTCTT GCTTGCTTTG CTATTTACAC CACAAAGGAA AAAGCTGCAC 5220
TGCTATACAA GAAAATTATG GAAAAATATT CTGTAACCTT TATAAGTAGG CATAACAGTT 5280
ATAATCATAA CATACTGTTT TTTCTTACTC CACACAGGCA TAGAGTGTCT GCTATTAATA 5340
ACTATGCTCA AAAATTGTGT ACCTTTAGCT TTTAATTG TAAAGGGGTT AATAAGGAAT 5400
ATTGATGTA TAGTGCCTG ACTAGAGATC ATAATCAGCC ATACCACATT TGTAGAGGT 5460
TIACTTGCTT TAAAAACCT CCCACACCTC CGCCTGAACC TGAAACATAA AATGAATGCA 5520
ATTGTTGTTG TTAAC TTGTT TATTGCAGCT TATAATGGTT ACAAATAAAG CAATAGCATC 5580
ACAAATTTCA CAAATAAAGC ATTTTTTTCA CTGCATTCTA GTTGTGGTTT GTCCAAACTC 5640
ATCAATGTAT CTTATCATGT CTGGATCCCC AGGAAGCTCC TCTGTGTCCT CATAAACCTT 5700
AACCTCCTCT ACTTGAGAGG ACATTCCAAT CATAGGCTGC CCATCCACCC TCTGTGTCCT 5760
CCTGTTAATT AGGTCACCTA ACAAAAAGGA AATTGGGTAG GGGTTTTTCA CAGACCGCTT 5820
TCTAAGGGTA ATTTTAAAAAT ATCTGGGAAG TCCCTCCAC TGCTGTGTTT CAGAAGTGT 5880
GGTAAACAGC CCACAAATGT CAACAGCAGA AACATACAAG CTGTCAGCTT TGCACAAGGG 5940
CCCAACACCC TGCTCATCAA GAAGCACTGT GGTGCTGTG TTAGTAATGT GCAAAACAGG 6000
AGGCACATTT TCCCCACCTG TGTAGGTCC AAAATATCTA GTGTTTTTCA TTTTACTTGG 6060
ATCAGGAACC CAGCACTCCA CTGGATAAGC ATTATCCTTA TCGAAAACAG CCTTGTGGTC 6120
AGTGTTTCATC TGCTGACTGT CAACTGTAGC ATTTTTTGGG GTTACAGTTT GAGCAGGATA 6180
TTTGGTCCTG TAGTTTGCTA ACACACCCTG CAGCTCCAAA GGTTCCTCCAC CAACAGCAAA 6240
AAAATGAAAA TTTGACCCTT GAATGGGTTT TCCAGCACCA TTTTCATGAG TTTTGTGT 6300
CCCTGAATGC AAGTTTAACA TAGCAGTTAC CCCAATAACC TCAGTTTAA CAGTAACAGC 6360
TTCCACATC AAAATATTTT CACAGGTAA GTCTCATTT AAATTAGGCA AAGGAATTAT 6420
ACACTCCGCT ATCGCTACGT GACTGGGTCA TGGCTGCGCC CCGACACCCG CCAACACCCG 6480
CTGACGCGCC CTGACGGGCT TGTCTGCTCC CGGCATCCGC TTACAGACAA GCTGTGACCG 6540
TCTCCGGGAG CTGCATGTGT CAGAGGTTTT CACCGTCATC ACCGAAACGC GCGAGGCAGC 6600
GGATCATAAT CAGCCATACC ACATTGTAG AGGTTTTACT TGCTTTAAAA AACCTCCAC 6660
ACCTCCCCCT GAACCTGAAA CATAAAATGA ATGCAATTGT TGTGTTAAC TTGTTTATTG 6720

CAGCTTATAA TGGTTACAAA TAAAGCAATA GCATCACAAA TTTCAGAAAT AAAGCATTIT 6780
TTTCACTGCA TTCTAGTTGT GGTGTGTCCA AACTCATCAA TGTATCTTAT CATGTCTGGA 6840
TCATAATCAG CCATACCACA TTGTAGAGG TTTTACTTGC TTTAAAAAAC CTCCCACACC 6900
TCCCCTGAA CCTGAAACAT AAAATGAATG CAATTGTTGT TGTAACTTG TTTATTGCAG 6960
CTTATAATGG TTACAAATAA AGCAATAGCA TCACAAATT CACAAATAAA GCATTTTTTT 7020
CACTGCATT CAGTTGTGGT TTGTCCAAAC TCATCAATGT ATCTTATCAT GTCTGGATCC 7080
CAAGCTTACC ATGGTAACCC CTGGTCCCGT TCAGCCACCA CCACCCACCC CAGCACACCT 7140
CCAACCTCAG CCAGACAAGG TTGTGACAC AAGAGAGCCC TCAGGGGCAC AGAGAGAGTC 7200
TGGACACGTG GGGAGTCAGC CGTGTATCAT CGGAGGCGGC CGGGCACCCA CATCTGGTAT 7260
AAAAGGAGGC AGTGGCCAC AGAGGAGCAC AGCTGTGTTT GGCTGCAGGG CCAAGAGCGC 7320
TGTCAAGAAG ACCCACACGC CCCCTCCAG CAGCTGAATT CCAGCTGGCA TTCCGGTACT 7380
GTTGGTAAAA TGGAAGACGC CAAAAACATA AAGAAAGGCC CGGCGCCATT CTATCCTCTA 7440
GAGGATGGAA CCGCTGGAGA GCAACTGCAT AAGGCTATGA AGAGATACGC CCTGGTTCCT 7500
GGAACAATTG CTTTACAGA TGCACATATC GAGGTGAACA TCACGTACGC GGAATACTTC 7560
GAAATGTCCG TTCGGTTGGC AGAAGCTATG AAACGATATG GGCTGAATAC AAATCACAGA 7620
ATCGTCTGAT GCAGTGAAAA CTCTCTTCAA TTCTTTATGC CGGTGTTGGG CGCGTTATTT 7680
ATCGGAGTTG CAGTTGCGCC CGCGAAGCAG ATTTATAATG AACGTGAATT GCTCAACAGT 7740
ATGAACATTT CGCAGCCTAC CGTAGTGTTT GTTTCCAAAA AGGGGTTGCA AAAAATTTTG 7800
AACGTGCAAA AAAAATTACC AATAATCCAG AAAATTATTA TCATGGATT CAAAACGGAT 7860
TACCAGGGAT TTCAGTCGAT GTACACGTT CACACATCTC ATCTACCTCC CGGTTTTAAT 7920
GAATACGATT TTGTACCAGA GTCTTTTGAT CGTGACAAAA CAATTGCACT GATAATGAAT 7980
TCCTCTGGAT CTAATGGGTT ACCTAAGGGT GTGGCCCTTC CGCATAGAAC TGCCTGCGTC 8040
AGATTCTCGC ATGCCAGAGA TCCTATTTTT GGCAATCAAA TCATTCCGA TACTGCGATT 8100
TTAAGTGTTG TTCCATTCCA TCACGGTTTT GGAATGTTTA CTACACTCGG ATATTTGATA 8160
TGTGGATTT CAGTCCTCTT AATGTATAGA TTTGAAGAAG AGCTGTTTT ACGATCCCTT 8220
CAGGATTACA AAATCAAAG TCGGTTGCTA GTACCAACCC TATTTTCATT CTTGCGCAAA 8280

WO

A

C

C

A

AC

AT

CT

TT

TT

GG

AT

TT

AT

GAT

TCT

TAA

TTC

TGT

CTA

TAA

CCAC

TTAT

ATAG

GTAA

CATA

CTGA

AGCACTCTGA TTGACAAATA CGATTATCT AATTACACG AAATTGCTTC TGGGGGCGCA 8340
CCTCTTTTGA AAGAAGTCGG GGAAGCGGT GCAAAACGCT TCCATCTTCC AGGGATACGA 8400
CAAGGATATG GGCTCACTGA GACTACATCA GCTATTCTGA TTACACCCGA GGGGGATGAT 8460
AAACCGGGCG CGGTCGGTAA AGTTGTTCCA TTTTTTGAAG CGAAGGTTGT GGATCTGGAT 8520
ACCGGGAAAA CGCTGGGCGT TAATCAGAGA GGCGAATTAT GTGTCAGAGG ACCTATGATT 8580
ATGTCCGGTT ATGTAAACAA TCCGGAAGCG ACCAACGCCT TGATTGACAA GGATGGATGG 8640
CTACATTCTG GAGACATAGC TTA CTGGGAC GAAGACGAAC ACTTCTTCAT AGTTGACCGC 8700
TTGAAGTCTT TAATTAAATA CAAAGGATAT CAGGTGGCCC CGGCTGAATT GGAATCGATA 8760
TTGTTACAAC ACCCAACAT CTTGACGCG GCGGTGGCAG GTCTTCCCGA CGATGACGCC 8820
GGTGAACTTC CGCCGCCGT TGTGTTTTG GAGCACGGAA AGACGATGAC GGAAAAAGAG 8880
ATCGTGGATT ACGTCGCCAG TCAAGTAACA ACCCGGAAAA AGTTGCGCGG AGGAGTTGTG 8940
TTTGTGGACG AAGTACCGAA AGGTCTTACC GGAAACTCG ACGCAAGAAA AATCAGAGAG 9000
ATCCTCATAA AGGCCAAGAA GGGCGGAAAG TCCAAATTGT AAAATGTAAC TGTATTGAGC 9060
GATGACGAAA TTCTTAGCTA TTGTAATGAC TCTAGAGGAT CTTGTGAAG GAACCTTACT 9120
TCTGTGGTGT GACATAATTG GACAACTAC CTACAGAGAT TTAAAGCTCT AAGGTAAATA 9180
TAAATTTTT AAGTGATAA TGTGTAAAC TACTGATTCT AATTGTTTGT GTATTTTAGA 9240
TTCCAACCTA TGGAAGTAT GAATGGGAGC AGTGTGGAA TGCCTTTAAT GAGGAAAACC 9300
TGTTTTGCTC AGAAGAAATG CCATCTAGTG ATGATGAGGC TACTGCTGAC TCTCAACATT 9360
CTACTCCTCC AAAAAAGAAG AGAAAGGTAG AAGACCCCAA GGAATTCCT TCAGAATTGC 9420
TAAGTTTTTT GAGTCATGCT GTGTTAGTA ATAGAACTCT TGCTTGCTTT GCTATTTACA 9480
CCACAAAGGA AAAAGCTGCA CTGCTATACA AGAAAATTAT GGAAAAATAT TCTGTAACCT 9540
TTATAAGTAG GCATAACAGT TATAATCATA ACATACTGTT TTTTCTTACT CCACACAGGC 9600
ATAGAGTGTG TGCTATTAAT AACTATGCTC AAAAATTGTG TACCTTTAGC TTTTAAATT 9660
GTAAAGGGGT TAATAAGGAA TATTGATGT ATAGTGCCTT GACTAGAGAT CATAATCAGC 9720
CATACCACAT TTGTAGAGGT TTTACTTGCT TTA AAAAACC TCCCACACCT CCCCCTGAAC 9780
CTGAAACATA AAATGAATGC AATTGTGTT GTTAACTGT TTATTGCAGC TTATAATGGT 9840

TACAAATAAA GCAATAGCAT CACAAATTC ACAAATAAAG CATTITTTTC ACTGCATTCT 9900
AGTTGTGGTT TGTCCAACT CATCAATGTA TCTTATCATG TGTGGATCCC CAGGAAGCTC 9960
CTCTGTGTCC TCATAAACCC TAACCTCCTC TACTTGAGAG GACATTCCAA TCATAGGCTG 10020
CCCATCCACC CTCTGTGTCC TCCTGTAAAT TAGGTCACTT AACAAAAAGG AAATTGGGTA 10080
GGGGTTTTTC ACAGACCGCT TTCTAAGGT AATTTTAAAA TATCTGGGAA GTCCCTTCCA 10140
CTGCTGTGTT CCAGAAGTGT TGGTAAACAG CCCACAAATG TCAACAGCAG AAACATACAA 10200
GCTGTCAGCT TTGCACAAGG GCCCAACACC CTGCTCAGCA AGAAGCACTG TGGTTGCTGT 10260
GTTAGTAATG TGCAAAACAG GAGGCACATT TTCCCCACCT GTGTAGGTTT CAAAATATCT 10320
AGTGTITTC TTTTACTTG GATCAGGAAC CCAGCACTCC ACTGGATAAG CATTATCCTT 10380
ATCCAAAACA GCCTGTGGT CAGTGTTCAT CTGCTGACTG TCAACTGTAG CATTITTTTG 10440
GGTTACAGTT TGAGCAGGAT ATTTGCTCT GTAGTTTGCT AACACACCCT GCAGCTCCAA 10500
AGGTTCCCCA CCAACAGCAA AAAAATGAAA ATTTGACCCT TGAATGGGTT TTCCAGCACC 10560
ATTTTCATGA GTTTTTTGTG TCCCTGAATG CAAGTTTAAC ATAGCAGTTA CCCCAATAAC 10620
CTCAGTTTIA ACAGTAACAG CTTCCACAT CAAAATATTT CCACAGGTTA AGTCCTCATT 10680
TAAATTAGGC AAAGGAA 10697

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10549 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TTCTTGAAGA CGAAAGGGCC TCGTGATACG CCTATTTTIA TAGGTAAATG TCATGATAAT 60
AATGGTITCT TAGACGTCAG GTGGCACTTT TCGGGGAAAT GTGCGCGGAA CCCCTATTTG 120

TTTATTTTTC TAAATACATT CAAATATGTA TCCGCTCATG AGACAATAAC CCTGATAAAT 180
GCTTCAATAA TATTGAAAAA GGAAGAGTAT GAGTATTCAA CATTTCCTGT TCGCCCTTAT 240
TCCCTTTTTT GCGGCATTTT GCCTTCCTGT TTTTGCTCAC CCAGAAACGC TGGTGAAAGT 300
AAAAGATGCT GAAGATCAGT TGGGTGCAGC AGTGGGTAC ATCGAACTGG ATCTCAACAG 360
CGGTAAGATC CTTGAGAGTT TTCGCCCCGA AGAACGTTTT CCAATGATGA GCACTTTTAA 420
AGTTCTGCTA TGTGGCGCGG TATTATCCCG TGTTGACGCC GGGCAAGAGC AACTCGGTGG 480
CGGCATACAC TATTCTCAGA ATGACTTGGT TGACTIONTCA CCAGTCACAG AAAAGCATCT 540
TACGGATGGC ATGACAGTAA GAGAATTATG CAGTGCTGCC ATAACCATGA GTGATAACAC 600
TGCGGCCAAC TTACTIONTGA CAACGATCGG AGGACCGAAG GAGCTAACCG CTTTTTTGCA 660
CAACATGGGG GATCATGTAA CTCGCCTTGA TCGTTGGGAA CCGGAGCTGA ATGAAGCCAT 720
ACCAAACGAC GAGCGTGACA CCACGATGCC TGCAGCAATG GCAACAACGT TCGCCTAACT 780
ATTAACGGC GAACTACTTA CTCTAGCTTC CCGGCAACAA TTAATAGACT GGATGGAGGC 840
GGATAAAGTT GCAGGACCAC TTCTGCGCTC GCGCCTTCGG GCTGGCTGGT TTATTGCTGA 900
TAAATCTGGA GCCGGTGAGC GTGGGTCTCG CGGTATCATT GCAGCACTGG GGCCAGATGG 960
TAAGCCCTCC CGTATCGTAG TTATCTACAC GACGGGGAGT CAGGCAACTA TGGATGAACG 1020
AAATAGACAG ATCGCTGAGA TAGGTGCTC ACTGATTAA GATTGGTAAC TGTCAGACCA 1080
AGTTTACTCA TATATACTTT AGATTGATTT AAAACTTCAT TTTAATTAA AAAGGATCTA 1140
GGTGAAGATC CTTTTTGATA ATCTCATGAC CAAAATCCCT TAACGTGAGT TTTGCTTCCA 1200
CTGAGCGTCA GACCCCGTAG AAAAGATCAA AGGATCTTCT TGAGATCCTT TTTTCTGCG 1260
CGTAATCTGC TGCTTGCAA CAAAAAACC ACCGCTACCA GCGGTGGTTT GTTTGCCGGA 1320
TCAAGAGCTA CCAACTCTTT TTCCGAAGGT AACTGGCTTC AGCAGAGCGC AGATACCAAA 1380
TACTGTCCTT CTAGTGTAGC CTTAGTTAGG CCACCACTTC AAGAACTCTG TAGCACC GCC 1440
TACATACCTC GCTCTGCTAA TCCTGTTACC AGTGGCTGCT GCCAGTGGCG ATAAGTCGTG 1500
TCTTACCGGG TTGACTCAA GACGATAGT ACCGATAAG GCGCAGCGT CCGGCTGAAC 1560
GGGGGTTCC TGCACACAGC CCAGCTTGA GCGAACGACC TACACCGAAC TGAGATACCT 1620
ACAGCGTGAG CATTGAGAAA GCGCCACGCT TCCGAAGGG AGAAAGCGG ACAGGTATCC 1680

GCAGAGGCCG AGGCCGCCCTC GGCCTCTGAG CTATTCCAGA AGTAGTGAGG AGGCTTTTTT 3300
GGAGGCCTAG GCTTTTGCAA AAAGCTTCAC GCTGCCGCAA GCACTCAGGG CGCAAGGGCT 3360
GCTAAAGGAA GCGGAACACG TAGAAAGCCA GTCCGCAGAA ACGGTGCTGA CCCC GGATGA 3420
ATGTCAGCTA CTGGGCTATC TGGACAAGGG AAAACGCAAG CGCAAAGAGA AAGCAGGTAG 3480
CTTGCACTGG GCTTACATGG CGATAGCTAG ACTGGGCGGT TTTATGGACA GCAAGCGAAC 3540
CGGAATGCC AGCTGGGGCG CCCTCTGGTA AGTTGGGAA GCCCTGCAA GTAAACTGGA 3600
TGGCTTTCTT GCGGCCAAGG ATCTGATGGC GCAGGGGATC AAGATCTGAT CAAGAGACAG 3660
GATGAGGATC GTTTCGCATG ATTGAACAAG ATGGATTGCA GCGAGTTCT CCGGCCGCTT 3720
GGGTGGAGAG GCTATTCGGC TATGACTGGG CACAACAGAC AATCGGCTGC TCTGATGCCG 3780
CCGTGTTCCG GCTGTCAGCG CAGGGGCGCC CGTTCTTTT TGTCAAGACC GACCTGTCCG 3840
GTGCCCTGAA TGAATGCAG GACGAGGCAG CGCGCTATC GTGGCTGGCC ACGACGGGCG 3900
TTCCTTGCGC AGCTGTGCTC GACCTGTGCA CTGAAGCGGG AAGGGACTGG CTGCTATTGG 3960
GCGAAGTGCC GGGGCAGGAT CTCCTGTCTAT CTCACCTTGC TCCTGCCGAG AAAGTATCCA 4020
TCATGGCTGA TGCAATGCGG CGGCTGCATA CGCTTGATCC GGCTACCTGC CCATTGACC 4080
ACCAAGCGAA ACATCGCATC GAGCGAGCAC GACTCGGAT GGAAGCCGGT CTTGTGATC 4140
AGGATGATCT GGACGAAGAG CATCAGGGGC TCGGCCAGC CGAACTGTTT GCCAGGCTCA 4200
AGGCGCGCAT GCGCGACGGC GAGGATCTCG TCGTGACCCA TGGCGATGCC TGCTTGCCGA 4260
ATATCATGGT GGAAAATGGC CGCTTTTCTG GATTCAATGA CTGTGGCCGG CTGGGTGTGG 4320
CGGACCGCTA TCAGGACATA GCGTTGGCTA CCGTGATAT TGTGAAGAG CTGGCGGCG 4380
AATGGGCTGA CCGCTTCCTC GTGCTTTACG GTATCGCCGC TCCCATTG CAGCGCATCG 4440
CCTTCTATCG CCTTCTTGAC GAGTTCTTCT GAGCGGGACT CTGGGGTTG AAATGACCGA 4500
CCAAGCGACG CCAACCTGC CATCAGGAGA TTTCGATTCC ACCGCGCGCT TCTATGAAAG 4560
GTTGGGCTTC GGAATCGTTT TCCGGGACGC CGGCTGGATG ATCCTCCAGC GCGGGGATCT 4620
CATGCTGGAG TTCTTCGCCC ACCCGGGGCT CGATCCCCTC GCGAGTTGGT TCAGCTGCTG 4680
CCTGAGGCTG GACGACCTCG CGGAGTTCTA CCGGCACTGC AAATCCGTCG GCATCCAGGA 4740
AACCAGCAGC GGCTATCCGC GCATCCATGC CCGGAACTG CAGGAGTGGG GAGGCACGAT 4800

GGCCGCTTTG GTCCCGGATC TTTGTGAAGG AACCTTACTT CTGTGGTGTG ACATAATTGG 4860
ACAAACTACC TACAGAGATT TAAAGCTCTA AGGTAAATAT AAAATTTTTA AGTGATAAT 4920
GTGTAAACT ACTGATTCTA ATTGTTTGTG TATTTTAGAT TCCAACCTAT GGAAGTGATG 4980
AATGGGAGCA GTGGTGAAT GCCTTAAATG AGGAAAACCT GTTTTGCTCA GAAGAAATGC 5040
CATCTAGTGA TGATGAGGCT ACTGCTGACT CTCAACATTG TACTCCTCCA AAAAGAAGA 5100
GAAAGGTAGA AGACCCCAAG GACTTTCCTT CAGAATTGCT AAGTTTTTTG AGTCATGCTG 5160
TGTTTAGTAA TAGAACTCTT GCTTGCTTTG CTATTTACAC CACAAAGGAA AAAGCTGCAC 5220
TGCTATACAA GAAAATTATG GAAAAATATT CTGTAACCTT TATAAGTAGG CATAACAGTT 5280
ATAATCATAA CAACTGTTT TTTCTTACTC CACACAGGCA TAGAGTGTCT GCTATTAATA 5340
ACTATGCTCA AAAATTGTGT ACCTTTAGCT TTTTAATTG TAAAGGGGTT AATAAGGAAT 5400
ATTTGATGTA TAGTGCCTTG ACTAGAGATC ATAATCAGCC ATACCACATT TGTAGAGGTT 5460
TIACTTGCTT TAAAAAACCT CCCACACCTC CCCCTGAACC TGAACATAA AATGAATGCA 5520
ATTGTTGTTG TTAAGTTGTT TATTGCAGCT TATAATGTT ACAAATAAAG CAATAGCATC 5580
ACAAATTCA CAAATAAAGC ATTTTTTCA CTGCATTCTA GTTGTGGTTT GTCCAAACTC 5640
ATCAATGTAT CTATCATGT CTGGATCCCC AGGAAGCTCC TCTGTGCTC CATAAACCTT 5700
AACCTCCTCT ACTTGAGAGG ACATTCCAAT CATAGGCTGC CCATCCACCC TCTGTGCTC 5760
CCTGTAAATT AGGTCACTTA AAAAAAGGA AATTGGGTAG GGGTTTTTCA CAGACCGCTT 5820
TCTAAGGGTA ATTTTAAAT ATCTGGGAAG TCCCTCCAC TGCTGTGTT CAGAAGTGT 5880
GGTAAACAGC CCACAAATGT CAACAGCAGA AACATACAAG CTGTCAGCTT TGCACAAGGG 5940
CCCAACACCC TGCTCATCAA GAAGCACTGT GGTGCTGTG TTAGTAATGT GCAAAACAGG 6000
AGGCACATTT TCCCCACCTG TGTAGGTTCC AAAATATCTA GTGTTTTCAT TTTTACTTGG 6060
ATCAGGAACC CAGCACTCCA CTGGATAAGC ATTATCCTTA TCCAAAACAG CCTTGTTGGT 6120
AGTGTTTATC TGCTGACTGT CAACTGTAGC ATTTTTTGGG GTTACAGTT GAGCAGGATA 6180
TTTGCTCCTG TAGTTTGCTA ACACACCCTG CAGCTCCAAA GGTCCCCAC CAACAGCAAA 6240
AAAATGAAAA TTGACCTT GAATGGGTTT TCCAGCACCA TTTTCATGAG TTTTGTGT 6300
CCCTGAATGC AAGTTTAAAC TAGCAGTTAC CCCAATAACC TCAGTTTAA CAGTAACAGC 6360

W

A

C

T

T

T

C

C

C

AC

AC

TA

AI

TC

TG

AA

AC

TT

AG

TC

ATC

GTC

TTCCACATC AAAATATTTT CACAGGTAA GTCCTCATT AAATTAGGCA AAGGAATTAT 6420
ACACTCCGCT ATCGCTACGT GACTGGGTCA TGGCTGCGCC CCGACACCCG CCAACACCCG 6480
CTGACGCGCC CTGACGGGCT TGTCTGCTCC CGGCATCCGC TTACAGACAA GCTGTGACCG 6540
TCTCCGGGAG CTGCATGTGT CAGAGGTTTT CACCGTCATC ACCGAAACGC GGGAGGCAGC 6600
GGATCATAAT CAGGCATACC ACATTGTAG AGGTTTTACT TGCTTTAAAA AACCTCCCAC 6660
ACCTCCCCCT GAACCTGAAA CATAAATGA ATGCAATTGT TGTGTTAAC TTGTTTATG 6720
CAGCTTATAA TGTTACAAA TAAAGCAATA GCATCACAAA TTTCACAAAT AAAGCATTTT 6780
TTTCACTGCA TTCTAGTTGT GGTGTGCTCA AACTCATCAA TGTATCTTAT CATGCTGGA 6840
TCATAATCAG CCATACCACA TTTGTAGAGG TTTTACTTGC TTAAAAAAC CTCCACACC 6900
TCCCCCTGAA CCTGAAACAT AAAATGAATG CAATTGTTGT TGTTAACTTG TTTATTGCAG 6960
CTTATAATGG TTACAAATAA AGCAATAGCA TCACAAATTT CACAAATAAA GCATTTTTTT 7020
CACTGCATTC TAGTTGTGCT TGTCCAAAC TCATCAATGT ATCTTATCAT GTCTGGATCC 7080
CAAGTTCATC TATTTCTCC CACATCTGGT ATAAAAGGAG GCAGTGGCCC ACAGAGGAGC 7140
ACAGCTGTGT TTGGCTGCAG GGCCAAGAGC GCTGTCAAGA AGACCCACAC GCCCCCTCC 7200
AGCAGCTGAA TTCCAGCTGG CATTCCGGTA CTGTTGGTAA AATGGAAGAC GCCAAAAACA 7260
TAAAGAAAGG CCCGGCGCCA TTCTATCCTC TAGAGGATGG AACCGCTGGA GAGCAACTGC 7320
ATAAGGCTAT GAAGAGATAC GCCCTGGTTC CTGGAACAAT TGCTTTTACA GATGCACATA 7380
TCGAGGTGAA CATCACGTAC GCGGAATACT TCGAAATGTC CGTTCGGTTG GCAGAAGCTA 7440
TGAAACGATA TGGGCTGAAT ACAAATCACA GAATCGTCGT ATGCAGTGAA AACTCTCTTC 7500
AATTCTTTAT GCGGTGTTG GCGCGTTAT TTATCGGAGT TGCAGTTGCG CCCGCGAACG 7560
ACATTATAA TGAACGTGAA TTGCTCAACA GTATGAACAT TTCGCAGCCT ACCGTAGTGT 7620
TTGTTTCCAA AAAGGGGTTG CAAAAATTT TGAACGTGCA AAAAAATTA CCAATAATCC 7680
AGAAAAATTAT TATCATGGAT TCTAAAACGG ATTACCAGG ATTTCAGTCG ATGTACACGT 7740
TCGTACATC TCATCTACCT CCGGTTTTA ATGAATACGA TTTTGTACCA GAGTCCTTG 7800
ATCGTGACAA AACAATTGCA CTGATAATGA ATTCCTCTGG ATCTACTGGG TTACCTAAGG 7860
GTGTGGCCCT TCCGCATAGA ACTGCCTGCG TCAGATTCTC GCATGCCAGA GATCCTATTT 7920

TTGGCAATCA AATCATTCCG GATACTGCCA TTTTAAGTGT TGTTCATTG CATCACGGTT	7980
TTGGAATGTT TACTACACTC GGATATTTGA TATGTGGATT TCGAGTCGTC TTAATGTATA	8040
GATTTGAAGA AGAGCTGTTT TTACGATCCC TTCAGGATTA CAAAATTCAA AGTCCGTTGC	8100
TAGTACCAAC CCTATTTTCA TTCTTCGCCA AAAGCACTCT GATTGACAAA TACGATTTAT	8160
CTAATTTACA CGAAATTGCT TCTGGGGGCG CACCTCTTTC GAAAGAACTC GGGGAAGCGG	8220
TTGCAAAACG CTTCCATCTT CCAGGGATAC GACAAGGATA TGGGCTCACT GAGACTACAT	8280
CAGCTATTCT GATTACACCC GAGGGGGATG ATAAACCGGG CGCGGTCCGT AAAGTTGTTT	8340
CATTTTTTGA AGCGAAGGTT GTGGATCTGG ATACCGGAA AACGCTGGGC GTTAATCAGA	8400
GAGGCGAATT ATGTGTCAGA GGACCTATGA TTATGTCCGG TTATGTAAAC AATCCGGAAC	8460
CGACCAACGC CTTGATTGAC AAGGATGGAT GGCTACATTC TGGAGACATA GCTTACTGGG	8520
ACGAAGACGA ACACTTCTTC ATAGTTGACC GCTTGAAGTC TTAAATTAAA TACAAAGGAT	8580
ATCAGGTGGC CCCCCTGAA TTGGAATCGA TATTGTTACA ACACCCCAAC ATCTTCGACG	8640
CGGGCGTGGC AGGTCTTCCC GACGATGACG CCGGTGAACT TCCCGCCGCC GTTGTTGTTT	8700
TGGAGCACGG AAAGACGATG ACGGAAAAAG AGATCGTGGA TTACGTGCCC AGTCAAGTAA	8760
CAACCGCGAA AAAGTTGCGC GGAGGAGTTG TGTTTGTGGA CGAAGTACCG AAAGGTCTTA	8820
CCGGAAAACT CGACGCAAGA AAAATCAGAG AGATCCTCAT AAAGGCCAAG AAGGGCGGAA	8880
AGTCCAAATT GTAAAATGTA ACTGTATTCA GCGATGACGA AATTCTTAGC TATTGTAATG	8940
ACTCTAGAGG ATCTTTGTGA AGGAACCTTA CTCTGTGGT GTGACATAAT TGGACAACT	9000
ACCTACAGAG ATTTAAAGCT CTAAGGTAAA TATAAAATTT TTAAGTGTAT AATGTGTAA	9060
ACTACTGATT CTAATTGTTT GTGTATTTTA GATTCCAACC TATGGAAGT ATGAATGGGA	9120
GCAGTGGTGG AATGCCTTTA ATGAGGAAAA CCTGTTTTGC TCAGAAGAAA TGCCATCTAG	9180
TGATGATGAG GCTACTGCTG ACTCTCAACA TTCTACTCCT CCAAAAAAGA AGAGAAAGGT	9240
AGAAGACCCC AAGGACTTTC CTTCAGAATT GCTAAGTTTT TTGAGTCATG CTGTGTTTAG	9300
TAATAGAACT CTGCTTGCT TTGCTATTTA CACCACAAAG GAAAAAGCTG CACTGCTATA	9360
CAAGAAAAAT ATGAAAAAT ATTCTGTAAC CTTTATAAGT AGGCATAACA GTTATAATCA	9420
TAACATACTG TTTTTTCTTA CTCCACACAG GCATAGAGTG TCTGCTATTA ATAACATATGC	9480

TCAAAAATTG TGTACCTTTA GCTTTTAAAT TTGIAAAGGG GTTAATAAGG AATATTTGAT 9540
GTATAGTGCC TTGACTAGAG ATCATAATCA GCCATACCAC ATTTGTAGAG GTTTTACTTG 9600
CTTTAAAAAA CCTCCACAC CTCCCCCTGA ACCTGAAACA TAAAATGAAT GCAATTGTTG 9660
TTGTAACTT GTTTATTGCA GCTTATAATG GTTACAAATA AAGCAATAGC ATCACAAATT 9720
TCACAAATAA AGCATTITTT TCACTGCATT CTAGTTGTGG TTTGTCCAAA CTCATCAATG 9780
TATCTTATCA TGTCTGGATC CCCAGGAAGC TCCTCTGTGT CCTCATAAAC CCTAACCTCC 9840
TCTACTTGAG AGGACATTCC AATCATAGGC TGCCCATCCA CCCTCTGTGT CCTCCTGTTA 9900
ATTAGGTCAC TTAACAAAAA GGAAATTGGG TAGGGGTTTT TCACAGACCG CTTTCTAAGG 9960
GTAATTTTAA AATATCTGGG AAGTCCCTTC CACTGCTGTG TTCCAGAAGT GTTGGTAAAC 10020
AGCCCAAAA TGTCAACAGC AGAACATAC AAGCTGTCAG CTTTGCACAA GGGCCCAACA 10080
CCCTGCTCAG CAAGAAGCAC TGTGGTTGCT GTGTTAGTAA TGTGCAAAAC AGGAGGCACA 10140
TTTTCCCCAC CTGTGTAGGT TCCAAAATAT CTAGTGTITT CATTTTTACT TGGATCAGGA 10200
ACCCAGCACT CCACTGGATA AGCATTATCC TTATCCAAAA CAGCCTGTG GTCAGTGTTT 10260
ATCTGCTGAC TGTCAACTGT AGCATTITTT GGGGTIACAG TTTGAGCAGG ATATTTGGTC 10320
CTGTAGTTTG CTAACACACC CTGCAGCTCC AAAGGTTCCC CACCAACAGC AAAAAAATGA 10380
AAATTTGACC CTTGAATGGG TTTTCCAGCA CCATTTTCAT GAGTTTTTTG TGTCCCTGAA 10440
TGCAAGTTTA ACATAGCAGT TACCCCAATA ACCTCAGTTT TAACAGTAAC AGCTTCCCAC 10500
ATCAAAATAT TTCCACAGGT TAAGTCCTCA TTAAATTAG GCAAAGGAA 10549

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10558 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TTCTTGAAGA CGAAAGGGCC TCGTGATACG CCTATTTTAA TAGGTTAATG TCATGATAAT	60
AATGGTTTCT TAGACGTCAG GTGGCACTTT TCGGGGAAAT GTGCGCGGAA CCCCTATTG	120
TTTATTTTTC TAAATACATT CAAATATGTA TCCGCTCATG AGACAATAAC CCTGATAAAT	180
GCTTCAATAA TATTGAAAAA GGAAGAGTAT GAGTATTCAA CATTTCGGTG TCGCCCTTAT	240
TCCCTTTTTT GCGGCATTTT GCCTTCCTGT TTTTGCTCAC CCAGAAACGC TGGTGAAAGT	300
AAAAGATGCT GAAGATCAGT TGGGTGCACG AGTGGGTIAC ATCGAACTGG ATCTCAACAG	360
CGGTAAGATC CTTGAGAGTT TTCGCCCCGA AGAACGTTTT CCAATGATGA GCACTTTTAA	420
AGTTCTGCTA TGTGGCGCGG TATTATCCCG TGTTGACGCC GGGCAAGAGC AACTCGGTG	480
CCGCATACAC TATTCTCAGA ATGACTTGGT TGAGTACTCA CCAGTCACAG AAAAGCATCT	540
TACGGATGGC ATGACAGTAA GAGAATTATG CAGTGCTGCC ATAACCATGA GTGATAACAC	600
TGCGGCCAAC TTAATTCTGA CAACGATCGG AGGACCGAAG GAGCTAACCG CTTTTTGA	660
CAACATGGGG GATCATGTAA CTCGCCTTGA TCGTTGGGAA CCGGAGCTGA ATGAAGCCAT	720
ACCAAACGAC GAGCGTGACA CCACGATGCC TGCAGCAATG GCAACAACGT TCGCGAAACT	780
ATTAACTGGC GAACTACTTA CTCTAGCTTC CCGGCAACAA TTAATAGACT GGATGGAGGC	840
GGATAAAGTT GCAGGACCAC TTCTGCGCTC GGCCCTTCCG GCTGGCTGGT TTATTGCTGA	900
TAAATCTGGA GCCGGTGAGC GTGGGTCTCG CGGTATCATT GCAGCACTGG GGCCAGATGG	960
TAAGCCCTCC CGTATCGTAG TTATCTACAC GACGGGGAGT CAGGCAACTA TGGATGAACG	1020
AAATAGACAG ATCGCTGAGA TAGGTGCCTC ACTGATTAA GATTGGTAAC TCTCAGACCA	1080
AGTTTACTCA TATATACTTT AGATTGATTT AAAACTTCAT TTTTAATTIA AAAGGATCTA	1140
GGTGAAGATC CTTTTTGATA ATCTCATGAC CAAAATCCCT TAACGTGAGT TTTGTTCCA	1200
CTGAGCGTCA GACCCCGTAG AAAAGATCAA AGGATCTTCT TGAGATCCTT TTTTCTGCG	1260
CGTAATCTGC TGCTTGCAAA CAAAAAACC ACCGCTACCA GCGGTGTTTT GTTTGCCGGA	1320
TCAAGAGCTA CCAACTCTTT TTCCGAAGGT AACTGGCTTC AGCAGAGCGC AGATACCAAA	1380
TACTGTCTT CTAGGTAGC CGTAGTAGG CCACCACTTC AAGAACTCTG TAGCACCGCC	1440
TACATACCTC GCTCTGCTAA TCCTGTTACC AGTGGCTGCT GCCAGTGGCG ATAACCTGTC	1500

TCTTACCGGG TTGGA CTCAA GACGATAGTT ACCGGATAAG GCGCAGCGGT CGGGCTGAAC	1560
GGGGGGTTTCG TGCACACAGC CCAGCTTGGA GCGAACGACC TACACCGAAC TGAGATACCT	1620
ACAGCGTGAG CATTGAGAAA GCGCCACGCT TCCCGAAGGG AGAAAGCGG ACAGGTATCC	1680
GGTAAGCGGC AGGGTCGGAA CAGGAGAGCG CACGAGGGAG CTTCCAGGGG GAAACGCCTC	1740
GTATCTTTAT AGTCTGTGCG GGTTCGCCA CCTCTGACTT GAGCGTCGAT TTTTGTGATG	1800
CTCGTCAGGG GGGCGGAGCC TATGGAAAAA CGCCAGGAAC GCGGCCTTTT TACGGTTCCT	1860
GGCCTTTTGC TGGCCTTTTG CTCACATGTT CTTTCTGCG TTATCCCCTG ATTCTGTGGA	1920
TAACCGTATT ACCGCCTTTG AGTGAGCTGA TACCGCTCGC CGCAGCCGAA CGACCGAGCG	1980
CAGCGAGTCA GTGAGCGAGG AAGCGGAAGA GCGCCTGATG CGGTATTTTC TCCTTACGCA	2040
TCTGTGCGGT ATTTACACACC GCATATGCTG CACTCTCAGT ACAATCTGCT CTGATGCCGC	2100
ATAGTTAAGC CAGTATTGGA CCTCGAGGGA TCTTTGTGAA GGAACCTTAC TTCTGTGGTG	2160
TGACATAATT GGACAACTA CCTACAGAGA TTAAAGCTC TAAGGTAAAT ATAAAATTTT	2220
TAAGTGATA ATGTGTTAAA CTA CTGATTG TAATTGTTT TGTATTTTAG ATTCCAACCT	2280
ATGGAAGTGA TGAATGGGAG CACTGGTGGA ATGCCCTTAA TGAGGAAAAC CTGTTTTGCT	2340
CAGAAGAAAT GCCATCTAGT GATGATGAGG CTA CTGCTGA CTCTCAACAT TCTACTCCTC	2400
CAAAAAGAA GAGAAAGGTA GAAGACCCCA AGGACTTTCC TTCAGAATTG CTAAGTTTTT	2460
TGAGTCATGC TGTGTTTAGT AATAGAACTC TTGCTTGCTT TGCTATTTAC ACCACAAAGG	2520
AAAAAGCTGC ACTGCTATAC AAGAAAATTA TGGAAAAATA TTCTGTAACC TTTATAAGTA	2580
GGCATAACAG TTATAATCAT AACATACTGT TTTTCTTAC TCCACACAGG CATAGAGTGT	2640
CTGCTATTAA TAACTATGCT CAAAATTGT GTACCTTTAG CTTTTTAATT TGTAAGGGG	2700
TTAATAAGGA ATATTTGATG TATAGTGCTT TGACTAGAGA TCATAATCAG CCATACCACA	2760
TTTGTAGAGG TTTTACTTGC TTTAAAAAAC CTCCACACC TCCCCTGAA CCTGAAACAT	2820
AAAATGAATG CAATTGTTGT TGTTAACTTG TTTATTGCG CTTATAATGG TTACAAATAA	2880
AGCAATAGCA TCACAAATTT CACAAATAAA GCATTTTTTT CACTGCATTG TAGTTGTGGT	2940
TTGTCCAAAC TCATCAATGT ATCTTATCAT GTCTGGATCC GGCTGTGGAA TGTGTGTCAG	3000
TTAGGGTGTG GAAAGTCCCC AGGCTCCCCA GCAGGCAGAA GTATGCAAAG CATGCATCTC	3060

TTTGCTCCTG TAGTTTGCTA ACACACCCTG CAGCTCCAAA GGTTCCTCCAC CAACAGCAAA 6240
AAAAAGAAAA TTTGACCCTT GAATGGGTTT TCCAGCACCA TTTTCATGAG TTTTTTGTGT 6300
CCCTGAATGC AAGTTTAAAC TAGCAGTTAC CCCAATAACC TCAGTTTTAA CAGTAACAGC 6360
TTCCACATC AAAATATTTT CACAGGTAA GTCTCATTT AAATTAGGCA AAGGAATTAT 6420
ACACTCCGCT ATCGCTACGT GACTGGGTCA TGGCTGGCC CCCACACCCG CCAACACCCG 6480
CTGACGCGCC CTGACGGGCT TGTCTGCTCC GGGCATCGC TTACAGACAA GCTGTGACCG 6540
TCTCCGGGAG CTGCATGTGT CAGAGTTTT CACCGTCATC ACCGAAACGC GCGAGGCAGC 6600
GGATCATAAT CAGCCATACC ACATTGTAG AGGTTTTACT TGCTTTAAAA AACCTCCAC 6660
ACCTCCCCCT GAACCTGAAA CATAAAATGA ATGCAATTGT TGTGTAAAC TTGTTTATTG 6720
CAGCTTATAA TGGTTACAAA TAAAGCAATA GCATCACAAA TTTCACAAAT AAAGCATTIT 6780
TTTCACTGCA TTCTAGTTGT GGTGTGCTCA AACTCATCA TGTATCTTAT CATGTCTGGA 6840
TCATAATCAG CCATACCACA TTTGTAGAGG TTTTACTTGC TTTAAAAAAC CTCCACACC 6900
TCCCCCTGAA CCTGAAACAT AAAATGAATG CAATTGTTGT TGTTAACTTG TTTATTGCAG 6960
CTTATAATGG TTACAAATAA AGCAATAGCA TCACAAATT CACAAATAA GCATTTTTTT 7020
CACTGCATTC TAGTTGTGGT TGTCCAAAC TCATCAATGT ATCTTATCAT GTCTGGATCC 7080
CAGTGGGGAG TCAGCCGTGT ATCATCGCCC ACATCTGGTA TAAAAGGAGG CAGTGGCCCA 7140
CAGAGGAGCA CAGCTGTGTT TGGCTGCAGG GCCAAGAGCG CTGTCAAGAA GACCCACACG 7200
CCCCCTCCA GCAGCTGAAT TCCAGCTGGC ATTCCGGTAC TGTGGTAA ATGGAAGACG 7260
CCAAAAACAT AAAGAAAGGC CCGGCCCAT TCTATCCTCT AGAGGATGGA ACCGCTGGAG 7320
AGCAACTGCA TAAGGCTATG AAGAGATACG CCCTGGTTCC TGAACAATT GCTTTTACAG 7380
ATGCACATAT CGAGGTGAAC ATCACGTACG CGGAATACTT CGAAATGTCC GTTCGGTTGG 7440
CAGAAGCTAT GAAACGATAT GGGCTGAATA CAAATCACAG AATCGTCGTA TGCAGTGA 7500
ACTCTCTCA ATTCTTTATG CCGGTGTTGG GCGCGTTATT TATCGGACTT GCAGTTGCGC 7560
CCGGAACGA CATTTATAAT GAACCTGAAT TGCTCAACAG TATGAACATT TCGCAGCCTA 7620
CCGTAGTGT TGTTCCTAAA AAGGGGTGCG AAAAAATTTT GAACGTGCA AAAAAATTAC 7680
CAATAATCCA GAAAATTATT ATCATGGATT CTAAAACGGA TTACCAGGGA TTTCAGTCGA 7740

TGTACACGTT CGTCACATCT CATCTACCTC CCGGTTTTAA TGAATACGAT TTTGTACGAG 7800
AGTCCTTTGA TCGTGACAAA ACAATTGCAC TGATAATGAA TTCCTCTGGA TCTACTGGGT 7860
TACCTAAGGG TGTGGCCCTT CCGCATAGAA CTGCCTGCGT CAGATTCTCG CATGCCAGAG 7920
ATCCTATTTT TGGCAATCAA ATCATTCCGG AACTGCGAT TTTAAGTGT GTTCCATTCC 7980
ATCACGGTTT TGGAATGTTT ACTACACTCG GATATTTGAT ATGTGGATT CGAGTCGTCT 8040
TAATGTATAG ATTTGAAGAA GAGCTGTTTT TACGATCCCT TCAGGATTAC AAAATTCAAA 8100
GTGCGTTGCT AGTACCAACC CTATTTTCAT TCTTCGCCAA AAGCACTCTG ATTGACAAAT 8160
ACGATTTATC TAATTACAC GAAATTGCTT CTGGGGGCGC ACCTCTTTCG AAAGAAGTCG 8220
GGGAAGCGGT TGCAAAACGC TTCCATCTTC CAGGGATACG ACAAGGATAT GGGCTCACTG 8280
AGACTACATC AGCTATTCTG ATTACACCCG AGGGGGATGA TAAACCGGGC GCGGTCGGTA 8340
AAGTTGTTCC ATTTTTTGAA GCGAAGGTTG TGGATCTGGA TACCGGGAAA ACGGTGGGCG 8400
TTAATCAGAG AGGCGAATTA TGTGTCAGAG GACCTATGAT TATGTCCGGT TATGTAAACA 8460
ATCCGGAAGC GACCAACGCC TTGATTGACA AGGATGGATG GCTACATTCT GGAGACATAG 8520
CTTACTGGGA CGAAGACGAA CACTTCTTCA TAGTTGACCG CTGGAAGTCT TTAATTAAAT 8580
ACAAAGGATA TCAGGTGGCC CCCGCTGAAT TGGAATCGAT ATTGTTACAA CACCCCAACA 8640
TCTTCGACGC GGGCGTGGCA GGTCTTCCCG ACGATGACGC CGGTGAACTT CCCGCCGCCG 8700
TTGTTGTTTT GGAGCACGGA AAGACGATGA CGGAAAAGA GATCCTGGAT TACGTCGCCA 8760
GTCAAGTAAC AACCGCGAAA AAGTTGCGCG GAGGAGTTGT GTTTGTGGAC GAAGTACCGA 8820
AAGGTCTTAC CGGAAACTC GACGCAAGAA AAATCAGAGA GATCCTCATA AAGGCCAAGA 8880
AGGGCGGAAA GTCCAAATTG TAAAATGTAA CTGTATTAG CGATGACGAA ATTCTTAGCT 8940
ATTGTAATGA CTCTAGAGGA TCTTTGTGAA GGAACCTTAC TTCTGTGGTG TGACATAATT 9000
GGACAACTA CCTACAGAGA TTTAAAGCTC TAAGGTAAAT ATAAAATTT TAAGTGATA 9060
ATGTGTTAAA CTAAGTATTC TAATTGTTT TGTATTTTAT ATTCCAACCT ATGGAAGTGA 9120
TGAATGGGAG CAGTGGTGGG ATGCCTTTAA TGAGGAAAAC CTGTTTTGCT CAGAAGAAAT 9180
GCCATCTAGT GATGATGAGG CTAAGTCTGA CTCTCAACAT TCTACTCCTC CAAAAAGAA 9240
GAGAAAGGTA GAAGACCCCA AGGACTTTCC TTCAGAATTG CTAAGTTTTT TGAGTCATGC 9300

TGTGTTTAGT AATAGAACTC TTGCTTGCTT TGCTATTAC ACCACAAAGG AAAAAGCTGC 9360
ACTGCTATAC AAGAAAATTA TGGAAAAATA TTCTGTAACC TTTATAAGTA GGCATAACAG 9420
TTATAATCAT AACATACTGT TTTTCTTAC TCCACACAGG CATAGAGTGT CTGCTATTAA 9480
TAACTATGCT CAAAAATTGT GTACCTTAG CTTTTAATT TGTAAAGGG TTAATAAGGA 9540
ATATTTGATG TATAGTGCTT TGAAGTACG TCATAATCAG CCATACCACA TTTGTAGAGG 9600
TTTACTTGC TTTAAAAAC CTCCACACC TCCCCTGAA CCTGAAACAT AAAATGAATG 9660
CAATTGTTGT TGTAACTTG TTTATTGAG CTTATAATGG TTACAAATAA AGCAATAGCA 9720
TCACAAATT CACAAATAAA GCATTTTTT CACTGCATC TAGTTGTGGT TTGTCCAAAC 9780
TCATCAATGT ATCTTATCAT GTCTGGATCC CCAGGAAGCT CCTCTGTGTC CTCATAAACC 9840
CTAACCTCCT CTACTTGAGA GGACATCCA ATCATAGGCT GCCCATCCAC CCTCTGTGTC 9900
CTCCTGTAA TTAGGTCAT TAACAAAAG GAAATTGGG AGGGTTTTT CACAGACCGC 9960
TTTCTAAGGG TAATTTTAA ATATCTGGA AGTCCCTCC ACTGCTGTGT TCCAGAAGTG 10020
TTGGTAAACA GCCCACAAAT GTCAACAGCA GAAACATACA AGCTGTCAGC TTTGCACAAG 10080
GGCCCAACAC CCTGCTCAGC AAGAAGCACT GTGGTTGCTG TGTTAGTAAT GTGCAAAACA 10140
GGAGGCACAT TTTCCCACC TGTGTAGGT CCAAAATATC TAGTGTTC ATTTTACTT 10200
GGATCAGGAA CCCAGCACTC CACTGGATAA GCATTATCCT TATCCAAAC AGCCTTGTGG 10260
TCAGTGTCA TCTGCTGACT GTCAACTGTA GCATTTTTT GGGTTACAGT TTGAGCAGGA 10320
TATTTGGTCC TGTAGTTTGC TAACACACCC TGCAGCTCCA AAGGTTCCCC ACCAACAGCA 10380
AAAAATGAA AATTGACCC TTGAATGGT TTTCCAGCAC CATTTTCATG AGTTTTTGT 10440
GTCCCTGAAT GCAAGTTTAA CATAGCAGT ACCCAATAA CCTCAGTTT AACAGTAACA 10500
GCTTCCCACA TCAAAATATT TCCACAGGT AAGTCCTCAT TTAAATTAGG CAAAGGAA 10558

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10569 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii)

(iv)

(xi)

TTCTTG/

AATGGT

TTTATT

GCTTCA

TCCCTT

AAAAGA

CGGTAA

AGTTCT

CCGCAT

TACGGA

TGCGG

CAACA

ACCAA

ATTAA

GGATA

TAAAT

TAAGC

AAATA

AGTTT

GGTGA

CTGAC

CGTAA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TTCTTGAAGA CGAAAGGGCC TCGTGATACG CCTATTTTAA TAGGTTAATG TCATGATAAT	60
AATGGTTTCT TAGACGTCAG GTGGCACTTT TCGGGGAAAT GTGCGCGGAA CCCCTATTG	120
TTTATTTTTC TAAATACATT CAAATATGTA TCCGCTCATG AGACAATAAC CCTGATAAAT	180
GCTTCAATAA TATTGAAAAA GGAAGAGTAT GAGTATTCAA CATTTCGGTG TCGCCCTTAT	240
TCCCTTTTTT GCGGCATTTT GCCTTCCTGT TTTTGCTCAC CCAGAAACGC TGGTGAAAGT	300
AAAAGATGCT GAAGATCAGT TGGGTGCACG AGTGGGTAC ATCGAACTGG ATCTCAACAG	360
CGGTAAGATC CTGAGAGTT TTCGCCCCGA AGAACGTTTT CCAATGATGA GCACTTTTAA	420
AGTTCTGCTA TGTGGCGCGG TATTATCCCG TGTGACGCC GGGCAAGAGC AACTCGGTG	480
CGGCATACAC TATTCTCAGA ATGACTTGGT TGAGTACTCA CCAGTCACAG AAAAGCATCT	540
TACGGATGCC ATGACAGTAA GAGAATTATG CAGTGCTGCC ATAACCATGA GTGATAACAC	600
TGCGGCCAAC TTAATTCTGA CAACGATCGG AGGACCGAAG GAGCTAACCG CTTTTTTGCA	660
CAACATGGGG GATCATGTAA CTCGCCTTGA TCGTTGGGAA CCGGAGCTGA ATGAAGCCAT	720
ACCAAACGAC GAGCGTGACA CCACGATGCC TGCAGCAATG GCAACAACGT TCGCGAAACT	780
ATTAACTGGC GAACTACTTA CTCTAGCTTC CCGGCAACAA TTAATAGACT GGATGGAGGC	840
GGATAAAGTT GCAGGACCAC TTCTGCGCTC GGCCCTCCG GCTGGCTGGT TTATTGCTGA	900
TAAATCTGGA GCCGGTGAGC GTGGGTCTCG CGGTATCATT GCAGCACTGG GGCCAGATGG	960
TAAGCCCTCC CGTATCCTAG TTATCTACAC GACGGGGAGT CAGGCAACTA TGGATGAACG	1020
AAATAGACAG ATCGCTGAGA TAGGTGCCTC ACTGATTAAG CATTGGTAAC TGTCAGACCA	1080
AGTTTACTCA TATATACTTT AGATTGATTT AAAACTTCAT TTTTAATTTA AAAGGATCTA	1140
GGTGAAGATC CTTTTTGATA ATCTCATGAC CAAAATCCCT TAACGTGAGT TTTGTTCCAA	1200
CTGAGCGTCA GACCCCGTAG AAAAGATCAA AGGATCTTCT TGAGATCCTT TTTTCTGCG	1260
CGTAATCTGC TGCTTGCAAA CAAAAAACC ACCGCTACCA GCGGTGTTTT GTTGCCGGA	1320

TCAAGAGCTA CCAACTCTTT TTCGAAGGT AACTGGCTTC AGCAGAGCGC AGATACCAAA 1380
TACTGTCCTT CTAGTGIAGC CGTAGTIAGG CCACCACTTC AAGAACTCTG TAGCACCGCC 1440
TACATACCTC GCTCTGCTAA TCCTGTIACC AGTGGCTGCT GCCAGTGGCG ATAAGTCGTG 1500
TCTTACCGGG TTGGACTCAA GACGATACTT ACCGGATAAG GCGCAGCGGT CGGGCTGAAC 1560
GGGGGGTTCG TGCACACAGC CCAGCTTGA GCGAACGACC TACACCGAAC TGAGATACCT 1620
ACAGCGTGAG CATTGAGAAA GCGCCACGCT TCCGAAGGG AGAAAGGCGG ACAGGTATCC 1680
GGTAAGCGGC AGGTCGGAA CAGGAGAGCG CACGAGGGAG CTTCCAGGGG GAAACGCTG 1740
GTATCTTTAT AGTCCTGTG GTTTTGCCA CCTCTGACTT GAGCGTCGAT TTTTGTGATG 1800
CTCGTCAGGG GGGCGGAGCC TATGGAAAA CGCCAGCAAC GCGGCCTTTT TACGGTTCCT 1860
GGCCTTTTGC TGGCCTTTTG CTCACATGTT CTTTCTGCG TTATCCCCTG ATTCTGTGGA 1920
TAACCGTATT ACCGCCTTTG AGTGAGCTGA TACCGCTCGC GCGAGCCGAA CGACCGAGCG 1980
CAGCGAGTCA GTGAGCGAGG AAGCGGAAGA GCGCCTGATG CGGTATTTTC TCCTIACGCA 2040
TCTGTCCGGT ATTTACACACC GCATATGGTG CACTCTCAGT ACAATCTGCT CTGATGCCGC 2100
ATAGTTAAGC CAGTATTGCA CCTCGAGGGA TCTTTGTGAA GGAACCTTAC TTCTGTGCTG 2160
TGACATAATT GGACAACTA CCTACAGAGA TTAAAGCTC TAAGGTAAAT ATAAAAATTT 2220
TAAGTGATA ATGTGTTAAA CTACTGATTC TAATTGTTTG TGTATTTTAG ATTCCAACCT 2280
ATGGAAGTGA TGAATGGGAG CAGTGGTGGA ATGCCTTTAA TGAGGAAAAC CTGTTTTGCT 2340
CAGAAGAAAT GCCATCTAGT GATGATGAGG CTACTGCTGA CTCTCAACAT TCTACTCCTC 2400
CAAAAAAGAA GAGAAAGTGA GAAGACCCCA AGGACTTTCC TTCAGAATTG CTAAGTTTTT 2460
TGAGTCATGC TGTGTTTAGT AATAGAACTC TTGCTTGCTT TGCTATTTAC ACCACAAAGG 2520
AAAAAGCTGC ACTGCTATAC AAGAAAATTA TGGAAAAATA TTCTGTAACC TTTATAAGTA 2580
GGCATAACAG TTATAATCAT AACATACTGT TTTTCTTAC TCCACACAGG CATAGAGTGT 2640
CTGCTATTAA TAACATGCT CAAAAATTGT GTACCTTTAG CTTTTTAATT TGTAAGGGG 2700
TTAATAAGGA ATATTGATG TATAGTGCCT TGAAGTGA TAATAATCAG CCATACCACA 2760
TTGTAGAGG TTTTACTTGC TTAAAAAAC CTCCACACC TCCCCCTGAA CCTGAAACAT 2820
AAAATGAATG CAATTGTTGT TGTAACTTG TTTATTGAG CTTATAATGG TTACAAATAA 2880

AGCAATAGCA TCACAAATTT CACAAATAAA GCATTTTTTT CACTGCATTG TAGTTGTGGT 2940
TTGTCCAAAC TCATCAATGT ATCTIATCAT GTCTGGATCC GGCTGTGGAA TGTGTGTCAG 3000
TTAGGGTGTG GAAAGTCCCC AGGCTCCCCA GCAGGCAGAA GTATGCAAAG CATGCATCTC 3060
AATTAGTCAG CAACCAGGTG TGGAAAGTCC CCAGGCTCCC CAGCAGGCAG AAGTATGCAA 3120
AGCATGCATC TCAATTAGTC AGCAACCATA GTCCCGCCCC TAACTCCGCC CATCCCGCCC 3180
CTAACTCCGC CCAGTTCCGC CCATTCTCG CCCCATGGCT GACTAATTTT TTTTATTTAT 3240
GCAGAGGCCG AGGCCGCCTC GGCCTCTGAG CTATTCCAGA AGTAGTGAGG AGGCTTTTTT 3300
GGAGGCCTAG GCTTTTGCAA AAAGCTTCAC GCTGCCGCAA GCACTCAGGG CGCAAGGGCT 3360
GCTAAAGGAA GCGGAACACG TAGAAAGCCA GTCCGCAGAA ACGGTGCTGA CCCCAGATGA 3420
ATGTCAGCTA CTGGGCTATC TGGACAAGGG AAAACGCAAG CGCAAAGAGA AAGCAGGTAG 3480
CTTGCACTGG GCTTACATGG CGATAGCTAG ACTGGCGGCT TTTATGGACA GCAAGCGAAC 3540
CGGAATTGCC AGCTGGGGCG CCCTCTGGTA AGGTTGGGAA GCCCTGCAA GTAAACTGGA 3600
TGGCTTTCTT GCGGCCAAGG ATCTGATGGC GCAGGGGATC AAGATCTGAT CAAGAGACAG 3660
GATGAGGATC GTTTCGCATG ATTGAACAAG ATGGATTGCA CGCAGGTTCT CCGGCCGCTT 3720
GGGTGGAGAG GCTATTCGGC TATGACTGGG CACAACAGAC AATCGGCTGC TCTGATGCCG 3780
CCGTGTTCCG GCTGTCAGCG CAGGGGCGCC CGGTTCTTTT TGTCAAGACC GACCTGTCCG 3840
GTGCCCTGAA TGAAGTGCAG GACGAGGCAG CGCGGCTATC GTGGCTGGCC ACGACGGGCG 3900
TTCCTTGCGC AGCTGTGCTC GACGTTGTCA CTGAAGCGGG AAGGGACTGG CTGCTATTGG 3960
GCGAAGTGCC GGGGCAGGAT CTCCTGTCTC CTCACCTTGC TCCTGCCGAG AAAGTATCCA 4020
TCATGGCTGA TGCAATGCGG CGGCTGCATA CGCTTGATCC GGCTACCTGC CCATTGACC 4080
ACCAAGCGAA ACATCGCATC GAGCGAGCAC GTAAGTGGAT GGAAGCCGGT CTGTGCGATC 4140
AGGATGATCT GGACGAAGAG CATCAGGGGC TCGGCCAGC CGAAGTCTC GCCAGGCTCA 4200
AGGCGCGCAT GCGCGACGGC GAGGATCTCG TCGTGACCCA TGGCGATGCC TGCTTGCCGA 4260
ATATCATGGT GGAAAATGCC CGCTTTTCTG GATTCATCGA CTGTGGCCGG CTGGGTGTGG 4320
CGGACCGCTA TCAGGACATA GCGTTGGCTA CCGGTGATAT TGCTGAAGAG CTGGCGGGCG 4380
AATGGGCTGA CCGCTTCTC GTGCTTTACG GTATCGCCGC TCCCGATTG CAGCGCATCG 4440

CCTTCTATCG CCTTCTTGAC GAGTTCTTCT GAGCGGGACT CTGGGGTTCC AAATGACCGA 4500
CCAAGCGAGG CCAACCTGC CATCAGGAGA TTTCGATTCC ACCGCCGCCT TCTATGAAAG 4560
GTTGGGCTTC GGAATCGTTT TCCGGGACGC CGGCTGGATG ATCCTCCAGC GCGGGGATCT 4620
CATGCTGGAG TTCTTCGCCC ACCCGGGGCT CGATCCCTC GCGAGTTGGT TCAGCTGCTG 4680
CCTGAGGCTG GACGACCTCG CGGAGTTCTA CCGGCAGTGC AAATCCGTGC GCATCCAGGA 4740
AACCAGCAGC GGCTATCCGC GCATCCATGC CCCCGAAC TG CAGGAGTGGG GAGGCACGAT 4800
GGCCGCTTTG GTCCCGGATC TTTGTGAAGG AACCTTACTT CTGTGGTGTG ACATAATTGG 4860
ACAACTACC TACAGAGATT TAAAGCTCTA AGGTAAATAT AAAATTTTIA AGTGATAAT 4920
GTGTAAACT ACTGATTCTA ATTGTTTGTG TATTTTAGAT TCCAACCTAT GGAAGTATG 4980
AATGGGAGCA GTGGTGAAT GCCTTAATG AGGAAAACCT GTTTTGCTCA GAAGAAATGC 5040
CATCTAGTGA TGATGAGGCT ACTGCTGACT CTCAACATTC TACTCCTCCA AAAAGAAGA 5100
GAAAGGTAGA AGACCCAAG GACTTTCCTT CAGAATTGCT AAGTTTTTTG AGTCATGCTG 5160
TGTTTAGTAA TAGAACTCTT GCTTGCTTTG CTATTTACAC CACAAAGGAA AAAGCTGCAC 5220
TGCTATACAA GAAAATTATG GAAAAATATT CTGTAACCTT TATAAGTAGG CATAACAGTT 5280
ATAATCATAA CATACTGTTT TTTCTTACTC CACACAGGCA TAGAGTGTCT GCTATTAATA 5340
ACTATGCTCA AAAATTGTGT ACCTTAGCT TTTTAATTG TAAAGGGTT AATAAGGAAT 5400
ATTTGATGTA TAGTGCCTTG ACTAGAGATC ATAATCAGCC ATACCACATT TGTAGAGGTT 5460
TACTTGCTT TAAAAACCT CCCACACCTC CCCCTGAACC TGAAACATAA AATGAATGCA 5520
ATTGTTGTTG TTAAC TTGTT TATTGCAGCT TATAATGGTT ACAAATAAAG CAATAGCATC 5580
ACAAATTCA CAAATAAAGC ATTTTTTCA CTGCATTCTA GTTGTGGTTT GTCCAACTC 5640
ATCAATGTAT CTTATCATGT CTGGATCCCC AGGAAGCTCC TCTGTGTCCT CATAAACCT 5700
AACCTCCTCT ACTTGAGAGG ACATTCCAAT CATAGGCTGC CCATCCACCC TCTGTGTCCT 5760
CCTGTAAAT AGGTCACCTA AAAAAAGGA AATTGGGTAG GGGTTTTTCA CAGACCGCTT 5820
TCTAAGGTA ATTTTAAAT ATCTGGGAAG TCCCTCCAC TGCTGTGTT CAGAAGTGT 5880
GGTAAACAGC CCACAAATGT CAACAGCAGA AACATACAAG CTGTCAGCTT TGCACAAGG 5940
CCCAACCCC TGCTCATCAA GAAGCACTGT GGTGCTGTG TTAGTAATGT GCAAAACAGG 6000

AGGCACATTT TCCCCACCTG TGTAGGTTCC AAAATATCTA GTGTTTTCAT TTTTACTTGG 6060
ATCAGGAACC CAGCACTCCA CTGGATAAGC ATTATCCTTA TCCAAAACAG CCTTGTGGTC 6120
AGTGTTCATC TGCTGACTGT CAACTGTAGC ATTTTTTGGG GTTACAGTTT GAGCAGGATA 6180
TTTGGTCCTG TAGTTTGCTA ACACACCCTG CAGCTCCAAA GGTCCCCAC CAACAGCAAA 6240
AAAATGAAAA TTTGACCCCTT GAATGGGTTT TCCAGCACCA TTTTCATGAG TTTTTGTGT 6300
CCCTGAATGC AAGTTTAAAC TAGCAGTTAC CCCAATAACC TCAGTTTTAA CAGTAACAGC 6360
TCCCCACATC AAAATATTTT CACAGGTAA GTCTCATTT AAATTAGGCA AAGGAATTAT 6420
ACACTCCGCT ATCGCTACGT GACTGGGTCA TGGCTGCGCC CGGACACCCG CCAACACCCG 6480
CTGACGCGCC CTGACGGGCT TGTCTGCTCC CGGCATCCGC TTACAGACAA GCTGTGACCG 6540
TCTCCGGGAG CTGCATGTGT CAGAGGTTTT CACCGTCATC ACCGAAACGC GCGAGGCAGC 6600
GGATCATAAT CAGCCATACC ACATTGTAG AGGTTTACT TGCTTTAAA AACCTCCCAC 6660
ACCTCCCCCT GAACCTGAAA CATAAAATGA ATGCAATTGT TGTGTTAAC TTGTTTATTG 6720
CAGCTTATAA TGGTTACAAA TAAAGCAATA GCATCACAAA TTTACAAAT AAAGCATTTT 6780
TTTCACTGCA TTCTAGTTGT GGTGTGCTCA AACTCATCA TGTATCTTAT CATGTCTGGA 6840
TCATAATCAG CCATACCACA TTTGTAGAGG TTTTACTTGC TTTAAAAAC CTCCCACACC 6900
TCCCCCTGAA CCTGAAACAT AAAATGAATG CAATTGTTGT TGTTAACTTG TTTATTGCAG 6960
CTTATAATGG TTACAAATAA AGCAATAGCA TCACAAATTT CACAAATAAA GCATTTTTTT 7020
CACTGCATTG TAGTTGTGGT TTGTCCAAAC TCATCAATGT ATCTTATCAT GTCTGGATCC 7080
CACTCCAACC TCAGCCAGAC AAGGTTGTG ACACAAGACC CACATCTGGT ATAAAAGGAG 7140
GCACTGGCCC ACAGAGGAGC ACAGCTGTGT TTGGCTGCAG GGCCAAGAGC GCTGTCAAGA 7200
AGACCCACAC GCCCCCTCC AGCAGCTGAA TTCCAGCTGG CATTCCGGTA CTGTTGGTAA 7260
AATGGAAGAC GCCAAAAACA TAAAGAAAG CCCGGCGCCA TTCTATCCTC TAGAGGATGG 7320
AACCGCTGGA GAGCAACTGC ATAAGGCTAT GAAGAGATAC GCCCTGGTTC CTGGAACAAT 7380
TGCTTTTACA GATGCACATA TCGAGGTGAA CATCACGTAC GCGGAATACT TCGAAATGTC 7440
CGTTCGGTTG GCAGAAGCTA TGAAACGATA TGGGCTGAAT ACAAATCACA GAATCGTCGT 7500
ATGCAGTGAA AACTCTCTTC AATTCTTAT GCCGGTGTG GCGCGTTAT TTATCGGAGT 7560

TGCAGTTGCG CCCGCGAAGC ACATTTATAA TGAACGTGAA TTGCTCAACA GTATGAACAT 7620
TTCCGAGCCT ACCGTAGTGT TTGTTTCCAA AAAGGGGTTG CAAAAAATTT TGAACGTGCA 7680
AAAAAAATTA CCAATAATCC AGAAAATTAT TATCATGGAT TCTAAAACGG ATTACCAGGG 7740
ATTTCAGTCG ATGTACACGT TCGTCACATC TCATCTACCT CCCGGTTTTA ATGAATACGA 7800
TTTTGTACCA GAGTCCTTTG ATCGTGACAA AACAATTGCA CTGATAATGA ATTCTCTGG 7860
ATCTACTGGG TTACCTAAGG GTGTGGCCCT TCCGCATAGA ACTGCCTGCG TCAGATTCTC 7920
GCATGCCAGA GATCCTATTT TTGGCAATCA AATCATTCGG GATACTGCCA TTTTAAGTGT 7980
TGTTCCATTC CATCACGGTT TTGGAATGTT TACTACACTC GGATATTTGA TATGTGGATT 8040
TCGAGTCGTC TTAATGTATA GATTGAAGA AGAGCTGTTT TTACGATCCC TTCAGGATT 8100
CAAAATTCAA AGTGCCTTGC TAGTACCAAC CCTATTTTCA TTCTTCGCCA AAAGCACTCT 8160
GATTGACAAA TACGATTIAT CTAATTTACA CGAAATGCT TCTGGGGCGG CACCTCTTTC 8220
GAAAGAAGTC GGGGAAGCGG TTGCAAAACG CTTCCATCTT CCAGGGATAC GACAAGGATA 8280
TGGGCTCACT GAGACTACAT CAGCTATTCT GATTACACCC GAGGGGGATG ATAAACCGGG 8340
CGCGGTCGGT AAAGTTGTTT CATTTTTTGA AGCGAAGGTT GTGGATCTGG ATACCGGGAA 8400
AACGCTGGGC GTTAATCAGA GAGCGCAATT ATGTGTCAGA GGACCTATGA TTATGTCCGG 8460
TTATGTAAAC AATCCGGAAG CGACCAACGC CTGATTGAC AAGGATGGAT GGCTACATTC 8520
TGGAGACATA GCTTACTGGG AGGAAGACGA ACACTTCTTC ATAGTTGACC GCTTGAAGTC 8580
TTAATTAAA TACAAAGGAT ATCAGGTGGC CCCCCTGAA TTGGAATCGA TATTGTTACA 8640
ACACCCCAAC ATCTTCGACG CGGGCGTGGC AGGTCTTCCC GACGATGACG CCGGTGAACT 8700
TCCCGCCGCC GTTGTGTTT TGGAGCACGG AAAGACGATG ACGGAAAAAG AGATCGTGGA 8760
TTACGTCGCC AGTCAAGTAA CAACCGCGAA AAAGTTGCGC GGAGGAGTTG TGTGTTGGA 8820
CGAAGTACCG AAAGGTCTTA CCGGAAAACG CGACGCAAGA AAAATCAGAG AGATCCTCAT 8880
AAAGGCCAAG AAGGGCGGAA AGTCCAAATT GTAAATGTA ACTGTATTCA GCGATGACGA 8940
AATTCTTAGC TATTGTAATG ACTCTAGAGG ATCTTTGTA AGGAACCTTA CTCTGTGGT 9000
GTGACATAAT TGGACAAACT ACCTACAGAG ATTTAAAGCT CTAAGGTAAA TATAAAATTT 9060
TTAAGTGTAT AATGTGTAA ACTACTGATT CTAATTGTTT GTGTATTTTA GATTCCAACC 9120

TA

TC

CC

TT

GA

AG

TC

GT

AT

TA

AA

TT

CC

CC

TC

TT

CT

TG

CA

CA

TT

CA

GA

TA

GC

(2)

20	TATGGAAGCTG ATGAATGGGA GCAGTGGTGG AATGCCTTTA ATGAGGAAAA CCTGTTTTGC	9180
30	TCAGAAGAAA TGCCATCTAG TGATGATGAG GCTACTGCTG ACTCTCAACA TTCTACTCCT	9240
40	CCAAAAAGA AGAGAAAGGT AGAAGACCCC AAGGACTTTC CTTCAGAATT GCTAAGTTTT	9300
50	TTGAGTCATG CTGTGTTTAT TAATAGAACT CTTGCTTGCT TTGCTATTTA CACCACAAAG	9360
60	GAAAAAGCTG CACTGCTATA CAAGAAAATT ATGGAAAAAT ATTCTGTAAC CTTTATAAGT	9420
70	AGGCATAACA GTTATAATCA TAACATACTG TTTTTTCTTA CTCCACACAG GCATAGAGTG	9480
80	TCTGCTATTA ATAACTATGC TCAAAAATTG TGTACCTTTA GCTTTTAAAT TGTAAAGGG	9540
90	GTAAATAAGG AATATTTGAT GTATAGTGCC TTGACTAGAG ATCATAATCA GCCATACCAC	9600
100	ATTGTAGAG GTTTTACTTG CTTTAAAAAA CCTCCACAC CTCCCCCTGA ACCTGAAACA	9660
110	TAAATGAAT GCAATTGTTG TTGTTAACTT GTTTATTGCA GCTTATAATG GTTACAAATA	9720
120	AAGCAATAGC ATCACAAATT TCACAAATAA AGCATTTTTT TCACTGCATT CTAGTTGTGG	9780
130	TTTGTCCAAA CTCATCAATG TATCTTATCA TGTCTGGATC CCCAGGAAGC TCCTCTGTGT	9840
140	CCTCATAAAC CCTAACCTCC TCTACTTGAG AGGACATTCC AATCATAGGC TGCCCATCCA	9900
150	CCCTCTGTGT CCTCCTGTTA ATTAGGTCAC TTAACAAAAA GGAAATTGGG TAGGGGTTTT	9960
160	TCACAGACCG CTTTCTAAGG GTAATTTTAA AATATCTGGG AAGTCCCTTC CACTGCTGTG	10020
170	TTCCAGAAGT GTTGGTAAAC AGCCACAAAA TGTCAACAGC AGAAACATAC AAGCTGTCAG	10080
180	CTTTCACAAA GGGCCCAACA CCCTGCTCAG CAAGAAGCAC TGTGGTTGCT GTGTTAGTAA	10140
190	TGTGCAAAAC AGGAGGCACA TTTTCCCCAC CTGTGTAGGT TCCAAAATAT CTAGTGTTTT	10200
200	CATTTTACT TGGATCAGGA ACCCAGCACT CCACTGGATA AGCATTATCC TTATCCAAAA	10260
210	CAGCCTTGTC GTCAGTGTTC ATCTGCTGAC TGTCAACTGT AGCATTTTTT GGGGTTACAG	10320
220	TTTGAGCAGG ATATTTGGTC CTGTAGTTTG CTAACACACC CTGCAGCTCC AAAGGTTCCC	10380
230	CACCAACAGC AAAAAAATGA AAATTTGACC CTTGAATGGG TTTTCCAGCA CCATTTTCAT	10440
240	GAGTTTTTTG TGTCCCTGAA TGCAAGTTTA ACATAGCAGT TACCCCAATA ACCTCAGTTT	10500
250	TAACAGTAAC AGCTTCCCAC ATCAAAATAT TTCCACAGGT TAAGTCCTCA TTAAATTAG	10560
260	GCAAAGGAA	10569

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10558 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TTCTTGAAGA CGAAAGGGCC TCGTGATACG CCTATTTTTA TAGGTTAATG TCATGATAAT	60
AATGGTTTCT TAGACGTCAG GTGGCACTTT TCGGGGAAAT GTGGCGGAA CCCCTATTG	120
TTTATTTTTC TAAATACATT CAAATATGTA TCCGCTCATG AGACAATAAC CCTGATAAAT	180
GCTTCAATAA TATTGAAAAA GGAAGAGTAT GAGTATTCAA CATTTCCGTG TCGCCCTTAT	240
TCCCTTTTTT GCGGCATTTT GCCTTCCTGT TTTTGCTCAC CCAGAAACGC TGGTGAAAGT	300
AAAAGATGCT GAAGATCAGT TGGGTGCACG AGTGGGTTAC ATCGAACTGG ATCTCAACAG	360
CGGTAAGATC CTGAGAGTT TTCGCCCGA AGAACGTTTT CCAATGATGA GCACTTTTAA	420
AGTTCGCTA TGTGGCGCGG TATTATCCCG TGTGACGCC GGGCAAGAGC AACTCGGTG	480
CCGCATACAC TATTCTCAGA ATGACTTGGT TGAGTACTCA CCAGTCACAG AAAAGCATCT	540
TACGGATGGC ATGACAGTAA GAGAATTATG CAGTGCTGCC ATAACCATGA GTGATAACAC	600
TGCGGCCAAC TTACTTCTGA CAACGATCGG AGGACCGAAG GAGCTAACCG CTTTTTGA	660
GAACATGGGG GATCATGTAA CTGCCTTGA TCGTTGGGAA CCGGAGCTGA ATGAAGCCAT	720
ACCAAACGAC GAGCGTGACA CCACGATGCC TGCAGCAATG GCAACAACGT TCGCGAACT	780
ATTAACTGGC GAACTACTTA CTCTAGCTTC CCGGCAACAA TTAATAGACT GGATGGAGGC	840
GGATAAAGTT GCAGGACCAC TTCTGCGCTC GGCCCTTCCG GCTGGCTGGT TTATTGCTGA	900
TAAATCTGGA GCCGGTGAGC GTGGGTCTCG CGGTATCATT GCAGCACTGG GGCCAGATGG	960
TAAGCCCTCC CGTATCGTAG TTATCTACAC GACGGGGAGT CAGGCAACTA TGGATGAACG	1020
AAATAGACAG ATCGCTGAGA TAGGTGCCTC ACTGATTAAG CATTGGTAAC TGTGACCA	1080

WC

AG

GG

CT

CG

TC

TA

TA

TC

GG

AC

GG

GT

CT

GG

TA

CA

TC

AT

TG

TA

AT

CA

CA

TG

AA

GG

AGTTTACTCA TATATACTTT AGATTGATTT AAAACTTCAT TTTTAATTTA AAAGGATCTA 1140
GGTGAAGATC CTTTTTGATA ATCTCATGAC CAAAATCCCT TAACGTGAGT TTTTCGTTCCA 1200
CTGAGCGTCA GACCCCGTAG AAAAGATCAA AGGATCTTCT TGAGATCCTT TTTTCTGCG 1260
CGTAATCTGC TGCTTGCAAA CAAAAAACC ACCGCTACCA GCGGTGGTTT GTTTGCCGGA 1320
TCAAGAGCTA CCAACTCTTT TTCCGAAGGT AACTGGCTTC AGCAGAGCGC AGATACCAAA 1380
TACTGTCCTT CTAAGTGTAGC CGTAGTTAGG CCACCACTTC AAGAACTCTG TAGCACC GCCC 1440
TACATACCTC GCTCTGCTAA TCCTGTTACC AGTGGCTGCT GCCAGTGGCG ATAAGTCTGT 1500
TCTTACCGGG TTGGAATCAA GACCATAGTT ACCGGATAAG GCGCAGCGGT CGGGCTGAAC 1560
GGGGGGTTTC TGCACAGAGC CCAGCTTGGA GCGAAGCACC TACACCGAAC TGAGATACCT 1620
ACAGCGTGAG CATTGAGAAA GCGCCACGCT TCCCGAAGGG AGAAAGGCGG ACAGGTATCC 1680
GGTAAGCGGC AGGCTCGGAA CAGGAGAGCG CACGAGGGAG CTTCCAGGGG GAAACGCCTG 1740
GTATCTTAT AGTCCTGTCTG GGTTCGCGCA CCTCTGACTT GAGCGTCGAT TTTTGTGATG 1800
CTCGTCAGGG GGGCGGAGCC TATGGAAAAA CGCCAGCAAC GCGGCCTTTT TACGTTTCT 1860
GGCCTTTTGC TGGCCTTTTG CTCACATGTT CTTTCCTGCG TTATCCCCTG ATTCTGTGGA 1920
TAACCGTATT ACCGCCTTTG AGTGAGCTGA TACCGCTCGC CGCAGCCGAA CGACCGAGCG 1980
CAGCGAGTCA GTGAGCGAGG AAGCGGAAGA GCGCCTGATG CGGTATTTTC TCCTTACGCA 2040
TCTGTGCGGT ATTTCACACC GCATATGGTG CACTCTCAGT ACAATCTGCT CTGATGCCGC 2100
ATAGTTAAGC CAGTATTGGA CCTCGAGGGA TCTTTGTGAA GGAACCTTAC TTCTGTGGTG 2160
TGACATAATT GGACAACTA CCTACAGAGA TTTAAAGCTC TAAGGTAAAT ATAAAATTTT 2220
TAAGTGTATA ATGTGTTAAA CTACTGATTC TAATTGTTTG TGTATTTTAG ATTCCAACCT 2280
ATGGAATGA TGAATGGGAG CAGTGGTGGA ATGCCTTTAA TGAGGAAAAC CTGTTTTGCT 2340
CAGAAGAAAT GCCATCTAGT GATGATGAGG CTACTGCTGA CTCTCAACAT TCTACTCCTC 2400
CAAAAAAGAA GAGAAAGGTA GAAGACCCCA AGGACTTTCC TTCAGAATTG CTAAGTTTTT 2460
TGAGTCATGC TGTGTTTGTG AATAGAACTC TTGCTTGCTT TGCTATTTAC ACCACAAAGG 2520
AAAAAGCTGC ACTGCTATAC AAGAAAATTA TGGAAAAATA TTCTGTAAAC TTTATAAGTA 2580
GGCATAACAG TTATAATCAT AACATACTGT TTTTCTTAC TCCACACAGG CATAGAGTGT 2640

CTGCTATTAA TAACTATGCT CAAAAATTGT GTACCTTTAG CTTTTTAATT TGTAAGGGG 2700
TTAATAAGGA ATATTTGATG TATAGTGCCT TGACTAGAGA TCATAATCAG CCATACCACA 2760
TTTGTAGAGG TTTTACTTGC TTAAAAAAC CTCCCACACC TCCCCCTGAA CCTGAAACAT 2820
AAAATGAATG CAATTGTTGT TGTAACTTG TTTATTGCAG CTTATAATGG TTACAAATAA 2880
AGCAATAGCA TCACAAATTT CACAAATAAA GCATTTTTTT CACTGCATTC TAGTTGTGGT 2940
TTGTCCAAAC TCATCAATGT ATCTTATCAT GTCTGGATCC GGCTGTGGAA TGTGTGTCAG 3000
TTAGGGTGTG GAAAGTCCCC AGGCTCCCCA GCAGGCAGAA GTATGCAAAG CATGCATCTC 3060
AATTAGTCAG CAACCAGGTG TGGAAAGTCC CCAGGCTCCC CAGCAGGCAG AAGTATGCAA 3120
AGCATGCATC TCAATTAGTC AGCAACCATA GTCCCGCCCC TAACTCCGCC CATCCCGCCC 3180
CTAACTCCGC CCAGTTCGGC CCATTCTCGG CCCCATGGCT GACTAATTTT TTTTATTTAT 3240
GCAGAGGCCG AGGCCGCTC GGCCTCTGAG CTATTCCAGA AGTAGTGAGG AGGCTTTTTT 3300
GGAGGCCTAG GCTTTTGCAA AAAGCTTCAC GCTGCCGCAA GCACTCAGGG CGCAAGGGCT 3360
GCTAAAGGAA GCGGAACACG TAGAAAGCCA GTCCGCAGAA ACGGTGCTGA CCCCGGATGA 3420
ATGTCAGCTA CTGGGCTATC TGGACAAGGG AAAACGCAAG CGCAAAGAGA AAGCAGCTAG 3480
CTTGCACTGG GCTTACATGG CGATAGCTAG ACTGGGCGGT TTTATGGACA GCAAGCGAAC 3540
CGGAATTGCC AGTGGGGGCG CCCTCTGGTA AGGTTGGGAA GCCCTGCAAA GTAACTGGA 3600
TGGCTTTCTT GCCGCCAAGG ATCTGATGGC GCAGGGGATC AAGATCTGAT CAAGAGACAG 3660
GATGAGGATC GTTTCGCATG ATTGAACAAG ATGGATTGCA CGCAGGTTCT CCGGCCGCTT 3720
GGGTGGAGAG GCTATTCGGC TATGACTGGG CACAACAGAC AATCGGCTGC TCTGATGCCG 3780
CCGTGTTCCG GCTGTCAGCG CAGGGGCGCC CGGTTCTTTT TGTCAAGACC GACCTGTCCG 3840
GTGCCCTGAA TGAAGTCAG GACGAGGCAG CGCGGCTATC GTGGCTGGCC ACGACGGGCG 3900
TTCCTTGCGC AGCTGTGCTC GACGTTGTCA CTGAAGCGGG AAGGGACTGG CTGCTATTGG 3960
GCGAAGTGCC GGGGCAGGAT CTCCTGTCAT CTCACCTTGC TCCTGCCGAG AAAGTATCCA 4020
TCATGGCTGA TGCAATGCCG CGGCTGCATA CGCTTGATCC GGCTACCTGC CCATTGACC 4080
ACCAAGCGAA ACATCGCATC GAGCGAGCAC GTACTCGGAT GGAAGCCGGT CTTGTGATC 4140
AGGATGATCT GGACGAAGAG CATCAGGGGC TCGCGCCAGC CGAACTGTTT GCCAGGCTCA 4200

WO

AC

AT

CC

AA

CC

CC

GT

CA

CC

AA

GG

AC

GT

AA

CA

GA

TG

TG

AT

AC

AT

TT

AT

AC

AT

AA

AGGCGCGCAT GCCCGACGGC GAGGATCTCG TCGTGACCCA TGGCGATGCC TGCTTGCCGA	4260
ATATCATGGT GGAAAATGGC CGCTTTTCTG GATTGATCGA CTGTGGCCGG CTGGGTGTGG	4320
CGGACCGCTA TCAGGACATA GCCTTGGCTA CCCGTGATAT TGCTGAAGAG CTGGCGGGC	4380
AATGGGCTGA CCGCTTCCTC GTGCTTIACG GTATCGCCGC TCCCGATTGG CAGCGCATCG	4440
CCTTCTATCG CCTTCTTGAC GAGTCTTCT GAGCGGGA CTGGGGTTGG AAATGACCGA	4500
CCAAGCGAGC CCAACCTGC CATCAGGAGA TTTCGATTCC ACCGCCGCCT TCTATGAAAG	4560
GTGGGGCTTC GGAATCGTTT TCCGGGACGC CGGCTGGATG ATCCTCCAGC GCGGGGATCT	4620
CATGCTGGAG TTCTTCGCCC ACCCGGGGCT CGATCCCTC GCGAGTTGGT TCAGCTGCTG	4680
CCTGAGGCTG GACGACCTCG CGGAGTTCTA CCGGCAGTGC AAATCCGTCG GCATCCAGGA	4740
AACCAGCAGC GGCTATCCGC GCATCCATGC CCCCGAACTG CAGGAGTGGG GAGGCACGAT	4800
GGCCGCTTTG GTCCCGGATC TTTGTGAAG AACCTTACTT CTGTGGTGTG ACATAATTGG	4860
ACAACTACC TACAGAGATT TAAAGCTCTA AGGTAAATAT AAAATTTTAA AGTGATAAT	4920
GTGTAAACT ACTGATTCTA ATTGTTTGTG TATTTTAGAT TCCAACCTAT GGAAGTATG	4980
AATGGGAGCA GTGGTGGAAT GCCTTTAATG AGGAAAACCT GTTTTGCTCA GAAGAAATGC	5040
CATCTAGTGA TGATGAGGCT ACTGCTGACT CTCAACATTC TACTCCTCCA AAAAAGAAGA	5100
GAAAGGTAGA AGACCCCAAG GACTTTCCTT CAGAATTGCT AAGTTTTTTG AGTCATGCTG	5160
TGTTTAGTAA TAGAACTCTT GCTTGCTTTG CTATTACAC CACAAAGGAA AAAGCTGCAC	5220
TGCTATACAA GAAAATTATG GAAAAATATT CTGTAACTT TATAAGTAGG CATAACAGTT	5280
ATAATCATAA CATACTGTTT TTTCTTACTC CACACAGGCA TAGAGTGTCT GCTATTAATA	5340
ACTATGCTCA AAAATTGTGT ACCTTAGCT TTTTAATTG TAAAGGGGT AATAAGGAAT	5400
ATTGATGTA TAGTGCCTTG ACTAGAGATC ATAATCAGCC ATACCACATT TGTAGAGGT	5460
TTACTTGCTT TAAAAACCT CCCACACCTC CCCCTGAACC TGAAACATAA AATGAATGCA	5520
ATTGTGTG TAACTTGT TATTGCAGCT TATAATGGT ACAAATAAAG CAATAGCATC	5580
ACAAATTCA CAAATAAAGC ATTTTTTCA CTGCATTCTA GTTGTGTTT GTCCAAACTC	5640
ATCAATGTAT CTTATCATGT CTGGATCCCC AGGAAGCTCC TCTGTGCTCT CATAAACCTT	5700
AACCTCCTCT ACTTGAGAG ACATTCCAAT CATAGGCTGC CCATCCACCC TCTGTGCTCT	5760

CCTGTTAATT AGGTCACTTA AAAAAAGGA AATTGGGTAG GGGTTTTTCA CAGACCGCTT 5820
TCTAAGGGTA ATTTTAAAT ATCTGGGAAG TCCCTTCCAC TGCTGTGTTT CAGAAGTGTT 5880
GGTAAACAGC CCACAAATGT CAACAGCAGA AACATACAAG CTGTCAGCTT TGCACAAGGG 5940
CCCAACACCC TGCTCATCAA GAAGCACTGT GGTGCTGTG TTAGTAATGT GCAAAACAGG 6000
AGGCACATTT TCCCCACCTG TGTAGGTTCC AAAATATCTA GTGTTTTTCA TTTTACTTGG 6060
ATCAGGAACC CAGCACTCCA CTGGATAAGC ATTATCCTTA TCCAAAACAG CCTTGTGGTC 6120
AGTGTTTCATC TGCTGACTGT CAACTGTAGC ATTTTTTGGG GTTACAGTTT GAGCAGGATA 6180
TTTGGTCCTG TAGTTTGCTA ACACACCTG CAGCTCCAAA GGTTCCCCAC CAACAGCAAA 6240
AAAATGAAAA TTTGACCCTT GAATGGGTTT TCCAGCACCA TTTTCATGAG TTTTTGTGT 6300
CCCTGAATGC AAGTTTAAAC TAGCAGTTAC CCAATAACC TCAGTTTAA CAGTAACAGC 6360
TTCCACATC AAAATATTT CACAGGTAA GTCTCATTT AAATTAGGCA AAGGAATTAT 6420
ACACTCCGCT ATCGCTACGT GACTGGGTCA TGGCTGCGCC CCGACACCG CCAACACCG 6480
CTGACGGGCC CTGACGGGCT TGTCTGCTCC CGGCATCCG TTACAGACAA GCTGTGACCG 6540
TCTCCGGGAG CTGCATGTGT CAGAGGTTTT CACCGTCATC ACCGAAACGC GCGAGGCAGC 6600
GGATCATAAT CAGCCATACC ACATTTGTAG AGGTTTTACT TGCTTTAAAA AACCTCCAC 6660
ACCTCCCCCT GAACCTGAAA CATAAATGA ATGCAATTGT TGTGTAAAC TTGTTTATTG 6720
CAGCTTATAA TGGTTACAAA TAAAGCAATA GCATCACAAA TTTCACAAAT AAAGCATTTT 6780
TTTCACTGCA TTCTAGTTGT GGTGTGTTCA AACTCATCAA TGTATCTTAT CATGTCTGGA 6840
TCATAATCAG CCATACCACA TTTGTAGAGG TTTTACTTGC TTTAAAAAC CTCCACACC 6900
TCCCCCTGAA CCTGAAACAT AAAATGAATG CAATTGTGT TGTAACTTG TTTATTGCAG 6960
CTTATAATGG TTACAAATAA AGCAATAGCA TCACAAATTT CACAAATAAA GCATTTTTTT 7020
CACTGCATTC TAGTTGTGGT TTGTCCAAAC TCATCAATGT ATCTTATCAT GTCTGGATCC 7080
CAGCCAGACA AGTTGTGTTA CACAAGACCC ACATCTGGTA TAAAAGGAGG CAGTGGCCCA 7140
CAGAGGAGCA CAGCTGTGTT TGGCTGCAGG GCCAAGAGCG CTGTCAAGAA GACCCACAGC 7200
CCCCCTCCA GCAGCTGAAT TCCAGCTGGC ATTCCGGTAC TGTGCTAAA ATGGAAGACG 7260
CCAAAAACAT AAAGAAAGGC CCGGCCCAT TCTATCTCT AGAGGATGGA ACCGCTGGAG 7320

A

A

C

A

C

C

C

T

A

T

T

T

T

T

T

T

T

T

T

T

T

T

T

T

T

T

AGCAACTGCA TAAGGCTATG AAGAGATACG CCCTGGTTCC TGAACAATT GCTTTTACAG 7380
ATGCACATAT CGAGGTGAAC ATCACGTACG CGGAATACTT CGAAATGTCC GTTCGGTTGG 7440
CAGAAGCTAT GAAACGATAT GGGCTGAATA CAAATCACAG AATCGTCGTA TGCAGTGAAA 7500
ACTCTCTTCA ATTCTTTATG CCGGTGTTGG GCGCGTIATT TATCGGACTT GCAGTTGCCG 7560
CCGCGAACGA CATTTATAAT GAACGTGAAT TGCTCAACAG TATGAACATT TGCAGCCTA 7620
CGGTAGTGT TGTTCCTAAA AAGGGGTTGC AAAAAATTTT GAACGTGCAA AAAAAATTAC 7680
CAATAATCCA GAAAAATTAT ATCATGGATT CTAAACGGA TTACCAGGA TTTCAGTCGA 7740
TGTACACGTT CGTCACATCT CATCTACCTC CCGGTTTAA TGAATACGAT TTGTACCAG 7800
AGTCCTTTGA TCGTGACAAA ACAATTGCAC TGATAATGAA TTCCTCTGGA TCTACTGGGT 7860
TACCTAAGGG TGTGGCCCTT CCGCATAGAA CTGCCTGCGT CAGATTCTCG CATGCCAGAG 7920
ATCCTATTTT TGGCAATCAA ATCATTCCGG AACTGCGAT TTAAAGTGT GTTCCATTCC 7980
ATCACGGTTT TGAATGTTT ACTACACTCG GATATTGAT ATGTGGATT CGAGTCGTCT 8040
TAATGTATAG ATTTGAAGAA GAGCTGTTTT TACGATCCCT TCAGGATTAC AAAATTCAA 8100
GTGCGTTGCT AGTACCAACC CTATTTTCAT TCTTCGCCAA AAGCACTCTG ATTGACAAA 8160
ACGATTATC TAATTACAC GAAATTGCTT CTGGGGCGC ACCTCTTCG AAAGAAGTCG 8220
GGGAAGCGGT TGCAAAACGC TTCCATCTC CAGGGATACG ACAAGGATAT GGGCTCACTG 8280
AGACTACATC AGCTATTCTG ATTACACCCG AGGGGGATGA TAAACCGGGC GCGTCGCTA 8340
AAGTTGTTCC ATTTTTTGAA GCGAAGGTTG TGGATCTGGA TACCGGAAA ACGCTGGCG 8400
TTAATCAGAG AGGCGAATTA TGTGTCAGAG GACCTATGAT TATGTCCGGT TATGTAAACA 8460
ATCCGGAAGC GACCAACGCC TTGATTGACA AGGATGGATG GCTACATTCT GGAGACATAG 8520
CTTACTGGGA CGAAGACGAA CACTTCTTCA TAGTTGACCG CTTGAAGTCT TTAATTAAAT 8580
ACAAAGGATA TCAGGTGGCC CCCGCTGAAT TGAATCGAT ATTGTTACAA CACCCCAACA 8640
TCTTCGACGC GGGCGTGGCA GGTCTTCCCG ACGATGACGC CGGTGAACTT CCCGCCGCCG 8700
TTGTGTTTTT GGAGCACGGA AAGACGATGA CGGAAAAGA GATCGTGGAT TACGTGCCA 8760
GTCAAGTAAC AACC CGGAAA AAGTTGCCG GAGGAGTTGT GTTTGTGGAC GAAGTACCGA 8820
AAGGTCTTAC CGGAAAAC TC GACGCAAGAA AAATCAGAGA GATCCTCATA AAGGCCAAGA 8880

AGGGCGGAAA GTCCAAATTG TAAAATGTAA CTGTATTCAG CGATGACGAA ATTCTTAGCT	8940	GT
ATTGTAATGA CTCTAGAGGA TCTTTGTGAA GGAACCTTAC TTCTGTGGTG TGACATAATT	9000	GC
GGACAACTA CCTACAGAGA TTAAAGCTC TAAGGTAAAT ATAAATTTT TAAGTGATA	9060	(2
ATGTGTAAA CTA CTGATTG TAATTGTTG TGTATTTTAT ATTCCAACCT ATGGAAGTGA	9120	
TGAATGGGAG CAGTGGTGGA ATGCCCTTAA TGAGGAAAAC CTGTTTGTCT CAGAAGAAAT	9180	
GCCATCTAGT GATGATGAGG CTA CTGCTGA CTCTCAACAT TCTACTCCTC CAAAAAGAA	9240	
GAGAAAGTA GAAGACCCCA AGGACTTTCC TTCAGAATTG CTAAGTTTTT TGAGTCATGC	9300	
TGTGTTTACT AATAGAACTC TTGCTTGCTT TGCTATTTAC ACCACAAAGG AAAAGCTGC	9360	
ACTGCTATAC AAGAAAATTA TGGAATAA TTCTGTAACC TTTATAAGTA GGCATAACAG	9420	
TTATAATCAT AACATACTGT TTTTCTTAC TCCACACAGG CATAGAGTGT CTGCTATTAA	9480	
TAATATGCT CAAAAATTGT GTACCTTATG CTTTTTAATT TGTAAGGGG TTAATAAGGA	9540	
ATATTTGATG TATAGTGCCT TGACTAGAGA TCATAATCAG CCATACCACA TTTGTAGAGG	9600	TTC
TTTTACTTGC TTAAAAAAC CTCCACACC TCCCCTGAA CCTGAAACAT AAAATGAATG	9660	AAI
CAATTGTTGT TGTTAACTTG TTTATTGCAG CTTATAATGG TTACAAATAA AGCAATAGCA	9720	TTI
TCACAAATT CACAAATAAA GCATTTTTT CACTGCATTC TAGTTGTGGT TTGTCCAAAC	9780	GCI
TCATCAATGT ATCTTATCAT GTCTGGATCC CCAGGAAGCT CCTCTGTGTC CTCATAACC	9840	TCC
CTAACCTCCT CTACTTGAGA GGACATTCCA ATCATAGGCT GCCCATCCAC CCTCTGTGTC	9900	AAA
CTCCTGTAA TTAGGTCACT TAACAAAAG GAAATTGGGT AGGGGTTTT CACAGACCGC	9960	CGG
TTTCTAAGGG TAATTTTAAA ATATCTGGGA AGTCCCTCC ACTGCTGTGT TCCAGAAGTG	10020	AGI
TTGTTAAACA GCCACAAAT GTCAACAGCA GAAACATACA AGCTGTCAGC TTGCACAAG	10080	CCG
GGCCCAACAC CCTGCTCAGC AAGAAGCACT GTGGTTGCTG TGTTAGTAAT GTGCAAAACA	10140	TAC
GGAGGCACAT TTTCCCACCC TGTGTAGGTT CAAAATATC TAGTGTTC ATTCTTACTT	10200	TGC
GGATCAGGAA CCCAGCACTC CACTGGATAA GCATTATCCT TATCCAAAAC AGCCTTGTGG	10260	CAA
TCAGTGTTCA TCTGCTGACT GTCAACTGTA GCATTTTTT GGGTTACAGT TTGAGCAGGA	10320	ACC
TATTTGGTCC TGTAGTTTGC TAACACACCC TGCAGCTCCA AAGTTCCCC ACCAACAGCA	10380	ATT
AAAAATGAA AATTGACCC TTGAATGGGT TTCCAGCAC CATTTTCATG AGTTTTTGT	10440	GGA

GTCCCTGAAT GCAAGTTTAA CATAGCAGTT ACCCCAATAA CCTCAGTTTT AACAGTAACA 10500
GCTTCCCACA TCAAAATATT TCCACAGGTT AAGTCCTCAT TTAAATTAGG CAAAGGAA 10558

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6245 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

TTCTTGAAGA CGAAAGGGCC TCGTGATACG CCTATTTTTA TAGGTTAATG TCATGATAAT 60
AATGGTTTCT TAGACGTCAG GTGGCACTTT TCGGGGAAAT GTGCGGGGAA CCCCTATTTG 120
TTTATTTTTT TAAATACATT CAAATATGTA TCCGCTCATG AGACAATAAC CCTGATAAAT 180
GCTTCAATAA TATTGAAAAA GGAAGAGTAT GAGTATTCAA CATTTCGGTG TCGCCCTTAT 240
TCCCTTTTTT GCGGCATTTT GCCTTCCTGT TTTTGCTCAC CCAGAAACGC TGGTGAAAGT 300
AAAAGATGCT GAAGATCACT TGGGTGCACG AGTGGGTTAC ATCGAACTGG ATCTCAACAG 360
CGGTAAGATC CTTGAGAGTT TTGCCCCGA AGAACGTTTT CCAATGATGA GCACTTTTAA 420
AGTTCGTCTA TGTGGCGCGG TATTATCCCG TGTGACGCC GGGCAAGAGC AACTCGGTG 480
CCGCATACAC TATTCTCAGA ATGACTTGGT TGAGTACTCA CCAGTCACAG AAAAGCATCT 540
TACGGATGGC ATGACAGTAA GAGAATTATG CAGTGTGCGC ATAACCATGA GTGATAACAC 600
TGCGGCCAAC TTACTTCTGA CAACGATCGG AGGACCGAAG GAGCTAACCG CTTTTTGA 660
CAACATGGGG GATCATGTAA CTCGCCTTGA TCGTTGGGAA CCGGAGCTGA ATGAAGCCAT 720
ACCAAACGAC GAGCGTGACA CCACGATGCC TGCAGCAATG GCAACAACGT TGGGCAAAC 780
ATTAAGTGGC GAACTACTTA CTCTAGCTTC CCGGCAACAA TTAATAGACT GGATGGAGGC 840
GGATAAAGTT GCAGGACCAC TTCTGCGCTC GGCCCTTCGG GCTGGCTGGT TTATTGCTGA 900

TAAATCTGGA GCCGGTGAGC GTGGGTCTCG CGGTATCATT GCAGCACTGG GGCCAGATGG 960
TAAGCCCTCC CGTATCGTAG TTATCTACAC GACGGGGAGT CAGGCAACTA TGGATGAACG 1020
AAATAGACAG ATCGCTGAGA TAGGTGCCCTC ACTGATTAAG CATTGGTAAC TGTGAGACCA 1080
AGTTTACTCA TATATACTTT AGATTGATT AAAACTTCAT TTTTAATTAA AAAGGATCTA 1140
GGTGAAGATC CTTTTTGATA ATCTCATGAC CAAAATCCCT TAACGTGAGT TTTCGTTCCA 1200
CTGAGCGTCA GACCCCGTAG AAAAGATCAA AGGATCTTCT TGAGATCCTT TTTTCTGCG 1260
CGTAATCTGC TGCTTGCAAA CAAAAAACC ACCGCTACCA GCGGTGGTTT GTTTGCCGGA 1320
TCAAGAGCTA CCAACTCTTT TTCCGAAGGT AACTGGCTTC AGCAGAGCGC AGATACCAAA 1380
TACTGTCTT CTAGTGTAGC CGTAGTTAGG CCACCACTTC AAGAACTCTG TAGCACC GCC 1440
TACATACCTC GCTCTGCTAA TCCTGTTACC AGTGGCTGCT GCCAGTGGCG ATAAGTCGTG 1500
TCTTACCGGG TTGGA CTCAA GACGATAGTT ACCGGATAAG GCGCAGCGGT CGGGCTGAAC 1560
GGGGGGTTG TGACACAGC CCAGCTTGA GCGAACGACC TACACCGAAC TGAGATACCT 1620
ACAGCGTGAG CATTGAGAAA GCGCCACGCT TCCCGAAGGG AGAAAGGCGG ACAGGTATCC 1680
GGTAAGCGGC AGGCTCGGAA CAGGAGAGCG CACGAGGAG CTTCAGGGG GAAACGCCTG 1740
GTATCTTTAT AGTCTGTGCG GGTTCGCCA CCTCTGACTT GAGCGTCGAT TTTTGTGATG 1800
CTCGTCAGGG GGGCGGAGCC TATGGAAAAA CGCCAGCAAC GCGGCCTTTT TACGGTTCCT 1860
GGCCTTTGCG TGGCCTTTTG CTCACATGTT CTTTCTGCG TTATCCCTG ATTCTGTGGA 1920
TAACCGTATT ACCGCCTTTG AGTGAGCTGA TACCGCTCGC GCGAGCCGAA CGACCGAGCG 1980
CAGCGACTCA GTGAGCGAGG AAGCGGAAGA GCGCCTGATG CGGTATTTT TCCTTACGCA 2040
TCTGTGCGGT ATTTACACACC GCATATGGTG CACTCTCAGT ACAATCTGCT CTGATGCCGC 2100
ATAGTTAAGC CAGTATACAC TCCGCTATCG CTACGTGACT GGGTCATGGC TGGCCCCGA 2160
CACCCGCCAA CACCCGCTGA CGCGCCCTGA GGGGCTTGTC TGCTCCCGGC ATCCGCTTAC 2220
AGACAAGCTG TGACCGTCTC CGGGAGCTGC ATGTGTCAGA GGTTTTCACC GTCATCACCG 2280
AAACGCGCGA GGCAGCGGAT CATAATCAGC CATACCACAT TTGTAGAGGT TTTACTTGCT 2340
TTAAAAAACC TCCACACCT CCCCTGAAC CTGAAACATA AAATGAATGC AATTGTTGTT 2400
GTAACTTGT TTATTGCAGC TTATAATGGT TACAAATAAA GCAATAGCAT CACAAATTC 2460

ACA

TCT

AAA

AAT

AATA

TATC

TGGC

CCAC

GAAG

GCTG

TTTA

CGGT

AGTG

GTTG

CAGC

AAAT

CAGT

GTAC

ACTG

GCCA

CCAT

GTCC

ATTG

GACA

GAAG

CTCA

0 ACAAATAAAG CATTITTTTC ACTGCATTCT AGTTGTGGTT TGTCCAAACT CATCAATGTA 2520
0 TCTTATCATG TCTGGATCAT AATCAGCCAT ACCACATTTG TAGAGGTTTT ACTTGCTTTA 2580
0 AAAAACCTCC CACACCTCCC CCTGAACCTG AAACATAAAA TGAATGCAAT TGTGTGTGT 2640
0 AACTTGTTTA TTGCAGCTTA TAATGGTTAC AAATAAAGCA ATAGCATCAC AAATTTGACA 2700
0 AATAAAGCAT TTTTTCACCT GCATTCTAGT TGTGGTTTGT CCAAATCAT CAATGTATCT 2760
1 TATCATGTCT GGATCCCAAG TTCATCTATT TCCTCCACACA TCTGGTATAA AAGGAGGCAG 2820
TGGCCACAG AGGAGCACAG CTGTGTTTGG CTGCAGGGCC AAGAGCGCTG TCAAGAAGAC 2880
CCACAGCCCC CCTCCAGCA GCTGAATTCC AGCTGGCATT CCGGTACTGT TGGTAAATG 2940
GAAGACGCCA AAAACATAAA GAAAGGCCCG GCGCCATTCT ATCCTCTAGA GGATGGAACC 3000
GCTGGAGAGC AACTGCATAA GGCTATGAAG AGATACGCCC TGGTTCCTGG AACAATTGCT 3060
TTTACAGATG CACATATCGA GGTGAACATC ACGTACGGCG AATACTTGA AATGTCCGTT 3120
CGGTTGGCAG AAGCTATGAA ACGATATGGG CTGAATACAA ATCACAGAAT CGTGTATGC 3180
AGTGAAACT CTCITCAATT CTTIATGCCG GTGTTGGGCG CGTTATTAT CGGAGTTGCA 3240
GTTGCGCCCG CGAACGACAT TTATAATGAA CGTGAATTGC TCAACAGTAT GAACATTTCC 3300
CAGCCTACCG TAGTGTGTGT TTCCAAAAG GGGTTGCAA AAATTTTGAA CGTGCAAAA 3360
AAATTACCAA TAATCCAGAA AATTATTATC ATGGATTCTA AAACGGATTA CCAGGGATT 3420
CAGTCGATGT ACACGTTCTG CACATCTCAT CTACCTCCCG GTTTTAATGA ATACGATTT 3480
GTACCAGAGT CCTTTGATCG TGACAAAACA ATTGCACTGA TAATGAATC CTCTGGATCT 3540
ACTGGGTAC CTAAGGGTGT GGCCCTTCG CATAGAACTG CCTGCGTCAG ATTCTCGCAT 3600
GCCAGAGATC CTATTTTGG CAATCAAATC ATTCCGATA CTGCGATTTT AAGTGTGT 3660
CCATTCCATC ACGGTTTTGG AATGTTTACT ACACTCGGAT ATTTGATATG TGGATTTGCA 3720
GTCGTCTTAA TGTATAGATT TGAAGAAGAG CTGTTTTTAC GATCCCTTCA GGATTACAAA 3780
ATTCAAAGTG CGTTGCTAGT ACCAACCCTA TTTTCATTCT TCGCCAAAAG CACTCTGATT 3840
GACAAATACG ATTTATCTAA TTTACAGAA ATTGCTTCTG GGGGCGCACC TCTTTGAAA 3900
GAAGTCGGG AAGCGGTTGC AAAACGCTTC CATCTTCCAG GGATACGACA AGGATATGGG 3960
CTCACTGAGA CTACATCAGC TATTCTGATT ACACCCGAGG GGGATGATAA ACCGGGCGCG 4020

GTGCGTAAAG TTGTTCCATT TTTTGAAGCG AAGGTTGTGG ATCTGGATAC CGGGAAAACG 4080
CTGGGCGTTA ATCAGAGAGG CGAATTATGT GTCAGAGGAC CTATGATTAT GTCCGGTTAT 4140
GTAAACAATC CGGAAGCGAC CAACGCCTTG ATTGACAAGG ATGGATGGCT ACATTCTGGA 4200
GACATAGCTT ACTGGGACGA AGACGAACAC TTCTTCATAG TTGACCGCTT GAAGTCTTTA 4260
ATTAAATACA AAGGATATCA GGTGGCCCCC GCTGAATTGG AATCGATATT GTTACAACAC 4320
CCCAACATCT TCGACGCGGG CGTGGCAGGT CTTCCCGACG ATGACGCCGG TGAACCTCCC 4380
GCGGCCGTTG TTGTTTTGGA GCACGGAAG ACGATGACGG AAAAAGACAT CGTGGATTAC 4440
GTGCCCAGTC AAGTAACAAC CGCGAAAAAG TTGCGCGGAG GAGTTGTGTT TGTGGACGAA 4500
GTACCGAAAG GTCTTACCGG AAAACTCGAC GCAAGAAAAA TCAGAGAGAT CCTCATAAAG 4560
GCCAAGAAGG GCGGAAAGTC CAAATTGTAA AATGTAAGT TATTAGCGA TGACGAAATT 4620
CTTAGCTATT GTAATGACTC TAGAGGATCT TTGTGAAGGA ACCTTACTTC TGTGGTGTGA 4680
CATAATTGGA CAAACTACCT ACAGAGATTT AAAGCTCTAA GGTAAATATA AAATTTTAA 4740
GTGTATAATG TGTTAAACTA CTGATTCTAA TTGTTGTGT ATTTTAGATT CCAACCTATG 4800
GAACTGATGA ATGGGAGCAG TGGTGAATG CCTTTAATGA GGAAAACCTG TTTTGCTCAG 4860
AAGAAATGCC ATCTAGTGAT GATGAGGCTA CTGCTGACTC TCAACATTCT ACTCCTCCAA 4920
AAAAGAAGAG AAAGGTAGAA GACCCCAAGG ACTTTCCTTC AGAATTGCTA AGTTTTTTGA 4980
GTCATGCTGT GTTAGTAAT AGAACTCTTG CTGCTTTGC TATTACACC ACAAAGGAAA 5040
AAGCTGCACT GCTATACAAG AAAATTATGG AAAAATATTC TGTAACCTTT ATAAGTAGGC 5100
ATAACAGTTA TAATCATAAC ATACTGTTTT TTCTTACTCC ACACAGGCAT AGAGTGTCTG 5160
GTATTAATAA CTATGCTCAA AAATTGTGTA CCTTTAGCTT TTTAATTGT AAAGGGGTTA 5220
ATAAGGAATA TTTGATGTAT AGTGCCTTGA CTAGAGATCA TAATCAGCCA TACCACATTT 5280
GTAGAGGTTT TACTTGCTTT AAAAAACCTC CCACACCTCC CCCTGAACCT GAAACATAAA 5340
ATGAATGCAA TTGTTGTGT TAACTTGTTT ATTGCAGCTT ATAATGGTTA CAAATAAAGC 5400
AATAGCATCA CAAATTCAC AAATAAAGCA TTTTTTCAC TGCATTCTAG TTGTGGTTTG 5460
TCCAAACTCA TCAATGTATC TTATCATGTC TGGATCCCCA GGAAGCTCCT CTGTGTCCTC 5520
ATAAACCCCTA ACCTCCTCTA CTGAGAGGA CATTCCAATC ATAGGCTGCC CATCCACCCT 5580

C

AC

AC

GC

CA

TT

CT

AC

AA

TT

AC

AC

(2

TT

AA

TT

GC

TC

CTGTGTCCTC CTGTTAATTA GGTCACTTAA CAAAAAGGAA ATTGGGTAGG GGTTTTTCAC	5640
AGACCGCTTT CTAAGGGTAA TTTTAAATA TCTGGGAAGT CCCTTCCACT GCTGTGTTC	5700
AGAAGTGTG GTAAACAGCC CACAAATGTC AACAGCAGAA ACATACAAGC TGTGAGCTTT	5760
GCACAAGGGC CCAACACCCT GCTCAGCAAG AAGCACTGTG GTTGCTGTG TAGTAATGTG	5820
CAAAACAGGA GGCACATTTT CCCACCTGT GTAGGTTCCA AAATATCTAG TGTTTTGATT	5880
TTTACTTGGA TCAGGAACCC AGCACTCCAC TGGATAAGCA TTATCCTTAT CAAAACAGC	5940
CTTGTGGTCA GTGTTTCATCT GCTGACTGTC AACTGTAGCA TTTTTTGGGG TTACAGTTG	6000
AGCAGGATAT TTGGTCCTGT AGTTTGCTAA CAGACCTGC AGCTCCAAAG GTTCCCAGC	6060
AACAGCAAAA AAATGAAAT TTGACCCTG AATGGGTTTT CCAGCACCAT TTCATGAGT	6120
TTTTGTGTC CCTGAATGCA AGTTTAACAT AGCAGTTACC CCAATAACCT CAGTTTAAAC	6180
AGTAACAGCT TCCCACATCA AAATATTTC ACAGGTTAAG TCCTCATTIA AATTAGGCAA	6240
AGGAA	6245

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6254 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

TTCTTGAAGA CGAAAGGGCC TCGTGATACG CCTATTTTTA TAGGTTAATG TCATGATAAT	60
AATGTTTCT TAGACGTCAG GTGGCACTTT TCGGGGAAAT GTGCGCGGAA CCCCTATTTG	120
TTATTTTTC TAAATACATT CAAATATGTA TCCGCTCATG AGACAATAAC CCTGATAAAT	180
GCTTCAATAA TATTGAAAAA GGAAGAGTAT CAGTATTCAA CATTTCCGTG TCGCCCTTAT	240
TCCCTTTTTT GCGGCATTTT GCCTTCCTGT TTTTGCTCAC CCAGAAACGC TGGTGAAAGT	300

AAAAGATGCT GAAGATCAGT TGGGTGCACG AGTGGGTTAC ATCGAACTGG ATCTCAACAG	360	GGCCT
CGGTAAGATC CTTGAGAGTT TTCGCCCCGA AGAACGTTTT CCAATGATGA GCACTTTTAA	420	TAACC
AGTTCTGCTA TGTGGCGCGG TATTATCCCG TGTTGACGCC GGGCAAGAGC AACTCGGTCC	480	CAGGG
CGGCATACAC TATTCTCAGA ATGACTTGGT TGAGTACTCA CCAGTCACAG AAAAGCATCT	540	TCTGT
TACGGATGGC ATGACAGTAA GAGAATTATC CAGTGCTGCC ATAACCATGA GTGATAACAC	600	ATAGT
TGCGGCCAAC TTA CTCTCTGA CAACGATCGG AGGACCGAAG GAGCTAACCG CTTTTTTGCA	660	CACCC
CAACATGGGG GATCATGTAA CTCGCCTTGA TCGTTGGGAA CCGGAGCTGA ATGAAGCCAT	720	AGACA
ACCAAACGAC GAGCGTGACA CCACGATGCC TGCAGCAATG GCAACAACGT TCGCGAACT	780	AAACC
ATTA ACTGGC GAACTACTTA CTCTAGCTTC CCGGCAACAA TTAATAGACT GGATGGAGGC	840	TTAAA
GGATAAAGTT GCAGGACCAC TTCTGCGCTC GGCCCTTCGG GCTGGCTGGT TTATTGCTGA	900	GTAA
TAAATCTGGA GCCGGTGAGC GTGGGTCTCG CGGTATCATT GCAGCACTGG GGCCAGATGG	960	ACAAA
TAAGCCCTCC CGTATCGTAG TTATCTACAC GACGGGGAGT CAGGCAACTA TGGATGAACG	1020	TCTTA
AAATAGACAG ATCGCTGAGA TAGGTGCCTC ACTGATTAAG CATTGGTAAC TGTGAGACCA	1080	AAAAA
AGTTTACTCA TATATACTTT AGATTGATTT AAAACTTCAT TTTTAATTIA AAAGGATCTA	1140	AACTT
GGTGAAGATC CTTTTTGATA ATCTCATGAC CAAAATCCCT TAACGTGAGT TTTCGTTCCA	1200	AATAA
CTGAGCGTCA GACCCCGTAG AAAAGATCAA AGGATCTTCT TGAGATCCTT TTTTCTGCG	1260	TATCA
CGTAATCTGC TGCTTGCAAA CAAAAAACC ACCGCTACCA GCGGTGGTTT GTTTGCCGGA	1320	AGGAG
TCAAGAGCTA CCAACTCTTT TTCCGAAGGT AACTGGCTTC AGCAGAGCGC AGATACCAA	1380	CAAGA
TACTGTCCTT CTAGTGTAGC CGTAGTIAGG CCACCACTTC AAGAACTCTG TAGCACCGCC	1440	GGTAA
TACATACCTC GCTCTGCTAA TCCTGTTACC AGTGGCTGCT GCCAGTGGCG ATAAGTCGTG	1500	GATGG
TCTTACCGGG TTGGA CTCA GACGATAGTT ACCGGATAAG GCGCAGCGGT CGGGCTGAAC	1560	ACAAI
GGGGGGTTTC TGCACACAGC CCAGCTTGA GCGAACGACC TACACCGAAC TGAGATACCT	1620	ATGTC
ACAGCGTGAG CATTGAGAAA GCGCCACGCT TCCGAAGGG AGAAAGGCGG ACAGGTATCC	1680	GTGGI
GGTAAGCGGC AGGCTCGGAA CAGGAGAGCG CACGAGGGAG CTTCCAGGGG GAAACGCCTG	1740	GGAGI
GTATCTTTAT AGTCCTGTCT GGTTCGCCA CCTCTGACTT GAGCGTCGAT TTTTGTGATG	1800	AACA
CTCGTCAGGG GGGCGGAGCC TATGGAAAA CGCCAGCAAC GCGGCCTTTT TACGGTTCCT	1860	GTGCI

GGCCTTTTGC TGGCCTTTTG CTCACATGTT CTTTCCTGCG TTATCCCGCTG ATTCTGTGGA 1920
TAACCGTATT ACCGCCTTTG AGTGAGCTGA TACCGCTCGC CGCAGCCGAA CGACCGAGCG 1980
CAGCGAGTCA GTGAGCGAGG AAGCGGAAGA GCGCCTGATG CCGTATTTTC TCCTTACGCA 2040
TCTGTGCGGT ATTTACACACC GCATATGGTG CACTCTCAGT ACAATCTGCT CTGATGCCGC 2100
ATAGTTAAGC CAGTATACAC TCCGCTATCG CTACGTGACT GGGTCATGGC TGGCCCCGA 2160
CACCCGCCAA CACCCGCTGA CGCGCCCTGA CGGGCTTGTC TGCTCCCGGC ATCCGCTTAC 2220
AGACAAGCTG TGACCGTCTC CGGGAGCTGC ATGTGTCAGA GGTITTCACC GTCATCACCG 2280
AAACCGCGGA GGCAGCGGAT CATAATCAGC CATAACCAT TTGTAGAGGT TTTACTTGCT 2340
TTAAAAAACC TCCCACACCT CCCCTGAAC CTGAAACATA AAATGAATGC AATTGTTGTT 2400
GTAACTTGT TTATTGCAGC TTATAATGGT TACAAATAAA GCAATAGCAT CACAAATTC 2460
ACAAATAAAG CATTTTTTTC ACTGCATTCT AGTTGTGGTT TGTCCAAACT CATCAATGTA 2520
TCTTATCATG TCTGGATCAT AATCAGCCAT ACCACATTG TAGAGGTTTT ACTTGCTTTA 2580
AAAAACCTCC CACACCTCCC CCTGAACCTG AAACATAAAA TGAATGCAAT TGTGTGTGT 2640
AACTTGTTTA TTGCAGCTTA TAATGGTTAC AAATAAAGCA ATAGCATCAC AAATTCACA 2700
AATAAAGCAT TTTTTTCACT GCATTCTAGT TGTGGTTTGT CCAAATCAT CAATGTATCT 2760
TATCATGTCT GGATCCCACT GGGGAGTCAG CCGTGTATCA TCGCCACAT CTGGTATAAA 2820
AGGAGGCAGT GGCCACAGA GGAGCACAGC TGTGTTTGGC TGCAGGGCCA AGAGCGCTGT 2880
CAAGAAGACC CACACGCCCC CCTCCAGCAG CTGAATTCCA GCTGGCATT CCGTACTGTT 2940
GGTAAATGG AAGACGCCAA AAACATAAAG AAAGGCCCGG CGCCATTCTA TCCTCTAGAG 3000
GATGGAACCG CTGGAGAGCA ACTGCATAAG GCTATGAAGA GATACGCCCT GGTTCCTGGA 3060
ACAATTGCTT TTACAGATGC ACATATCGAG GTGAACATCA CGTACGGGA AACTTCGAA 3120
ATGTCCGTTT GGTTGGCAGA AGCTATGAAA CGATATGGGC TGAATACAAA TCACAGAATC 3180
GTCGTATGCA GTGAAACTC TCTCAATTC TTTATGCCGG TGTGGGCGC GTTATTATC 3240
GGAGTTGCAG TTGCGCCCGC GAACGACATT TATAATGAAC GTGAATTGCT CAACAGTATG 3300
AACATTCGC AGCCTACCGT AGTGTGTTT TCCAAAAAGG GGTGCAAAA AATTTTGAAC 3360
GTGCAAAAAA AATTACCAAT AATCCAGAAA ATTATTATCA TGGATTCTAA AACGGATTAC 3420

CAGGGATTTC AGTCGATGTA CACGTTTCGTC ACATCTCATC TACCTCCCGG TTTAATGAA 3480
TACGATTTTG TACCAGAGTC CTTTGATCGT GACAAAACAA TTGCACTGAT AATGAATTCC 3540
TCTGGATCTA CTGGGTTACC TAAGGGTGTG GCCCTTCGGC ATAGAACTGC CTGCGTCAGA 3600
TTCTCGCATG CCAGAGATCC TATTTTGGC AATCAAATCA TTCCGGATAC TGCGATTTTA 3660
AGTGTGTTC CATTCCATCA CGGTTTTGGA ATGTTTACTA CACTCGGATA TTTGATATGT 3720
GGATTTTCGAG TCGTCTTAAT GTATAGATTG GAAGAAGAGC TGTTTTACG ATCCCTTCAG 3780
GATTACAAAA TTCAAAGTGC GTTGCTAGTA CCAACCCTAT TTTCATTCTT CGCCAAAAGC 3840
ACTCTGATTG ACAAATACGA TTTATCTAAT TTACACGAAA TTGCTTCTGG GGGCGCACCT 3900
CTTTCGAAAG AAGTCGGGA AGCGGTGCA AAACGCTTCC ATCTTCAGG GATACGACAA 3960
GGATATGGGC TCACTGAGAC TACATCAGCT ATTCTGATTA CACCCGAGGG GGATGATAAA 4020
CGGGGCGCGG TCGGTAAAGT TGTTCATTT TTTGAAGCGA AGTTGTGGA TCTGGATACC 4080
GGGAAAACGC TGGGCGTTAA TCAGAGAGGC GAATTATGTG TCAGAGGACC TATGATTATG 4140
TCCGGTTATG TAAACAATCC GGAAGCGACC AACGCCCTGA TTGACAAGGA TGGATGGCTA 4200
CATTCTGGAG ACATAGCTTA CTGGGACGAA GACGAACACT TCTTCATAGT TGACCGCTTG 4260
AAGTCTTTAA TTAAATACAA AGGATATCAG GTGGCCCCCG CTGAATTGGA ATCGATATTG 4320
TTACAACACC CCAACATCTT CGACGCGGGC GTGGCAGGTC TTCCCGACGA TGACGCGGT 4380
GAACTTCCCG CCGCGTTGT TGTTTTGGAG CACGAAAGA CGATGACGGA AAAAGAGATC 4440
GTGGATTACG TCGCCAGTCA AGTAACAACC GCGAAAAAGT TGCGCGGAGG AGTTGTGTTT 4500
GTGGACGAAG TACCGAAAGG TCTTACCGGA AAACTCGACG CAAGAAAAAT CAGAGAGATC 4560
CTCATAAAGG CCAAGAAGGG CGGAAAGTCC AAATTGTAAA ATGTAAGTGT ATTCAGCGAT 4620
GACGAAATTC TTAGCTATTG TAATGACTCT AGAGGATCTT TGTGAAGGAA CCTTACTTCT 4680
GTGGTGTGAC ATAATTGGAC AAACCTACCTA CAGAGATTTA AAGCTCTAAG GTAAATATAA 4740
AATTTTAAAG TGTATAATGT GTTAACTAC TGATTCTAAT TGTGTGTGTA TTTIAGATTG 4800
CAACCTATGG AACTGATGAA TGGGAGCAGT GGTGGAATGC CTTAATGAG GAAAACCTGT 4860
TTTGCTCAGA AGAAATGCCA TCTAGTGATG ATGAGGCTAC TGCTGACTCT CAACATTCTA 4920
CTCTCCAAA AAAGAAGAGA AAGGTAGAAG ACCCAAGGA CTTTCCTTCA GAATTGCTAA 4980

GTITTTTGAG TCATGCTGTG TTTAGTAATA GAACTCTTGC TTGCTTTGCT ATTTACACCA 5040
CAAAGGAAAA AGCTGCACTG CTATACAAGA AAATTATGGA AAAATATTCT GTAACCTTTA 5100
TAAGTAGGCA TAACAGTTAT AATCATAACA TACTGTTTTT TCTTACTCCA CACAGGCATA 5160
GAGTGTCTGC TATTAATAAC TATGCTCAAA AATTGTGTAC CTTTAGCTTT TTAATTGTGA 5220
AAGGGGTAA TAAGGAATAT TTGATGTATA GTGCCTTGAC TAGAGATCAT AATCAGCCAT 5280
ACCAGATTG TAGAGGTTTT ACTTGCTTTA AAAACCTCC CACACCTCCC CCTGAACCTG 5340
AAACATAAAA TGAATGCAAT TGTGTGTGT AACTTGTTA TTGCAGCTTA TAATGGTTAC 5400
AAATAAGCA ATAGCATCAC AAATTCACA AATAAGCAT TTTTTCCT GCATTCTAGT 5460
TGTGGTTGT CCAAACCTCAT CAATGTATCT TATCATGTCT GGATCCCCAG GAAGCTCCTC 5520
TGTGCTCTCA TAAACCCTAA CCTCCTCTAC TTGAGAGGAC ATTCCAATCA TAGGCTGCCC 5580
ATCCACCCTC TGTGCTCTCC TGTTAATTAG GTCACCTAAC AAAAAGGAAA TTGGGTAGGG 5640
GTTTTTCACA GACCGCTTTC TAAGGGTAAT TTAAAATAT CTGGGAAGTC CCTTCCACTG 5700
CTGTGTTCCA GAAGTGTGG TAAACAGCCC ACAAATGTCA ACAGCAGAAA CATAAAGCT 5760
GTCAGCTTTG CACAAGGGCC CAACACCCTG CTCAGCAAGA AGCACTGTGG TTGCTGTGTT 5820
AGTAATGTGC AAAACAGGAG GCACATTTTC CCCACCTGTG TAGGTTCCAA AATATCTAGT 5880
GTTTTCATTT TTAATTGGAT CAGGAACCCA GCACTCCACT GGATAAGCAT TATCCTTATC 5940
CAAAACAGCC TTGTGGTCAG TGTTCACTG CTGACTGTCA ACTGTAGCAT TTTTGGGGT 6000
TACAGTTTGA GCAGGATATT TGGTCCTGTA GTTIGCTAAC ACACCCTGCA GCTCCAAAGG 6060
TTCCCCACCA ACAGCAAAAA AATGAAAATT TGACCCTTGA ATGGGTTTTT CAGCACCATT 6120
TTCATGAGTT TTTTGTGTCC CTGAATGCAA GTTTAACATA GCAGTTACCC CAATAACCTC 6180
AGTTTTAACA GTAACAGCTT CCCACATCAA AATATTCCA CAGGTTAAGT CCTCATTTAA 6240
ATTAGGCAAA GGAA 6254

(2) INFORMATION FOR SEQ ID NO:9:

- (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6265 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

TTCTTGAAGA CGAAAGGGCC TCGTGATACG CCTATTTTAA TAGGTTAATG TCATGATAAT 60
AATGGTTTCT TAGACGTCAG GTGGCACTTT TCGGGGAAAT GTGCGCGGAA CCCCTATTTG 120
TTTATTTTTC TAAATACATT CAAATATGTA TCCGCTCATG AGACAATAAC CCTGATAAAT 180
GCTTCAATAA TATTGAAAAA GGAAGAGTAT GAGTATTCAA CATTTCCGTG TCGCCCTTAT 240
TCCCTTTTTT GCGGCATTTT GCCTTCCTGT TTTTGCTCAC CCAGAAACGC TGGTGAAAGT 300
AAAAGATGCT GAAGATCAGT TGGGTGCACG AGTGGGTIAC ATCGAACTGG ATCTCAACAG 360
CGGTAAGATC CTTGAGAGTT TTCGCCCCGA AGAACGTTTT CCAATGATGA GCACTTTTAA 420
AGTTCTGCTA TGTGGCGCGG TATTATCCCG TGTGACGCC GGGCAAGAGC AACTCGGTCC 480
CCGCATACAC TATTCTCAGA ATGACTTGCT TGAGTACTCA CCAGTCACAG AAAAGCATCT 540
TACGGATGGC ATGACAGTAA GAGAATTATG CAGTGCTGCC ATAACCATGA GTGATAACAC 600
TGCGGCCAAC TTA CTCTCTGA CAACGATCGG AGGACCGAAG GAGCTAACCG CTTTTTTGCA 660
CAACATGGGG GATCATGTAA CTCGCCTTGA TCGTTGGGAA CCGGAGCTGA ATGAAGCCAT 720
ACCAAACGAC GAGCGTGACA CCACGATGCC TGCAGCAATG GCAACAACGT TCGCGAAACT 780
ATTAAGTGGC GAACTACTTA CTCTAGCTTC CCGGCAACAA TTAATAGACT GGATGGAGGC 840
GGATAAAGTT GCAGGACCAC TTCTGCGCTC GGGCCTTCCG GCTGGCTGGT TTATTGCTGA 900
TAAATCTGGA GCCGGTGAGC GTGGGTCTCG CGGTATCATT GCAGCACTGG GGCCAGATGG 960
TAAGCCCTCC CGTATCGTAG TTATCTACAC GACGGGGAGT CAGGCAACTA TGGATGAACG 1020
AAATAGACAG ATCGCTGAGA TAGGTGCCTC ACTGATTAAAG CATTGGTAAAC TGTCAGACCA 1080
AGTTTACTCA TATATACTTT AGATTGATTT AAAACTTCAT TTTTAATTTA AAAGGATCTA 1140
GGTGAAGATC CTTTTTGATA ATCTCATGAC CAAAATCCCT TAACGTGAGT TTTCGTTCCA 1200
CTGAGCGTCA GACCCCGTAG AAAAGATCAA AGGATCTTCT TGAGATCCTT TTTTCTGCG 1260

CGT

TCA

TAC

TAC

TCT

GGG

ACA

GGT

GTA

CTC

GGC

TAA

CAA

TCT

ATT

CAA

AG

AA

TT

GT

AC

TCT

AT

AT

AT

T

CGTAATCTGC TGCTTGCAAA CAAAAAACC ACCGCTACCA GCGGTGGTTT GTTTGCCGGA 1320
TCAAGAGCTA CCAACTCTTT TTCCGAAGGT AACTGGCTTC AGCAGAGCGC AGATACCAA 1380
TACTGTCTT CTAGTGTAGC CGTAGTIAGG CCACCACTTC AAGAACTCTG TAGCACC GCC 1440
TACATACCTC GCTCTGCTAA TCCTGTTACC AGTGGCTGCT GCCAGTGGCG ATAAGTCTG 1500
TCTTACCGGG TTGGACTCAA GACGATAGTT ACCGGATAAG GCGCAGCGGT CGGGCTGAAC 1560
GGGGGGTTCG TGCACACAGC CCAGCTTGA GCGAACGACC TACACCGAAC TGAGATACCT 1620
ACAGCGTGAG CATTGAGAAA GCGCCACGCT TCCGAAGGG AGAAAGGCGG ACAGGTATCC 1680
GGTAAGCGGC AGGGTCGGAA CAGGAGAGCG CACGAGGGAG CTTCAGGGG GAAACGCTG 1740
GTATCTTTAT AGTCCTGTG GGTTCGCCA CCTCTGACTT GAGCGTCGAT TTTTGTGATG 1800
CTCGTCAGGG GGGCGGAGCC TATGGAAAA CGCCAGCAAC GCGGCCTTTT TACGGTTCCT 1860
GGCCTTTTGC TGGCCTTTG CTCACATGTT CTTCTCTGCG TTATCCCTG ATTCTGTGGA 1920
TAACCGTATT ACCGCCTTG AGTGAGCTGA TACCGCTCGC CGCAGCCGAA CGACCGAGCG 1980
CAGCGAGTCA GTGAGCGAGG AAGCGGAAGA GGCCTGATG CGGTATTTTC TCCTTACGCA 2040
TCTGTGGGGT ATTTACACCC GCATATGGTG CACTCTCACT ACAATCTGCT CTGATGCCGC 2100
ATAGTTAAGC CAGTATACAC TCCGCTATCG CTACGTGACT GGGTCATGGC TGCGCCCCGA 2160
CACCCGCCAA CACCCGCTGA CGCGCCCTGA CGGGCTTGTC TGCTCCCGGC ATCCGCTTAC 2220
AGACAAGCTG TGACCGTCTC CGGGAGCTGC ATGTGTCAGA GGTTTTCACC GTCATACCG 2280
AAACGCGCGA GGCAGCGGAT GATAATCAGC CATAACACAT TTGTAGAGGT TTTACTTGCT 2340
TTAAAAAACC TCCCACACCT CCCCTGAAC CTGAAACATA AAATGAATGC AATTGTTGTT 2400
GTTAACITGT TTATTGCAGC TTATAATGGT TACAAATAAA GCAATAGCAT CACAAATTC 2460
ACAAATAAAG CATTTTTTTC ACTGCATTCT AGTTGTGGTT TGTCCAAACT CATCAATGTA 2520
TCTTATCATG TCTGGATCAT AATCAGCCAT ACCACATTTG TAGAGGTTTT ACTTGCTTTA 2580
AAAAACCTCC CACACCTCCC CCTGAACCTG AAACATAAAA TGAATGCAAT TGTGTTGTT 2640
AACTTGTTTA TTGCAGCTTA TAATGTTAC AAATAAAGCA ATAGCATCAC AAATTTTACA 2700
AATAAAGCAT TTTTTTCACT GCATTCTAGT TGTGGTTTGT CCAAATCAT CAATGTATCT 2760
TATCATGTCT GGATCCCACT CCAACCTCAG CCAGACAAGG TTGTTGACAC AAGACCCACA 2820

TCTGGTATAA AAGGAGGCAG TGGCCACAG AGGAGCACAG CTGTGTTTGG CTGCAGGGCC 2880
AAGAGCGCTG TCAAGAAGAC CCACAGCCCC CCTCCAGCA GCTGAATTCC AGCTGGCATT 2940
CCGGTACTGT TGGTAAATG GAAGAGGCCA AAAACATAAA GAAAGGCCCG GCGCCATTCT 3000
ATCCTCTAGA GGATGGAACC GCTGGAGAGC AACTGCATAA GGCTATGAAG AGATACGCCC 3060
TGGTTCCTGG AACAAATTGCT TTTACAGATG CACATATCGA GGTGAACATC ACGTACGCGG 3120
AATACTTGA AATGTCCGTT CGGTTGGCAG AAGCTATGAA ACGATATGGG CTGAATACAA 3180
ATCAGAGAAT CGTCGTATGC AGTGAAACT CTCTTCAATT CTTTATGCCG GTGTTGGGCG 3240
CGTTATTTAT CGGAGTTGCA GTTGCGCCCC CGAACGACAT TTATAATGAA CGTGAATTGC 3300
TCAACAGTAT GAACATTTTCG CAGCCTACCG TAGTGTTTGT TTCCAAAAG GGGTTGCAAA 3360
AAATTTTGAA CGTGCAAAA AAATTACCAA TAATCCAGAA AATTATTATC ATGGATTCTA 3420
AAACGGATTA CCAGGGATT CAGTCGATGT ACACGTTGCT CACATCTCAT CTACCTCCCG 3480
GTTTTAATGA ATACGATTTT GTACCAGAGT CCTTTGATCG TGACAAAACA ATTGCACTGA 3540
TAATGAATTC CTCTGGATCT ACTGGGTAC CTAAGGGTGT GGGCCTTCGG CATAGAACTG 3600
CCTGCGTCAG ATTCTCGCAT GCCAGAGATC CTATTTTGG CAATCAAATC ATTCCGGATA 3660
CTGCGATTTT AAGTGTTGTT CCATTCCATC ACGGTTTGG AATGTTTACT ACACTCGGAT 3720
ATTTGATATG TGGATTTTGA GTCGTCTTAA TGTATAGATT TGAAGAAGAG CTGTTTTTAC 3780
GATCCCTTCA GGATTACAAA ATTCAAAGTG CGTTGCTAGT ACCAACCCTA TTTTCATTCT 3840
TCGCCAAAAG CACTCTGATT GACAAATACG ATTTATCTAA TTTACACGAA ATTGCTTCTG 3900
GGGGCGCACC TCTTTCGAAA GAAGTCGGGG AAGCGGTTGC AAAACGCTTC CATCTTCCAG 3960
GGATACGACA AGGATATGGG CTCACTGAGA CTACATCAGC TATTCTGATT ACACCGGAGG 4020
GGGATGATAA ACCGGGCGCG GTCGGTAAAG TTGTTCCATT TTTTGAAGCG AAGGTTGTGG 4080
ATCTGGATAC CGGGAAAACG CTGGGCGTTA ATCAGAGAGG CGAATTATGT GTCAGAGGAC 4140
CTATGATTAT GTCCGTTAT GTAAACAATC CGGAAGCGAC CAACGCCTTG ATTGACAAGG 4200
ATGGATGGCT ACATTCTGGA GACATAGCTT ACTGGGACGA AGACGAACAC TTCTTCATAG 4260
TTGACCGCTT GAAGTCTTTA ATTAAATACA AAGGATATCA GGTGGCCCCC GCTGAATTGG 4320
AATCGATATT GTTACAACAC CCCAACATCT TCGACGCGG CGTGGCAGGT CTTCCCGACG 4380

ATGACGCCGG TGAACCTCCC GCCGCCGTTG TTGTTTTGGA GCACGGAAAG ACGATGACGG 4440
AAAAAGAGAT CGTGGATTAC GTGCCAGTC AAGTAACAAC CGCGAAAAAG TTGCGGGGAG 4500
GAGTTGTGTT TGTGGACGAA GTACCGAAAG GTCTTACCGG AAAACTCGAC GCAAGAAAAA 4560
TCAGAGAGAT CCTCATAAAG GCCAAGAAGG GCGGAAAGTC CAAATTGTAA AATGTAAGTG 4620
TATTCAGCGA TGACGAAATT CTTAGCTATT GTAATGACTC TAGAGGATCT TTGTGAAGGA 4680
ACCTTACTTC TGTGGTGTGA CATAATTGGA CAACTACCT ACAGAGATTT AAAGCTCTAA 4740
GGTAAATATA AAATTTTAA GTGTATAATG TGTAAACTA CTGATTCTAA TTGTTTGTGT 4800
ATTTTAGATT CCAACCTATG GAACTGATGA ATGGGAGCAG TGGTGAATG CCTTTAATGA 4860
GGAAACCTG TTTTGCTCAG AAGAAATGCC ATCTAGTGAT GATGAGGCTA CTGCTGACTC 4920
TCAACATTCT ACTCCTCCAA AAAAGAAGAG AAAGGTAGAA GACCCCAAGG ACTTTCCTTC 4980
AGAATTGCTA AGTTTTTTGA GTCATGCTGT GTTAGTAAT AGAACTCTTG CTTGCTTTGC 5040
TATTACACC ACAAAGGAAA AAGCTGCACT GCTATACAAG AAAATTATGG AAAAATATTC 5100
TGTAACCTTT ATAAGTAGGC ATAACAGTTA TAATCATAAC ATACTGTTTT TTCTTACTCC 5160
ACACAGGCAT AGAGTGCTCG CTATTAATAA CTATGCTCAA AAATTGTGTA CCTTTAGCTT 5220
TTTAATTTGT AAAGGGGTTA ATAAGGAATA TTTGATGTAT AGTGCCTTGA CTAGAGATCA 5280
TAATCAGCCA TACCACATTT GTAGAGTTT TACTTGCTTT AAAAAACCTC CCACACCTCC 5340
CCCTGAACCT GAAACATAAA ATGAATGCAA TTGTTGTTGT TAACTTGTTT ATTGCAGCTT 5400
ATAATGGTTA CAAATAAAGC AATAGCATCA CAAATTTTAC AAATAAAGCA TTTTTTCAC 5460
TGCATTCTAG TTGTGGTTTG TCCAACTCA TCAATGTATC TTATCATGTC TGGATCCCCA 5520
GGAAGCTCCT CTGTGTCCTC ATAAACCCTA ACCTCCTCTA CTTGAGAGGA CATTCCAATC 5580
ATAGGCTGCC CATCCACCCT CTGTGTCCTC CTGTTAATTA GGTCACTTAA CAAAAAGGAA 5640
ATTGGGTAGG GGTTTTTTAC AGACCGCTTT CTAAGGGTAA TTTTAAATA TCTGGGAAGT 5700
CCCTTCCACT GCTGTGTTCC AGAAGTGTG GTAAACAGCC CACAAATGTC AACAGCAGAA 5760
ACATACAAGC TGTCAGCTTT GCACAAGGGC CCAACACCCT GCTCAGCAAG AAGCACTGTG 5820
GTTGCTGTGT TAGTAATGTG CAAAACAGGA GGCACATTTT CCCACCTGT GTAGGTTCCA 5880
AAATATCTAG TGTTTTTATT TTTACTTGGA TCAGGAACCC AGCACTCCAC TGGATAAGCA 5940

TTATCCTTAT CCAAAACAGC CTTGTGGTCA GTGTTTCATCT GCTGACTGTC AACTGTAGCA 6000
TTTTTTGGGG TTACAGTTTG AGCAGGATAT TTGGTCCTGT AGTTTGCTAA CACACCCTGC 6060
AGCTCCAAAG GTTCCCCACC AACAGCAAAA AAATGAAAAT TTGACCCTTG AATGGGTTTT 6120
CCAGCACCAT TTTTCATGACT TTTTGTGTC CCTGAATGCA AGTTTAACAT AGCAGTTACC 6180
CCAATAACCT CAGTTTTAAC AGTAACAGCT TCCCACATCA AAATATTTC ACAGGTTAAG 6240
TCCTCATTTA AATTAGGCAA AGGAA 6265

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6254 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

TTCTTGAAGA CGAAAGGGCC TCGTGATACG CCTATTTTAA TAGGTTAATG TCATGATAAT 60
AATGGTTTCT TAGACGTCAG GTGGCACTTT TCGGGGAAAT GTGCGCGGAA CCCCTATTTC 120
TTTATTTTTC TAAATACATT CAAATATGTA TCCGCTCATG AGACAATAAC CCTGATAAAT 180
GCTTCAATAA TATTGAAAAA GGAAGAGTAT GAGTATTCAA CATTTCCGTG TCGCCCTTAT 240
TCCCTTTTTT GCGGCATTTT GCCTTCCTGT TTTTGCTCAC CCAGAAACGC TGGTGAAAGT 300
AAAAGATGCT GAAGATCAGT TGGGTGCACG AGTGGGTTAC ATCGAACTGG ATCTCAACAG 360
CGGTAAGATC CTTGAGAGTT TTCGCCCCGA AGAACGTTTT CCAATGATGA GCACTTTTAA 420
AGTTCTGCTA TGTGGCGCGG TATTATCCCG TGTGACGCC GGGCAAGAGC AACTCGGTG 480
CGGCATACAC TATTCTCAGA ATGACTTGGT TGAGTACTCA CCAGTCACAG AAAAGCATCT 540
TACGGATGGC ATGACAGTAA GAGAATTATG CAGTGCTGCC ATAACCATGA GTGATAACAC 600
TGCGGCCAAC TTAATTCTGA CAACGATCGG AGGACCGAAG GAGCTAACCG CTTTTTTGCA 660

CAACATGGGG GATCATGTAA CTGGCCTTGA TCCTTGGGAA CCGGAGCTGA ATGAAGCCAT 720
ACCAAACGAC GAGCGTGACA CCACGATGCC TGCAGCAATG GCAACAACGT TGGCGAAACT 780
ATTAAGTGGC GAACTACTTA CTCTAGCTTC CCGGCAACAA TTAATAGACT GGATGGAGGC 840
GGATAAAGTT GCAGGACCAC TTCTGCGCTC GGCCCTTCGG GCTGGCTGCT TTATTGCTGA 900
TAAATCTGGA GCCGGTGAGC GTGGGTCTCG CGGTATCATT GCAGCACTGG GGCCAGATGG 960
TAAGCCCTCC CGTATCGTAG TTATCTACAC GACGGGGAGT CAGGCAACTA TGGATGAACG 1020
AAATAGACAG ATCGCTGAGA TAGGTGCCTC ACTGATTAAG CATTGGTAAAC TGTCAGACCA 1080
AGTTTACTCA TATATACTTT AGATTGATTT AAAACTTCAT TTTTAATTIA AAAGGATCTA 1140
GGTGAAGATC CTTTTTGATA ATCTCATGAC CAAAATCCCT TAACGTGAGT TTTCGTTCCA 1200
CTGAGCGTCA GACCCCGTAG AAAAGATCAA AGGATCTTCT TGAGATCCTT TTTTCTGCG 1260
CGTAATCTGC TGCTTGCAA CAAAAAACC ACCGCTACCA GCGGTGTTT GTTTGCCGGA 1320
TCAAGAGCTA CCAACTCTTT TTCCGAAGGT AACTGGCTTC AGCAGAGCGC AGATACCAA 1380
TACTGTCTT CTAGTGTAGC CGTAGTTAGG CCACCACTTC AAGAACTCTG TAGCACCGCC 1440
TACATACCTC GCTCTGCTAA TCCTGTTACC ACTGGCTGCT GCCAGTGGCG ATAAGTCGTG 1500
TCTTACCGGG TTGGACTCAA GACGATAGTT ACCGGATAAG GCGCAGCGGT CGGGCTGAAC 1560
GGGGGGTTCG TGCACACAGC CCAGCTTGA GCGAACGACC TACACCGAAC TGAGATACCT 1620
ACAGCGTGAG CATTGAGAAA GCGCCACGCT TCCGAAGGG AGAAAGGCGG ACAGGTATCC 1680
GGTAAGCGGC AGGGTCGGAA CAGGAGAGCG CACGAGGGAG CTCCAGGGG GAAACGCCTG 1740
GTATCTTTAT AGTCTGTGCG GGTTTCGCCA CCTCTGACTT GAGCGTCGAT TTTGTGATG 1800
CTCGTCAGGG GGGCGGAGCC TATGAAAAA CGCCAGCAAC GCGGCCTTTT TACGGTTCCT 1860
GGCCTTTTGC TGGCCTTTTG CTCACATGTT CTTTCTGCG TTATCCCTG ATTCTGTGGA 1920
TAACCGTATT ACCGCCTTTG AGTGAGCTGA TACCGCTCGC CGCAGCCGAA CGACCGAGCG 1980
CAGCGAGTCA GTGAGCGAGG AAGCGGAAGA GCGCTGATG CGGTATTTTC TCCTTACGCA 2040
TCTGTGCGGT ATTTACACCC GCATATGGTG CACTCTCAGT ACAATCTGCT CTGATGCCGC 2100
ATAGTTAAGC CAGTATACAC TCCGCTATCG CTACGTGACT GGGTCATGGC TGCGCCCCGA 2160
CACCCGCCAA CACCCGCTGA CGCGCCTGA CGGGCTTGTC TGCTCCCGGC ATCCGCTTAC 2220

AGACAAGCTG TGACCGTCTC CGGGAGCTGC ATGTGTCAGA GGTTCACACC GTCATCACCG 2280
AAACGGCGGA GGCAGCGGAT CATAATCAGC CATACCACAT TTGTAGAGGT TTTACTTGCT 2340
TTAAAAAACC TCCCACACCT CCCCCTGAAC CTGAAACATA AAATGAATGC AATTGTTGTT 2400
GTAACTTGT TTATTGCAGC TTATAATGCT TACAAATAAA GCAATAGCAT CACAAATTC 2460
ACAAATAAAG CATTTTTTTC ACTGCATTCT AGTTGTGGTT TGTCCAAACT CATCAATGTA 2520
TCTTATCATG TCTGGATCAT AATCAGCCAT ACCACATTTG TAGAGGTTTT ACTTGCTTTA 2580
AAAAACCTCC CACACCTCCC CCTGAACCTG AAACATAAAA TGAATGCAAT TGTGTTGTT 2640
AACTTGTTTA TTGCAGCTTA TAATGGTTAC AAATAAAGCA ATAGCATCAC AAATTCACA 2700
AATAAAGCAT TTTTTCCTACT GCATTCTAGT TGTGTTTGT CCAAATCAT CAATGTATCT 2760
TATCATGTCT GGATCCCAGC CAGACAAGGT TGTGACACA AGACCCACAT CTGGTATAAA 2820
AGGAGGCAGT GGCCACAGA GGAGCACAGC TGTGTTGGC TGCAGGGCCA AGAGCGCTGT 2880
CAAGAAGACC CACACGCCCC CCTCCAGCAG CTGAATTCCA GCTGGCATTG CGGTACTGTT 2940
GGTAAAATGG AAGACGCCAA AAACATAAAG AAAGGCCCGG CGCCATTCTA TCCTCTAGAG 3000
GATGGAACCG CTGGACAGCA ACTGCATAAG GCTATGAAGA GATACGCCCT GGTTCCTGGA 3060
ACAATTGCTT TTACAGATGC ACATATCGAG CTGAACATCA CGTACGGGA ATACTTCGAA 3120
ATGTCCGTTT GGTGGCAGA AGCTATGAAA CGATATGGGC TGAATACAAA TCACAGAATC 3180
GTCGTATGCA GTGAAACTC TCTCAATTC TTTATGCCGG TGTGGGGCG GTTATTTATC 3240
GGAGTTGCAG TTGCGCCCGC GAACGACATT TATAATGAAC GTGAATTGCT CAACAGTATG 3300
AACATTTGCG AGCCTACCGT AGTGTGTTT TCCAAAAAGG GGTGCAAAA AATTTGAAC 3360
GTGCAAAAAA AATTACCAAT AATCCAGAAA ATTATTATCA TGGATTCTAA AACGGATTAC 3420
CAGGGATTTC AGTCGATGTA CACGTTCTG ACATCTCATC TACCTCCCGG TTTAATGAA 3480
TACGATTTTG TACCAGAGTC CTTGATCGT GACAAAACAA TTGCACTGAT AATGAATTCC 3540
TCTGGATCTA CTGGGTTACC TAAGGGTGTG GCCCTTCCGC ATAGAACTGC CTGCGTCAGA 3600
TTCTCGCATG CCAGAGATCC TATTTTGGC AATCAAATCA TTCCGGATAC TGCGATTTTA 3660
AGTGTGTTT CATTCCATCA CGGTTTTGGA ATGTTTACTA CACTCGGATA TTTGATATGT 3720
GGATTTGAG TCGTCTTAAT GTATAGATTT GAAGAAGAGC TGTGTTTACG ATCCCTTCAG 3780

GATTACAAAA TTCAAAGTGC GTTGCTAGTA CCAACCCTAT TTTCATTCTT CGCCAAAAGC	3840
ACTCTGATTG ACAAATACGA TTTATCTAAT TTACACGAAA TTGCTTCTGG GGGCGCACCT	3900
CTTTCGAAAG AAGTCGGGGA AGCGGTTGCA AAACGCTTCC ATCTTCCAGG GATACGACAA	3960
GGATATGGGC TCACTGAGAC TACATCAGCT ATTCTGATT A CACCCGAGGG GGATGATAAA	4020
CCGGGCGCGG TCGGTAAAGT TGTTCCATTT TTTGAAGCGA AGGTTGTGGA TCTGGATACC	4080
GGGAAAACGC TGGGCGTTAA TCAGAGAGGC GAATTATGTG TCAGAGGACC TATGATTATG	4140
TCCGGTTATG TAAACAATCC GGAAGCGACC AACGCCTTGA TTGACAAGGA TGGATGGCTA	4200
CATTCTGGAG ACATAGCTTA CTGGGACGAA GACGAACACT TCTTCATAGT TGACCGCTTG	4260
AAGTCTTTAA TTAAATACAA AGGATATCAG GTGGCCCCCG CTGAATTGGA ATCGATATTG	4320
TTACAACACC CCAACATCTT CGACGCGGGC GTGGCAGGTC TTCCCGACGA TGACGCCGGT	4380
GAACCTCCCG CCGCCGTTGT TGTTTTGGAG CACGGAAGA CGATGACGGA AAAAGAGATC	4440
GTGGATTACG TCGCCAGTCA AGTAACAACC GCGAAAAAGT TCGCGGAGG AGTTGTGTTT	4500
GTGGACGAAG TACCGAAAGC TCTTACCGGA AAACGACG CAAGAAAAAT CAGAGAGATC	4560
CTCATAAAGG CCAAGAAGGG CGGAAAGTCC AAATTGTAAA ATGTAAGTGT ATTCAGCGAT	4620
GACGAAATTC TTAGCTATTG TAATGACTCT AGAGGATCTT TGTGAAGGAA CCTTACTTCT	4680
GTGGTGTGAC ATAATTGGAC AAACCTACCTA CAGAGATTTA AAGCTCTAAG GTAAATATAA	4740
AATTTTAAAG TGTATAATGT GTTAAACTAC TGATTCTAAT TGTTTGTGTA TTTTAGATTC	4800
CAACCTATGG AACTGATGAA TGGGAGCACT GGTGGAATGC CTTTAATGAG GAAAACCTGT	4860
TTTGCTCAGA AGAAATGCCA TCTAGTGATG ATGAGGCTAC TGCTGACTCT CAACATTCTA	4920
CTCCTCCAAA AAAGAAGAGA AAGGTAGAAG ACCCCAAGGA CTTTCCTTCA GAATTGCTAA	4980
GTTTTTTGAG TCATGCTGTG TTAGTAATA GAACTCTTGC TTGCTTTGCT ATTTACACCA	5040
CAAAGGAAAA AGCTGCACTG CTATAGAAGA AAATTATGGA AAAATATTCT GTAACCTTTA	5100
TAAGTAGGCA TAACAGTTAT AATCATAACA TACTGTTTTT TCTTACTCCA CACAGGCATA	5160
GAGTGTCTGC TATTAATAAC TATGCTCAAA AATTGTGTAC CTTTAGCTTT TTAATTTGTA	5220
AAGGGGTTAA TAAGGAATAT TTGATGTATA GTGCCTTGAC TAGAGATCAT AATCAGCCAT	5280
ACCACATTTG TAGAGGTTTT ACTTGCTTTA AAAAACCTCC CACACCTCCC CCTGAACCTG	5340

AAACATAAAA TGAATGCAAT TGTGTGTGT AACTTGTTTA TTGCAGCTTA TAATGGTTAC	5400	AC
AAATAAAGCA ATAGCATCAC AAATTTTACA AATAAAGCAT TTTTTCCTACT GCATTCTACT	5460	GG
TGTGGTTTGT CCAAATCAT CAATGTATCT TATCATGTCT GGATCCCCAG GAAGCTCCTC	5520	GT
TGTGTCCTCA TAAACCCTAA CTCCTCTAC TTGAGAGGAC ATTCCAATCA TAGGCTGCCC	5580	TA
ATCCACGCTC TGTGTCCTCC TGTTAATTAG GTCACTTAAC AAAAAGGAAA TTGGGTAGGG	5640	GT
GTTTTTCACA GACCGCTTTC TAAGGGTAAT TTAAATAT CTGGGAAGTC CCTTCCACTG	5700	CA
CTGTGTTCCA GAAGTGTGG TAAACAGCCC ACAAATGTCA ACAGCAGAAA CATACAAGCT	5760	AT
GTCAGCTTTG CACAAGGGCC CAACACCCTG CTCAGCAAGA AGCACTGTGG TTGCTGTGTT	5820	AT
AGTAATGTGC AAAACAGGAG GCACATTTTC CCCACCTGTG TAGGTTCCAA AATATCTAGT	5880	GCC
GTTTTCATTT TTAATTGGAT CAGGAACCCA GCACTCCACT GGATAAGCAT TATCCTTATC	5940	GGA
CAAAACAGCC TTGTGGTCAG TGTTCATCTG CTGACTGTCA ACTGTAGCAT TTTTGGGGT	6000	TTG
TACACTTTGA GCAGGATATT TGGTCTGTGA GTTTGCTAAC ACACCCTGCA GCTCCAAAGG	6060	CCA
TTCCCCACCA ACAGCAAAAA AATGAAAATT TGACCCTTGA ATGGGTTTTT CAGCACCATT	6120	TCA
TTCATGAGTT TTTTGTGTCC CTGAATGCAA GTTAAACATA GCAGTTACCC CAATAACCTC	6180	CGG
AGTTTAAACA GTAACAGCTT CCCACATCAA AATATTTCCA CAGGTAAAGT CCTCATTAA	6240	CAG
ATTAGGCAAA GGAA	6254	GAG

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1442 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GGTACCCAGG CTGCATAACC AGGAGGTGAG TGGCAGGTGA GTGAAATTTT ATCTGTAGTT	60	(2)
---	----	-----

ACAGCCACTC CTCATCACTC GCATTACCAC CAGAGCTCCA CTCCCTGTCA GATCAGCGGC 120
GGCATTAGAT TCTCATAGGA GCTCGAACCC TATTCTAAAC TGTTCATGTG AGGGATCTAG 180
GTTGCAAGCT CCCTATGAGA ATCTAATGCC TGATGATCTG TCACGGTCTC CCATCACCCC 240
TAGATGGGAC CATCTACTTG CAGGAAAACA AGCTCAGGCT CCCACTGATT CTACACGATG 300
GTGAATTGTG GAATTATTTT ATTATATATA TTACAATGTA ATAATAATAG AAATAAAGCA 360
CACAATAAAT GTAATGTGCT TGAATCATCC CGAAACCATC CCACCCTGGT CTGTGAAAAA 420
ATTGTCTTCC ATGAAACCAG TCCCTGGTGC CAAAAACGTT GAGGACCACT GCTCCACAGA 480
ATCTATCGGT CACTCTTCTT CCCCTCACCC CCTTGCCCTA AAAGCACACC CTGCAAACCT 540
GCCATGAATT GACACTCTGT TTCTATCCCT TTTCCCCTTG TGTCTGTGTC TGGAGGAAGA 600
GGATAAAGGA CAAGTGCCC CAAGTCCTAG CGGGCAGCTC GAGGAAGTGA AACTTACAG 660
TTGGTCTCCT GTTTCCTTAC CAAGCTTACC ATGGTAACCC CTGGTCCCGT TCAGCCACCA 720
CCACCCACC CAGCACACCT CCAACCTCAG CCAGACAAGG TTGTTGACAC AAGAGAGCCC 780
TCAGGGGCAC AGAGAGAGTC TGGACACGTG GGGAGTCAGC CGTGTATCAT CGGAGGCGGC 840
CGGGCACATG GCAGGGATGA GGGAAAGACC AAGAGTCCTC TGTGGGCCCC AAGTCCTAGA 900
CAGACAAAAC CTAGACAATC ACGTGGCTGG CTGCATGCCT GTGGCTGTTG GGCTGGGCAG 960
GAGGAGGGAG GGGCGCTCTT TCCTGGAGGT GGTCCAGAGC ACCGGGTGGA CAGCCCTGGG 1020
GGAAACTTC CACGTTTTGA TGGAGGTTAT CTTTGATAAC TCCACAGTGA CCTGGTTGCG 1080
CAAAGGAAAA GCAGGCAACG TGAGCTGTTT TTTTTTCTC CAAGCTGAAC ACTAGGGGTC 1140
CTAGGCTTTT TGGGTCACCC GGCATGGCAG ACAGTCAACC TGGCAGGACA TCCGGGAGAG 1200
ACAGACACAG GCAGAGGGCA GAAAGGTCAA GGGAGTTCT CAGGCCAAGG CTATTGGGGT 1260
TTGCTCAATT GTTCTGAAT GCTCTTACAC ACGTACACAC ACAGAGCAGC ACACACACAC 1320
ACACACACAT GCCTCAGCAA GTCCCAGAGA GGGAGGTGTC GAGGGGGACC CGCTGGCTGT 1380
TCAGACGGAC TCCCAGAGCC AGTGAGTGGG TGGGGCTGGA ACATGAGTTC ATCTATTTCC 1440
TG 1442

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 761 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(i:

(:

(ii) MOLECULE TYPE: DNA (genomic)

(:

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

AAGCT

CAACC

GGACA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

(2) I

AAGCTTACCA TGGTAACCCC TGGTCCCGTT CAGCCACCAC CACCCACCC AGCACACCTC	60
CAACCTCAGC CAGACAAGGT TGTGACACA AGAGAGCCCT CAGGGGCACA GAGAGAGTCT	120
GGACACGTGG GGAGTCAGCC GTGTATCATC GGAGGCGGCC GGGCACATGG CAGGGATGAG	180
GGAAAGACCA AGAGTCCTCT GTTGGGCCCA AGTCCTAGAC AGACAAAACC TAGACAATCA	240
CGTGGCTGGC TGCATGCCTG TGGCTGTTGG GCTGGGCAGG AGGAGGGAGG GGCGCTCTTT	300
CCTGGAGGTG GTCCAGAGCA CCGGCTGAC AGCCCTGGGG GAAAACCTCC ACGTTTGTAT	360
GGAGGTTATC TTTGATAACT CCACAGTGAC CTGGTTCGCC AAAGGAAAAG CAGGCAACGT	420
GAGCTGTTTT TTTTCTCC AAGCTGAACA CTAGGGGTCC TAGGCTTTTT GGGTCACCCG	480
GCATGGCAGA CAGTCAACCT GGCAGGACAT CCGGAGAGA CAGACACAGG CAGAGGGCAG	540
AAAGGTCAAG GGAGGTTCTC AGGCCAAGGC TATTGGGGT TGCTCAATTG TTCCTGAATG	600
CTCTTACACA CGTACACACA CAGAGCAGCA CACACACACA CACACACATG CCTCAGCAAG	660
TCCCAGAGAG GGAGGTGTCG AGGGGGACCC GCTGGCTGTT CAGACGGACT CCCAGAGCCA	720
GTGAGTGGGT GGGGCTGGA CATGAGTTCA TCTATTCCT G	761

(

(i

)

AGTT

(2)

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 165 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

AAGCTTACCA TGTAACCCC TGGTCCCGTT CAGCCACCAC CACCCACCC AGCACACCTC	60
CAACCTCAGC CAGACAAGGT TGTGACACA AGAGAGCCCT CAGGGGCACA GAGAGAGTCT	120
GGACACCTGG GGAGTCAGCC GTGTATCATC GGAGGCGGCC GGGCA	165

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

AGTTCATCTA TTTCCT

16

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

GTGGGGAGTC AGCCGTGTAT CATCG

25

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 36 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

CTCCAACCTC AGCCAGACAA GGTGTGAC ACAAGA

36

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GCCAGACAAG GTTGTGACA CAAGA

25

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 115 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

```
CCCACATCTG GTATAAAGG AGGCAGTGGC CCACAGAGGA GCACAGCTGT GTTGGCTGC      60
AGGGCCAAGA GCGCTGTCAA GAAGACCCAC ACGCCCCCTT CCAGCAGCTG AATTC      115
```

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 345 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

```
GGCCAGACGC CAACAAGGTA GGAGCTGGAG CATTCGGGCT GGGTTTCACC CCACCGCAGC      60
GAGGCCTTTT GGGGTGGAGC CTCAGGCTC AGGCATACT ACAAACCTTG CCAGCAAATC      120
CGCCTCCTGC CTCCACCAAT CGCCAGTCAG GAAGGCAGCC TACCCGCTG TCTCCACCTT      180
TGAGAAACAC TCATCCTCAG GCCATGCACT GGAATTCAC AACCTTCCAC CAAACTCTGC      240
AAGATCCCAG AGTGAGAGGC CTGTATTTC CTGCTGGTGG CTCCAGTTCA GGAACAGTAA      300
ACCCTGTTCT GACTACTGCC TCTCCCTTAT CGTCAATCTT CTCGA      345
```

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4302 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

TCGACCTCGA GGGATCTTTG TGAAGGAACC TTA	60
CTTCTGT GGTGTGACAT AATTGGACAA	
ACTACCTACA GAGATTTAAA GCTCTAAGGT AA	120
ATATAAAA TTTTAAAGTG TATAATGTGT	
TAAACTACTG ATTCTAATTG TTTGTGTATT TT	180
AGATTCCA ACCTATGGAA CTGATGAATG	
GGAGCACTGG TGGAAATGCCT TTAATGAGGA	240
AAACCTGTTT TGCTCAGAAG AAATGCCATC	
TAGTGATGAT GAGGCTACTG CTGACTCTCA	300
ACATTCTACT CCTCCAAAAA AGAAGAGAAA	
GGTAGAAGAC CCCAAGGACT TTCCTTCAGA	360
ATTGCTAAGT TTTTGTAGTC ATGCTGTGTT	
TAGTAATAGA ACTCTTGCTT GCTTTGCTAT	420
TTACACCACA AAGGAAAAAG CTGCACTGCT	
ATACAAGAAA ATTATGGAAA AATATTCTGT	480
AACCTTTATA AGTAGGCATA ACAGTTATAA	
TCATAACATA CTGTTTTTTC TTA	540
CTCCACA CAGGCATAGA GTGTCTGCTA	
TTAATAACTA	
TGCTCAAAAA TTGTGTACCT TTAGCTTTTT	600
AATTGTAAA GGGGTAAATA AGGAATATTT	
GATGTATAGT GCCTTGACTA GAGATCATAA	660
TCAGCCATAC CACATTGTGA GAGGTTTTAC	
TTGCTTTAAA AAACCTCCCA CACCTCCCC	720
TGAACCTGAA ACATAAAATG AATGCAATTG	
TTGTGTGTTAA CTGTTTATT GCAGCTTATA	780
ATGGTTACAA ATAAAGCAAT AGCATCACAA	
ATTTACAAA TAAAGCATTT TTTTCACTGC	840
ATTCTAGTTG TGCTTTGTCC AAATCATCA	
ATGTATCTTA TCA	900
TGTCTGG ATCCGGCTGT GGAATGTGTG	
TCAGTTAGGG TGTGAAAGT	
CCCCAGGCTC CCCAGCAGG AGAAGTATGC	960
AAAGCATGCA TCTCAATTAG TCAGCAACCA	
GGTGTGAAAA GTCCCCAGG TCCCCAGCAG	1020
GCAGAAGTAT GCAAAGCATG CATCTCAATT	
AGTCAGCAAC CATAGTCCCG CCCCTAACTC	1080
CGCCCATCCC GCCCCTAACT CCGCCCACTT	
CCGCCCATTG TCGGCCCCAT GGCTGACTAA	1140
TTTTTTTAT TTATGCAGAG GCCGAGGCCG	
CCTCGGCCTC TGAGCTATTC CAGAAGTAGT	1200
GAGGAGGCTT TTTTGGAGGC CTAGGCTTTT	
GCAAAAAGCT TCACGCTGCC GCAAGCACTC	1260
AGGGCGCAAG GGCTGCTAAA GGAAGCGGAA	
CACGTAGAAA GCCAGTCCGC AGAAACGGTG	1320
CTGACCCCGG ATGAATGTCA GCTACTGGGC	

TATCTGGACA AGGGAAAACG CAAGCGCAAA GAGAAAGCAG GTAGCTTGCA GTGGGCTTAC 1380
ATGGCGATAG CTAGACTGGG GGGTTTTATG GACAGCAAGC GAACCGGAAT TGCCAGCTGG 1440
GGCGCCCTCT GGTAAGGTTG GGAAGCCCTG CAAAGTAAAC TGGATGGCTT TCTTGCGGCC 1500
AAGGATCTGA TGGCGCAGGG GATCAAGATC TGATCAAGAG ACAGGATGAG GATCGTTTCG 1560
CATGATTGAA CAAGATGGAT TGCACGCAGG TTCTCCGGCC GCTTGGGTGG AGAGGCTATT 1620
CGGCTATGAC TGGGCACAAC AGACAATCGG CTGCTCTGAT GCCGCCGTGT TCCGGCTGTC 1680
AGCGCAGGGG CGCCCGTTT TTTTGTCAA GACCGACCTG TCCGGTGCCC TGAATGAACT 1740
GCAGGACGAG GCAGCGCGGC TATCGTGGCT GGCCACGACG GCGGTTCCCT GCGCAGCTGT 1800
GCTCGACGTT GTCACTGAAG CGGGAAGGGA CTGGCTGCTA TTGGGCGAAG TGCCGGGGCA 1860
GGATCTCCTG TCATCTCACC TTGCTCCTGC CGAGAAACTA TCCATCATGG CTGATGCAAT 1920
GCGGCGGCTG CATA CGCTTG ATCCGGCTAC CTGCCATTG GACCACCAAG CGAAACATCG 1980
CATCGAGCGA GCACGTAATC GGATGGAAGC CGGTCTTGTC GATCAGGATG ATCTGGACGA 2040
AGAGCATCAG GGGCTCGCGC CAGCCGAACT GTTCGCCAGG CTCAAGGCGC GCATGCCCGA 2100
CGGCGAGGAT CTGCTCGTGA CCCATGGCGA TGCCTGCTTG CGGAATATCA TGGTGAAAA 2160
TGGCCGCTTT TCTGGATTCA TCGACTGTGG CCGGCTGGGT GTGGCGGACC GCTATCAGGA 2220
CATAGCGTTG GCTACCCGTG ATATTGCTGA AGAGCTTGGC GGCGAATGGG CTGACCGCTT 2280
CCTCGTGCTT TACGGTATCG CCGCTCCCGA TTCGCAGCGC ATCGCCTTCT ATCGCCTTCT 2340
TGACGAGTTC TTCTGAGCGG GACTCTGGGG TTCGAAATGA CCGACCAAGC GACGCCCAAC 2400
CTGCCATCAC GAGATTTGGA TTCCACCGCC GCCTTCTATG AAAGGTTGGG CTTGGAATC 2460
GTTTTCCGGG ACGCCGGCTG GATGATCCTC CAGCGCGGGG ATCTCATGCT GGAGTTCTTC 2520
GCCACCCCGG GGCTCGATCC CCTCGCGAGT TGGTTCAGCT GCTGCCTGAG GCTGGACGAC 2580
CTCGCGGAGT TCTACCGGCA GTGCAAATCC GTCGGCATCC AGGAAACCAG CAGCGGCTAT 2640
CGGCGCATCC ATGCCCGCGA ACTGCAGGAG TGGGAGGCA CGATGGCCGC TTTGGTCCCG 2700
GATCTTTGTG AAGGAACCTT ACTTCTGTGG TGTGACATAA TTGACAAAC TACCTACAGA 2760
GATTTAAAGC TCTAAGGTAA ATATAAAATT TTAAAGTGA TAATGTGTTA AACTACTGAT 2820
TCTAATTGTT TGTGATTTT AGATTCCAAC CTATGGAAT GATGAATGGG AGCACTGGTG 2880

GAATGCCTTT AATGAGGAAA ACCTGTTTTG CTCAGAAGAA ATGCCATCTA GTGATGATGA	2940
GGCTACTGCT GACTCTCAAC ATTCTACTCC. TCCAAAAAG AAGAGAAAGG TAGAAGACCC	3000
CAAGGACTTT CCTTCAGAAT TGCTAAGTTT TTTGAGTCAT GCTGTGTTTA GTAATAGAAC	3060
TCTTGCTTGC TTTGCTATTT ACACCACAAA GGAAAAAGCT GCACTGCTAT ACAAGAAAAT	3120
TATGGAAAAA TATTCTGTAA CCTTTATAAG TAGGCATAAC AGTTATAATC ATAACATACT	3180
GTTTTTTCTT ACTCCACACA GGCATAGAGT GTCGCTATT AATAACTATG CTCAAAAATT	3240
GTGTACCTTT AGCTTTTTTAA TTTGTAAAGG GGTTAATAAG GAATATTGA TGTATAGTGC	3300
CTTGACTAGA GATCATAATC AGCCATACCA CATTGTAGA GGTTTTACTT GCTTTAAAAA	3360
ACCTCCCAGA CCTCCCCCTG AACCTGAAAC ATAAATGAA TGCAATTGTT GTTGTTAACT	3420
TGTTTATTGC AGCTTATAAT GGTACAAAT AAAGCAATAG CATCACAAAT TTCACAAATA	3480
AAGCATTITT TTCACTGCAT TCTAGTTGTG GTTGTGCCAA ACTCATCAAT GTATCTTATC	3540
ATGTCTGGAT CCCCAGGAAG CTCCTCTGTG TCCTCATAAA CCTAACCTC CTCTACTGA	3600
GAGGACATTG CAATCATAGG CTGCCCATCC ACCCTCTGTG TCCTCCTGTT AATTAGGTCA	3660
CTTAACAAAA AGGAAATTGG GTAGGGGTTT TTCACAGACC GCTTTCTAAG GGTAATTTTA	3720
AAATATCTGG GAAGTCCCTT CCACTGCTGT GTTCCAGAAG TGTTGGTAAA CAGCCCACAA	3780
ATGTCAACAG CAGAAACATA CAAGCTGTCA GCTTTGCACA AGGGCCCAAC ACCCTGCTCA	3840
TCAAGAAGCA CTGTGGTTGC TGTGTTAGTA ATGTGCAAAA CAGGAGGCAC ATTTTCCCCA	3900
CCTGTGTAGG TTCCAAAAATA TCTAGTGTIT TCATTTTAC TTGGATCAGG AACCCAGCAC	3960
TCCACTGGAT AAGCATTATC CTIATCCAAA ACAGCCTTGT GGTGAGTGT CATCTGCTGA	4020
CTGTCAACTG TAGCATTTTT TGGGGTTACA GTTTGAGCAG GATATTGGT CCTGTAGTTT	4080
GCTAACACAC CCTGCAGCTC CAAAGGTTCC CCACCAACAG CAAAAAATG AAAATTGAC	4140
CCTTGAATGG GTTTTCCAGC ACCATTTTCA TGAGTTTTTT GTGTCCCTGA ATGCAAGTTT	4200
AACATAGCAG TTACCCCAAT AACCTCAGTT TTAACAGTAA CAGCTTCCCA CATCAAAATA	4260
TTTCCACAGG TTAAGTCCTC ATTTAAATTA GGCAAAGGAA TT	4302

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

W

I

A

I

G

To

A

CC

AC

CC

TA

TG

CA

AC

AT.

CGA

AA

AA

AA

-159-

(A) LENGTH: 6170 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

TTCTTGAAGA CGAAAGGGCC TCGTGATACG CCTATTTTTA TAGGTTAATG TCATGATAAT	60
AATGGTTTCT TAGACGTCAG GTGGCACTTT TCGGGGAAAT GTGCGCGGAA CCCCTATTTG	120
TTTATTTTTC TAAATACATT CAAATATGTA TCCGCTCATG AGACAATAAC CCTGATAAAT	180
GCTTCAATAA TATTGAAAAA GGAAGAGTAT GAGTATTCAA CATTTCGGTG TCGCCCTTAT	240
TCCCTTTTTT GCGGCATTTT GCCTTCCTGT TTTTGCTCAC CCAGAAACGC TGGTGAAAGT	300
AAAAGATGCT GAAGATCAGT TGGGTGCACG AGTGGGTTAC ATCGAACTGG ATCTCAACAG	360
CGGTAAGATC CTTGAGAGTT TTCGCCCCGA AGAACGTTTT CCAATGATGA GCACTTTTAA	420
AGTTCTGCTA TGTGGCGCGG TATTATCCCG TGTTGACGCC GGGCAAGAGC AACTCGGTGG	480
CCGCATACAC TATTCTCAGA ATGACTTGGT TGAGTACTCA CCAGTCACAG AAAAGCATCT	540
TACGGATGGC ATGACAGTAA GAGAATTATG CAGTGCTGCC ATAACCATGA GTGATAACAC	600
TGCGGCCAAC TTACTTCTGA CAACGATCGG AGGACCGAAG GAGCTAACCG CTTTTTTGCA	660
CAACATGGGG GATCATGTAA CTCGCCTTGA TCGTTGGGAA CCGGAGCTGA ATGAAGCCAT	720
ACCAAACGAC GAGCGTGACA CCACGATGCC TGCAGCAATG GCAACAACGT TCGGCAAAC	780
ATTAACTGGC GAACTACTTA CTCTAGCTTC CCGGCAACAA TTAATAGACT GGATGGAGGC	840
GGATAAAGTT GCAGGACCAC TTCTGCGCTC GGCCCTTCCG GCTGGCTGGT TTATTGCTGA	900
TAAATCTGGA GCCGGTGAGC GTGGGTCTCG CGGTATCATT GCAGCACTGG GGCCAGATGG	960
TAAGCCCTCC CGTATCGTAG TTATCTACAC GACGGGGAGT CAGGCAACTA TGGATGAACG	1020
AAATAGACAG ATCGCTGAGA TAGGTGCCTC ACTGATTAAG CATTGGTAAC TGTCAGACCA	1080

AGTTTACTCA TATATACTTT AGATTGATTT AAAACTTCAT TTTTAATTTA AAAGGATCTA 1140
GGTGAAGATC CTTTTTGATA ATCTCATGAC CAAAATCCCT TAACGTGAGT TTTGGTTCCA 1200
CTGAGCGTCA GACCCCGTAG AAAAGATCAA AGGATCTTCT TGAGATCCTT TTTTCTGCG 1260
CGTAATCTGC TGCTTGCAA CAAAAAACC ACCGCTACCA GCGGTGGTTT GTTGGCCGA 1320
TCAAGAGCTA CCAACTCTT TCCGAAGGT AACTGGCTTC AGCAGAGCGC AGATACCAAA 1380
TACTGTCTT CTAGTGTAGC CGTAGTTAGC CCACCACTTC AAGAACTCTG TAGCACC GCC 1440
TACATACCTC GCTCTGTAA TCTGTACC AGTGGCTGCT GCCAGTGGCG ATAAGTCTG 1500
TCTTACCGG TTGGACTCAA GACGATACTT ACCGGATAAG GCGCAGCGGT CGGGCTGAAC 1560
GGGGGGTTCG TGCACACAGC CCAGCTTGA GCGAAGCACC TACACCGAAC TGAGATACCT 1620
ACAGCGTGAG CATTGAGAAA GCGCCAGCT TCCCGAAGG AGAAAGCGG ACAGGTATCC 1680
GGTAAGCGG AGGGTCGGAA CAGGAGAGCG CACGAGGGAG CTTCCAGGG GAAACGCCG 1740
GTATCTTAT AGTCTGTG GGTTCGCCA CCTCTGACTT GAGCGTCAT TTTGTGATG 1800
CTCGTCAGG GGGCGGAGC TATGAAAAA CGCCAGCAAC GCGGCTTTT TACGGTCTCT 1860
GGCCTTTTGC TGGCCTTTG CTCACATGT CTTCTCTGCT TATCCCTG ATTCTGTGA 1920
TAACCGTATT ACCGCTTTG AGTGAGCTGA TACCGCTCGC GCGAGCCGAA CGACCGAGCG 1980
CAGCGAGTCA GTGAGCGAGG AAGCGGAAGA GCGCCTGATG CGGTATTTT TCCTTACGCA 2040
TCTGTGCGGT ATTTACACACC GCATATGGT CACTCTCAGT ACAATCTGCT CTGATGCCG 2100
ATAGTTAAGC CAGTATACAC TCCGCTATCG CTACGTGACT GGGTCATGC TGGCCCCGA 2160
CACCCGCCAA CACCCGCTGA CGCGCCCTGA CGGGCTTGTG TGCTCCCGG ATCCGCTTAC 2220
AGACAAGCTG TGACCGTCTC CGGAGCTGC ATGTGTCAGA GGTTTTACC GTCATCACCG 2280
AAACCGCGGA GGCAGCGGAT CATAATCAGC CATACCACAT TTGTAGAGGT TTTACTTGCT 2340
TTAAAAACC TCCCACACCT CCCCCTGAAC CTGAAACATA AAATGAATGC AATTGTTGT 2400
GTAACTTGT TTATTCAGC TTATAATGGT TACAAATAAA GCAATAGCAT CACAAATTC 2460
ACAAATAAG CATTTTTTCT ACTGCATTCT ACTTGTGGT TGTCCAACT CATCAATGA 2520
TCTTATCATG TCTGGATCAT AATCAGCCAT ACCACATTG TAGAGGTTTT ACTTGCTTTA 2580
AAAAACCTCC CACACCTCCC CCTGAACCTG AAACATAAAA TGAATGCAAT TGTGTGTGT 2640

AACTTGTTTA TTGCAGCTTA TAATGGTTAC AAATAAAGCA ATAGCATCAC AAATTTTACA 2700
AATAAAGCAT TTTTTCAC TGCATTCTAGT TGTGGTTTGT CCAAACATCAT CAATGTATCT 2760
TATCATGTCT GGATCCCAAG CTTCATGCC TGCAGGTCGA CTCTAGAGGA TCCCGGGTA 2820
CCGAGCTCGA ATTCCAGCTG GCATTCCGGT ACTGTTGGTA AAATGGAAGA CGCCAAAAAC 2880
ATAAAGAAAG GCGCGGGCC ATTCTATCCT CTACAGGATG GAACCGCTGG AGAGCAACTG 2940
CATAAGGCTA TGAAGAGATA CGCCCTGGTT CCTGGAACAA TTGCTTTTAC AGATGCACAT 3000
ATCGAGGTGA ACATCAGCTA CGCGGAATAC TTCGAAATGT CCGTTCGGTT GGCAGAAGCT 3060
ATGAAACGAT ATGGGCTGAA TACAAATCAC AGAATCGTCG TATGCAGTGA AAATCTCTT 3120
CAATCTTTA TGCCGGTGTT GGGCGGTTA TTTATCGGAG TTGCAGTTGC GCGCGGAAC 3180
GACATTTATA ATGAACGTGA ATTGCTCAAC ACTATGAACA TTTCCGAGCC TACCGTAGTG 3240
TTTGTTTCCA AAAAGGGGT GCAAAAAATT TTGAACGTGC AAAAAAATT ACCAATAATC 3300
CAGAAAATTA TTATCATGGA TTCTAAAACG GATTACCAGG GATTTCAGTC GATGTACACG 3360
TTCGTACAT CTCATCTACC TCCCGTTTT AATGAATACG ATTTGTACC AGATCCTTT 3420
GATCGTGACA AAACAATTGC ACTGATAATG AATTCCTCTG GATCTACTGG GTTACCTAAG 3480
GGTGTGGCCC TTCCGCATAG AACTGCCTGC GTCAGATTCT CGCATGCCAG AGATCCTATT 3540
TTTGGAATC AAATCATTCC GGATACTGCG ATTTTAAAGTG TTGTTCCATT CCATCAGGT 3600
TTTGGAATGT TTAATCACT CGGATATTG ATATGTGGAT TTCGAGTCGT CTTAATGTAT 3660
AGATTTGAAG AAGAGCTGTT TTTACGATCC CTTACAGGATT ACAAATTC AAGTGCGTTG 3720
CTAGTACCAA CCTATTTTC ATTCTTCGCC AAAAGCACTC TGATTGACAA ATACGATTTA 3780
TCTAATTAC ACGAAATTGC TTCTGGGGG GCACCTCTT CGAAAGAAGT CGGGGAAGCG 3840
GTTGCAAAAC GCTTCCATCT TCCAGGGATA CGACAAGGAT ATGGGCTCAC TGAGACTACA 3900
TCAGCTATTC TGATTACACC CGAGGGGGAT GATAAACCGG GCGCGGTCGG TAAAGTTGTT 3960
CCATTTTTTG AAGCGAAGGT TGTGGATCTG GATACCGGA AAACGCTGGG CGTTAATCAG 4020
AGAGGCGAAT TATGTGTCAG AGGACCIATG ATTATGTCCG GTTATGTAAA CAATCCGGAA 4080
GGGACCAACG CCTTGATTGA CAAGGATGGA TGGCTACATT CTGGAGACAT AGCTTACTGG 4140
GACGAAGACG AACACTTCT CATAGTTGAC CGCTTGAAGT CTTAATTAA ATACAAAGGA 4200

TATCAGGTGG CCCCCGCTGA ATTGGAATCG ATATTGTTAC AACACCCCAA CATCTTCGAC	4260	AT
GCGGGCGTGG CAGGTCTTCC CGACGATGAC GCGGCTGAAC TTCCCGCCGC CGTTGTTGTT	4320	AA
TTGGAGCAGC GAAAGACGAT GACGGAAAAA GAGATCGTGG ATTACGTGCG -GAGTCAAGTA	4380	CA
ACAACCGCGA AAAAGTTGCG CGGAGGAGTT GTGTTTGTGG ACGAAGTACC GAAAGGTCTT	4440	CC
ACCGGAAAAAC TCGACGCAAG AAAAATCAGA GAGATCCTCA TAAAGGCCAA GAAGGGCGGA	4500	AA
AAGTCCAAAT TGTAATATGT AACTGTATTC AGCGATGACG AAATTCTTAG CTATTGTAAT	4560	ATG
GACTCTAGAG GATCTTTGTG AAGGAACCTT ACITCTGTGG TGTGACATAA TTGGACAAAC	4620	CAI
TACCTACAGA GATTIAAAGC TCTAAGGTAA ATATAAAATT TTTAAGTGTA TAATGTGTTA	4680	(2)
AACTACTGAT TCTAATTGTT TGTGTATTTT AGATTCCAAC CTATGGAACCT GATGAATGGG	4740	
AGCAGTGGTG GAATGCCCTT AATGAGGAAA ACCTGTTTTG CTCAGAAGAA ATGCCATCTA	4800	
GTGATGATGA GGCTACTGCT GACTCTCAAC ATTCTACTCC TCCAAAAAAG AAGAGAAAGG	4860	
TAGAAGACCC CAAGGACTTT CCTTCAGAAT TGCTAAGTTT TTTGAGTCAT GCTGTGTTTA	4920	
GTAATAGAAC TCTTGCTTGC TTTGCTATTT ACACCACAAA GGAAAAAGCT GCACTGCTAT	4980	
ACAAGAAAAAT TATGGAAAAA TATTCTGTAA CCTTATAAG TAGGCATAAC AGTTATAATC	5040	
ATAACATACT GTTTTTTCTT ACTCCACACA GGCAATAGAGT GTCTGCTATT AATAACTATG	5100	
CTCAAAAATT GTGTACCTTT AGCTTTTTAA TTTGTAAAGG GGTAAATAAG GAATATTTGA	5160	
TGTATAGTGC CTTGACTAGA GATCATAATC AGCCATACCA CATTGTAGA GGTTTTACTT	5220	TTCT
GCTTTAAAAA ACCTCCACACA CCTCCCCCTG AACCTGAAAC ATAAATGAA TGCAATTGTT	5280	AATG
GTTGTIAACT TGTTTATTGC AGCTTATAAT GGTTACAAAT AAAGCAATAG CATCACAAAT	5340	TTTA
TTCAAAAATA AAGCATTTTT TTCACTGCAT TCTAGTTGTG GTTTGTCCAA ACTCATCAAT	5400	GCTT
GTATCTTATC ATGTCTGGAT CCCCAGGAAG CTCCTCTGTG TCCTCATAAA CCTAACCTC	5460	TCCC
CTCTACTTGA GAGGACATTC CAATCATAGG CTGCCCATCC ACCCTCTGTG TCCTCCTGTT	5520	AAAA
AATTAGGTCA CTTAACAAAA AGGAAATTGG GTAGGGGTTT TTCACAGACC GCTTTCTAAG	5580	CGGT
GGTAATTTTA AAATATCTGG GAAGTCCCTT CCACTGCTGT GTTCAGAAG TGTTGGTAAA	5640	AGTT
CAGCCCACAA ATGTCAACAG CAGAAACATA CAAGCTGTCA GCTTTGCACA AGGGCCCAAC	5700	CCGC
ACCCTGCTCA GCAAGAAGCA CTGTGGTTGC TGTGTTACTA ATGTGCAAAA CAGGAGGCAC	5760	TACGG

ATTTTCCCCA CCTGTGTAGG TTCCAAAATA TCTAGTGTTT TCATTTTAC TTGGATCAGG 5820
AACCCAGCAC TCCACTGGAT AAGCATTATC CTTATCCAAA ACAGCCTTGT GGTCACTGTT 5880
CATCTGCTGA CTGTCAACTG TAGCATTTTT TGGGGTTACA GTTTGAGCAG GATATTTGGT 5940
CCTGTAGTTT GCTAACACAC CCTGCAGCTC CAAAGGTTCC CCACCAACAG CAAAAAATG 6000
AAAATTGAC CCTTGAATGG GTTTTCCAGC ACCATTTTCA TGAGTTTTTT GTGTCCCTGA 6060
ATGCAAGTTT AACATAGCAG TTACCCCAAT AACCTCAGTT TTAACAGTAA CAGCTTCCCA 6120
CATCAAAATA TTTCCACAGG TTAAGTCCTC ATTAAATTA GGCAAAGGAA 6170

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10533 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

TTCTTGAAGA CGAAAGGGCC TCGTGATACG CCTATTTTAA TAGGTTAATG TCATGATAAT 60
AATGGTTTCT TAGACGTCAG GTGGCACTTT TCGGGGAAAT GTGCGCGGAA CCCCTATTTG 120
TTTATTTTTC TAAATACATT CAAATATGTA TCCGCTCATG AGACAATAAC CCTGATAAAT 180
GCTTCAATAA TATTGAAAAA GGAAGAGTAT GAGTATTCAA CATTTCCGTG TCGCCCTTAT 240
TGCCTTTTTT GCGGCATTTT GCCTTCCTGT TTTTGCTCAC CCAGAAACGC TGGTGAAAGT 300
AAAAGATGCT GAAGATCAGT TGGGTGCACG AGTGGGTIAC ATCGAACTGG ATCTCAACAG 360
CGGTAAGATC CTTGAGAGTT TTGCCCCGA AGAAGCTTTT CCAATGATGA GCACTTTTAA 420
AGTTCTGCTA TGTGGCGGGG TATTATCCCG TGTGACGCC GGGCAAGAGC AACTCGGTG 480
CCGCATACAC TATTCTCAGA ATGACTTGGT TGACTACTCA CCAGTCACAG AAAAGCATCT 540
TACGGATGGC ATGACAGTAA GAGAATTATG CAGTGCTGCC ATAACCATGA GTGATAACAC 600

TGCGGCCAAC TTACTTCTGA CAACGATCGG AGGACCGAAG GAGCTAACCG CTTTTTTGCA	660
CAACATGGGG GATCATGTAA CTCGCCTTGA TCGTTGGGAA CCGGAGCTGA ATGAAGCCAT	720
ACCAAACGAC GAGCGTGACA CCACGATGCC TGCAGCAATG GCAACAACGT TCGCGAAACT	780
ATTAAGTGGC GAACTACTTA CTCTAGCTTC CCGGCAACAA TTAATAGACT GGATGGAGGC	840
GGATAAAGTT GCAGGACCAC TTCTGCGCTC GGCCCTTCGG GCTGGCTGGT TTATTGCTGA	900
TAAATCTGGA GCCGGTGAGC GTGGGTCTCG CGGTATCATT GCAGCACTGG GGCCAGATGG	960
TAAGCCCTCC CGTATCGTAG TTATCTACAC GACGGGGAGT CAGGCAACTA TGGATGAACG	1020
AAATAGACAG ATCGCTGAGA TAGGTGCCTC ACTGATTAAG CATTGGTAAAC TGTGAGACCA	1080
AGTTTACTCA TATATACTTT AGATTGATTT AAAACTTCAT TTTTAATTTA AAAGGATCTA	1140
GGTGAAGATC CTTTTTGATA ATCTCATGAC CAAAATCCCT TAACGTGAGT TTTCTGTTCCA	1200
CTGAGCGTCA GACCCCGTAG AAAAGATCAA AGGATCTTCT TGACATCCTT TTTTCTGCG	1260
CGTAATCTGC TGCTTGCAAA CAAAAAACC ACCGCTACCA GCGGTGTTTT GTTTGCCGGA	1320
TCAAGAGCTA CCAACTCTTT TTCCGAAGGT AACTGGCTTC AGCAGAGCGC AGATACCAAA	1380
TACTGTCCTT CTAGTGTAGC CGTAGTTAGG CCACCACTTC AAGAACTCTG TAGCACCGCC	1440
TACATACCTC GCTCTGCTAA TCCTGTTACC AGTGGCTGCT GCCAGTGGCG ATAAGTCGTG	1500
TCTTACCGGG TTGGACTCAA GACGATAGTT ACCGGATAAG GCGCAGCGGT CGGGCTGAAC	1560
GGGGGGTTTG TGCACACAGC CCAGCTTGA GCGAACGACC TACACCGAAC TGACATACCT	1620
ACAGCGTGAG CATTGAGAAA GCGCCACGCT TCCCGAAGGG AGAAAGGCGG ACAGGTATCC	1680
GGTAAGCGGC AGGCTCGGAA CAGGAGAGCG CACGAGGGAG CTTCCAGGGG GAAACGCCTG	1740
GTATCTTTAT AGTCCTGTG GGTTCGCCA CCTCTGACTT GAGCGTCGAT TTTGTGATG	1800
CTCGTCAGGG GGGCGGAGCC TATGGAAAA CGCCAGCAAC GCGGCCTTTT TACGGTTCCT	1860
GGCCTTTTGC TGGCCTTTTG CTCACATGTT CTTTCCTGCG TTATCCCCTG ATTCTGTGGA	1920
TAACCGTATT ACCGCCTTTG AGTGAGCTGA TACCGCTCGC CGCAGCCGAA CGACCGAGCG	1980
CAGCGAGTCA GTGAGCGAGG AAGCGGAAGA GCGCTGATG CGGTATTTTC TCCTTACGCA	2040
TCTGTGCGGT ATTTACACC GCATATGGTG CACTCTCAGT ACAATCTGCT CTGATGCCGC	2100
ATAGTTAAGC CAGTATTCGA CCTCGAGGGA TCTTGTGAA GGAACCTTAC TTCTGTGGTG	2160

TGACATAATT GGACAACTA CCTACAGAGA TTAAAGCTC TAAGGTAAAT ATAAAAATTT 2220
TAAGTGTATA ATGTGTAAA CTACTGATTC TAATTGTTTG TGTATTTTAG ATTCCAACCT 2280
ATGGAAGTGA TGAATGGGAG CAGTGGTGA ATGCCTTTAA TGAGGAAAAC CTGTTTGGCT 2340
CAGAAGAAAT GCCATCTAGT GATGATGAGG CTACTGCTGA CTCTCAACAT-TCTACTCCTC 2400
CAAAAAAGAA GAGAAAGGTA GAAGACCCCA AGGACTTTCC TTCAGAATTG CTAAGTTTTT 2460
TGAGTCATGC TGTGTTTAGT AATAGAACTC TTGCTTGCTT TGCTATTTAC ACCAGAAAGG 2520
AAAAAGCTGC ACTGCTATAC AAGAAAATTA TGGAAAAATA TTCTGTAACC TTTATAAGTA 2580
GGCATAACAG TTATAATCAT AACATACTGT TTTTCTTAC TCCACACAGG CATAGAGTGT 2640
CTGCTATTAA TAACTATGCT CAAAAATTGT GTACCTTTAG CTTTTTAATT TGTAAGGGG 2700
TTAATAAGGA ATATTGATG TATAGTCCT TGAAGTACG TCATAATCAG CCATACCACA 2760
TTTGTAGAGG TTTTACTTGC TTTAAAAAAC CTCCACACC TCCCCCTGAA CCTGAAACAT 2820
AAAATGAATG CAATTGTTGT TGTAACTTG TTTATTGCAG CTTATAATGG TTACAAATAA 2880
AGCAATAGCA TCACAAATTT CACAAATAAA GCATTTTTTT CACTGCATTC TAGTTGTGGT 2940
TTGTCCAAAC TCATCAATGT ATCTTATCAT GTCTGGATCC GGCTGTGGAA TGTGTGTCAG 3000
TTAGGGTGTG GAAAGTCCC AGGCTCCCA GCAGGCAGAA GTATGCAAAG CATGCATCTC 3060
AATTAGTCAG CAACCAGGTG TGGAAAGTCC CCAGGCTCCC CAGCAGGCAG AAGTATGCAA 3120
AGCATGCATC TCAATTAGTC AGCAACCATA GTCCGCCCC TAACTCCGCC CATCCCGCCC 3180
CTAACTCCGC CCAGTCCGC CCATTCTCG CCCCATGGCT GACTAATTT TTTATTTAT 3240
GCAGAGGCCG AGGCCGCCTC GGCCTCTGAG CTATTCCAGA AGTAGTGAGG AGGCTTTTTT 3300
GGAGGCCTAG GCTTTTGCAA AAAGCTTCAC GCTGCCGCAA GCACTCAGG CGCAAGGGCT 3360
GCTAAAGGAA GCGGAACACG TAGAAAGCCA GTCCGCAGAA ACGGTGCTGA CCCCAGATGA 3420
ATGTCAGCTA CTGGGCTATC TGGACAAGGG AAAACGCAAG CGCAAAGAGA AAGCAGGTAG 3480
CTTGCACTGG GCTTACATGG CGATAGCTAG ACTGGGCGGT TTTATGGACA GCAAGCGAAC 3540
CGGAATTGCC AGCTGGGGCG CCCTCTGCTA AGGTTGGGA GCCCTGCAA GTAACTGGA 3600
TGGCTTTCTT GCCGCCAAGG ATCTGATGGC GCAGGGGATC AAGATCTGAT CAAGAGACAG 3660
GATGAGGATC GTTTCGCATG ATTGAACAAG ATGGATTGCA CGCAGGTTCT CCGGCCGCTT 3720

GGGTGGAGAG GCTATTCGGC TATGACTGGG CACAACAGAC AATCGGCTGC TCTGATGCCG	3780	AI
CCGTGTTCCG GCTGTCAGCG CAGGGGCGCC CGGTTCTTTT TGTCAAGACC GACCTGTCCG	3840	AC
GTGCCCTGAA TGAAGTCAG GACGAGGCAG CGCGGCTATC GTGGCTGGCC ACGACGGGCG	3900	AI
TTCTTGCGC AGCTGTGCTC GACGTTGTCA CTGAAGCGGG AAGGGACTGG CTGCTATTGG	3960	TI
GCGAAGTGCC GGGGCAGGAT CTCCTGTGTC CTCACCTGC TCCTGCCGAG AAAGTATCCA	4020	AT
TCATGGCTGA TGCAATGCGG CGGCTGCATA CGCTTGATCC GGCTACCTGC CCATTGACC	4080	AC
ACCAAGCGAA ACATCGCATC GAGCGAGCAC GACTCGGAT GGAAGCCGGT CTGTGCGATC	4140	AT
AGGATGATCT GGACGAAGAG CATCAGGGGC TCGCGCCAGC CGAACTGTTT GCCAGGCTCA	4200	AA
AGGCGGCGAT GCCCGACGGC GAGGATCTCG TCGTGACCCA TGGCGATGCC TGCTTGCCGA	4260	CC
ATATCATGGT GAAAATGGC CGCTTTTCTG GATTCATCGA CTGTGGCCGG CTGGGTGTGG	4320	TC
CGGACCGCTA TCAGGACATA GCGTTGGCTA CCCGTGATAT TGCTGAAGAG CTTGGCGGCG	4380	GG
AATGGGCTGA CCGCTTCCTC GTGCTTTACG GTATCGCCGC TCCCGATTG CAGCGCATCG	4440	CC
CCTTCTATCG CTTTCTTGAC GAGTTCTTCT GAGCGGGACT CTGGGGTTG AAATGACCGA	4500	AG
CCAAGCGAGC CCCAACCTGC CATCAGGAGA TTTGGATTCC ACCGCGCCT TCTATGAAAG	4560	AT
GTTGGGCTTC GGAATCGTTT TCCGGGACGC CGGCTGGATG ATCCTCCAGC GCGGGGATCT	4620	AG
CATGCTGGAG TTCTTCGCCC ACCCGGGCT CGATCCCCTC GCGAGTTGGT TCAGCTGCTG	4680	TT
CCTGAGGCTG GACGACCTCG CGGAGTTCTA CCGGCAGTGC AAATCCGTCG GCATCCAGGA	4740	AA
AACCAGCAGC GGCTATCCGC GCATCCATGC CCCGAACTG CAGGAGTGGG GAGGCACGAT	4800	CC
GGCCGCTTTG GTCCCGGATC TTTGTGAAGG AACCTTACTT CTGTGGTGTG ACATAATTGG	4860	TT
ACAACTIACC TACAGAGATT TAAAGCTCTA AGGTAAATAT AAAATTTTIA AGTGATAAT	4920	AC
GTGTTAACT ACTGATTCTA ATTGTTTGTG TATTTTAGAT TCCAACCTAT GGAAGTGATG	4980	CT
AATGGGAGCA GTGGTGGAAT GCCTTTAATG AGGAAAACCT GTTTTGCTCA GAAGAAATGC	5040	TC
CATCTAGTGA TGATGAGGCT ACTGCTGACT CTCAACATTC TACTCTCCA AAAAAGAAGA	5100	GG
GAAAGGTAGA AGACCCCAAG GACTTTCCTT CAGAATTGCT AAGTTTTTTG AGTCATGCTG	5160	AC
TGTTTAGTAA TAGAACTCTT GCTTGCTTTG CTATTACAC CACAAAGGAA AAAGCTGCAC	5220	CAC
TGCTATACAA GAAAATTATG GAAAATATT CTGTAACCTT TATAAGTAGG CATAACAGTT	5280	TT

ATAATCATAA CATACTGTTT TTTCTTACTC CACACAGGCA TAGAGTGTCT GCTATTAATA 5340
ACTATGCTCA AAAATTGTGT ACCTTTAGCT TTTTAATTG TAAAGGGGTT AATAAGGAAT 5400
ATTTGATGTA TAGTGCCTTG ACTAGAGATC ATAATCAGCC ATACCACATT TGTAGAGGTT 5460
TTACTTGCTT TAAAAAACCT CCCACACCTC CCCCTGAACC TGAAACATAA AATGAATGCA 5520
ATTGTTGTTG TTAAGTGTG TATTGCAGCT TATAATGGT ACAAATAAAG CAATAGCATC 5580
ACAAATTTCA CAAATAAAGC ATTTTTTTC CTGCATTCTA GTTGTGGTTT GTCCAAACTC 5640
ATCAATGTAT CTTATCATGT CTGGATCCCC AGGAAGCTCC TCTGTGTCCT CATAAACCTT 5700
AACCTCCTCT ACTTGAGAGG ACATTCCAAT CATAGGCTGC CCATCCACCC TCTGTGTCCT 5760
CCTGTTAATT AGGTCACTTA AAAAAAGGA AATTGGGTAG GGGTTTTTCA CAGACCGCTT 5820
TCTAAGGGTA ATTTTAAAAAT ATCTGGGAAG TCCCTTCCAC TGCTGTGTTT CAGAAGTGTT 5880
GGTAAACAGC CCACAAATGT CAACAGCAGA AACATACAAG CTGTCAGCTT TGCACAAGGG 5940
CCCAACACCC TGCTCATCAA GAAGCACTGT GGTGCTGTG TTAGTAATGT GCAAAACAGG 6000
AGGCACATT TCCCCACCTG TGTAGTTCC AAAATATCTA GTGTTTTCAT TTTTACTTGG 6060
ATCAGGAACC CAGCACTCCA CTGGATAAGC ATTATCCTTA TCCAAAACAG CCTGTGTGTC 6120
AGTGTTTCATC TGCTGACTGT CAACTGTAGC ATTTTTTGGG GTTACAGTTT GAGCAGGATA 6180
TTTGGTCTG TAGTTTGCTA ACACACCCTG CAGCTCCAAA GGTTCCCCAC CAACAGCAAA 6240
AAAAATGAAAA TTTGACCCTT GAATGGGTTT TCCAGCACCA TTTTCATGAG TTTTTGTGT 6300
CCCTGAATGC AAGTTTAAAC TAGCAGTTAC CCCAATAACC TCAGTTTAA CAGTAACAGC 6360
TTCCACATC AAAATATTTT CACAGGTAA GTCCTCATTT AAATTAGGCA AAGGAATTAT 6420
ACACTCCGCT ATCGCTACGT GACTGGGTCA TGGCTGGCC CCGACACCCG CCAACACCCG 6480
CTGACGCGCC CTGACGGGCT TGTCTGCTCC CGGCATCCG TIACAGACAA GCTGTGACCG 6540
TCTCCGGGAG CTGCATGTGT CAGAGGTTTT CACCGTCATC ACCGAAACGC GCGAGGCAGC 6600
GGATCATAAT CAGCCATACC ACATTGTAG AGGTTTTACT TGCTTTAAAA AACCTCCCAC 6660
ACCTCCCCCT GAACCTGAAA CATAAAATGA ATGCAATTGT TGTGTAAAC TTGTTTATTG 6720
CAGCTTATAA TGTTACAAA TAAAGCAATA GCATCAGAAA TTTCACAAAT AAAGCATTTT 6780
TTTCACTGCA TTCTAGTTGT GTTTGTCCA AACTCATCAA TGTATCTTAT CATGTCTGGA 6840

TCATAATCAG CCATACCACA TTTGTAGAGG TTTTACTTGC TTTAAAAAAC CTCCGACACC	6900	CA
TCCCCCTGAA CCTGAAACAT AAAATGAATG CAATTGTTGT TGTAACTTG TTTATTGCAG	6960	TG
CTTATAATGG TTACAAATAA AGCAATAGCA TCACAAATTT CACAAATAAA GCATTTTTTT	7020	CT
CACTGCATTG TAGTTGTGGT TTGTCCAAAC TCATCAATGT ATCTTATCAT GTCTGGATCC	7080	TG
CACCCACATC TGGTATAAAA GGAGGCAGTG GCCCACAGAG GAGCACAGCT GTGTTTGGCT	7140	TC
GCAGGGCCAA GAGCGCTGTC AAGAAGACCC ACACGCCCCC CTCCAGCAGC TGAATTCCAG	7200	GA
CTGGCATTCC GGTACTGTTG GTAAAATGGA AGACGCCAAA AACATAAAGA AAGGCCCGGC	7260	GC
GCCATTCTAT CCTCTAGAGG ATGGAACCGC TGGAGAGCAA CTGCATAAGG CTATGAAGAG	7320	AA
ATAGCCCTG GTTCTGGAA CAATTGCTTT TACAGATGCA CATATCGAGG TGAACATCAC	7380	TG
GTACGGGAA TACTTCGAAA TGTCCGTTG GTTGGCAGAA GCTATGAAAC GATATGGGCT	7440	GT
GAATACAAAT CACAGAATCG TCGTATGCAG TGAAACTCT CTTCAATTCT TTATGCCGGT	7500	AG
GTGGGCGCG TTATTTATCG GAGTTGCAGT TGGCGCCGCG AACGACATT ATAATGAACG	7560	GT
TGAATTGCTC AACAGTATGA ACATTTCGCA GCCTACCGTA GTGTTTGTTC CAAAAAGGG	7620	TT
GTTGCAAAAA ATTTTGAACG TGCAAAAAAA ATTACCAATA ATCCAGAAAA TTATTATCAT	7680	GT
GGATTCTAAA ACGGATTACC AGGGATTTC GTCGATGTAC ACGTTCGTCA CATCTCATCT	7740	TT
ACCTCCCGGT TTTAATGAAT ACGATTTTGT ACCAGAGTCC TTTGATCGTG ACAAACAAT	7800	TGC
TGCACTGATA ATGAATTCCT CTGGATCTAC TGGGTACCT AAGGGTGTGG CCCTCCGCA	7860	AAA
TAGAACTGCC TCGTCAGAT TCTCGCATGC CAGAGATCCT ATTTTGGCA ATCAAATCAT	7920	CT
TCCGGATACT GCGATTTTAA GTGTGTTC ATTCCATCAC GGTTTTGGAA TGTTIACAT	7980	TT
ACTCGGATAT TTGATATGTG GATTTGAGT CGTCTTAATG TATAGATTG AAGAAGAGCT	8040	AGA
GTTTTIACGA TCCCTTCAGG ATTACAAAAT TCAAAGTCCG TTGCTAGTAC CAACCCTATT	8100	ACA
TTCAATCTTC GCCAAAAGCA CTCTGATTGA CAAATACGAT TTATCTAATT TACACGAAAT	8160	TGC
TGCTTCTGGG GGCGCACCTC TTTCGAAAGA AGTCGGGGAA GCGGTGCAA AACGCTTCCA	8220	TTT
TCTTCCAGGG ATACGACAAG GATATGGGCT CACTGAGACT ACATCAGCTA TTCTGATTAC	8280	GAT
ACCCGAGGGG GATGATAAAC CGGGCGCGGT CGGTAAAGTT GTTCCATTTT TTGAAGCGAA	8340	TTC
GGTGTGGAT CTGGATACCG GAAAACGCT GGGCGTTAAT CAGAGAGGCG AATTATGTGT	8400	AAA

CAGAGGACCT ATGATTATGT CCGGTTATGT AAACAATCCG GAAGCGACCA ACGCCTTGAT 8460
TGACAAGGAT GGATGGCTAC ATTCTGGAGA CATAGCTTAC TGGGACGAAG ACGAACACTT 8520
CTTCATAGTT GACCGCTTGA AGTCTTTAAT TAAATACAAA GGATATCAGG TGGCCCCCGC 8580
TGAATTGGAA TCGATATTGT TACAACACCC CAACATCTTC GACGCGGGCG TGGCAGGTCT 8640
TCCCGACGAT GACGCCGGTG AACTTCCCGC CGCCGTTGTT GTTTTGGAGC ACGGAAAGAC 8700
GATGACGGAA AAAGAGATCG TGGATTACGT CGCCAGTCAA GTAACAACCG CGAAAAAGTT 8760
GCGCGGAGGA GTTGTGTTTG TGGACGAAGT ACCGAAAGGT CTTACCGGAA AACTCGACGC 8820
AAGAAAAATC AGAGAGATCC TCATAAAGGC CAAGAAGGGC GGAAAGTCCA AATTGTAAAA 8880
TGTAAGTGTG TTCAGCGATG ACGAAATTCT TAGCTATTGT AATGACTCTA GAGGATCTTT 8940
GTGAAGGAAC CTTACTTCTG TGGTGTGACA TAATTGGACA AACTACCTAC AGAGATTTAA 9000
AGCTCTAAGG TAAATATAAA ATTTTAAAGT GTATAATGTG TTAAACTACT GATTCTAATT 9060
GTTTGTGTAT TTTAGATTCC AACCTATGGA ACTGATGAAT GGGAGCAGTG GTGGAATGCC 9120
TTTAATGAGG AAAACCTGTT TTGCTCAGAA GAAATGCCAT CTAGTGATGA TGAGGCTACT 9180
GCTGACTCTC AACATTCTAC TCCTCCAAAA AAGAAGAGAA AGGTAGAAGA CCCCAAGGAC 9240
TTTCCTTCAG AATTGCTAAG TTTTTGACT CATGCTGTGT TTAGTAATAG AACTCTTGCT 9300
TGCTTTGCTA TTTACACCAC AAAGGAAAAA GCTGCACTGC TATACAAGAA AATTATGGAA 9360
AAATATTCTG TAACCTTTAT AAGTAGGCAT AACAGTTATA ATCATAACAT ACTGTTTTTT 9420
CTTACTCCAC ACAGGCATAG ACTGTCTGCT ATTAATAACT ATGCTCAAAA ATTGTGTACC 9480
TTTAGCTTTT TAATTTGTAA AGGGGTTAAT AAGGAATATT TGATGTATAG TGCCTTGACT 9540
AGAGATCATA ATCAGCCATA CCACATTGTT AGAGGTTTTA CTGCTTTTAA AAAACCTCCC 9600
ACACCTCCCC CTGAACCTGA AACATAAAAT GAATGCAATT GTTGTGTGTA ACTTGTTTAT 9660
TGCAGCTTAT AATGTTTACA AATAAAGCAA TAGCATCACA AATTCACAA ATAAAGCATT 9720
TTTTTCACTG CATTCTAGTT GTGGTTTGTC CAAACTCATC AATGTATCTT ATCATGTCTG 9780
GATCCCCAGG AAGCTCCTCT GTGTCCCTCAT AAACCCTAAC CTCCTCTACT TGAGAGGACA 9840
TTCCAATCAT AGGCTGCCCC TCCACCCTCT GTGTCTCCT GTTAATTAGG TCACTTAACA 9900
AAAAGGAAAT TGGGTAGGGG TTTTTCACAG ACCGCTTCT AAGGGTAATT TTAAATATC 9960

-170-

TGGGAAGTCC CTTCCTGCTG TGTGTTCCAG AAGTGTGGT AAACAGCCCA CAAATGTCAA 10020
CAGCAGAAAC ATACAAGCTG TCAGCTTTGC ACAAGGGCCC AACACCCTGC TCAGCAAGAA 10080
GCACTGTGGT TGCTGTGTTA GTAATGTGCA AAACAGGAGG CACATTTTCC CCACCTGTGT 10140
AGGTTCCAAA ATATCTAGTG TTTTCATTTT TACTTGGATC AGGAACCCAG CACTCCACTG 10200
GATAAGCATT ATCCTTATCC AAAACAGCCT TGTGGTCAGT GTTCATCTGC TGACTGTCAA 10260
CTGTAGCATT TTTTGGGGTT ACAGTTTGTG CAGGATATTT GGTCTGTAG TTTGCTAACA 10320
CACCTGTCAG CTCCAAAGGT TCCCACCAA CAGCAAAAAA ATGAAAATT GACCCTTGAA 10380
TGGGTTTTTC AGCACCATT TCATGAGTTT TTTGTGTCCC TGAATGCAAG TTAAACATAG 10440
CAGTTACCCC AATAACCTCA GTTTTAACAG TAACAGCTTC CCACATCAAA ATATTCCAC 10500
AGGTTAAGTC CTCATTAAAA TTAGGCAAAG GAA 10533

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6229 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

TTCTTGAAGA CGAAAGGGCC TCGTGATACG CCTATTTTAA TAGGTTAATG TCATGATAAT 60
AATGGTTTCT TAGACGTCAG GTGGCACTTT TCGGGGAAAT GTGCGCGGAA CCCCTATTTG 120
TTTATTTTTC TAAATACATT CAAATATGTA TCCGCTCATG AGACAATAAC CCTGATAAAT 180
GCTTCAATAA TATTGAAAAA GGAAGAGTAT GAGTATTCAA CATTTCCGTG TCGCCCTTAT 240
TCCCTTTTTT GCGGCATTTT GCCTTCCTGT TTTTGCTCAC CCAGAAACGC TGGTGAAAGT 300
AAAAGATGCT GAAGATCAGT TGGGTGCACG AGTGGGTIAC ATCGAACTGG ATCTCAACAG 360
CGGTAAGATC CTGAGAGTT TCGCCCCGA AGAACGTTTT CCAATGATGA GCACTTTTAA 420

AGTTCTGCTA TGTGGCGCGG TATTATCCCG TGTGACGCC GGGCAAGAGC AACTCGGTGG 480
CCGCATACAC TATTCTCAGA ATGACTTGGT TGAGTACTCA CCAGTCACAG AAAAGCATCT 540
TACGGATGGC ATGACAGTAA GAGAATTATG CAGTGCTGCC ATAACCATGA GTGATAACAC 600
TGCGGCCAAC TTA CTCTCTGA CAACGATCGG AGGACCGAAG GAGCTAACCG CTTTTTTGCA 660
CAACATGGGG GATCATGTAA CTGCGCTTGA TCGTTGGGAA CCGGAGCTGA ATGAAGCCAT 720
ACCAAACGAC GAGCGTGACA CCACGATGCC TGCAGCAATG GCAACAACGT TCGCGAAACT 780
ATTAAGTGGC GAACTACTTA CTCTAGCTTC CCGGCAACAA TTAATAGACT GGATGGAGGC 840
GGATAAAGTT GCAGGACCAC TTCTGCGCTC GGGCCTTCCG GCTGGCTGGT TTATTGCTGA 900
TAAATCTGGA GCGGGTGAGC GTGGGTCTCG CGGTATCATT GCAGCACTGG GGGCAGATGG 960
TAAGCCCTCC CGTATCGTAG TTATCTACAC GACGGGGAGT CAGGCAACTA TGGATGAACG 1020
AAATAGACAG ATCGCTGAGA TAGGTGCCTC ACTGATTAAG CATTGGTAAC TGTGAGACCA 1080
AGTTTACTCA TATATACTTT AGATTGATTT AAACTTCAT TTTTAATTAA AAAGGATCTA 1140
GGTGAAGATC CTTTTTGATA ATCTCATGAC CAAAATCCCT TAACGTGAGT TTTCGTTCCA 1200
CTGAGCGTCA GACCCCGTAG AAAAGATCAA AGGATCTTCT TGAGATCCTT TTTTCTGCG 1260
CGTAATCTGC TGCTTGCAAA CAAAAAACC ACCGCTACCA GCGGTGGTTT GTTTGCCGGA 1320
TCAAGAGCTA CCAACTCTTT TTCCGAAGGT AACTGGCTTC AGCAGAGCGC AGATACCAAA 1380
TACTGTCCTT CTAGTGTAGC CGTAGTTAGG CGACCACTTC AAGAACTCTG TAGCACCGCC 1440
TACATACCTC GCTCTGCTAA TCCTGTTACC AGTGGCTGCT GCCAGTGGCG ATAAGTCGTG 1500
TCTTACCGGG TTGACTCAA GACGATAGTT ACCGGATAAG GCGCAGCGGT CGGGCTGAAC 1560
GGGGGGTTG TGCACACAGC CCAGCTTGA GCGAACGACC TACACCGAAC TGAGATACCT 1620
ACAGCGTGAG CATTGAGAAA GCGCCACGCT TCCCGAAGGG AGAAAGGCGG ACAGGTATCC 1680
GGTAAGCGGC AGGGTCGGAA CAGGAGAGCG CACGAGGGAG CTCCAGGGG GAAACGCCTG 1740
GTATCTTAT ACTCCTGTCG GGTTCGCCA CCTCTGACTT GAGCGTCGAT TTTTGTGATG 1800
CTCGTCAGGG GGGCGGAGCC TATGGAAAA CGCCAGCAAC GCGGCCTTTT TACGGTTCCT 1860
GGCCTTTTGC TGGCCTTTTG CTCACATGTT CTTTCTGCG TTATCCCTG ATTCTGTGGA 1920
TAACCGTATT ACCGCCTTG AGTGAGCTGA TACCGCTCGC CGCAGCCGAA CGACCGAGCG 1980

CAGCGAGTCA GTGAGCGAGG AAGCGGAAGA GCGCCTGATG CGGTATTTTC TCCTTACGCA	2040	GTGTGGC
TCTGTGCGGT ATTTACACACC GCATATGGTG CACTCTCAGT ACAATCTGCT CTGATGCCGC	2100	TTGGCA
ATAGTTAAGC CAGTATACAC TCCGCTATCG CTACGTGACT GGGTCATGGC TGGCCCCGA	2160	TTGGAA
CACCCGCCAA CACCCGCTGA CGCGCCCTGA CGGGCTTGTC TGCTCCCGGC ATCCGCTTAC	2220	GATTTG
AGACAAGCTG TGACCGTCTC CGGGAGCTGC ATGTGTCAGA GGTTTTCACC GTCATCACCG	2280	TAGTAC
AAACGCGCGA GGCAGCGGAT CATAATCAGC CATAACCACAT TTGTAGAGGT TTTACTTGCT	2340	CTAATI
TTAAAAAACC TCCCACACCT CCCCCTGAAC CTGAAACATA AAATGAATGC AATTGTTGTT	2400	TTGCAA
GTAACTTGT TTATTGCAGC TTATAATGGT TACAAATAAA GCAATAGCAT CACAAATTTT	2460	CAGCTA
AGAAATAAAG CATTTTTTTC ACTGCATTCT AGTTGTGTTT TGTCCAAACT CATCAATGTA	2520	CATTIT
TCTTATCATG TCTGGATCAT AATCAGCCAT ACCACATTG TAGAGGTTTT ACTTGCTTTA	2580	GAGGCC
AAAAACCTCC CACACCTCCC CCTGAACCTG AAACATAAAA TGAATGCAAT TGTGTTGTTT	2640	CGACC
AACTTGTTTA TTGCAGCTTA TAATGGTTAC AAATAAAGCA ATAGCATCAC AAATTCACA	2700	ACGAA
AATAAAGCAT TTTTTCACCT GCATTCTAGT TGTGGTTTGT CCAAATCAT CAATGTATCT	2760	ATCAG
TATCATGTCT GGATCCACCC CACATCTGGT ATAAAAGGAG GCAGTGGCCC ACAGAGGAGC	2820	CGGGC
ACAGCTGTGT TTGGCTGCAG GGCCAAGAGC GCTGTCAAGA AGACCCACAC GCCCCCTCC	2880	TGGAG
AGCAGCTGAA TTCCAGCTGG CATTCCGGTA CTGTTGGTAA AATGGAAGAC GCCAAAAACA	2940	CAACC
TAAAGAAAGG CCCGGCGCCA TTCTATCCTC TAGAGGATGG AACCGCTGGA GAGCAACTGC	3000	CCGG
ATAAGGCTAT GAAGAGATAC GCCCTGGTTC CTGGAACAAT TGCTTTTACA GATGCACATA	3060	AGTCC
TCGAGGTGAA CATCACGTAC GCGGAATACT TCGAAATGTC CGTTCGGTTG GCAGAAGCTA	3120	ACTC
TGAAACGATA TGGGCTGAAT ACAAATCACA GAATCGTCGT ATGCAGTGAA AACTCTCTTC	3180	ACCT
AATTCTTTAT GCCGGTGTTC GCGCGTTTAT TTATCGGAGT TGCAGTTGCG CCCGCGAACC	3240	ACTA
ACATTTATAA TGAACGTGAA TTGCTCAACA GTATGAACAT TTGCAGCCT ACCGTAGTGT	3300	GCAG
TTGTTTCCAA AAAGGGGTTG CAAAAATTT TGAACGTGCA AAAAAATTA CCAATAATCC	3360	TGAI
AGAAAATTAT TATCATGGAT TCTAAACGG ATTACCAGGG ATTTCACTCG ATGTACACGT	3420	AGAF
TCGTACATC TCATCTACCT CCCGGTTTTA ATGAATACGA TTTGTIACCA GAGTCCTTTG	3480	TAA
ATCGTGACAA AACAATTGCA CTGATAATGA ATTCCTCTGG ATCTACTGGG TTACCTAAGG	3540	CAA

GTGTGGCCCT TCCGCATAGA ACTGCCTGCG TCAGATTCTC GCATGCCAGA GATCCTATTT	3600
TTGGCAATCA AATCATTCCG GATACTGCGA TTTTAAGTGT TGTTCATTG CATCAGGGTT	3660
TTGGAATGTT TACTACACTC GGATATTTGA TATGTGGATT TCGAGTCGTC TTAATGTATA	3720
GATTTGAAGA AGAGCTGTTT TTACGATCCC TTCAGGATTA CAAAATTCAA AGTGCCTTGC	3780
TAGTACCAAC CCTATTTTCA TTCTTCGCCA AAAGCACTCT GATTGACAAA TACGATTTAT	3840
CTAATTTACA CGAAATTGCT TCTGGGGGCG CACCTCTTTC GAAAGAAGTC GGGGAAGCGG	3900
TTGCAAAACG CTTCATCTT CCAGGGATAC GACAAGGATA TGGGCTCACT GAGACTACAT	3960
CAGCTATTCT GATTACACCC GAGGGGGATG ATAAACCGGG CGCGGTCGGT AAAGTTGTTT	4020
CATTTTTTGA AGCGAAGGT GTGGATCTGG ATACCGGGAA AACGCTGGGC GTTAATCAGA	4080
GAGGCGAATT ATGTGTCAGA GGACCTATGA TTATGTCCGG TTATGTAAAC AATCCGGAAG	4140
CGACCAACGC CTTGATTGAC AAGGATGGAT GGCTACATTC TGGAGACATA GCTTACTGGG	4200
ACGAAGACGA ACACTTCTTC ATAGTTGACC GCTTGAAGTC TTTAATTAAA TACAAAGGAT	4260
ATCAGGTGGC CCCCCTGAA TTGGAATCGA TATTGTTACA ACACCCCAAC ATCTTCGACG	4320
CGGGCGTGGC AGGTCTTCCC GACGATGACG CCGGTGAACT TCCCGCGGCC GTTGTGTTT	4380
TGGAGCACGG AAAGACGATG ACGGAAAAAG AGATCCTGGA TTACGTGCC AGTCAAGTAA	4440
CAACCGCGAA AAAGTTGCCG GGAGGAGTTG TGTGTTGGA CGAAGTACCG AAAGGTCTTA	4500
CCGGAAAACT CGACGCAAGA AAAATCAGAG AGATCCTCAT AAAGGCCAAG AAGGGCGGAA	4560
AGTCCAAATT GTAAATGTA ACTGTATTCA GCGATGACGA AATTCTTAGC TATTGTAATG	4620
ACTCTAGAGG ATCTTTGTGA AGGAACCTTA CTTCTGTGGT GTGACATAAT TGGACAACT	4680
ACCTACAGAG ATTTAAAGCT CTAAGGTAAA TATAAAATTT TTAAGTGTAT AATGTGTAA	4740
ACTACTGATT CTAATTGTTT GTGTATTTTA GATTCCAACC TATGGAAGTC ATGAATGGGA	4800
GCAGTGGTGG AATGCCTTTA ATGAGGAAAA CCTGTTTTGC TCAGAAGAAA TGCCATCTAG	4860
TGATGATGAG GCTACTGCTG ACTCTCAACA TTCTACTCCT CCAAAAAAGA AGAGAAAGGT	4920
AGAAGACCCC AAGGACTTTC CTTGAGAATT GCTAAGTTTT TTGAGTCATG CTGTGTTAG	4980
TAATAGAACT CTTGCTTGCT TTGCTATTTA CACCACAAAG GAAAAAGCTG CACTGCTATA	5040
CAAGAAAATT ATGGAAAAAT ATTCTGTAAC CTTTATAAGT AGGCATAACA GTTATAATCA	5100

TAACATACTG TTTTTTCTTA CTCCACACAG GCATAGAGTG TCTGCTATTA ATAACATATGC 5160
TCAAAAATTG TGTACCTTTA GCTTTTAAAT TTGTAAAGGG GTTAATAAGG AATATTTGAT 5220
GTATACTGCC TTGACTAGAG ATCATAATCA GCCATACCAC ATTTGTAGAG GTTTTACTTG 5280
CTTTAAAAAA CCTCCCACAC CTCCCCCTGA ACCTGAAAGA TAAAATGAAT GCAATTGTG 5340
TTGTAACTT GTTTATTGCA GCTTATAATG GTTACAAATA AAGCAATAGC ATCACAAATT 5400
TCACAAATAA AGCATTITTT TCACTGCATT CTAGTTGTGG TTTGTCCAAA CTCATCAATG 5460
TATCTTATCA TGTCTGGATC CCCAGGAAGC TCCTCTGTGT CCTCATAAAC CCTAACCTCC 5520
TCTACTTGAG AGGACATTCC AATCATAGGC TGCCCATCCA CCCTCTGTGT CCTCCTGTTA 5580
ATTAGGTCAC TTAACAAAAA GGAAATTGGG TAGGGGTTTT TCACAGACCG CTTTCTAAGG 5640
GTAATTTTAA AATATCTGGG AAGTCCCTTC CACTGCTGTG TTCCAGAAGT GTTGGTAAAC 5700
AGCCCACAAA TGTCAACAGC AGAAACATAC AAGCTGTCAG CTTTGCACAA GGGCCCAACA 5760
CCCTGCTCAG CAAGAAGCAC TGTGGTGTCT GTGTTAGTAA TGTGCAAAAC AGGAGGCACA 5820
TTTTCCCCAC CTGTGTAGGT TCCAAAATAT CTAGTGTITT CATTTTTACT TGGATCAGGA 5880
ACCCAGCACT CCACTGGATA AGCATTATCC TTATCCAAA CAGCCTTGTG GTCAGTGTTT 5940
ATCTGCTGAC TGTCAACTGT AGCATTITTT GGGGTIACAG TTTGAGCAGG ATATTTGGTC 6000
CTGTAGTTTG CTAACACACC CTGCAGCTCC AAAGGTTCCC CACCAACAGC AAAAAAATGA 6060
AAATTIGACC CITGAATGGG TTTTCCAGCA CCATTTTCAT GAGTTTTTTG TGTCCCTGAA 6120
TGCAAGTTTA ACATAGCAGT TACCCCAATA ACCTCAGTTT TAACAGTAAC AGCTTCCCAC 6180
ATCAAAATAT TTCCACAGGT TAAGTCCTCA TTAAATTAG GCAAAGGAA 6229

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10768 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

TT

AA

TT

GC

TC

AA

CG

AG

CC

TA

TG

CA

AC

AT

GG

TA

TA

AA

AG

GG

CT

CG

TC

TA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

TTCTTGAAGA CGAAAGGGCC TCGTGATACG CCTATTTTTA TAGGTTAATG TCATGATAAT	60
AATGGTTTCT TAGACGTCAG GTGGCACTTT TCGGGGAAAT GTGCGCGGAA CCCCTATTTC	120
TTTATTTTTC TAAATACATT CAAATATGTA TCCGCTCATG AGACAATAAC CCTGATAAAT	180
GCTTCAATAA TATTGAAAAA GGAAGAGTAT GAGTATTCAA CATTTCGGTG TCGCCCTTAT	240
TCCCTTTTTT GCGGCATTTT GCCTTCCTGT TTTTGCTCAC CCAGAAACGC TGGTGAAAGT	300
AAAAGATGCT GAAGATCAGT TGGGTGCACG AGTGGGTAC ATCGAACTGG ATCTCAACAG	360
CGGTAAGATC CTTGAGAGTT TCGCCCCGA AGAAGCTTTT CCAATGATGA GCACTTTTAA	420
AGTTCTGCTA TGTGGCGCGG TATTATCCCG TGTGACGCC GGGCAAGAGC AACTCGGTCC	480
CCGCATACAC TATTCTCAGA ATGACTTGGT TGAGTACTCA CCAGTCACAG AAAAGCATCT	540
TACGGATGGC ATGACAGTAA GAGAATTATG CAGTGCTGCC ATAACCATGA GTGATAACAC	600
TGGGGCCAAC TTAATTCTGA CAACGATCGG AGGACCGAAG GAGCTAACCG CTTTTTGCA	660
CAACATGGGG GATCATGTAA CTCGCCCTGA TCGTTGGGAA CCGGAGCTGA ATGAAGCCAT	720
ACCAAACGAC GAGCGTGACA CCACGATGCC TGCAGCAATG GCAACAACGT TCGCGAAACT	780
ATTAAGTGGC GAACTACTTA CTCTAGCTTC CCGGCAACAA TTAATAGACT GGATGGAGGC	840
GGATAAAGTT GCAGGACCAC TTCTGCGCTC GGCCCTTCGG GCTGGCTGGT TTATTGCTGA	900
TAAATCTGGA GCCGGTGAGC GTGGGTCTCG CGGTATCATT GCAGCACTGG GGCCAGATGG	960
TAAGCCCTCC CGTATCGTAG TTATCTACAC GACGGGGAGT CAGGCAACTA TGGATGAACG	1020
AAATAGACAG ATCGCTGAGA TAGGTGCCTC ACTGATTAA CATTGGTAAC TGTCAGACCA	1080
AGTTTACTCA TATATACITT AGATTGATTT AAAACTTCAT TTTTAATTAA AAAGGATCTA	1140
GGTGAAGATC CTTTTTGATA ATCTCATGAC CAAAATCCCT TAACGTGAGT TTTCGTTCCA	1200
CTGAGCGTCA GACCCCGTAG AAAAGATCAA AGGATCTTCT TGAGATCCTT TTTTCTGCG	1260
CGTAATCTGC TGCTTGCAAA CAAAAAACC ACCGCTACCA GCGGTGGTTT GTTTGCCGGA	1320
TCAAGAGCTA CCAACTCTTT TTCCGAAGGT AACTGGCTTC AGCAGAGCGC AGATACCAAA	1380
TACTGTCCTT CTAGTGTAGC CGTAGTTAGG CCACCACTTC AAGAACTCTG TAGCACCGCC	1440

TACATACCTC GCTCTGCTAA TCCTGTTACC AGTGGCTGCT GCCAGTGGCG ATAAGTCGTG 1500
TCTTACCGGG TTGGACTCAA GACGATAGTT ACCGGATAAG GCGCAGCGGT CGGGCTGAAC 1560
GGGGGGTTCG TGCACACAGC CCAGCTTGA GCGAACGACC TACACCGAAC TGAGATACCT 1620
ACAGCGTGAG CATTGAGAAA GCGCCACGCT TCCCGAAGGG AGAAAGGCGG ACAGGTATCC 1680
GGTAAGCGGC AGGCTCGGAA CAGGAGAGCG CACGAGGGAG CTTCAGGGG GAAACGCCTG 1740
GTATCTTTAT AGTCCTGTGG GGTTCGCCA CCTCTGACTT GAGCGTCGAT TTTTGTGATG 1800
CTCGTCAGGG GGGCGGAGCC TATGAAAAA CGCCAGCAAC GCGGCCTTTT TACGGTTCCT 1860
GGCCTTTTGC TGGCCTTTTG CTCACATGTT CTTTCCTGCG TTATCCCCTG ATTCTGTGGA 1920
TAACCGTATT ACCGCCTTTG AGTGAGCTGA TACCGCTCGC CGCAGCCGAA CGACCGAGCG 1980
CAGCGAGTCA GTGAGCGAGG AAGCGGAAGA GCGCCTGATG CGGTATTTTC TCCTTACGCA 2040
TCTGTGCGGT ATTTACACACC GCATATGGTG CACTCTCAGT ACAATCTGCT CTGATGCCGC 2100
ATAGTTAAGC CAGTATTCGA CCTCGAGGGA TCTTTGTGAA GGAACCTTAC TTCTGTGGTG 2160
TGACATAATT GGACAAACTA CCTACAGAGA TTAAAGCTC TAAGGTAAAT ATAAAATTTT 2220
TAAGTGATA ATGTGTTAAA CTACTGATTC TAATTGTTTG TGTATTTTAC ATTCCAACCT 2280
ATGGAAGTGA TGAATGGGAG CAGTGGTGGA ATGCCCTTAA TGAGGAAAAC CTGTTTTGCT 2340
CAGAAGAAAT GCCATCTAGT GATGATGAGG CTACTGCTGA CTCTCAACAT TCTACTCCTC 2400
CAAAAAAGAA GAGAAAGGTA GAAGACCCCA AGGACTTTCC TTCAGAATTG CTAAGTTTTT 2460
TGAGTCAATG TGTGTTTAGT AATAGAACTC TTGCTTGCTT TGCTATTTAC ACCACAAAGG 2520
AAAAAGCTGC ACTGCTATAC AAGAAAATTA TGGAAAAATA TTCTGTAACC TTTATAAGTA 2580
GGCATAACAG TTATAATCAT AACATACTGT TTTTCTTAC TCCACACAGG CATAGAGTGT 2640
CTGCTATTAA TAACTATGCT CAAAAATTGT GTACCTTTAG CTTTTTAATT TGTAAAGGGG 2700
TTAATAAGGA ATATTTGATG TATAGTGCCT TGAAGAGAGA TCATAATCAG CCATACCACA 2760
TTTGTAGAGG TTTTACTTGC TTTAAAAAAC CTCCACACCC TCCCCTGAA CCTGAAACAT 2820
AAAATGAATG CAATTGTTGT TGTAACTTG TTTATTGCAG CTTATAATGG TTACAAATAA 2880
AGCAATAGCA TCACAAATTT CACAAATAAA GCATTTTTTT CACTGCATTG TAGTTGTGGT 2940
TTGTCCAAAC TCATCAATGT ATCTTATCAT GTCTGGATCC GGCTGTGGAA TGTGTGTCAG 3000

TTAGGGTGTG GAAAGTCCCC AGGCTCCCCA GCAGGCAGAA STATGCAAAG CATGCATCTC 3060
AATTAGTCAG CAACCAGGTG TGGAAAGTCC CCAGGCTCCC CAGCAGGCAG AAGTATGCAA 3120
AGCATGCATC TCAATTAGTC AGCAACCATA GTCCCGCCCC TAACTCCGCC CATCCCGCCC 3180
CTAACTCCGC CCAGTTCGGC CCATTCTCGG CCCCATGGCT GACTAATTTT TTTTATTTAT 3240
GCAGAGGCCG AGGCCGCCTC GGCCTCTGAG CTATTCCAGA AGTAGTGAGG AGGCTTTTTT 3300
GGAGGCCTAG GCTTTTGCAA AAAGCTTCAC GCTGCCGCAA GCACTCAGGG CGCAAGGGCT 3360
GCTAAAGGAA GCGGAACACG TAGAAAGCCA GTCCGCAGAA ACGGTGCTGA CCCCGGATGA 3420
ATGTCAGCTA CTGGGCTATC TGGACAAGGG AAAACGCAAG CGCAAAGAGA AAGCAGGTAG 3480
CTTGCACTGG GCTTACATGG CGATAGCTAG ACTGGGCGGT TTTATGGACA GCAAGCGAAC 3540
CGGAATTGCC AGCTGGGGCG CCCTCTGGTA AGGTTGGGAA GGCCTGCAAA GTAAACTGGA 3600
TGGCTTTCTT GCCGCCAAGG ATCTGATGGC GCAGGGGATC AAGATCTGAT CAAGAGACAG 3660
GATGAGGATC GTTTCGCATG ATTGAACAAG ATGGATTGCA CGCAGGTTCT CCGGCCGCTT 3720
GGGTGGAGAG GCTATTCGGC TATGACTGGG CACAACAGAC AATCGGCTGC TCTGATGCCG 3780
CCGTGTTCCG GCTGTCAGCG CAGGGGCGCC CGGTTCTTTT TGTCAACACC GACCTGTCCG 3840
GTGCCCTGAA TGAAGTGCAG GACGAGGCAG CGCGGCTATC GTGGCTGGCC ACCACGGGCG 3900
TTCCTTGCGC AGCTGTGCTC GACGTTGTCA CTGAAGCGGG AAGGGACTGG CTGCTATTGG 3960
GCGAAGTGCC GGGGCAGGAT CTCCTGTCAT CTCACCTTGC TCCTGCCGAG AAAGTATCCA 4020
TCATGGCTGA TGCAATGCGG CGGCTGCATA CGCTTGATCC GGCTACCTGC CCATTGACC 4080
ACCAAGCGAA ACATCGCATC GAGCGAGCAC GTACTCGGAT GGAAGCCGGT CTGTGCGATC 4140
AGGATGATCT GGACGAAGAG CATCAGGGGC TCGCGCCAGC CGAACTGTTC GCCAGGCTCA 4200
AGGCGCGCAT GCCCGACGGC GAGGATCTCG TCGTGACCCA TGGCGATGCC TGCTTGCCGA 4260
ATATCATGGT GGAAAATGGC CGCTTTTCTG GATTATCGA CTGTGGCCGG CTGGGTGTGG 4320
CGGACCGCTA TCAGGACATA GCGTTGGCTA CCCGTGATAT TGCTGAAGAG CTTGGCGGCG 4380
AATGGGCTGA CCGCTTCCTC GTGCTTTACG GTATCGCCGC TCCCGATTGG CAGCGCATCG 4440
CCTTCTATCG CCTTCTTGAC GAGTTCTTCT GAGCGGGACT CTGGGGTTGG AAATGACCGA 4500
CCAAGCGACG CCCAACCTGC CATCAGGAGA TTTCGATTCC ACCGCCGCCT TCTATGAAAG 4560

GTTGGGCTTC GGAATCGTTT TCCGGGACGC CGGCTGGATG ATCCTCCAGC GCGGGGATCT	4620	AGTGTI
CATGCTGGAG TTCTTCGCCC ACCCCGGGCT CGATCCCCTC GCGAGTTGGT TCAGCTGCTG	4680	TTTGGI
CCTGAGGCTG GACGACCTCG CGGAGTTCTA CCGGCAGTGC AAATCCGTCG GCATCCAGGA	4740	AAAATC
AACCAGCAGC GGCTATCCGC GCATCCATGC CCCCGAACCTG CAGGAGTGGG GAGGCACGAT	4800	CCCTG/
GGCCGCTTIG GTCCCGGATC TTTGTGAAGG AACCTTACTT CTGTGGTGTG ACATAATTGG	4860	TTCCG/
ACAAACTACC TACAGAGATT TAAAGCTCTA AGGTAAATAT AAAATTTTTA AGTGATAAT	4920	ACACT/
GTGTTAAACT ACTGATTCTA ATTGTTTGTG TATTTTAGAT TCCAACCTAT GGAAGTGATG	4980	CTGAC/
AATGGGAGCA GTGGTGAAT GCCTTTAATG AGGAAAACCT GTTTTGCTCA GAAGAAATGC	5040	TCTCC/
CATCTAGTGA TGATGAGGCT ACTGCTGACT CTCAACATTC TACTCCTCCA AAAAAGAAGA	5100	GGATC/
GAAAGGTAGA AGACCCCAAG GACTTTCCTT CAGAATTGCT AAGTTTTTTG AGTCATGCTG	5160	ACCTC/
TGTTTAGTAA TAGAACTCTT GCTTGCTTIG CTATTTACAC CACAAAGGAA AAAGCTGCAC	5220	CAGCT/
TGCTATACAA GAAAATTATG GAAAAATATT CTGTAACCTT TATAAGTAGG CATAACAGTT	5280	TTTCA/
ATAATCATAA CATACTGTTT TTTCTTACTC CACACAGGCA TAGAGTGTCT GCTATTAATA	5340	TCATA/
ACTATGCTCA AAAATTGTGT ACCTTTAGCT TTTTAATTIG TAAAGGGGTT AATAAGGAAT	5400	TCCCC/
ATTTGATGTA TAGTGCCTTG ACTAGAGATC ATAATCAGCC ATACCACATT TGTAGAGGTT	5460	CTTAT/
TTACTTGCTT TAAAAAACCT CCCACACCTC CCCCTGAACC TGAAACATAA AATGAATGCA	5520	CACTC/
ATTGTTGTG TTAACCTGTT TATTGCAGCT TATAATGGTT ACAAATAAAG CAATAGCATC	5580	CAGG/
ACAAATTICA CAAATAAAGC ATTTTTTTCA CTGCATTCTA GTTGTGGTTT GTCCAAACTC	5640	CGGA/
ATCAATGTAT CTTATCATGT CTGGATCCCC AGGAAGCTCC TCTGTGTCCT CATAAACCCCT	5700	TCCG/
AACCTCCTCT ACTTGAGAGG ACATTCCAAT CATAGGCTGC CCATCCACCC TCTGTGTCCT	5760	TTTG/
CCTGTIAATT AGGTCACTTA AAAAAAGGA AATTGGGTAG GGGTTTTTCA CAGACCGCTT	5820	GCAA/
TCTAAGGGTA ATTTTAAAAAT ATCTGGGAAG TCCCTTCCAC TGCTGTGTTT CAGAAGTGTT	5880	AAAC/
GGTAAACAGC CCACAAATGT CAACAGCAGA AACATACAAG CTGTCAGCTT TGCACAAGGG	5940	ATTC/
CCCAACACCC TGCTCATCAA GAAGCACTGT GGTGCTGTG TTAGTAATGT GCAAAACAGG	6000	TCTA/
AGGCACATTT TCCCCACCTG TGTAGGTTCC AAAATATCTA GTGTTTTCAT TTTTACTTGG	6060	CCCT/
ATCAGGAACC CAGCACTCCA CTGGATAAGC ATTATCCTTA TCCAAAACAG CCTTGTGGTC	6120	CGG/

AGTGTTCATC TGCTGACTGT CAACTGTAGC ATTTTTTGGG GTTACAGTTT GAGCAGGATA 6180
TTTGGTCCTG TAGTTTGCTA ACACACCCTG CAGCTCCAAA GGTCCCCAC CAACAGCAAA 6240
AAAATGAAAA TTTGACCCTT GAATGGGTTT TCCAGCACCA TTTTCATGAG TTTTTGTGT 6300
CCCTGAATGC AAGTTTAACA TAGCAGTTAC CCAATAACC TCAGTTTAA CAGTAACAGC 6360
TTCCACATC AAAATATTC CACAGGTAA GTCTCATTT AAATTAGGCA AAGGAATTAT 6420
ACACTCCGCT ATCGTACGT GACTGGGTCA TGGCTGGCC CCGACACCG CCAACACCG 6480
CTGACGCGCC CTGACGGGCT TGTCTGCTCC CGGCATCCGC TTACAGACAA GCTGTGACCG 6540
TCTCCGGGAG CTGCATGTGT CAGAGGTTTT CACCGTCATC ACCGAAACGC GCGAGGCAGC 6600
GGATCATAAT CAGCCATACC ACATTTGTAG AGGTTTTACT TGCTTTAAA AACCTCCCAC 6660
ACCTCCCCCT GAACCTGAAA CATAAAATGA ATGCAATTGT TGTGTAAAC TTGTTATTG 6720
CAGCTTATAA TGGTTACAAA TAAAGCAATA GCATCACAAA TTTACAAAT AAAGCATTTT 6780
TTTCACTGCA TTCTAGTTGT GGTTTGTTCCA AACTCATCAA TGTATCTTAT CATGTCTGGA 6840
TCATAATCAG CCATACCACA TTTGTAGAGG TTTTACTTGC TTAAAAAAC CTCCCACACC 6900
TCCCCCTGAA CCTGAAACAT AAAATGAATG CAATTGTGT TGTAACTTG TTTATTGCAG 6960
CTTATAATGG TTACAAATAA AGCAATAGCA TCACAAATTT CACAAATAAA GCATTTTTTT 7020
CACTGCATTC TAGTTGTGGT TTGTCCAAAC TCATCAATGT ATCTTATCAT GTCTGGATCC 7080
CAGGCCAGAC GCCAACAAGG TAGGAGCTGG AGCATTCCGG CTGGGTTTCA GCCCACCAG 7140
CGGAGGCCTT TTGGGGTGGA GCCCTCAGGC TCAGGGCATA CTACAACTT TGCCAGCAAA 7200
TCCGCTCCT GCCTCCACCA ATCGCCAGTC AGGAAGGCAG CCTACCCCGC TGTCTCCACC 7260
TTTGAGAAAC ACTCATCCTC AGGCCATGCA GTGGAATTCC ACAACCTTCC ACCAAACTCT 7320
GCAAGATCCC AGAGTGAGAG GCCTGTATTT CCTGCTGGT GGCTCCAGTT CAGGAACAGT 7380
AAACCCTGTT CTGACTACTG CCTCTCCCTT ATCGTCAATC TTCTCGAAAT TCCAGCTGGC 7440
ATTCCGGTAC TGTTGTTAAA ATGGAAGACG CCAAAAACAT AAAGAAAGGC CCGGCGCCAT 7500
TCTATCCTCT AGAGGATGGA ACCGCTGGAG AGCAACTGCA TAAGGCTATG AAGAGATACC 7560
CCCTGGTICC TGAACAATT GCTTTTACAG ATGCACATAT CGAGGTGAAC ATCACGTACG 7620
CGGAATACTT CGAAATGTCC GTTCGGTTGG CAGAAGCTAT GAAACGATAT GGGCTGAATA 7680

CAAATCACAG AATCGTCGTA TGCAGTGAAA ACTCTCTTCA ATTCTTTATG CCGGTGTTGG	7740	TAA
GCGCGTTIATT TATCGGAGTT GCAGTTGCCG CCGCGAACGA CATTATAAT GAACGTGAAT	7800	TGT
TGCTCAACAG TATGAACATT TCGCAGCCTA CCGTAGTGT TGTTCCTAAA AAGGGGTTGC	7860	TGA
AAAAAATTTT GAACGTGCAA AAAAAATTAC CAATAATCCA GAAAATTATT ATCATGGATT	7920	CTC
CTAAAACGGA TTACCAGGGA TTTCAGTCGA TGTACACGTT CGTCACATCT CATCTACCTC	7980	TTC
CCGGTTTTTAA TGAATACGAT TTTGTACCAG AGTCCTTTGA TCGTGACAAA ACAATTGCAC	8040	TGC
TGATAATGAA TTCCTCTGGA TCTACTGGGT TACCTAAGGG TGTGGCCCTT CCGGATAGAA	8100	TTC
CTGCCTGCCG CAGATTCTCG CATGCCAGAG ATCCTATTTT TGGAATCAA ATCATTCCGG	8160	TCC
ATACTGCGAT TTTAAGTGTT GTTCCATTCC ATCACGGTTT TGAATGTTT ACTACACTCG	8220	CTI
GATATTTGAT ATGTGGATTT CGAGTCGTCT TAATGTATAG ATTTGAAGAA GAGCTGTTTT	8280	TCA
TACGATCCCT TCAGGATTAC AAAATTCAAA GTGCGTTGCT AGTACCAACC CTATTTTCAT	8340	TCC
TCTTCGCCAA AAGCACTCTG ATTGACAAAT ACGATTTATC TAATTTACAC GAAATTGCTT	8400	CTI
CTGGGGGGCG ACCTCTTTCC AAAGAAGTCG GGAAGCGGT TGCAAAACGC TTCCATCTTC	8460	CAC
CAGGGATACG ACAAGGATAT GGGCTCACTG AGACTACATC AGCTATTCTG ATTACACCCG	8520	CCA
AGGGGGATGA TAAACCGGGC GCGGTCCGTA AAGTTGTTCC ATTTTTTGAA GCGAAGGTTG	8580	ATC
TGGATCTGGA TACCGGGAAA ACCTGGGCG TTAATCAGAG AGGCGAATTA TGTGTCAGAG	8640	GAA
GACCTATGAT TATGTCCGCT TATGTAAACA ATCCGGAAGC GACCAACGCC TTGATTGACA	8700	AGI
AGGATGGATG GCTACATTCT GGAGACATAG CTTACTGGGA CGAAGACGAA CACTTCTTCA	8760	GAA
TACTTGACCG CTTGAAGTCT TTAATTAAAT ACAAAGGATA TCAGGTGGCC CCCGCTGAAT	8820	GTC
TGGAATCGAT ATTGTTACAA CACCCCAACA TCTTCGACGC GGGCGTGCCA GGTCTTCCCG	8880	CCA
ACGATGACGC CGGTGAACTT CCCGCCGCCG TTGTTGTTTT GGAGCACGGA AAGACGATGA	8940	GCA
CGGAAAAAGA GATCGTGGAT TACGTCGCCA GTCAAGTAAC AACCGCGAAA AAGTTGCGCG	9000	GCA
GAGGAGTTGT GTTTGTGGAC GAAGTACCGA AAGGTCTTAC CGGAAAACCT GACGCAAGAA	9060	TGC
AAATCAGAGA GATCCTCATA AAGGCCAAGA AGGGCGGAAA GTCCAAATTG TAAAATGTAA	9120	TTI
CTGTATTGAG CGATGACGAA ATTCTTAGCT ATTGTAATGA CTCTAGAGGA TCTTTGTGAA	9180	ACC
GGAACCTTAC TTCTGTGGTG TGACATAATT GGACAAACTA CCTACAGAGA TTTAAAGCTC	9240	AAC

TAAGGTAAAT ATAAAAATTT TAAGTGATA ATGTGTTAAA CTACTGATTC TAATTGTTTG 9300
TGTATTTTAG ATTCCAACCT ATGGAAGTGA TGAATGGGAG CAGTGGTGA ATGCCTTTAA 9360
TGAGGAAAAC CTGTTTGTCT CAGAAGAAAT GCCATCTAGT GATGATGAGG CTACTGCTGA 9420
CTCTCAACAT TCTACTCCTC CAAAAAAGAA GAGAAAGGTA GAAGACCCCA AGGACTTTCC 9480
TTCAGAATTG CTAAGTTTTT TGAGTCATGC TGTGTTTAGT AATAGAACTC TTGCTTGCTT 9540
TGCTATTAC ACCACAAAGG AAAAAGCTGC ACTGCTATAC AAGAAAATTA TGGAAAAATA 9600
TTCTGTAACC TTTATAAGTA GGCATAACAG TTATAATCAT AACATACTGT TTTTCTTAC 9660
TCCACACAGG CATAGAGTGT CTGCTATTAA TAACTATGCT CAAAAATTGT GTACCTTTAG 9720
CTTTTAAAT TGTAAGGGG TTAATAAGGA ATATTGATG TATAGTGCCT TGAAGAGAGA 9780
TCATAATCAG CCATACCACA TTTGTAGAGG TTTTACTTGC TTTAAAAAAC CTCCGACACC 9840
TCCCCTGAA CCTGAAACAT AAAATGAATG CAATTGTTGT TGTAACTTG TTTATTGCAG 9900
CTTATAATGG TTACAAATAA AGCAATAGCA TCACAAATTT CACAAATAAA GCATTTTTTT 9960
CACTGCATTC TAGTTGTGGT TTGTCCAAAC TCATCAATGT ATCTTATCAT GTCTGGATCC 10020
CCAGGAAGCT CCTCTGTGTC CTCATAAACC CTAACTCCT CTACTTGAGA GGACATTCCA 10080
ATCATAGGCT GCCCATCCAC CCTCTGTGTC CTCCTGTAA TTAGGTCCT TAACAAAAAG 10140
GAAATTGGGT AGGGGTTTTT CACAGACCGC TTTCTAAGGG TAATTTTAAA ATATCTGGGA 10200
AGTCCCTTCC ACTGCTGTGT TCCAGAAGTG TTGGTAAACA GCCCAGAAAT GTCAACAGCA 10260
GAAACATACA AGCTGTCAGC TTGCACAAG GGCCCAACAC CCTGCTCAGC AAGAAGCACT 10320
GTGGTTGCTG TGTTAGTAAT GTGCAAAACA GGAGGCACAT TTTCCCACC TGTGTAGTT 10380
CCAAAATATC TAGTGTTTT ATTTTACTT GGATCAGGAA CCCAGCACTC CACTGGATAA 10440
GCATTATCCT TATCCAAAAC AGCCTTGTGG TCAGTGTTC TCTGCTGACT GTCAACTGTA 10500
GCATTTTTTG GGGTTACAGT TTGAGCAGGA TATTTGGTCC TGTAGTTTGC TAACACACCC 10560
TGCAGTCCA AAGGTTCCCC ACCAACAGCA AAAAAATGAA AATTTGACCC TTGAATGGGT 10620
TTTCCAGCAC CATTTTCATG AGTTTTTGT GTCCCTGAAT GCAAGTTTAA CATAGCAGTT 10680
ACCCCAATAA CCTCAGTTTT AACAGTAACA GCTTCCCACA TCAAAATATT TCCACAGGTT 10740
AAGTCCTCAT TTAAATTAGG CAAAGGAA 10768

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6464 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

TTCTTGAAGA CGAAAGGGCC TCGTGATACG CCTATTTTIA TAGGTTAATG TCATGATAAT	60	AA
AATGGTTTCT TAGACGTCAG GTGGCACTTT TCGGGGAAAT GTGGCGGAA CCCCTATTG	120	AG
TTTATTTTTC TAAATACATT CAAATATGTA TCCGCTCATG AGACAATAAC CCTGATAAAT	180	GG
GCTTCAATAA TATTGAAAAA GGAAGAGTAT GAGTATTCAA CATTTCGGTG TCGCCCTTAT	240	CT
TCCGTTTTTT GCGGCATTTT GCCTTCCTGT TTTTGCTCAC CCAGAAACGC TGGTGAAAGT	300	CG
AAAAGATGCT GAAGATCAGT TGGGTGCACG AGTGGGTTAC ATCGAACTGG ATCTCAACAG	360	TC
CGGTAAGATC CTTGAGAGTT TTCGCCCCGA AGAACGTTTT CCAATGATGA GCACTTTTAA	420	TA
AGTTCTGCTA TGTGGCGCGG TATTATCCCG TGTGACGCC GGGCAAGAGC AACTCGGTGG	480	CA
CCGCATACAC TATTCTCAGA ATGACTTGGT TGACTACTCA CCAGTCACAG AAAAGCATCT	540	TC
TACGGATGGC ATGACAGTAA GAGAATTATG CAGTGCTGCC ATAACCATGA GTGATAACAC	600	AT
TGCGGCCAAC TTAATTCTGA CAACGATCGG AGGACCGAAG GAGCTAAECG CTTTTTTGCA	660	CA
CAACATGGGG GATCATGTAA CTCGCCTTGA TCGTTGGGAA CCGGAGCTGA ATGAAGCCAT	720	AG
ACCAAACGAC GAGCGTGACA CCACGATGCC TGCAGCAATG GCAACAACGT TCGGCAAAC	780	AA
ATTAAGTGGC GAACTACTTA CTCTAGCTTC CCGGCAACAA TTAATAGACT GGATGGAGGC	840	TT
GGATAAAGTT GCAGGACCAC TTCTGCGCTC GGCCCTTCCG GCTGGCTGGT TTATTGCTGA	900	GT
TAAATCTGGA GCGGCTGAGC GTGGGTCTCG CGGTATCATT GCAGCACTGG GGCCAGATGG	960	AC
TAAGCCCTCC CGTATCGTAG TTATCTACAC GACGGGGAGT CAGGCAACTA TGGATGAACG	1020	TC

AAATAGACAG ATCGCTGAGA TAGGTGCCTC ACTGATTAAAG CATTGGTAAC TGTCAGACCA 1080
AGTTTACTCA TATATACTTT AGATTGATTI AAAACTTTCAT TTTTAATTTA AAAGGATCTA 1140
GGTGAAGATC CTTTTTGATA ATCTCATGAC CAAAATCCCT TAACGTGAGT TTTCGTTCCA 1200
CTGAGCGTCA GACCCCGTAG AAAAGATCAA AGGATCTTCT TGAGATCCTT TTTTCTGCG 1260
CGTAATCTGC TGCTTGCAAA CAAAAAACC ACCGCTACCA GCGGTGTTT GTTTGCCGGA 1320
TCAAGAGCTA CCAACTCTTT TTCCGAAGGT AACTGGCTTC AGCAGAGCGC AGATACCAA 1380
TACTGTCTT CTAGTGTAGC CGTAGTTAGG CCACCACTTC AAGAACTCTG TAGCACC GCC 1440
TACATACCTC GCTCTGTAA TCCTGTTACC AGTGGCTGCT GCCAGTGGCG ATAAGTCGTG 1500
TCTTACCGGG TTGGACTCAA GACGATAGT ACCGGATAAG GCGCAGCGGT CGGGCTGAAC 1560
GGGGGGTTTG TGCACACAGC CCAGCTTGA GCGAAGGACC TACACCGAAC TGAGATACCT 1620
ACAGCGTGAG CATTGAGAAA GCGCCACGCT TCCCAAGGG AGAAAGGCGG ACAGGTATCC 1680
GGTAAGCGG AGGGTCGGAA CAGGAGAGCG CACGAGGGAG CTTCCAGGGG GAAACGCCTG 1740
GTATCTTTAT AGTCTGTGCG GGTTCGCCA CCTCTGACTT GAGCGTCGAT TTTGTGATG 1800
CTCGTCAGGG GGGCGGAGCC TATGGAAAA CGCCAGCAAC GCGGCCTTTT TACGGTTCCT 1860
GGCCTTTTGC TGGCCTTTTG CTCACATGTT CTTTCCTGCG TTATCCCTG ATTCTGTGA 1920
TAACCGTATT ACCGCCTTTG AGTGAGCTGA TACCGCTCGC GCGAGCGGAA CGACCGAGCG 1980
CAGCGAGTCA GTGAGCGAGG AAGCGGAAGA GCGCCTGATG CGGTATTTT TCCTTACGCA 2040
TCTGTGCGGT ATTTACACACC GCATATGGTG CACTCTCAGT ACAATCTGCT CTGATGCCGC 2100
ATAGTTAAGC CAGTATACAC TCCGCTATCG CTACGTGACT GGGTCATGGC TCGGCCCCGA 2160
CACCCGCCAA CACCCGCTGA CGCGCCCTGA CGGGCTTGTC TGCTCCCGGC ATCCGCTTAC 2220
AGACAAGCTG TGACCGTCTC CGGAGCTGC ATGTGTCAGA GGTTCACC GTCATCACCG 2280
AAACGCCGGA GGCAGCGGAT CATAATCAGC CATACCACAT TTGTAGAGGT TTTACTTGCT 2340
TTAAAAACC TCCACACCT CCCCTGAAC CTGAAACATA AAATGAATGC AATTGTTGTT 2400
GTAACTTGT TTATTGCAGC TTATAATGGT TACAAATAA GCAATAGCAT CACAAATTC 2460
ACAAATAAAG CATTTTTTTC ACTGCATTCT AGTTGTGGTT TGTCCAACT CATCAATGTA 2520
TCTTATCATG TCTGGATCAT AATCAGCCAT ACCACATTG TAGAGTTTT ACTTGCTTTA 2580

AAAAACCTCC CACACCTCCC CCTGAACCTG AAACATAAAA TGAATGCAAT TGTGTTGTT	2640	AAAGC
AACTTGTTTA TTGCAGCTTA TAATGGTTAC AAATAAAGCA ATAGCATCAC AAATTCACA	2700	ATTC
AATAAAGCAT TTTTTCCTACT GCATTCTAGT TGTGGTTTGT CCAAACATCAT CAATGTATCT	2760	TTTG
TATCATGTCT GGATCCCAGG CCAGACGCCA ACAAGGTAGG AGCTGGAGCA TTCGGGCTGG	2820	GAAT
GTTTCACCCC ACCGCACGGA GGCCTTTTGG GGTGGAGCCC TCAGGCTCAG GGCATACTAC	2880	AACG
AAACTTTGCC AGCAAATCCG CCTCCTGCCT CCACCAATCG CCAGTCAGGA AGGCAGCCTA	2940	GACG
CCCCGCTGTC TCCACCTTTG AGAAACACTC ATCCTCAGGC CATGCAGTGG AATTCACAA	3000	GTGC
CCTTCGACCA AACTCTGCAA GATCCCAGAG TGAGAGGCCT GTATTTCCCT GCTGGTGGCT	3060	GTGC
CCAGTTCAGG AACAGTAAAC CCTGTTCTGA CTAATGCCTC TCCCTTATCG TCAATCTTCT	3120	CACG
CGAAATTCCA GCTGGCATTG CGGTACTGTT GGTAAAATGG AAGACGCCAA AAACATAAAG	3180	GCG
AAAGGCCCGG CGCCATTCTA TCCTCTAGAG GATGGAACCG CTGGAGAGCA ACTGCATAAG	3240	AAA
GCTATGAAGA GATACGCCCT GGTTCCCTGGA ACAATTGCTT TTACAGATGC ACATATCGAG	3300	AAA
GTGAACATCA CGTACGCGGA ATACTTCGAA ATGTCCGTTG GGTGGCAGA AGCTATGAAA	3360	AGA
CGATATGGGC TGAATACAAA TCACAGAATC GTCGTATGCA GTGAAAACTC TCTTCAATTG	3420	CAC
TTTATGCCCG TGTGGGCGC GTTATTTATC GGAGTTGCAG TTGGCCCCGC GAACGACATT	3480	TGA
TATAATGAAC GTGAATTGCT CAACAGTATG AACATTTGCG AGCCTACCGT AGTGTTTGTT	3540	GG
TCCAAAAAGG GGTGCAAAA AATTTTGAAC GTGCAAAAAA AATTACCAAT AATCCAGAAA	3600	AT
ATTATTATCA TGGATTCTAA AACGGATTAC CAGGGATTTC AGTCGATGTA CACGTTGCTC	3660	AC
ACATCTCATC TACCTCCCGG TTTAATGAA TACGATTTTG TACCAGAGTC CTTTGATCGT	3720	GA
GACAAAACAA TTGCACTGAT AATGAATTCC TCTGGATCTA CTGGGTACG TAAGGGTGTG	3780	AA
GCCCTTCGCG ATAGAACTGC CTGCGTCAGA TTCTCGCATG CCAGAGATCC TATTTTGGC	3840	TA
AATCAAATCA TTCCGGATAC TGCGATTTTA AGTGTGTTT CATTCCATCA CGGTTTTGGA	3900	AI
ATGTTTACTA CACTCGGATA TTTGATATGT GGATTTGAG TCGTCTTAAT GTATAGATT	3960	G
GAAGAAGAGC TGTTTTTACG ATCCCTTCAG GATTACAAAA TTCAAAGTGC GTTGCTAGTA	4020	A
CCAACCCCTAT TTTATTCTT CGCCAAAAGC ACTCTGATTG ACAAATACGA TTTATCTAAT	4080	A
TTACACGAAA TTGCTTCTGG GGGCGCACCT CTTTCGAAAG AAGTCGGGA AGCGGTTGCA	4140	A

AAACGCTTCC ATCTTCCAGG GATACGACAA GGATATGGGC TCACTGAGAC TACATCAGCT 4200
ATTCTGATTA CACCCGAGGG GGATGATAAA CCGGGCGCGG TCGGTAAAGT TGTTCGATTT 4260
TTTGAAGCGA AGGTTGTGGA TCTGGATACC GGGAAAACGC TGGGCGTTAA TCAGAGAGGC 4320
GAATTATGTG TCAGAGGACC TATGATTATG TCCGGTTATG TAAACAATCC GGAAGCGACC 4380
AACGCCTTGA TTGACAAGGA TGGATGGCTA CATTCTGGAG ACATAGCTTA CTGGGACGAA 4440
GACGAACTACT TCTTCATAGT TGACCGCTTG AAGTCTTTAA TTAAATACAA AGGATATCAG 4500
GTGGCCCCCG CTGAATTGGA ATCGATATTG TTACAACACC CCAACATCTT CGACGCGGGC 4560
GTGGCAGGTC TTCCCGACGA TGACGCGGT GAACCTCCCG CCGCCGTTGT TGTTTTGGAG 4620
CACGGAAAGA CGATGACGGA AAAAGAGATC GTGGATTACG TCGCCAGTCA AGTAACAACC 4680
GCGAAAAAGT TCGCGGGAGG AGTTGTGTTT GTGGACGAAG TACCGAAAGG TCTTACCGGA 4740
AAACTCGACG CAAGAAAAAT CAGAGAGATC CTCATAAAGG CCAAGAAGGG CGGAAAGTCC 4800
AAATTGTAAA ATGTAAGTGT ATTCAGCGAT GACGAAATTC TTAGCTATTG TAATGACTCT 4860
AGAGGATCTT TGTGAAGGAA CCTTACTTCT GTGGTGTGAC ATAATTGGAC AAACCTACCTA 4920
CAGAGATTIA AAGCTCTAAG GTAAATATAA AATTTTAAAG TGTATAATGT GTTAAACTAC 4980
TGATTCTAAT TGTGTGTGTA TTTTAGATTG CAACCTATGG AACTGATGAA TGGGAGCAGT 5040
GGTGAATGC CTTTAATGAG GAAAACCTGT TTTGCTCAGA AGAAATGCCA TCTAGTGATG 5100
ATGAGGCTAC TGCTGACTCT CAACATTCTA CTCCTCCAAA AAAGAAGAGA AAGGTAGAAG 5160
ACCCCAAGGA CTTTCCTTCA GAATTGCTAA GTTTTTGAG TCATGCTGTG TTTAGTAATA 5220
GAACTCTTGC TTGCTTTGCT ATTTACACCA CAAAGGAAAA AGCTGCACTG CTATACAAGA 5280
AAATTATGGA AAAATATTCT GTAACCTTIA TAAGTAGGCA TAACAGTTAT AATCATAACA 5340
TACTGTTTTT TCTTACTCCA CACAGGCATA GAGTGTCTGC TATTAATAAC TATGCTCAAA 5400
AATTGTGTAC CTTTAGCTTT TTAATTTGTA AAGGGGTAA TAAGGAATAT TTGATGTATA 5460
GTGCCTTGAC TAGAGATCAT AATCAGCCAT ACCACATTG TAGAGGTTTT ACTTGCTTIA 5520
AAAAACCTCC CACACCTCCC CCTGAACCTG AAACATAAAA TGAATGCAAT TGTGTGTGTT 5580
AACTTGTTTA TTGCAGCTTA TAATGGTTAC AAATAAGCA ATAGCATCAC AAATTCAGA 5640
AATAAAGCAT TTTTTCCT GCAATCTAGT TGTGGTTTGT CCAAACCTCAT CAATGTATCT 5700

-186-

TATCATGTCT GGATCCCCAG GAAGTCCTC TGTGTCCTCA TAAACCCTAA CCTCCTCTAC 5760
TTGAGAGGAC ATTCCAATCA TAGGCTGCCC ATCCACCCTC TGTGTCCTCC TGTTAATTAG 5820
GTCACCTAAC AAAAAGGAAA TTGGGTAGGG GTTTTTCACA GACCGCTTC TAAGGGTAAT 5880
TTTAAATAT CTGGGAAGTC CCTTCCACTG CTGTGTTTGA GAAGTGTGG TAAACAGCCC 5940
ACAAATGTCA ACAGCAGAAA CATAAAGCT GTCAGCTTTG CACAAGGGCC CAACACCCTG 6000
CTCAGCAAGA AGCACTGTGG TTGCTGTGTT AGTAATGTGC AAAACAGGAG GCACATTTTC 6060
CCCACCTGTG TAGGTTCCAA AATATCTAGT GTTTTCATTT TACTTGGAT CAGGAACCCA 6120
GCACTCCACT GGATAAGCAT TATCCTTATC CAAAACAGCC TTGTGTCAG TGTTCATCTG 6180
CTGACTGTCA ACTGTAGCAT TTTTGGGGT TACAGTTTGA GCAGGATATT TGGTCCTGTA 6240
GTTTGCTAAC ACACCCTGCA GCTCCAAAGG TTCCCCACCA ACAGCAAAAA AATGAAAATT 6300
TGACCCTTGA ATGGGTTTTT CAGCACCATT TTCATGAGTT TTTTGTGTCC CTGAATGCAA 6360
GTTTAACATA GCAGTTACCC CAATAACCTC AGTTTAAACA GTAACAGCTT CCCACATCAA 6420
AATATTTCCT CAGGTAACT CCTCATTAA ATTAGGCAAA GGAA 6464

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

TGASTCA

7

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 base pairs
- (B) TYPE: nucleic acid

-187-

(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

TGGNNNNNNN GCCAA

16

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

TGGCA

5

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

TGACACA

7

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

TGAGTCA

7

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

TGANACA

7

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

-189-

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

TGATACA

7

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

CCNTGTNT

8

WE CLAIM:

1. A method for quantifying the amount of transforming growth factor- β (TGF- β) in a liquid sample; which method
5 comprises:
 - (a) incubating said liquid sample together with
eucaryotic cells that contain a TGF- β responsive expression
vector having a gene encoding luciferase for a predetermined
time period sufficient for said eucaryotic cells to express a
10 detectable amount of said luciferase;
 - (b) measuring the amount of said luciferase
expressed during said time period; and
 - (c) determining the amount of TGF- β present in
said sample by comparing the measured amount of said luciferase
15 against a reference curve.
 2. The method in accordance with claim 1 wherein the
reference curve represents a series of measured amounts of said
luciferase produced from a series of known concentrations of
TGF- β by said eucaryotic cells.
 - 20 3. The method in accordance with claim 1 wherein said
eucaryotic cells are mammalian cells.
 4. The method in accordance with claim 3 wherein said
mammalian cells are members of the group consisting of mink
lung epithelial cells, HeLa cells, Chinese hamster ovary cells,
25 Hep3B cells, GM7373 cells, and NIH 3T3 cells.
 5. The method in accordance with claim 1 wherein the
TGF- β responsive expression vector is a plasmid comprising, in
the direction of transcription, a regulatory region that
includes at least one TGF- β inducible response element that is
30 operatively linked to a promoter, and a structural region
downstream of said promoter, said response element being
capable of inducing dose-dependent luciferase activity and said
structural region coding for said luciferase.
 - 35 6. The method in accordance with claim 5 wherein said
plasmid includes a nucleotide sequence that corresponds to a

-191-

sequence selected from the group consisting of SEQ ID NOS 1-10.

7. The method in accordance with claim 5 wherein said plasmid has the identifying characteristics of a plasmid selected from the group consisting of plasmid ATCC Accession Number 75627, plasmid ATCC Accession Number 74628 and plasmid ATCC Accession Number 75629.

8. The method in accordance with claim 5 wherein said TGF- β inducible response element comprises a nucleotide sequence that corresponds to a sequence selected from the group consisting of SEQ ID NOS 11-17.

9. The method in accordance with claim 5 wherein said promoter comprises a nucleotide sequence that corresponds to a sequence selected from the group consisting of SEQ ID NOS 18 and 19.

10. The method in accordance with claim 1 wherein said eucaryotic cells are stably transformed cells that contain said TGF- β responsive vector, and wherein said vector also includes a gene encoding a selectable marker.

11. The method in accordance with claim 10 wherein said vector is a plasmid comprising a nucleotide sequence that corresponds to a sequence selected from the group consisting of SEQ ID NOS 1-6.

12. The method in accordance with claim 1 wherein said eucaryotic cells are transiently transformed cells that contain said TGF- β responsive vector, and wherein said vector is a plasmid comprising a nucleotide sequence that corresponds to a sequence selected from the group consisting of SEQ ID NOS 7-10.

13. The method in accordance with claim 1 wherein said liquid sample is selected from the group consisting of a body fluid, culture medium and a tissue extract.

14. A method for quantifying the amount of transforming growth factor- β (TGF- β) in a liquid sample comprising:

(a) providing, in eucaryotic cells capable of expressing an indicator molecule, a plasmid comprising, in the direction of transcription, a regulatory region that includes

at least one TGF- β inducible response element that is operatively linked to a promoter, and a structural region downstream of said promoter, said response element being capable of inducing dose-dependent indicator molecule activity and said structural region coding for said indicator molecule;

(b) incubating said liquid sample with said eucaryotic cells for a predetermined time period sufficient for said eucaryotic cells to express a detectable amount of said indicator molecule;

(c) measuring the amount of said indicator molecule expressed during said time period; and

(d) comparing the measured amount of said indicator molecule produced in step (c) with the amount of indicator molecule produced in a control assay performed according to steps (a) through (c) by treating said liquid sample with an anti-TGF- β antibody to obtain a net measured amount of said indicator molecule induced by said TGF- β .

15. The method in accordance with claim 14 wherein said liquid sample contains an isoform of TGF- β selected from the group consisting of TGF- β 1, TGF- β 2 and TGF- β 3.

16. The method in accordance with claim 14 wherein said liquid sample is selected from the group consisting of a body fluid, culture medium and a tissue extract. 17. The method in accordance with claim 14 wherein said eucaryotic cell is a mammalian cell.

18. The method in accordance with claim 14 wherein said mammalian cell is selected from the group consisting of mink lung epithelial cells, HeLa cells, Chinese Hamster Ovary cells, Hep3B cells, GM7373 cells and NIH 3T3 cells.

19. The method in accordance with claim 14 wherein said indicator molecule is luciferase.

20. The method in accordance with claim 14 wherein said plasmid comprises a nucleotide sequence that corresponds to a sequence selected from the group consisting of SEQ ID NOs 1-10.

21. The method in accordance with claim 14 wherein said

TG
se
co

pr
se
an

pl
se
Nur
AT

eu
pl
se
ce

pl
se

eu
TG
NO
wi

eu
co
co
SE

co
sa
mo

-193-

TGF- β inducible response element comprises a nucleotide sequence that corresponds to a sequence selected from the group consisting of SEQ ID NOs 11-17.

22. The method in accordance with claim 14 wherein said promoter comprises a nucleotide sequence that corresponds to a sequence selected from the group consisting of SEQ ID NOs 18 and 19.

23. The method in accordance with claim 14 wherein said plasmid has the identifying characteristics of a plasmid selected from the group consisting of plasmid ATCC Accession Number 75627, plasmid ATCC Accession Number 74628 and plasmid ATCC Accession Number 75629.

24. The method in accordance with claim 14 wherein said eucaryotic cells are stably transformed cells that contain said plasmid, and wherein said plasmid contains a gene encoding a selectable marker for the selection of said stably transformed cells.

25. The method in accordance with claim 24 wherein said plasmid comprises a nucleotide sequence that corresponds to a sequence selected from the group consisting of SEQ ID NOs 1-6.

26. The method in accordance with claim 14 wherein said eucaryotic cells are stably transformed cells that contain the TGF- β response element having the nucleotide sequence in SEQ ID NO 11, and wherein said cells correspond to cells on deposit with ATCC having the ATCC Accession Number CRL 11508.

27. The method in accordance with claim 14 wherein eucaryotic cells comprise transiently transformed cells that contain said plasmid comprising a nucleotide sequence that corresponds to a sequence selected from the group consisting of SEQ ID NOs 7-10.

28. The method in accordance with claim 14 further comprising the step of:

(e) determining the amount of said TGF- β present in said sample by comparing the measured amount of said indicator molecule obtained in step (d) against a reference curve.

-194-

29. The method in accordance with claim 28 wherein said reference curve represents a series of measured amounts of said indicator molecule produced from a series of known concentrations of TGF- β in said eucaryotic cells.

5 30. A plasmid vector in substantially pure form capable of causing expression of an indicator molecule in a eucaryotic cell, said plasmid including in the direction of transcription, a first nucleotide sequence comprising a regulatory region that includes at least one TGF- β inducible response element
10 operatively linked to a promoter, a second nucleotide sequence comprising a structural region downstream of said promoter and coding for said indicator molecule, and a third nucleotide sequence comprising a gene encoding a selectable marker for the selection of a stably transformed cell, said response element
15 being capable of inducing dose-dependent luciferase activity and said structural region coding for said luciferase.

31. The plasmid vector in accordance with claim 30 capable of expressing a chemiluminescent indicator molecule.

20 32. The plasmid vector in accordance with claim 30 wherein said plasmid comprises a nucleotide sequence that corresponds to a sequence selected from the group consisting of SEQ ID NOS 1-6.

25 33. The plasmid vector in accordance with claim 30 wherein said TGF- β inducible response element comprises a nucleotide sequence that corresponds to a sequence selected from the group consisting of SEQ ID NOS 11-17.

30 34. The plasmid vector in accordance with claim 30 wherein said promoter comprises a nucleotide sequence that corresponds to a sequence selected from the group consisting of SEQ ID NOS 18 and 19.

35 35. The plasmid vector in accordance with claim 30 wherein said gene comprises the nucleotide sequence in SEQ ID NO 20.

36. A plasmid vector in substantially pure form and capable of causing expression of luciferase in a eucaryotic

-195-

cell, said plasmid comprising in the direction of
transcription, a regulatory region that includes at least one
TGF- β inducible response element that is operatively linked to
a promoter, and a structural region downstream of said promoter
for transcription therefrom and coding for said luciferase,
said response element being capable of inducing dose-dependent
luciferase activity and said structural region coding for said
luciferase, and wherein said plasmid has the identifying
characteristics of a plasmid selected from the group consisting
of plasmid ATCC Accession Number 75627, plasmid ATCC Accession
Number 74628 and plasmid ATCC Accession Number 75629.

37. A plasmid vector in substantially pure form and
capable of causing expression of luciferase in a eucaryotic
cell, said plasmid comprising in the direction of
transcription, a regulatory region that includes at least one
TGF- β inducible response element that is operatively linked to
a promoter, and a structural region downstream of said promoter
for transcription therefrom and coding for said luciferase,
said response element being capable of inducing dose-dependent
luciferase activity and said structural region coding for said
luciferase, and wherein said plasmid comprises a nucleotide
sequence that corresponds to a sequence selected from the group
consisting of SEQ ID Nos 7-10.

38. A eucaryotic cell containing a plasmid vector having
a nucleotide sequence that corresponds to a sequence selected
from the group consisting of SEQ ID NOS 1-10.

39. The eucaryotic cell in accordance with claim 38
wherein said cell is selected from the group consisting of mink
lung epithelial cells, HeLa cells, Chinese hamster ovary cells,
Hep3B cells, GM7373 cells and NIH 3T3 cells.

40. A kit useful in assaying the amount of TGF- β in a
liquid sample comprising (a) packaging material; (b) eucaryotic
cells contained within said packaging material, said cells
capable of expressing an indicator molecule and containing a
plasmid comprising, in the direction of transcription, a

-196-

regulatory region that includes at least one TGF- β inducible response element that is operatively linked to a promoter, and a structural region downstream of said promoter, said response element being capable of inducing dose-dependent indicator molecule activity and said structural region coding for said indicator molecule; and (c) an aliquot of TGF- β contained within said packaging material, said TGF- β used for generating a reference curve representing a measured amount of the indicator molecule produced from a known concentration of TGF- β .

41. The kit in accordance with claim 40 wherein said eucaryotic cells are selected from the group consisting of mink lung epithelial cells, HeLa cells, Chinese Hamster Ovary cells, Hep3B cells, GM7373 cells and NIH 3T3 cells.

42. The kit in accordance with claim 40 wherein said plasmid comprises a nucleotide sequence that corresponds to a sequence selected from the group consisting of SEQ ID NOs 1-10.

43. The kit in accordance with claim 40 wherein said plasmid comprises a plasmid having the identifying characteristics of a plasmid selected from the group consisting of plasmid ATCC Accession Number 75627, plasmid ATCC Accession Number 74628 and plasmid ATCC Accession Number 75629.

44. The kit in accordance with claim 40 wherein said packaging material comprises a label indicating that said eucaryotic cells can be used for determining the amount of TGF- β in said liquid sample comprising the steps of (a) incubating said cells with said liquid sample; (b) measuring the amount of said indicator molecule produced thereby; and (c) comparing the amount of measured indicator molecule with said reference curve.

45. The kit in accordance with claim 40 wherein said eucaryotic cells are stably transformed cells that contain the TGF- β response element having the nucleotide sequence in SEQ ID NO 11, and wherein said cells correspond to cells on deposit with ATCC having the ATCC Accession Number CRL 11508.

-197-

46. The kit in accordance with claim 40 further comprising: (d) an anti-TGF- β antibody for use in a parallel control assay for determining the amount of indicator molecule produced other than by TGF- β induction.

1/11




FIGURE 1




FIGURE 2A

3/11




FIGURE 2C

4/11




FIGURE 3A

5/11




FIGURE 3B

6/11




FIGURE 3C

7/11




FIGURE 4A




FIGURE 4B

9/11




FIGURE 4C

10/11




FIGURE 5

11/11




FIGURE 6

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/01153

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07H 21/00; C12N 15/18; C07K 14/495

US CL : 435/8, 69.1, 69.4, 320.1, 240.1; 530/399

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/8, 69.1, 69.4, 320.1, 240.1; 530/399

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Cell, Volume 71, issued 11 December 1992, J.L. Wrana et al., "TGF β Signals through a Heteromeric Protein Kinase Receptor Complex," pages 1003-1014, especially figure 1A and Results.	1-46
Y	Journal of Cellular Physiology, Volume 152, issued 1992, R. Flaumenhaft et al., "Cell Density Dependent Effects of TGF- β Demonstrated by a Plasminogen Activator-Based Assay for TGF- β ," pages 48-55, especially figure 5.	1-46
Y	The Journal of Biological Chemistry, Volume 193, issued 1951, O.H. Lowry et al., "Protein Measurement with the Folin Phenol Reagent," pages 265-275, especially pages 265-268.	1-46

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

Special categories of cited documents:	
A document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
E earlier document published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	*A* document member of the same patent family

Date of the actual completion of the international search

11 APRIL 1995

Date of mailing of the international search report

21 APR 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

Shelly Guest Cernak

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/01153

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 5,216,126 (COX ET AL.) 01 June 1993.	1-46
A	US, A, 5,268,295 (SERRERO) 07 December 1993.	1-46
A	Molecular and Cellular Biology, Volume 12, No. 4, issued April 1992, A. Riccio et al., "Transforming Growth Factor β 1-Responsive Element: Closely Associated Binding Sites for USF and CCAAT-Binding Transcription Factor-Nuclear Factor I in the Type 1 Plasminogen Activator Inhibitor Gene," pages 1846-1855.	1-46

B. FI
ElectSequ
APS
Diale
scarc

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/01153

to claim No

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

Sequence search of PIR, GeneSeq,

APS

Dialog

search terms: transforming growth factor, quantification, luciferase

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record.

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.